International Society for Pharmacoeconomics and Outcomes Research
ISPOR 11th Annual
European Congress
“Moving and Improving Concepts & Evidence
for Health Care Decisions”
8-11 November 2008 | Athens, Greece
PROGRAM &
Schedule
of events
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & sched u le of events
SATURDAY, 8 NOVEMBER
9:00-18:00
PRE-CONGRESS SHORT COURSES
12:00-18:00
ISPOR BOARD OF DIRECTORS MEETING (BY INVITATION ONLY) Patmos
(See page 13 for Short Course descriptions)
18:00-19:30EDUCATIONAL SYMPOSIUM (SPONSORED BY European Federation of Pharmaceutical IndUstries and Associations - EFPIA)
Achieving Better Health Outcomes for the Benefit of Patients - An Update on EFPIA’s Key HTA Principles Hesperides
(See page 97 for Symposia descriptions)
19:30-20:00
SYMPOSIUM Reception Hesperides Lobby
SUNDAY, 9 NOVEMBER
8:00-12:00
PRE-CONGRESS SHORT COURSES
(See page 13 for Short Course descriptions)
12:00-13:00EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Convention Level
13:00-13:10
WELCOME FROM THE ISPOR PRESIDENT Terpsichore ABC
Chris L. Pashos PhD, 2008-2009 ISPOR President & Vice President, HERQuLES, Abt BioPharma Solutions, Inc., Lexington, MA, USA
(See page 103 for biographical information)
13:10-13:20
WELCOME TO GREECE Terpsichore ABC
John Yfantopoulos PhD and the Greek Advisory Committee
13:20-13:30
CONGRESS INTRODUCTION AND OBJECTIVES Terpsichore ABC
C. Pashos
Program Planning Committee Co-Chairs: Uwe Siebert MD, MPH, MSc, ScD, Professor/Chair, Department of Public Health,
Medical Decision Making and Health Technology Assessment, UMIT - University of Health Sciences, Medical Informatics and
Technology, Hall i.T., Austria; John Yfantopoulos PhD, Professor of Health Economics, University of Athens and President of
the National Centre for Social Research, Athens, Greece
(See page 103 for biographical information)
13:30-14:45
(See page 103 for biographical information)
U. Siebert
J. Yfantopoulos
FIRST PLENARY SESSION Terpsichore ABC
Health Technology Assessment (HTA) in Europe – Is Harmonization Possible? Health technology assessment (HTA) is a multidisciplinary process that summarises information
about the medical, social, economic and ethical issues related to the use of a health technology
in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of
U. Siebert
P. Sawicki
L. Longworth
F. Kristensen
safe, effective, health policies that are patient focused and seek to achieve best value [ref:
EUnetHTA]. European countries have established independent evaluation processes for health
technologies. Whereas a health technology’s clinical outcomes are less country-specific, the economic, ethical and legal aspects of a technology are more
country-specific. Although initiatives to harmonize European evaluation processes are underway such as the EUnetHTA, individual countries still have different
HTA requirements. This plenary session will focus on the diversity in HTA processes, and their use in decision-making, as well as efforts to harmonize these
HTA processes in Europe.
Moderator: Uwe Siebert MD, MPH, MSc, ScD, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment,
UMIT - University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
Speakers: Peter Sawicki MD, PhD, Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany;
Louise Longworth PhD, Senior Research Fellow, School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK;
Finn Boerlum Kristensen MD, PhD, Director & Professor, Danish Centre for Health Technology Assessment, National Board of Health, Copenhagen, Denmark;
Adjunct Professor, University of Southern Denmark; Project Leader, European Network for HTA (EUnetHTA)
14:45-15:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Convention Level
(See page 34-85 for Research Poster Presentations) Cookies sponsored by Clinphone
15:15-16:15
RESEARCH PODIUM PRESENTATIONS - SESSION I (Page numbers refer to Podium Abstracts in Value in Health 11(6))
Economic Evaluations I Thalia 3-4
Moderator: Christos A. Alexakis PhD, Associate Professor, Department of Economics, University of Piraeus, Piraeus, Greece
pgA335EE1 DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS: DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION?
Van Helvoort-Postulart D1, Dellaert B2, Van der Weijden T3, Von Meyenfeldt M1, Dirksen CD1, 1Maastricht University Medical Center, Maastricht, The
Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Maastricht University, Maastricht, The Netherlands
20
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Sunday, 9 November
pgA335 EE2 STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC
OUTCOMES OF DIABETES COMPLICATIONS
Minshall ME1, Pelletier EM2, Smith PJ3, Forma FM4, 1IMS Health, Noblesville, IN, USA, 2IMS Health Consulting, Watertown, MA, USA, 3PharMetrics, a unit of
IMS, Watertown, MA, USA, 4Novo Nordisk Inc, Princeton, NJ, USA
pgA335EE3 VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS C VIRUS
Davis KL1, Mitra D1, Medjedovic J2, Beam C3, Rustgi V4, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland,
3
Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA
pgA336EE4 CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS
Le Lay K1, Boussetta S1, Moldofsky H2, Taieb C1, 1Pierre Fabre, Boulogne, France, 2Centre for Sleep and Chronobiology, Toronto, ON, Canada Performance of HTA Agencies Terpsichore ABC
Moderator: Manolis Karamalis MA, Director, Reimbursement and Health Economics - Central Eastern Europe, Greece and Israel, Medtronic International, Tolochenaz, Switzerland
pgA337 HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES
Schwarzer R, Siebert U, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T, Tirol, Austria
pgA338 HT2 UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS - ECONOMIC CRITICISMS
Karia R, Plested M, Cann K, Zwaferink H, Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA338 HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS: NICE, SMC, CADTH AND PBAC
Cann K, Karia R, Plested M, Samuels , Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA338 HT4 HEALTH TECHNOLOGY ASSESSMENTS: ARE THEY RELEVANT TO CLINICAL PRACTICE?
Zhang B1, Van Staa TP2, 1General Practice Research Database, London, Middlesex, UK, 2General Practice Research Database, London, UK
Medical Device Economic Evaluations Santorini 1-3
Moderator: Ron Akehurst BSc (Econ), Hon MFPHM, Professor of Health Economics, Dean of School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK
pgA336 MD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF
TYPE 1 DIABETES IN POLAND
Clegg JP1, Wéry E1, Karamalis M2, Pokorski J2, Mlynarski W3, Valentine WJ1, Goodall G4, 1IMS Health, Allschwil, Switzerland, 2Medtronic Poland Sp. z o.o,
Warsaw, Poland, 3Medical University of Lodz, Lodz, Poland, 4IMS Health, Basel, Switzerland
pgA419 MD2 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR® DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY
ARTERY BYPASS GRAFT SURGERY IN SPAIN Rodriguez Barrios JM1, Moreu J2, Cequier A3, Brosa M4, Vazquez N5, Hernandez J6, Crespo C7, Brasseur P8, 1Medtronic Iberia, Madrid, Madrid, Spain, 2Virgen
de la Salud Hospital, Toledo, Toledo, Spain, 3Belvitge Hospital, Barcelona, Barcelona, Spain, 4Oblikue, Barcelona, Barcelona, Spain, 5Juan Canalejo Hospital, A
Coruna, A Coruna, Spain, 6Malaga Clinic Hospital, Malaga, Malaga, Spain, 7Oblikue Consulting, Barcelona, Spain, 8Medtronic Sarl, Tolochenaz, Switzerland
pgA337 MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM’S PERSPECTIVE IN AUSTRIA
Tuschel A, Meissl M, Ogon M, Orthopaedic Hospital Vienna Speising, Vienna, Austria
pgA337 MD4 UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY: COST-EFFECTIVENESS OF ADDING IMPLANTABLE
CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY
Murthy A1, Tsintzos S2, 1Medtronic International, Tolochenaz, Vaud, Switzerland, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland Mental Health I (Attention-Deficit/Hyperactivity Disorder in Europe) Santorini 4-6
Moderator: Christina Vandoros MSc, Director, Government Affairs and Policy, Europe, Johnson & Johnson, Brussels, Belgium
pgA339 MH1 HOW MUCH SHOULD WE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER (ADHD)?
Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Persson U4, Santosh PJ5, Trott GE6, MTA Cooperative Group7, 1Institute for Innovation &
Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Erasmus MC, Rotterdam, The Netherlands, 3Columbia University, New York, NY, USA, 4The
Swedish Institute for Health Economics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg,
Aschaffenburg, Germany, 7National Institute of Mental Health, Bethesda, MD, USA
pgA339 MH2 THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOOD TO ADULTHOOD: A MEDICAID STUDY
Chen H, Sudharshan L, University of Houston, Houston, TX, USA
pgA339 MH3 COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN
AND ADOLESCENTS IN FINLAND: AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT)
Schlander M1, Hjelmgren J2, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Janssen-Cilag AB, Sollentuna, Sweden
pgA340 MH4 HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN
GERMANY – IMPACT OF COEXISTING CONDITIONS
Schlander M1, Schwarz O1, Trott GE2, Viapiano M3, Bonauer N3, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University
of Wuerzburg, Aschaffenburg, Germany, 3Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany
Quality of Life/Preference-based Measures I: Issues with Instruments Galaxy
Moderator: Nikos Maniadakis PhD, Assistant Professor of Health Economics and Management, Department of Economics, University of Piraeus, Dresia, Greece
pgA340 QL1 AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES: REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION
Wild D1, Martin M2, Hareendran A3, von Maltzahn R1, 1Oxford Outcomes Ltd, Oxford, UK, 2Health Research Associates Inc, Seattle, WA, USA, 3Pfizer, Ltd,
Sandwich, UK pgA340 QL2 TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES
Fernandez N1, Grataloup G1, Posner K2, 1Mapi Research Institute, Lyon, France, 2New York State Psychiatric Institute, New York, NY, USA
pgA341 QL3 ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS
Anfray C, Emery MP, Mapi Research Trust, Lyon, France
pgA341 QL4 PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA
Kontodimopoulos N1, Paliouras D2, Pappa E1, Papadopoulos AA3, Aletras VH4, Niakas D1, 1Hellenic Open University, Patras, Greece, 2Theagenio Cancer Hospital,
Thessalonica, Greece, 3Attikon University Hospital, Athens, Greece, 4University of Macedonia, Thessalonica, Greece
21
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Sunday, 9 November
16:30-17:30
RESEARCH PODIUM PRESENTATIONS – SESSION II
(Page numbers refer to Podium Abstracts in Value in Health 11(6))
Cardiovascular Disease Evaluations Thalia 3-4
Moderator: Michael Barry MD, PhD, FRCPI, Clinical Director, National Centre for Pharmacoeconomics, St. James’ Hospital, Dublin, Ireland
pgA341 CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?
Eisenstein EL1, Cowper PA1, Bae JP2, Kong DF1, Ramaswamy K3, Anstrom KJ1, 1Duke Clinical Research Institute, Durham, NC, USA, 2Eli Lilly and Company,
Indianapolis, IN, USA, 3Daiichi Sankyo Inc, Parsippany, NJ, USA
pgA342 CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ATRIAL FIBRILLATION: AF-QOL
Arribas F1, Ormaetxe JM2, Peinado R3, Fernandez C4, Ramírez P4, Badia XB5, Lara N5, 1Hospital 12 de Octubre, Madrid, Spain, 2Hospital de Basurto, Bilbao,
Spain, 3Hospital La Paz, Madrid, Spain, 4MEDA Pharma, Madrid, Spain, 5IMS Health, Barcelona, Spain
pgA342 CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN
MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES
Sorensen SV1, Webb SF2, Burge RT2, 1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA
pgA342 CV4 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE The Netherlands
Nuijten MJ1, Redekop WK2, 1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The
Netherlands
Economic Evaluations II Santorini 1-3
Moderator: Irene Fafaliou PhD, Associate Professor, Department of Economics, University of Piraeus, Piraeus, Greece
pgA448 PRS8 TOTAL COSTS OF TOBACCO FOR SOCIETY – WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS?
Reissell E1, Herse F1, Väänänen JJP1, Linden K2, Kotomäki T2, Parvinen PMT1, 1Nordic Healthcare Group, Helsinki, Finland, 2Pfizer Oy, Helsinki, Finland pgA343EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED
FOLLICULAR LYMPHOMA IN THE UK
Ray JA1, Carr E1, Geary U2, 1F. Hoffmann - La Roche, Basel, Switzerland, 2Roche Products Limited, Hertfordshire, UK
pgA343EE7 ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN ITALY: THE NATIONAL AND REGIONAL LEVEL
Cavallo M1, Cipriani F2, Demarteau N3, Gerzeli S1, Marocco A2, Bamfi F2, 1Bocconi University, Milano, Italy, 2GlaxoSmithKline Spa, Verona, Italy, 3GlaxoSmithKline Biologicals, Wavre, Belgium
pgA344EE8 COST-EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE
TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Millar DR1, Ducournau P2, McDonald A3, 1Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Western
Infirmary, Glasgow, UK
Mental Health II (Schizophrenia in Europe) Santorini 4-6
Moderator: Sotiria Papanicolaou BSc, MSc, MBA, Partner, PRMA consulting, Athens, Greece
pgA344 MH5 EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA Maurino J1, Montes JM2, Saiz Ruiz J3, Claret J4, Diez T1, 1AstraZeneca, Madrid, Spain, 2Hospital del Sureste, Arganda del Rey, Spain, 3Hospital Ramon y Cajal,
Madrid, Spain, 4Fundació Hospital de Día Nou Barris, Barcelona, Spain
pgA344 MH6 ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS FROM THE COMETA STUDY
Mantovani LG1, Ferrannini L2, Mencacci C3, Pirfo E4, Bernareggi M5, Giustra MG5, Berto P6, Sturkenboom MC7, Scalone L8, 1University of Naples, Federico II,
Naples, Italy, 2Mental Health Department ASL 3, Genova, Italy, 3Mental Health Department, Milan, Italy, 4Mental Health Department G. Maccacaro, Torino,
Italy, 5Janssen-Cilag SpA, Cologno Monzese, Milan, Italy, 6PBE consulting, Verona, Italy, 7Erasmus University Medical Center, Soest, The Netherlands, 8Centre of
Pharmacoeconomics, Milan, Italy
pgA345 MH7 PATIENT-REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY: A MIXED METHODS APPROACH TO
CAPTURING THE PATIENT’S PERSPECTIVE
Kinter ET1, Rudolph I2, Schmeding A2, Bridges JF1, 1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Janssen-Cilag GmbH,
Neuss, Germany
pgA345 MH8 DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE: REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT
ADHERENCE REGISTRY (E-STAR)
Geitona M1, Kousoulakou C2, Ollandezos M3, Papanicolaou S4, Athanasakis K3, Tsiantou V3, Kyriopoulos J3, 1University of Thessaly, Volos, Greece, 2Foundation for
Economic and Industrial Research, Athens, Greece, 3National School of Public Health, Athens, Greece, 4Janssen-Cilag Pharmaceutical SACI, Athens, Attika, Greece
Modelling in Economic Evaluation Terpsichore ABC
Moderator: Magdalini Hatzikou, BA, MBA, Pricing, Reimbursement and Health Outcome Manager, Novartis Hellas and Research Associate, Economics Department, University
of Thessaly and Treasurer of the Hellenic Society for Pharmacoeconomics – ISPOR Greece Chapter, Athens, Greece
pgA346 MO1 ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS
Al MJ1, Welte R2, 1Erasmus MC, Rotterdam, The Netherlands, 2GlaxoSmithKline, Munich, Germany
pgA346 MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES: DETERMINISTIC AND PROBABILISTIC APPROACHES
Taylor DC1, Kruzikas D2, Pawar V3, Gilmore K1, Naik S1, Weinstein MC4, 1i3 Innovus, Medford, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA, 3Innovus
Research, Inc, Medford, MA, USA, 4i3 Innovus Research Inc., Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
pgA346 MO3 COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL
Oppe M, Al MJ, Rutten-van Mölken MP, Erasmus MC, Rotterdam, The Netherlands pgA347 MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY
BREAST CANCER IN THE Netherlands
Joore MA1, Tjan Heijnen V1, Severens JL1, Novák A2, Oron U3, Pompen M3, Essers BA1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2AnovákServices, Apeldoorn, The Netherlands, 3Roche Netherland BV, Woerden, The Netherlands
22
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Sunday, 9 November / Monday, 10 november
Quality of Life/Preference-based Measures II: Application of Measures Galaxy
Moderator: Paul Kind, Professor, University of York, Outcomes Research Group, York, UK
pgA347 QL5 COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS
Maes IH1, Joore MA1, Cima RF2, Vlaeyen JW2, Anteunis LJ1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The
Netherlands
pgA347 QL6 ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS
Narvilkar P, Mahajan A, Dimri S, Kumar R, Sehgal M, Heron Health Private Ltd, Chandigarh, India
pgA348 QL7 INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES
McKenna SP1, Twiss J1, Meads DM1, Revicki D2, Pokrzywinski R3, Gale R4, 1Galen Research, Manchester, UK, 2United BioSource Corporation, Bethesda, MD,
USA, 3United Biosource Corporation, Pittsburgh, PA, USA, 4Novartis AG, Horsham, UK
pgA348 QL8 COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD
Lai JS1, Cook K2, Stone A3, Beaumont J4, Cella D4, 1Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, USA, 2University of Washington,
Houston, TX, USA, 3Stony Brook University, Stony Brook, NY, USA, 4Evanston Northwestern Healthcare, Evanston, IL, USA
17:30-18:30
RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION I Hesperides
(See page 34-85 for Research Poster Presentations)
17:30-19:30EXHIBITORS’ OPEN HOUSE RECEPTION Convention Level
(See page 34-85 for Research Poster Presentations) Reception sponsored by Evidence Research Unit
17:45-19:15
ISPOR EASTERN EUROPEAN CHAPTERS FORUM Santorini 1-3
Real World Data for Pharmacoeconomic Evaluation in Central and Eastern European Countries AND Current Issues in Vaccination
(Croatia) - Epidemiological and Pharmacoeconomical Approach
Presented by: The ISPOR Slovakia, Hungary, Czech Republic, Croatia and Poland Local Chapters
The forum will focus on optimal use of real world data and transferability of economic evaluations, including methods, clinical and economic results. The
session is intended to facilitate the international collaboration among professionals in countries with similar backgrounds and geographic locations. In addition,
ISPOR-Croatia will address the vaccination issues currently facing their country.
Moderators: Zoltán Kaló MD, BE, MSc, PhD, Associate Professor & Programme Director, Health Economics Research Centre, Eötvös Loránd University, Budapest,
Hungary; Tomáš Doležal MD, PhD, MuDr, Professor, Department of Pharmacology, 3rd Medical Faculty, Charles University, Prague,Czech Republic
Speakers: Ljubica Besker-Ivasovic MD, PhD, Executive Master Sanitary Economy and Management, Capoclinica, Clinica S. Anna, Bellinzona, Switzerland;
Tomas Tesar PharmD, PhD, MBA, Faculty of Pharmacy, Comenius University Bratislava, Slovakia; Tomasz Hermanowski PhD, Professor of Warsaw Technical
University Business School, Warsaw, Poland; Zoltán Kaló MD, BE, MSc, PhD, Associate Professor & Programme Director, Health Economics Research Centre,
Eötvös Loránd University, Budapest, Hungary; Tomáš Doležal MD, PhD, MuDr, Professor, Department of Pharmacology, 3rd Medical Faculty, Charles University,
Prague,Czech Republic
MONDAY, 10 NOVEMBER
7:00-8:00EDUCATIONAL SYMPOSIUM (SPONSORED BY UBC) Terpsichore ABC
Risk-sharing Agreements: All Pain or Some Gain?
(See page 97 for Symposia descriptions)
8:00-8:15EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
(See page 34-85 for Research Poster Presentations)
8:15-9:45
SECOND PLENARY SESSION Terpsichore ABC
(See page 103 for biographical information)
Improving Equity of Access to Pharmaceutical Therapies in Europe, Middle East & Africa
Despite improvements in indicators of health over the past few decades, health care inequities, specifically
access to drugs, between and within countries in Eastern Europe, Middle East, and Africa have persisted. This
plenary session will address equity of access to drugs in these regions.
Moderator: John Yfantopoulos PhD, Professor of Health Economics, University of Athens and President of the
National Centre for Social Research, Athens, Greece
J. Yfantopoulos
P. Vorobiev
O. Borisenko
M. Rawashdeh
I. Al-Abbadi
T. Stander
Equities of access to pharmaceuticals IN RUSSIA
Speakers: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow
Medical Academy, Moscow, Russia and President, ISPOR Russia Chapter; Oleg Borisenko MD, Executive
Director, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
Equi
ties of access to pharmaceuticals IN the MIDDLE EAST
Speakers: Mohammad Rawashdeh MSc, MRCP, FRCP, General Director, Jordan Food and Drug Administration,
Amman, Jordan; Ibrahim Al-Abbadi PhD, MBA, Assistant Professor, University of Jordan, Faculty of Pharmacy,
Amman, Jordan and President, ISPOR Jordan Chapter
Equi
ties of access to pharmaceuticals IN AFRICA
Speaker: Tienie Stander MBChB, MBA, Honorary Professor, North West University, School of Pharmacy, Johannesburg, South Africa and President, ISPOR
South Africa Chapter
23
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Monday, 10 november
9:45-10:15
(See page 34-85 for Research Poster Presentations)
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
Coffee sponsored by Lionbridge Life Sciences / Cookies sponsored by RTI Health Solutions
10:15-11:15
ISSUE PANELS – SESSION I (See page 86-88 for Issue Panel descriptions)
ECONOMIC OUTCOMES RESEARCH ISSUES
IP1: DISCRETE EVENT SIMULATION OR MARKOV MODEL: WAR OF THE WORLDS OR EXPANDING THE GALAXY? Thalia 3-4
Moderator: Bengt Jönsson PhD, Professor of Health Economics, Stockholm School of Economics, Stockholm, Sweden
Panelist(s): J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President Health Economics, United BioSource Corporation, Lexington, MA, USA; Mark J. Sculpher PhD,
Professor, University of York, York, UK; Andrea Manca PhD, Research Fellow, University of York, York, UK
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES
IP2: PATIENT-REPORTED OUTCOME (PRO) AND UTILITY DATA IN MARKET ACCESS DECISION-MAKING Galaxy
Moderator: Anne Heyes MBA, Research Manager, Mapi Values, Cheshire, UK
Panelist(s): Jan J. Busschbach PhD, Senior Research Associate, Erasmus Medical Center, Rotterdam, The Netherlands; Chloë Brown PhD, Director, Mapi Values, Lyon,
France
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP3:ADVANCING METHODS IN PERSONALIZED MEDICINE FOR CLINICAL DECISION-MAKING Thalia 1-2
(Speakers at this panel were invited, see page 103 for biographical information)
Moderator: Uwe Siebert MD, MPH, MSc, ScD, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
Panelists: M.J. Finley Austin MD, Director, US External Science Policy, F. Hoffmann-La Roche Ltd., Basel, Switzerland; David L. Veenstra PharmD, PhD, Associate
Professor, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA; Adrian Towse MA, MPhil, Director, Office Health Economics,
London, UK
IP4: ISPOR GREECE CHAPTER PANEL: IS ECONOMIC EVALUATION IN THE GREEK HEALTH CARE CONTEXT A FEASIBLE TARGET OR AN INTANGIBLE DREAM? Santorini 1-3
Moderator: Mary Geitona PhD, Assistant Professor, University of Thessaly, Volos, Greece
Panelist(s): Sotiria Papanicolaou MSc, MBA, Health Economics Manager, Janssen-Cilag Pharmaceutical SACI, Athens, Greece; Vassilis Kontozamanis MSc, MBA,
President, National Organization for Medicines, Athens, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus, Piraeus, Greece IP5: WHAT IS THE ROLE OF HTA IN INTERNATIONAL DECISION-MAKING? Terpsichore AB
Moderator: Mark JC Nuijten MD, PhD, MBA, Physician and Health Economist, Erasmus University, Rotterdam, The Netherlands
Panelist(s): Wolfgang Greiner PhD, Professor for Health Economics and Health Care Management, University of Bielefeld, Bielefeld, North Rhine-West, Germany; Peter J.
Neumann ScD, Professor, Tufts-New England Medical Center, Boston, MA, USA; Gerry Oster PhD, Vice-President, PAI, Brookline, MA, USA
11:15-11:30
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
(See page 34-85 for Research Poster Presentations)
11:30-12:30
RESEARCH PODIUM PRESENTATIONS – SESSION III
(Page numbers refer to Podium Abstracts in Value in Health 11(6))
Health Care Decisions Using Outcomes Research Case Studies Terpsichore AB
Moderators: Peter L. Kolominsky-Rabas MD, PhD, MBA, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWIG), Cologne, Germany;
Gottfried Endel MD, Main Association of Austrian Social Security Institutions, Vienna, Austria
pgA348 CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND
Zagorska A1, Krol Z1, Lipska I1, Falek A2, Sauvage P3, Barna A3, van Ormondt T4, 1Agency for Health Technology Assessment, Warszawa, Poland, 2Ministry of
Health, Warszawa, Poland, 3Ministry of Health, Paris, France, 4Law Online - EU expert, Leiden, The Netherlands
pgA349 CASE2DO TECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM,
AND IMPLICATIONS OF, ONTARIO’S EVIDENCE-BASED HTA PROCESS
Goeree RA, Ontario Health Technology Advisory Committee (OHTAC), Hamilton, ON, Canada
pgA349 CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND: AIMING AT VALUE-BASED PRICING
Hauksdottir R1, Björnsdottir I2, Kanavos P3, 1Icelandic Medicine Pricing and Reimbursement Committee, Reykjavik, Iceland, 2Bifröst University, Borgarnes,
Iceland, 3London School of Economics, London, UK
Cancer Economic Evaluations I Thalia 3-4
Moderator: Alan Brennan BSc, MSc, Director of Health Economics and Decision Science (HEDS), School of Health & Related Research (ScHARR), University of Sheffield,
Sheffield, UK
pgA350 CN1 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER
CENTER Miller LA, Lau J, Lal LS, Arbuckle R, University of Texas - MD Anderson Cancer Center, Houston, TX, USA
pgA350 CN2 ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT: AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE
METASTASIS IN THE UK
Gauthier A1, Gennari A2, Martin M3, Maetzel A4, 1i3 Innovus, Uxbridge, UK, 2National Cancer Research Institute, Genoa, Italy, 3i3 Innovus, Uxbridge, Middlesex,
UK, 4Amgen (Europe) GmbH / University of Toronto, Zug, Switzerland
pgA351 CN3 COST OF INITIAL PROSTATE CANCER TREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE: ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY
AND SPAIN
Benedict Á1, Black L2, Stokes ME3, 1United BioSource Corporation, Budapest, Hungary, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3United BioSource
Corporation, Dorval, QC, Canada
24
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Monday, 10 november
pgA351 CN4 YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUE TO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A
RISK FACTOR FOR CARCINOGENESIS—UNITED STATES 2003
Ekwueme DU1, Chesson HW1, Zhang KB2, Balamurugan A3, 1U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Macro International Inc,
Bethesda, MD, USA, 3Arkansas Department of Health, Little Rock, AR, USA
Infectious Disease Economic Evaluations Santorini 1-3
Moderator: Nikos Kotsopoulos, Health Economist, GlaxoSmithKline, Malandri, Greece
pgA351 IN1 COST-EFFECTIVENESS ANALYSIS OF REYATAZ® VERSUS KALETRA® IN THE TREATMENT OF NAÏVE HIV PATIENTS IN ITALY
Thuresson PO1, Heeg B1, Neubauer AS2, Intorcia M3, Van Hout BA1, 1Pharmerit BV, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Munich, Germany,
3
Bristol-Myers Squibb, Rome, Italy
pgA352 IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM
Lescrauwaet B1, Nevens F2, Zammit D1, Yuan Y3, Hay JW4, 1Bristol-Myers Squibb, Braine l’Alleud, Belgium, 2UZ Gasthuisberg KULeuven, Leuven, Belgium,
3
Bristol-Myers Squibb, Princeton, NJ, USA, 4University of Southern California, Los Angeles, CA, USA
pgA352 IN3 PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY
Kanbur B1, Azap A2, Arat M2, Sarioz F1, Tatar F1, 1Janssen-Cilag, Istanbul, Turkey, 2Ankara University, Ankara, Turkey
pgA352 PIN44 IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM: 48-WEEK FINDINGS FROM POOLED DUET TRIALS Martin SC1, Spaepen E2, Corbett CJ3, De Smedt G3, 1Johnson & Johnson Pharmaceutical Services, LLC, Mechelen, Belgium, 2SBD Analytics, Bekkevoort,
Belgium, 3Tibotec-Virco, Mechelen, Belgium
Muscular-Skeletal Disease Evaluations Thalia 1-2
Moderator: Mark J. Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
pgA353 MS1 PREVALENCE OF FIBROMYALGIA IN EUROPE - A TIP OF THE ICEBERG. RESULTS FROM A LARGE-SCALE SURVEY
Le Lay K1, Branco J2, Bannwarth B3, Matucci Cerinic M4, Blotman F5, Spaeth M6, Carbonell JA7, Failde I8, Saraiva F9, Nacci F4, Thomas E5, Boussetta S1, Taieb
C1, 1Pierre Fabre, Boulogne, France, 2CHLO, EPE/Hospital Egas Moniz, Lisboa, Portugal, 3Université V. Segalen, Bordeaux, France, 4Univ. Firenze, Florence, Italy,
5
Lapeyronie Hospital, Montpellier, France, 6Unit Rheumatology, Munich, Germany, 7Hospital de la Esperanz, Barcelona, Spain, 8Universidad de Cadiz, Cadix,
Spain, 9Hospital Santa Maria, EPE, Lisboa, Portugal
pgA353 MS2 LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES
Nadjar A1, Le Gal M1, Mainguy Y2, Le Lay K3, Taieb C3, 1MAPI Research Institute, Lyon, France, 2Pierre Fabre Laboratories, Labège, France, 3Pierre Fabre,
Boulogne, France
pgA353 MS3 POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UK
Hauber AB1, McCrink L2, Beard S2, Garcia-Cebrian A3, Maas G4, Das Gupta R5, Le TK6, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health
Solutions, Manchester, UK, 3Eli Lilly and Company Limited, Basingstoke, UK, 4Boehringer Ingelheim GmbH, Ingelheim, Germany, 5Boehringer Ingelheim,
Bracknell, Berkshire, UK, 6Eli Lilly and Company, Indianapolis, IN, USA
pgA354 MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE
STUDY
Braun J1, Inman RD2, van der Heijde D3, Mack M4, Parasuraman S5, Buchanan J5, Hsu B4, Beutler A4, Han C5, Deodhar A6, 1Rheumazentrum Ruhrgebiet, Herne,
Germany, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, The Netherlands, 4Centocor Research and Development, Inc,
Malvern, PA, USA, 5Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 6Oregon Health and Science University, Portland, OR, USA
Quality of Life/Preference-based Measures III: Novel Instruments Galaxy
Moderator: Louise Longworth PhD, Senior Research Fellow, School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK
pgA354 QL9 DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI)
Tiplady B1, Carrington R2, Battersby C3, Wilson K4, Cummings G5, Lyle D5, Ralston S4, 1PRO Consulting, London, UK, 2AstraZeneca R & D Charnwood,
Loughborough, UK, 3AstraZeneca R & D Alderley Park, Macclesfield, UK, 4University of Edinburgh, Edinburgh, UK, 5Wellcome Trust Clinical Research Facility,
Edinburgh, UK
pgA354 QL10 DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE
Cuervo J1, Rebollo P1, Zardain PC1, Tranche S2, Barreda MJ2, Prieto MA2, Sánchez-Baragaño M2, 1BAP Health Outcomes Research, Oviedo, Spain, 2SESPA,
Oviedo, Spain
pgA355 QL11 FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID
ARTHRITIS PATIENTS
Hazes M1, Purcaru O2, Coteur G3, Mease P4, 1Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands, 2UCB, Braine l’Alleud, Belgium,
3
UCB, Braine L’Alleud, Belgium, 4Seattle Rheumatology Associates, Seattle, WA, USA
pgA355 QL12 FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)
QUESTIONNAIRE
Chachuat A1, Koltowska-Haggstrom M2, Gilet H3, Auziere S4, Guillaume X4, Arnould B3, Viala M3, 1Pfizer, Paris, France, 2KIMS Medical Outcomes, Pfizer
Endocrine Care, Sollentuna, Sweden, 3Mapi Values, Lyon, France, 4TNS-Healthcare, Montrouge, France
12:00-13:00
ISPOR INSTITUTIONAL COUNCIL MEETING (BY INVITATION ONLY) Terpsichore C
12:30-14:00LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
(See page 34-85 for Research Poster Presentations)
Lunch sponsored by Abt Bio-Pharma Solutions
12:45-13:45EDUCATIONAL SYMPOSIUM (SPONSORED BY IMS HEALTH) Terpsichore AB
Finding Synergies between Pricing & Reimbursement and Health Economics and Outcomes Research
(See page 97 for Symposia descriptions) 25
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Monday, 10 november
14:00-15:00
RESEARCH PODIUM PRESENTATIONS – SESSION IV
(Page numbers refer to Podium Abstracts in Value in Health 11(6))
Arthritis Outcomes Measurement Thalia 4
Moderator: Panagiotis Mavros PhD, Director, Outcomes Research, Merck & Co., Inc., Whitehouse Station, NJ, USA
pgA355 AR1 PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Braakman-Jansen LM1, Taal E1, Kuper I2, van de Laar MA2, 1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente Hospital, Enschede,
The Netherlands
pgA356 AR2 A COST-EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM
THE STURE REGISTRY
Lekander I1, Borgström F1, Carli C2, Svarvar P3, Ljung T3, van Vollenhoven R2, 1i3 Innovus, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden,
3
Schering-Plough AB, Stockholm, Sweden
pgA356 AR3 TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE
QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Adams R1, Ng CT2, Gibbs A3, Bresnihan B4, Veale D5, Tilson L1, FitzGerald O5, Barry M1, 1National Centre for Pharmacoeconomics, Dublin, Ireland, 2St.Vincents
University, Dublin, Ireland, 3Galway Clinic, Galway, Ireland, 4St Vincents University Hospital, Dublin, Ireland, 5St.Vincents University Hospital, Dublin, Ireland
pgA356 AR4 MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Kim MM, Pahira J, Doshi JA, University of Pennsylvania, Philadelphia, PA, USA
Cancer Economic Evaluations II Thalia 1-2
Moderator: Chris L. Pashos PhD, Vice President and Executive Director, HERQuLES, Abt BioPharma Solutions, Inc., Lexington, MA, USA
pgA357 CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A
CISPLATIN-BASED TREATMENT REGIMEN IN THE UK
Gyldmark M1, Gatzemeier U2, Nicolson M3, Latimer N4, Walzer S5, 1F Hoffmann La Roche, Basel, Switzerland, 2Hospital Grosshansdorf, Grosshansdorf,
Germany, 3Royal Infirmary Aberdeen, Aberdeen, UK, 4Roche Products Ltd, Welwyn Garden City, UK, 5F. Hoffmann - La Roche Ltd, Basel, Switzerland
pgA357 CN6 COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING A TRANSMISSION
DYNAMIC MODEL
Usher C1, Tilson L1, Olsen J2, Rudbeck Jepsen M3, Walsh C4, Barry M1, 1National Centre for Pharmacoeconomics, Dublin, Ireland, 2University of Southern
Denmark, Odense, Denmark, 3Statens Serum Institut, Copenhagen, Denmark, 4Trinity College Dublin, Dublin, Ireland
pgA357 CN7 MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER: THE CASE OF PARTICLE THERAPY
Grutters JP1, Pijls-Johannesma M1, De Ruysscher D1, Dekker AL1, Peeters A1, Severens JL2, Lambin P1, Joore MA2, 1Maastro Clinic, Maastricht, The
Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands
pgA358 CN8 AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE
Nagy B1, Kutikova L2, Stastny M2, Vasile K3, Zsolnai Nagy I4, Mayer J5, 1Healthware Consulting Ltd, Budapest, Hungary, 2Bristol-Myers Squibb, Prague, Czech
Republic, 3Bristol-Myers Squibb, Bucharest, Romania, 4Bristol-Myers Squibb, Budapest, Hungary, 5University Hospital Brno, Brno, Czech Republic
Diabetes Economic Impact Santorini 1-3
Moderator: Mary Geitona PhD, Assistant Professor in Health Economics, Department of Economics, University of Thessaly, Volos, Greece
pgA358 DB1 ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UK: A COST-EFFECTIVENESS
ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS
Smith HT1, Valentine WJ2, Boye KS3, Kalsekar A3, Pratoomsoot C2, 1Eli Lilly and Company, Surrey, UK, 2IMS Health, Basel, Switzerland, 3Eli Lilly and Company,
Indianapolis, IN, USA
pgA507 PDB36 COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES
MELLITUS (T2DM) PATIENTS IN THE USA
Minshall ME1, Swan T2, Slusarek B2, Ikramuddin S2, 1IMS Health, Noblesville, IN, USA, 2University of Minnesota, Minneapolis, MN, USA
pgA359 DB3 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REAL WORLD CONDITIONS IN
GERMANY: LIVE-SPP STUDY
Schöffski O1, Dippel FW2, Breitscheidel L3, Benter U3, Müller M4, Volk M4, 1Universität Erlangen-Nürnberg, Nürnberg, Germany, 2Sanofi-Aventis Germany GmbH,
Berlin, Germany, 3Kendle GmbH, Munich, Germany, 4axaris software&systeme GmbH, Ulm, Germany
pgA359 DB4 COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES
Hammer M1, Lammert M2, Frier BM3, 1Novo Nordisk A/S, Bagsværd, Denmark, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 3Royal Infirmary of
Edinburgh, Edinburgh, UK
Health Policy Issues and Implications Terpsichore AB
Moderator: Angeliki Angeli MPharm, MSc, Institutional Relations and Communication Director, Sanofi-Aventis Greece, Athens, Greece
pgA359 HP1 ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007
Seoane-Vazquez E1, Rodriguez-Monguio R2, 1The Ohio State University, Columbus, OH, USA, 2University of Massachusetts, Amherst, MA, USA
pgA360 HP2 NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE: FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST
Hatzikou M1, Alexopoulos E2, Chatzistamatiou Z3, Geitona M, 1University of Thessaly, Volos, Greece, 2University of Patras, RIO, Greece, 3Alexandra General
Hospital, Neo Faliro, Greece
pgA360 HP3 TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US
CLAIMS DATABASE
Guelfucci F1, François C2, Milea D2, Saragoussi D2, Toumi M3, 1Altipharm, Paris, France, 2Lundbeck SAS, Paris, France, 3Université Lyon I, Villeurbanne, France
pgA360 HP4 THE IMPACT OF A MEDICAID EXPANSION TO INCLUDE POPULATION WITH LOW INCOME ON THE PREVENTABLE HOSPITALIZATIONS
Shin H, Kim S, Health Insurance Review & Assessment Service, Seoul, South Korea
26
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Monday, 10 november
Outcomes Research Issues Galaxy
Moderator: Sean Sullivan PhD, RPh, Professor of Pharmacy and Public Health and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program,
Seattle, WA, USA
pgA361 OR1EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS
Conlon J1, Xu X2, Zlateva G3, Knight T2, 1Covance, Inc, Princeton, NJ, USA, 2Covance Market Access Services Inc, Gaithersburg, MD, USA, 3Pfizer, Inc, New York,
NY, USA
pgA361 OR2
INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS
ter Borg J1, Al MJ2, 1IMS Health, Den Haag, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands
pgA361 OR3
ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS: DEVELOPMENT AND APPLICATION OF A TOOLKIT
De Wit GA, Tariq L, Wong A, Polder JJ, van Baal P, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
pgA566 PMC23 WHAT IS POLITICIAN’S AND CLINICIAN’S WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENT VALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES
Soini EJ1, Kukkonen J2, Myllykangas M3, Ryynänen OP4, 1ESiOR Oy, Department of Health Policy and Management, and Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 2Kuntohovi Spa, Joensuu, Finland, 3University of Kuopio, Kuopio, Finland, 4University of Kuopio and Kuopio University Hospital,
Kuopio, Finland
15:00-15:15
(See page 34-85 for Research Poster Presentations)
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
Coffee sponsored by Lionbridge Life Sciences / Cookies sponsored by RTI Health Solutions
15:15-16:15
WORKSHOPS – SESSION I (See page 89-96 for Workshop descriptions)
CLINICAL OUTCOMES RESEARCH
W1:TIME-DEPENDENT SURVIVAL MODELS IN HEALTH OUTCOMES STUDIES: POTENTIAL PITFALLS AND HOW TO AVOID THEM Thalia 3
Discussion Leaders: Victor A. Kiri MSc, PhD, CStat, Professor & Director of Pharmacoepidemiology, PAREXEL International, Uxbridge, London, UK; Maurille Feudjo-Tepie
MSc, PhD, Medical Statistician, GlaxoSmithKline R&D, London, UK; David Todem MSPH, PhD, Assistant Professor, Michigan State University, East Lansing, MI, USA;
Gilbert MacKenzie MSc, PhD, CStat, Professor & Director of Centre of Biostatistics, University of Limerick, Limerick, Ireland
ECONOMIC OUTCOMES RESEARCH
W2: CHALLENGES OF DEVELOPING ECONOMIC EVALUATIONS FOR ORPHAN DRUGS Santorini 1-3
Discussion Leaders: Michael F. Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Aline Gauthier MSc, Lead
Analyst, i3 Innovus Research Inc, Uxbridge, UK; Tsveta Milanova MSc, Health Outcomes Manager, GlaxoSmithKline R&D, Greenford, UK
W3:THRESHOLD PRICING ANALYSIS: AN ECONOMISTS’ CONTRIBUTION TO PHARMACEUTICAL PRICING Terpsichore AB
Discussion Leaders: Deirdre Mladsi BA, Global Head, RTI Health Solutions, Research Triangle Park, NC, USA; Hediyyih Narula BS, Health Outcomes Scientist, RTI Health
Solutions, Research Triangle Park, NC, USA; W. Neil Palmer BA, Vice President, RTI Health Solutions, Ottawa, ON, Canada; David W. Miller PhD, President, Miller Pharma
Consulting, London, UK
PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH
W4: HEALTH-BELIEFS – WHAT ROLE DO THEY PLAY IN OUTCOMES RESEARCH? Thalia 1-2
Discussion Leaders: Matthew D. Reaney MSc, PGDip, Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Aysha Malik-Aslam BSc,
Scientist, AHP Research, Uxbridge, UK; Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, UK; Jane Speight
MSc, PhD, Director, AHP Research, Uxbridge, UK
W5: PATIENT-REPORTED OUTCOME - VALUE BEYOND THE LABEL CLAIM Galaxy
Discussion Leaders: Ari Gnanasakthy MSc, Director, Novartis Pharmaceuticals, East Hanover, NJ, USA; Lynda C. Doward MRes, Associate Director of Research, Galen
Research, Manchester, UK; Mary G. Baker MBE, President, European Federation of Neurological Associations, Firenze, Italy USE OF REAL WORLD DATA
W6:THE ROLE OF OBSERVATIONAL STUDIES IN DEMONSTRATING PRODUCT VALUE AND BENCHMARKING PRODUCT SAFETY Thalia 4
Discussion Leaders: Thomas Goss PharmD, Vice President, Boston Healthcare Associates, Washington, DC, USA; Gergana Zlateva PhD, Director, Global Outcomes
Research, Pfizer Inc, New York, NY, USA HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W7: WHY IS IT SO DIFFICULT TO IMPLEMENT COST CONTAINMENT REFORMS AND MAKE VALUE-BASED DECISIONS IN THE GREEK HEALTH CARE SYSTEM? Terpsichore C
Discussion Leaders: Antonis Karokis MSc, Government and Public Affairs Manager, Wyeth, Athens, Greece; John Yfantopoulos PhD, Professor of Health Economics,
University of Athens and President of the National Centre for Social Research, Athens, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus,
Piraeus, Greece; Kyriakos Souliotis PhD, Lecturer, University of Peloponnese, Maroussi, Greece
16:15-16:30 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Convention Level
(See page 34-85 for Research Poster Presentations)
16:30-17:30
WORKSHOPS – SESSION II (See page 89-96 for Workshop descriptions)
CLINICAL OUTCOMES RESEARCH
W8: OPTIMIZING POSTMARKETING VACCINE EFFECTIVENESS STUDIES Thalia 3
Discussion Leaders: Jeffrey Stoddard MD, Vice President, Medical and Scientific Affairs, Risk Management and Post Marketing Programs, Covance Periapproval Services,
Conshohocken, PA, USA; James C. King Jr MD, Professor of Pediatrics, Chief, Division of General Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA
ECONOMIC OUTCOMES RESEARCH
W9:TRIVIAL OR IMPORTANT? THE NEEDS, BENEFITS AND IMPLICATIONS OF VARIABILITY Santorini 1-2
Discussion Leaders: Denis Getsios BA, Graduate Student, College of Pharmacy, Dalhousie University, Halifax, NS, Canada; Kristen Migliaccio-Walle BS, Director &
Research Scientist, Health Economics, United BioSource Corporation, Concord, MA, USA; Duygu Bozkaya MSc, MBA, Researcher, United BioSource Corporation,
Concord, MA, USA
27
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Monday, 10 november / Tuesday, 11 november
W10: GUIDELINES FOR APPROPRIATE SELECTION OF MODELING APPROACH IN PHARMACOECONOMIC EVALUATION Terpsichore AB
Discussion Leaders: David Thompson PhD, Vice President, i3 Innovus Research, Inc, Medford, MA, USA; Andreas Maetzel MD, MSc, PhD, Associate Director/
Assistant Professor, Amgen (Europe) GmbH/University of Toronto, Health Economics & Reimbursement, Zug, Switzerland; Monique Martin MSc, MBA, Vice-President UK
Operations, i3 Innovus Research Inc, Uxbridge, UK; Peter Lindgren PhD, Director, i3 Innovus Research Inc, Stockholm, Sweden
PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH
W11: MISSING DATA – IMPLICATIONS FOR OUTCOMES RESEARCH AND STRATEGIES TO MAXIMISE DATA INTEGRITY Thalia 1-2
Discussion Leaders: Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, Scotland, UK; Matthew D. Reaney MSc, PGDip,
Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Jane Speight MSc, PhD, Director, AHP Research, Uxbridge, UK
W12: RAISING THE VALUE OF DIRECT UTILITY MEASUREMENT APPROACHES FOR PHARMACEUTICAL MARKET ACCESS DECISION-MAKING: IS IT POSSIBLE? Galaxy
Discussion Leaders: Keith H. Tolley MPhil, Director, Tolley Health Economics Limited, Buxton, Derbyshire, UK; Jan J. Busschbach PhD, Senior Research Associate,
Erasmus Medical Center, Rotterdam, The Netherlands; Jane Scott PhD, Research Director, Mapi Values, Macclesfield, Cheshire, UK
USE OF REAL WORLD DATA
W13: HEALTH TECHNOLOGY ASSESSMENT RESEARCH IN EUROPE: GATHERING THE DATA Thalia 4
Discussion Leaders: Carl V. Asche PhD, Research Associate Professor, University of Utah College of Pharmacy, Salt Lake City, UT, USA; William C. Maier MPH, PhD,
Scientific Advisor, MAPI Research Trust, Lyon, France
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W14:DECISION CRITERIA BY HEALTH INSURERS: WHAT DO THEY WANT FROM US? Terpsichore C
Discussion Leaders: Eline Kogels MSc, Consultant, Kogels Consultancy Network, Amsterdam, The Netherlands; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars
Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
17:30-18:30
(See page 34-85 for Research Poster Presentations)
RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION II Hesperides
17:30-18:30
ISPOR’S RUSSIA CHAPTER MEETING (by invitation only) Santorini 1-3
17:30-19:30EXHIBITORS’ WINE & CHEESE RECEPTION Convention Level
(See page 34-85 for Research Poster Presentations)
Reception sponsored by TransPerfect Translations 19:30-23:00
ISPOR SOCIAL EVENT (REGISTRATION REQUIRED)
Join us at the Yacht Club of Greece for traditional Greek cuisine dining, while enjoying breathtaking views of Athens.
TUESDAY, 11 NOVEMBER
7:00-8:00EDUCATIONAL SYMPOSIUM (SPONSORED BY NHS INNOVATIONS LONDON) Terpsichore AB
The Do’s and Don’ts with Agencies Like NICE and IQWiG Agencies: Generating the Right Health Economic Data
for Successful Appraisals
(See page 97 for Symposia descriptions)
8:00-8:30EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Convention Level
(See page 34-85 for Research Poster Presentations)
8:30-9:30
ISPOR FORUMS
Health Care Decision-Makers around the World: A Global Road Map, Framework of the Decision-Making Process and Application of
HTA Methods Principles Terpsichore AB
Presented by: The ISPOR Health Technology Assessment and Evidence-Based Decisions SIG
The forum will provide clarification of the organizations and processes involved in national health care decision-making through a schematic framework and
discuss country specific health care delivery systems and reimbursements processes using The ISPOR Global Health Care Systems Road Map. The forum will
conclude with a description of the current application of recently published key principles for HTA methods using data from a global survey of HTA organizations
and reimbursement bodies.
Moderator: Kevin Mayo PhD, Co-Chair, ISPOR Global HTA Used in Health Care Reimbursement Working Group and Vice President Market Access Solutions,
Bridgehead International Consulting, Denville, NJ, USA
Speakers: Karl Matuszewski MS, PharmD, Co-Chair, ISPOR HTA of Emerging New Technologies Working Group and Senior Director, Clinical Knowledge
Service Clinical Practice Advancement Center, University HealthSystem Consortium, Oak Brook, IL, USA; Angeliki Angeli MSc, Institutional Relations and
Communication Director, Sanofi Aventis, Athens, Greece; Marcin Czech PhD, MD, MBA, Past President, ISPOR Poland Local Chapter & Adjunct, Dept of Pharmacoeconomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland; Bonnie Handke RN, MBA, Co-Chair, ISPOR HTA & Good Research Practices for
Reimbursement Decisions Working Group and Director, Health Policy and Planning, Medtronic, Inc, Neuromodulation, Minneapolis, MN, USA
Design and Analysis of Non-Randomized Studies of Treatment Effects Using Secondary Databases Galaxy
Presented by: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force
The Task Force will present major issues of design, analysis, and interpretation of findings from therapeutic effectiveness studies using secondary databases.
Methods to handle longitudinal data analysis with time-varying measures including time-dependent confounding will be addressed during this forum.
28
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Tuesday, 11 november
Speakers: Marc Berger MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; William Crown PhD, President, i3Innovus,
Waltham, MA, USA; Bradley Martin PhD, Associate Professor, College of Pharmacy, University of Arkansas, Little Rock, AK, USA; Uwe Seibert MD, MPH,
MSc, ScD, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University of Health Sciences,
Medical Informatics and Technology, Hall i.T., Austria
Patient Registry Design, Operations, Data & Taxonomy Santorini 1-2
Presented by: The ISPOR Patient Registry SIG
This session will focus on the practical design and operational considerations in developing registries, the use of patient registry information in evaluating
patient-reported outcomes, and the ISPOR Taxonomy of Patient Registries. Research to date on the classification, characteristics, design, implementation, and
analysis of registries as well as registry reporting & publishing will be presented.
Moderator: Elizabeth Molsen RN, Director, ISPOR Initiatives, ISPOR, Lawrenceville, NJ, USA
Speakers: Chris L. Pashos PhD, Chair, Patient Registry Classification, Strategy & Design Working Group and Vice President and Executive Director, HERQuLES.
Abt Associates; Leanne R. Larson MHA, Chair, Patient Registry Design & Operations Working Group and Vice President, Registry Consulting, Ovation Research
Group / ICON Clinical Research; Carl Asche PhD, MBA, MS, Associate Professor, University of Utah, Salt Lake City, UT, USA
Patient-Reported Outcomes Good Research Practices Thalia 1-2
Presented by: The ISPOR Patient-Reported Outcomes SIG
Health technology assessors and health care decision-makers use PRO studies to assess product efficacy and effectiveness. Concurrent with the increased
use and significance of PROs in clinical trials is a steady growth in electronic data capture (EDC) and the need to translate and adapt PRO instruments for use
outside the US and Europe. Good research practices in PRO development, modification, mode of administration and translational & linguistic validation are
important for improving the value of this information to decision-makers. This session will present the recommendations of the ISPOR PRO Good Research
Practices Task Forces.
Moderator: Donald Patrick PhD, MSPH, ISPOR PRO Task Force Developer & Member and Professor, University of Washington, Seattle, WA, USA
Speakers: Nancy Kline Leidy PhD, ISPOR PRO Existing Instruments & Their Modifications Task Force Member & Senior Vice President of Scientific Affairs,
United BioSource Corporation, Bethesda, MD, USA; Keith Wenzel BS, ISPOR ePRO Task Force Member & Product Director, ePRO, Perceptive Informatics, Inc.,
Boston, MA, USA; Diane Wild MSc, Chair, ISPOR PRO Translation & Linguistic Validation Task Force and Director, Oxford Outcomes, Oxford, UK
Equity and Access to Pharmaceutical Therapies in Russia (Presented in Russian with English handouts and slides) Terpsichore C
Presented by: The ISPOR-Russia Chapter
The ISPOR-Russia chapter will present information on access and equity to medical care challenges facing the Russian population. The forum will cover
problems with access to therapies, medicines and general health care that currently exist in Russia. The discussion will extend to possible solutions, role of
patients, and professional organizations in influencing and monitoring the situation and collaborating with the Russian government to improve conditions.
Moderator: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President
ISPOR Russia Chapter; Speakers: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow,
Russia and President ISPOR Russia Chapter; Oleg Borisenko MD, Executive Director, Russian Society for Pharmacoeconomics and Outcomes Research,
Moscow, Russia
How Do Local Financing Arrangements Impact the Availability of and Access to Medical Devices in Europe? A Multi-Country
Perspective Thalia 3-4
Organized by: The ISPOR Europe Medical Device & Diagnostics Council
National regulatory and financing mechanisms have a significant impact on the development of medical device and diagnostics. A greater understanding of how
different financing systems operate in the context of the medical device sector to develop and support policies that facilitate efficient, high-quality, innovative,
and sustainable health care will be discussed.
Moderator: Michael F. Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Speakers: Michael Baumler PhD, Research Fellow, Department for Health Care Management, Berlin University of Technology, Berlin, Germany; Corinna
Sorenson MPH, MHSA, Research Officer, LSE Health, London School of Economics, London, UK; Giulia Capellaro MSc, Research Fellow, Centre for Research
on Healthcare and Social Management, Bocconi University, Milan, Italy
9:30-10:00
(See page 34-85 for Research Poster Presentations)
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Convention Level
Cookies sponsored by RTI Health Solutions
10:00-11:00
ISSUE PANELS – SESSION II (See page 86-88 for Issue Panel descriptions)
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES
IP6: PUBLIC-PRIVATE PARTNERSHIPS IN PRO INSTRUMENT DEVELOPMENT: AN IDEA WHOSE TIME HAS COME? Santorini 1-3
Moderator: Nancy Kline Leidy PhD, Senior Vice President Scientific Affairs, United BioSource Corporation, Bethesda, MD, USA
Panelist(s): Laurie B. Burke RPh, MPH, Director, FDA/CDER/OND-IO, Silver Spring, MD, USA; Asha Hareendran PhD, Senior Director, Global Outcomes Research, Pfizer,
Ltd, UK & Chair, COPD PRO Working Group of the EFPIA Innovative Medicines Initiative (IMI) Respiratory calls, Sandwich, UK; Ingela Wiklund PhD, Director, Global Health
Outcomes, GlaxoSmithKline, UK & Co-Chair, COPD PRO Working Group of the EFPIA Innovative Medicines Initiative (IMI) Respiratory calls, Uxbridge, Middlesex, UK
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP7: IS THE PURSUIT OF QALY MAXIMISATION A NOBLE CAUSE? Terpsichore AB
(Speakers at this panel were invited, see page 103 for biographical information)
Moderator: Adrian Towse MA, MPhil, Director, Office Health Economics, London, UK
Panelist(s): Mark J. Sculpher PhD, Professor, University of York, York, UK; Erik Nord PhD, Senior Researcher, Norwegian Institute of Public Health, Oslo, Norway; Georg
Marckmann MD, MPH, Professor, Department of Medical Ethics, University of Tübingen, Tübingen, Germany
29
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Tuesday, 11 november
IP8: FAST IS BEST! IS RAPID HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT MARKET ACCESS DECISION-MAKING A GOOD THING? Galaxy
Moderator: Jeanni Van Loon MSc, Development Director - Europe, Mapi Values, Houten, The Netherlands
Panelist(s): Keith H. Tolley MPhil, Director, Tolley Health Economics Limited, Buxton, Derbyshire, UK; Meindert Boysen MSc, Associate Director Single Technology
Appraisals, National Institute for Health and Clinical Excellence (NICE), Manchester, UK; Andrew Walker PhD, Senior Lecturer, University of Glasgow, Glasgow, UK
IP9: MARKET ACCESS OF MEDICAL DEVICES IN EUROPE: HAVE METHODOLOGICAL APPROACHES BECOME A HINDRANCE OR HELP? Thalia 1-2
Moderator: Stacey J. Ackerman MSE, PhD, Vice President, Covance Market Access Services Inc, San Diego, CA, USA
Panelist(s): Uwe Siebert MD, MPH, MS, ScD, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Arne Heissel PhD, Director, Reimbursement & Health Economics, Spinal & Biologics,
Medtronic International, Tolochenaz, Switzerland; Inger Natvig Norderhaug PhD, Research Director, Norwegian Knowledge Center for the Health Services, Oslo, Norway
IP10:FUTURE SCIENTIFIC AND POLICY CONSEQUENCES OF THE IQWIG APPROACH FOR EUROPE Thalia 3-4
Moderator: Mark JC Nuijten MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
Panelist(s): Christoph Vauth MSc, Head Health Technology Unit, Leibniz University Hannover, Hannover, Germany; John Hutton PhD, Professor of Health Economics,
University of York, York, UK
11:00-12:00
RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION III Hesperides
(See page 34-85 for Research Poster Presentations)
11:30-13:00LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWINGS – SESSION III Convention Level
(See page 34-85 for Research Poster Presentations)
11:45-12:45EDUCATIONAL SYMPOSIUM (SPONSORED BY i3 INNOVUS) Terpsichore AB
Personalized Medicine and Targeted Therapy - Who Will Pay for Advances in Cancer Care?
(See page 97 for Symposia descriptions)
12:00-13:00ISPOR Health technology assessment and evidence based decisions special interest group – informal meeting
Santorini 1-2
13:00-14:20THIRD PLENARY SESSION Terpsichore AB
(See page 103 for biographical information)
an We Agree on International Guidelines for Economic Evaluation of Health
C
Care Interventions?
Economic (pharmacoeconomic) evaluation is a tool used to assist decision-making in the
financing and management of health care interventions (drugs, medical devices, and diagnostics)
M. Weinstein
M. Drummond
J. Caro
U. Siebert
in the health care system or national or private health insurance programs in an individual
country. Economic (pharmacoeconomic) guidelines can be used as a standard for preparation
of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study
reports. Although there are many similarities between these guidelines from countries and/or technology assessment institutions, methods used to assess
technologies may differ. During this session, two methods for economic evaluations used in health care decisions (i.e. incremental cost per QALY and efficiency
frontier analysis), as well as the consequences for patient access to innovative health technologies using these methods, will be debated.
Moderator: Milton Weinstein PhD, Professor Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
IS THE ESTIMATION OF INCREMENTAL COST PER QALY THE ANSWER?
Speaker: Michael F. Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
IS EFFICIENCY FRONTIER APPROACH THE ANSWER?
Speaker: J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA
WHY CAN’T WE WORK TOGETHER?
Speaker: Uwe Siebert MPH, MSc, Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University
of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
14:20-14:30
ISPOR RESEARCH AWARDS Terpsichore AB
14:30-14:45
(See page 34-85 for Research Poster Presentations)
14:45-15:45
WORKSHOPS – SESSION III (See page 89-96 for Workshop descriptions)
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Convention Level
CLINICAL OUTCOMES RESEARCH
W15: MAXIMISING CLINICAL TRIAL PARTICIPATION – HOW IMPORTANT IS THE SOCIAL CONTEXT? Thalia 1
Discussion Leaders: Matthew D. Reaney MSc, PGDip, Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Jane Speight MSc, PhD, Director, AHP
Research, Uxbridge, UK; Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, UK
ECONOMIC OUTCOMES RESEARCH
W16: QUANTIFYING AND DISPLAYING UNCERTAINTY AROUND AN EFFICIENCY FRONTIER Galaxy
Discussion Leaders: Isao Kamae MD, DrPH, Professor, Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan; J. Jaime Caro MDCM,
FRCPC, FAC, Senior Vice President Health Economics, United BioSource Corporation, Lexington, MA, USA
W17: PRACTICAL ISSUES IN THE EXECUTION OF A BUDGET IMPACT ANALYSIS: A CASE STUDY Thalia 2
Discussion Leaders: Stefan Walzer MA, International Economic Strategy Manager, F. Hoffmann-La Roche Pharmaceuticals AG, PBSE - Economic Value Strategy, Basel,
Switzerland; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
30
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
program & schedule of events: Tuesday, 11 november
PATIENT-REPORTED/PREFERENCE-BASED RESEARCH
W18: A CHECKLIST FOR GOOD RESEARCH PRACTICES FOR THE APPLICATION OF CONJOINT ANALYSIS IN HEALTH – FINAL REPORT Thalia 3
Discussion Leaders: John FP Bridges PhD, Assistant Professor, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA; A. Brett Hauber PhD,
Senior Economist and Head, RTI Health Solutions, Research Triangle Park, NC, USA; Maarten J. Ijzerman PhD, Professor of Clinical Epidemiology & HTA, University of
Twente, Enschede, The Netherlands
W19:ADDRESSING CROSS-CULTURAL ISSUES WITH PATIENT-REPORTED OUTCOMES ASSESSMENTS TO STRENGTHEN EVIDENCE OBTAINED IN AN INTERNATIONAL
CONTEXT Thalia 4
Discussion Leaders: Antoine Regnault PhD, Associate Statistician, Mapi Values France, Lyon, France; Isabelle Mear MA, Managing Director, Mapi Research Institute,
Lyon, France; Shalaka Marfatia MS, MPH, Manager Global Outcomes Research, Pfizer Inc, New York, NY, USA; Patrick Mollon MD, ESSEC, MBA, Associate Director,
Pfizer Ltd, Sandwich, UK
W26:THE NEW CHILD-FRIENDLY EUROQOL VERSION: EQ-5D-Y Terpsichore C
Discussion Leaders: Wolfgang Greiner PhD, Professor for Health Economics and Health Care Management, University of Bielefeld, Faculty of Public Health, Bielefeld,
North Rhine-West, Germany; Luciana Scalone PharmD, DSc, Researcher, Centre of Pharmacoeconomics, University of Milan, Milan, Italy; Paul Kind, Professor, University
of York, Outcomes Research Group, York, UK; Frank T. De Charro PhD, Health Economist, Erasmus University Rotterdam, Centre for Health Policy and Law, Rotterdam,
The Netherlands
USE OF REAL WORLD DATA
W20: USE OF REAL WORLD DATA: CHALLENGES IN THE ANALYSIS OF PATIENT REGISTRY DATA Santorini 1-2
Discussion Leaders: Christopher M. Blanchette PhD, MS, MA, Associate Scientist and Director, Lovelace Respiratory Research Institute, Albuquerque, NM, USA; Shital
Kamble BPharm, MMS, MS, Doctoral Student- Research Assistant, The University of North Carolina at Charlotte, Charlotte, NC, USA; Alex Exuzides PhD, Director, ICON
Clinical Research, San Francisco, CA, USA; Carl J. Gibbons BSc, (Psych), Research Analyst, Schering-Plough, Welwyn Garden City, UK
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W21: VALUE BASED PRICING IN GERMANY – OLD WINE IN NEW BOTTLES? Terpsichore AB
Discussion Leaders: Olaf Pirk MD, PhD, Principal, IMS Health, Nuremberg, Germany; Frank-Ulrich Fricke PhD, MSc, Principal, IMS Health, Nuremberg, Germany;
Christian Krauth PhD, Head of Working Group Health Economy, Hannover Medical School, Epidemiology, Social Medicine and Health System Research, Hannover,
Germany
15:45-16:00
(See page 34-85 for Research Poster Presentations)
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Convention Level
Cookies sponsored by RTI Health Solutions
16:00-17:00
WORKSHOPS – SESSION IV (See page 89-96 for Workshop descriptions)
CLINICAL OUTCOMES RESEARCH
W22: STATISTICAL MEASURES OF TREATMENT EFFECT IN ONCOLOGY: WHAT ARE WE MISSING? Thalia 3
Discussion Leaders: Deirdre Mladsi BA, Global Head, RTI Health Solutions, Research Triangle Park, NC, USA; William D. Irish PhD, Global Head, Biometrics, RTI Health
Solutions, Research Triangle Park, NC, USA; Kati Copley-Merriman MBA, MS, Global Head, Regulatory and Health Outcomes Strategy, RTI Health Solutions, Ann Arbor,
MI, USA; Durgesh Bhandary, Health Economics & Outcomes Research, AstraZeneca, Wilmington, NC, USA
ECONOMIC OUTCOMES RESEARCH
W23:COLLABORATIVE MULTI-NATIONAL HEALTH ECONOMIC AND PRO DATA GATHERING: A CASE STUDY HIGHLIGHTING THE ATHENS STROKE REGISTRY Santorini 1-2
Discussion Leaders: Krista Payne MEd, Director & Research Scientist, United BioSource Corporation, Montreal, QC, Canada; Kostas Vemnos MD, Professor, University
of Athens School of Medicine, Alexandra Hospital, Athens, Greece; Liberty Fajutrao MD, MSc, Senior Health Economics and Outcome Research Scientist, AstraZeneca
R&D, Sodertalje, Sweden
W24: MODELING OF INFECTIOUS DISEASES AND THEIR TREATMENT FOR HEALTH-ECONOMIC ANALYSIS Thalia 2
Discussion Leaders: Mario Ouwens PhD, Research Consultant, Mapi Values, Houten, The Netherlands; Debby Vissers MSc, Senior Research Associate, Mapi Values,
Houten, The Netherlands; Thierry Van Effelterre PhD, Mathematical Modeller, GlaxoSmithKline Biologicals, Rixensart, Belgium
PATIENT-REPORTED/PREFERENCE-BASED RESEARCH
W25: DISCRETE CHOICE MODELING FOR THE QUANTIFICATION OF HEALTH STATES: THE CASE OF THE EQ-5D Terpsichore AB
Discussion Leaders: Paul Krabbe PhD, Senior Scientist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Luciana Scalone PharmD, DSc,
Researcher, Centre of Pharmacoeconomics, Milan, Italy; Mark Oppe MSc, Researcher, Erasmus Medical Center, Rotterdam, The Netherlands; Elly Stolk PhD, Senior
Research Associate, Erasmus Medical Center, Rotterdam, The Netherlands
USE OF REAL WORLD DATA
W27:NON-US DATA SOURCES FOR DISEASE AND HEALTH MANAGEMENT: WHAT IS THERE, HOW ARE THEY USED LOCALLY AND HOW TO USE THEM FOR OTHER
RESEARCH Thalia 1
Discussion Leaders: Oliver Mast MSc, Head of Global Reimbursement, Roche Diagnostics, Mannheim, Germany; Tomas Sechser MD, PhD, Researcher, The Diabetes
Centre, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W28: FOOD FOR THOUGHT: SHOULD REIMBURSEMENT CRITERIA FOR PHARMACEUTICALS ALSO BE APPLIED TO NUTRITIONALS? Galaxy
Discussion Leaders: Eline Kogels MSc, Consultant, Kogels Consultancy Network, Amsterdam, The Netherlands; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars
Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
31
32
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
RESEARCH POSTER
PRESENTATIONS
ISSUE PANELS
WORKSHOPS
SPONSORED SYMPOSIA
CONGRESS COMMITTEES
33
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
research poster presentations
research poster presentationS - SESSION i
< < < < < <
PIN
< < <
PCV
PIH
< < <
PIN
< < <
< < <
< < <
< < < < < <
< < <
< < <
< < <
PIN
PCV
< < < < < <
PCV
< < < < < <
< < <
< < <
PCV
PRS
PCV
< < <
< < <
PCV
< < <
PRS
< < <
Hesperides
< < < < < <
PRS
< < < < < <
To Hesperides
< < <
PCV
< < < < < < <
Hesperides Foyer
PHP
< < < < < <
PHP
< < < < < <
< < < < < <
PHP
< < < < <
< < < < <
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
PIN
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
pgA362 PHP1 PATIENTS’ PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES - AN ADAPTIVE CONJOINT ANALYSIS
(ACA) APPROACH
Linden K1, Halme ML2, 1Pfizer Oy, Helsinki, Finland, 2Helsinki School of Economics, Helsinki, Finland
pgA362 PHP2 CONSUMERS’ PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE
Tsiantou V1, Roubou I2, Pavi E1, Kyriopoulos J1, 1National School of Public Health, Athens, Greece, 2Novartis (Hellas) S.A.C.I, Athens, Greece
pgA363 PHP3 INNOVATIVE HEALTH TECHNOLOGIES IN THE “ANTI-AGING-MEDICINE” FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING
Storz P, Gothe H, Daroszewska A, Häussler B, IGES Institut GmbH, Berlin, Germany
pgA363 PHP4 PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER
Pezij JW1, Bredenhoff E1, Bridges J2, Vrenken R3, IJzerman MJ1, 1University of Twente, Enschede, The Netherlands, 2Johns Hopkins University, Baltimore, MD,
USA, 3Healthcenter “de Oosterpoort”, Enschede, The Netherlands
pgA363 PHP5 HEALTH LITERACY – AN ECONOMIC PERSPECTIVE: A SYSTEMATIC REVIEW
Eichler K, Wieser S, Brügger U, Zurich University of Applied Sciences, Winterthur, Switzerland
HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
pgA364 PHP6 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN: A POPULATION-BASED STUDY
Bouza C, Lopez T, Muñoz R, Carlos III Health Institute, Madrid, Spain
pgA364 PHP7 COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH OESOPHAGEAL CANCER TO NORMATIVE DRG REIMBURSEMENT
Varga S1, Bogár L1, Sebestyen A2, Kriszbacher I1, Vas G1, Boncz I1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs,
Hungary
pgA364 PHP8 ADVERSE DRUG REACTIONS IN GERMANY: COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS
Rottenkolber D1, Rottenkolber M2, Schmiedl S3, Szymanski J3, Hasford J2, 1Munich Center of Health Sciences, Munich, Germany, 2Ludwig-Maximilians-Universität, Munich, Germany, 3University of Witten/Herdecke, HELIOS Klinikum Wuppertal, Wuppertal, Germany
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
34
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
pgA365 PHP9 DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY
Nagy Z1, Molnár MP2, Sebestyen A3, Kriszbacher I4, Vas G4, Boncz I4, 1Health Insurance Supervisory Authority, Budapest, Hungary, 2National Health Insurance
Fund Administration (OEP), Budapest, Hungary, 3National Health Insurance Fund Administration, Pecs, Hungary, 4University of Pecs, Pecs, Hungary
pgA365 PHP10 PHARMACY AND HOSPITAL MARKET PERFORMANCE INDICATORS IN FINLAND 1995-2007
Jormanainen V, Kannisto H, Mäntyranta T, Centre for Pharmacotherapy Development, Helsinki, Finland
pgA366 PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP): ARE ADDED THERAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?
Verplanken P1, Arickx F1, Bormans V1, Soete E1, Annemans L2, Robays H3, Van Wilder P1, 1RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium,
2
University of Ghent, Brussels University, Ghent, Belgium, 3Ghent University, Grimbergen, Belgium pgA366 PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT: ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM
Arickx F, Pierlet M, Soete E, VanHaeren E, Verplanken P, Van Wilder P, RIZIV INAMI National Health Insurance Agency, Brussels, Belgium
pgA366 PHP14 THE COMPETITIVE ACQUISITION PROGRAM (CAP): WHERE IS IT AFTER TWO YEARS?
Pierce CA, The Resource Group, Richfield, OH, USA
pgA366 PHP15 DETERMINANTS OF PHARMACEUTICAL CONSUMPTION IN A GENERAL POPULATION
Pappa E1, Kontodimopoulos N1, Papadopoulos AA2, Tountas Y3, Niakas D1, 1Hellenic Open University, Patras, Greece, 2Attikon University Hospital, Athens,
Greece, 3University of Athens, Athens, Greece
pgA367 PHP16 OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007
Tomic Z1, Sabo A1, Vukmirovic S1, Milijasevic B1, Satman M2, Golocorbin Kohn S1, Mikov M1, 1Medical faculty of Novi Sad, Novi Sad, Serbia and Montenegro,
2
Drug Agency Montenegro, Podgorica, Yugoslavia
pgA367 PHP17 SOURCES OF INFORMATION ON DRUGS USED BY GENERAL PRACTITIONERS IN POLAND
Ułanowski P, Jakubczyk M, Hermanowski T, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
pgA367 PHP18 COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND THERAPEUTIC DEVICES OR DRUGS
Rodríguez Bezos D, Serrano D, Rodríguez Barrios JM, Medtronic Iberica, Madrid, Spain
HEALTH CARE USE & POLICY STUDIES - Equity and Access
pgA368 PHP19 REGIONAL MARKET ACCESS INEQUALITIES FOR NEW ONCOLOGY DRUGS IN SPAIN
Vieta A, Gimenez E, Badia X, IMS Health, Barcelona, Spain
pgA368 PHP20 THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITAL WARDS IN HUNGARY
Nagy J1, Kövi R2, Sebestyen A3, Kiss Z2, Molnár A2, Krösi L2, Kriszbacher I4, Betlehem J4, Boncz I4, 1National Health Insurance Fund, Budapest, Hungary,
2
National Health Insurance Fund Administration (OEP), Budapest, Hungary, 3National Health Insurance Fund Administration, Pecs, Hungary, 4University of Pecs,
Pecs, Hungary pgA368 PHP21 THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY
Boncz I1, Nagy J2, Kőrösi L3, Kövi R3, Molnár A3, Kiss Z3, Kriszbacher I1, Varga S1, Sebestyen A4, 1University of Pecs, Pecs, Hungary, 2National Health Insurance
Fund, Budapest, Hungary, 3National Health Insurance Fund Administration (OEP), Budapest, Hungary, 4National Health Insurance Fund Administration, Pecs,
Hungary
pgA369 PHP22 COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION
Vas G1, Sebestyen A2, Ágoston I1, Varga S1, Kriszbacher I1, Betlehem J1, Boncz I1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA369 PHP23 CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY
Sebestyen A1, Lipp S1, Kriszbacher I2, Betlehem J2, Kiss Z3, Molnár A3, Kõrösi L3, Boncz I2, 1National Health Insurance Fund Administration, Pecs, Hungary,
2
University of Pecs, Pecs, Hungary, 3National Health Insurance Fund Administration, Budapest, Hungary
HEALTH CARE USE & POLICY STUDIES - Formulary Development
pgA369 PHP24 USE OF THE AMCP FORMAT IN THE U.S.: A NATIONAL SURVEY OF HEALTH PLANS
Neumann PJ1, Sullivan SD2, Schur C3, Gupta J4, Berk M3, 1Tufts Medical Center, Boston, MA, USA, 2University of Washington, Seattle, WA, USA, 3Social and
Scientific Systems, Silver Springs, MD, USA, 4Social & Scientific Systems, Silver Springs, MD, USA
pgA370 PHP25 EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR ANALYZING COST EFFECTIVENESS DATA FOR FORMULARY DRUG CLASSES
McGhan WF, Peterson AM, University of the Sciences, Philadelphia, PA, USA
HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
pgA371 PHP28 A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Saggia MG, Roche Brazil, Sao Paulo, Brazil
pgA371 PHP29 MICROCOSTING STUDY OF THE DAILY ICU COSTS IN THREE COUNTRIES
Tan S1, Martin J2, Pezzi A3, Bakker J1, Neurohr C4, Pitrelli A5, Hakkaart L1, Welte R4, 1Erasmus MC University Medical Center, Rotterdam, The Netherlands, 2Kliniken des Landkreises Göppingen gGmbH, Göppingen, Germany, 3Università degli Studi di Milano, Milan, Italy, 4GlaxoSmithKline, Munich, Germany, 5GlaxoSmithKline spa, Verona, Veneto, Italy
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
35
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA371 PHP30 COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007
Häussler B, Höer A, IGES Institut GmbH, Berlin, Germany
pgA371 PHP31 IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION ? - THE ALENDRONATE CASE IN BELGIUM
Arickx F, Pierlet M, Soete E, VanHaeren E, Verplanken P, VanWilder P, RIZIV National Health Insurance Agency, Brussels, Belgium
pgA372 PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT
Kalo Z1, Lukovics M2, Donkane Verebes E3, Sampar P4, 1Eotvos Lorand University, Budapest, Hungary, 2Szeged University, Szeged, Hungary, 3Integra Zrt;, Budapest, Hungary, 4PricewaterhouseCoopers Ltd, Budapest, Hungary
pgA372 PHP33 INFLUENCE OF MORBIDITY ON THE USE OF RESOURCES IN PRIMARY CARE: RETROSPECTIVE APPLICATION OF ACG AT A SPANISH INTERREGIONAL LEVEL
Sicras-Mainar A1, Navarro-Artieda R2, Velasco S1, Prados S3, Estelrich J1, 1Badalona Servicios Asistenciales, Barcelona, Spain, 2Hospital Germans Trias i Pujol,
Barcelona, Spain, 3Instituto aragonés de ciencias de la Salud, Barcelona, Spain
pgA372 PHP34 COSTS ASSOCIATED TO ADDITIONAL TEMPORAL SICK LEAVE DAYS IN THE IMSS
Contreras-Hernandez I, Olvera-Gomez JL, Garduño-Espinosa J, Social Security Mexican Institute, Mexico City, Mexico
pgA373 PHP35 PHARMACEUTICAL EXPENDITURE IN GREECE 1980-2006
Karampli E1, Ollandezos M1, Kousoulakou H2, Tsiantou V1, Athanasakis K1, Kyriopoulos J1, 1National School of Public Health, Athens, Greece, 2Foundation for
Economic and Industrial Research, Athens, Greece
pgA373 PHP36 PERFORMANCE OF YOUR 5-STAR HOSPITALS
Baser O, University of Michigan and STATinMED Research, Ann Arbor, MI, USA
pgA373 PHP37 HEALTH EXPENDITURES AND PERFORMANCE. THE ANÁLISIS OF THE FINANCIAL GAPS IN BUENOS AIRES PROVINCE
Maceira DA1, Kremer P2, 1CIPPEC Foundation, Buenos Aires, Argentina, 2Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC),
Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina
pgA373 PHP38 COST-EFFECTIVENESS OF PREVENTION: OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN The Netherlands?
Van den Berg M, van Gils P, De Wit GA, Schuit J, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
pgA374 PHP39 LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE
Williams TJ1, Eaton S2, Puri S1, Van Staa TP1, 1Medicines and Healthcare Product Regulatory Agency, London, UK, 2Medicines and Healthcare Product Regulatory Agency, Raleigh, NC, USA
pgA374 PHP40 INVESTIGATING THE PROMOTION OF HEALTH BEHAVIOR AND HEALTH-RELATED QUALITY OF LIFE BY APPLYING SELF-DETERMINATION THEORY: USING
“EXERCISE” AS AN EXAMPLE
Lin WL, Yao G, National Taiwan University, Taipei, Taiwan
pgA374 PHP41 ANALYSIS OF CLINICAL PHARMACISTS’ INTERVENTIONS IN A UNIVERSITY TEACHING HOSPITAL IN OMAN
Al Zadjali B1, Al Zakwani I1, Al Kindi M2, Al Barram A3, Al Siyabi K3, 1Sultan Qaboos University Hospital, Muscat, Oman, 2Sultan Qaboos University Hospial,
Muscat, Oman, 3Sultan Qaboos University Hospital, Muscat, Oman
pgA375 PHP42 EVALUATION OF THE AFTERNOON OUTPATIENT CLINICS OPERATION AT THE UNIVERSITY HOSPITAL IN LARISA
Geitona M1, Androutsou L2, Mpouki L3, 1University of Thessaly, Volos, Greece, 2University of Thessaly, Athens, Greece, 35th Regional Health Authority of Thessaly, Larisa, Greece
pgA375 PHP43 GREEK HOSPITALS’ SUPPLY CHAIN MANAGEMENT
Perros G1, Kalogeropoulou M2, Tsantiris S1, Tzonis P3, 1Hellenic Association Of Pubic Health Doctors, Athens, Greece, 2Kapodistrian University of Athens, Athens, Greece, 3Hellenic Association Of Pubic Health Doctors, Athens, Attiki, Greece
pgA375 PHP44 INEQUALITIES IN THE FINANCING OF DRUGS AMONG AUTONOMOUS REGIONS IN SPAIN
Badia X, Vieta A, IMS Health, Barcelona, Spain
pgA375 PHP45 THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE
Nixon F, Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA376 PHP46 CATEGORISING RESEARCH: WHERE IS THE FOCUS?
Samuels E, Plested M, Heron Evidence Development Ltd, Letchworth Garden City, UK
HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
pgA376 PHP47 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY CARE PATIENTS
Chen T, Li L, Zhejiang University, Hangzhou, China
pgA376 PHP48 THE EFFECTS OF NICE HTA’S ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY
NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES
Sepulveda B, Horowicz-Mehler N, Doyle JJ, Quintiles Global Consulting, Hawthorne, NY, USA
HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
pgA377 PHP49 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT AGENCIES (HTA)
Bending MW1, Kruger J1, Hutton J1, McGrath C2, 1University of York, York, North Yorkshire, UK, 2Pfizer Inc, Surrey, UK
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
36
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA377 PHP50 UNIVERSAL STEPS IN PERFORMING EARLY-STAGE MEDICAL TECHNOLOGY ASSESSMENT
O’Prinsen AC1, Gaultney J2, Redekop WK2, 1Philips Research Asia, Shanghai, China, 2Erasmus Medical Center, Rotterdam, The Netherlands
pgA377 PHP51 OTHER HEALTH TECHNOLOGY ASSESSMENT GROUPS OPERATING IN ENGLAND; ITS NOT JUST NICE THAT NEEDS TO BE TAKEN INTO CONSIDERATION
Way J1, Mallinson M1, Bridge JA2, 1Double Helix Consulting, London, UK, 2Pfizer, Surrey, UK
pgA378 PHP52 EVALUATION OF CURRENT ASSESSMENTS OF WORLDWIDE AGENCIES FOR HEALTH TECHNOLGY ASSESSMENT
Wiebinga C, van Engen A, Andreykiv M, Quintiles Consulting, Hoofddorp, The Netherlands
HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies
pgA378 PHP53 EXPANDING THE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI): MEASURES GROUPS AND REGISTRY-BASED REPORTING
Pierce CA, The Resource Group, Richfield, OH, USA
pgA378 PHP54 ANTIBIOTICS CONSUMPTION IN THE REPUBLIC OF SERBIA IN 2004, 2005, 2006 AND 2007
Radonjic V, Djukic L, Stefanovic D, Tesic D, Medicines and Medical Devices Agency of Serbia, Belgrade, Serbia and Montenegro
HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
pgA379 PHP55 CHIRALTY AND HOSPITAL FORMULARY: A SECOND LIFE FOR A BLOCKBUSTER
Vernaz-Hegi N1, Girardin F1, Muscionico D2, Salomon JL2, Bonnabry P1, 1Geneva University Hospitals, Geneva, Switzerland, 2OFAC, Geneva, Switzerland
pgA379 PHP56 IMPACT OF ICU SEDATION PRACTICE ON PATIENT MORBIDITY, COST AND HOSPITAL RESOURCE USE: A SYSTEMATIC REVIEW
Jackson D1, Proudfoot CW2, Knight CJ3, Cann K4, Lock K2, 1GE Healthcare, Bucks, UK, 2Heron Evidence Development Ltd, Letchworth Garden City, UK, 3Heron
Evidence Development Ltd, Letchworth, UK, 4Heron Evidence Development Ltd, Hertfordshire, UK
pgA379 PHP57 INAPPROPRIATE SEDATION IN ICUS: EVIDENCE FROM THE LITERATURE
Jackson D1, Proudfoot CW2, Knight CJ3, Cann K4, Lock K2, 1GE Healthcare, Bucks, UK, 2Heron Evidence Development Ltd, Letchworth Garden City, UK, 3Heron
Evidence Development Ltd, Letchworth, UK, 4Heron Evidence Development Ltd, Hertfordshire, UK
HEALTH CARE USE & POLICY STUDIES - Quality of Care
pgA380 PHP58 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE: THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA
Maceira DA1, Kremer P2, 1CIPPEC Foundation, Buenos Aires, Argentina, 2Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC),
Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina
HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
pgA380 PHP59 LABEL CLAIMS BASED ON PATIENT REPORTED OUTCOMES IN EMEA AND FDA APPROVALS SINCE 2000
Scott J, Mapi Values, Macclesfield, Cheshire, UK
pgA380 PHP60 COMPARISON OF THE HEALTH ECONOMIC GUIDELINES OF THE CZECH REPUBLIC, HUNGARY, POLAND AND THE SLOVAK REPUBLIC
Petříková A1, Doležal T2, Vašut K1, 1University of Veterinarian and Pharmaceutical Sciences Brno, Brno, Czech Republic, 2Charles University, Praha, Czech
Republic
CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies
pgA381 PCV1 THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT
van der Bij S1, Heintjes E1, Plat A1, Sturkenboom MC2, Penning-van Beest FJ1, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands, 2Erasmus University
Medical Center, Rotterdam, The Netherlands
pgA381 PCV2 UNDERUSE OF STATINES AMONG HIGH RISK PATIENTS
Heintjes EM1, Haak P1, Sturkenboom MC2, Penning-van Beest FJA1, Herings R1, 1PHARMO Institute, Utrecht, The Netherlands, 2Erasmus University Medical
Center, Rotterdam, The Netherlands
pgA381 PCV3 COMPARISON OF GOAL ATTAINMENT RATES BETWEEN USERS OF SIMVASTATIN 40 MG AND OTHER STATINS
Heintjes E1, Plat A1, Sturkenboom MC2, Penning-van Beest FJ1, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands, 2Erasmus University Medical Center, Rotterdam, The Netherlands
pgA381 PCV4 COMPARISON OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF SIROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN A SUBGROUP OF PATIENTS
WITH AND WITHOUT DIABETES
Brüggenjürgen B, McBride D, Roll S, Willich SN
Charité University Medical Center, Berlin, Germany
pgA382 PCV5 A REAL WORLD COMPARISON OF COMBINED LIPID TARGET ATTAINMENT BETWEEN COMBINATION NIACIN EXTENDED-RELEASE+ANY STATIN THERAPY
AND FIXED DOSE SIMVASTATIN+EZETIMIBE
Simko RJ1, Quimbo RA2, Cziraky MJ3, Balu S4, 1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore Inc, Wilmington, DE, USA, 3HealthCore, Inc, Wilmington,
DE, USA, 4Abbott Labs, Abbott Park, IL, USA
pgA382 PCV6 EFFECTIVENESS OF CLOPIDOGREL IN ADDITION TO ASPIRIN COMPARED TO ASPIRIN ALONE AFTER ACUTE CORONARY SYNDROME
Liew D1, Price N2, Chew DP3, 1The University of Melbourne, Melbourne, Australia, 2Sanofi-aventis Australia, Sydney, Australia, 3Flinders University, Bedford Park,
SA, Australia
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
37
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA382 PCV7 CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL
HYPERTENSION – A SYSTEMATIC REVIEW
Becla L, Osińska B, Malottki K, Lipska I, Agency for Health Technology Assessment, Warszawa, Poland
pgA383 PCV8 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG– A SINGLE CENTRE “REAL WORLD” EXPERIENCE
Lee VWY, Kum L, Lee T, Wong W, Chan C, Mak C, Lee KK, Yu CM, The Chinese University of Hong Kong, Shatin, Hong Kong
pgA383 PCV9 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTAN VS. CANDESARTAN
Sharplin P1, Beckham C2, Hogan S3, Chamberlain G1, 1CRC, Cardiff, UK, 2Bristol-Myers Squibb, Uxbridge, UK, 3Sanofi-Aventis, Guildford, UK
pgA383 PCV10 SUPERIOR FORGIVENESS WITH ALISKIREN IN THE PRESENCE OF IMPERFECT COMPLIANCE
Jung W1, Tousset E2, Lowy A3, Keefe D4, Vrijens B5, Vincze G3, 1Academic Hospital Villingen, Villingen-Schwenningen, Germany, 2Pharmionic Systems, Vise,
Belgium, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corp, East Hanover, NJ, USA, 5Pharmionic Systems, Visé, Belgium
pgA384 PCV11 EFFECTIVENESS OF DRUG-ELUTING STENTS VS. BARE METAL STENTS UNRESTRICTED USE IN PATIENTS WITH CORONARY HEART DISEASE IN SOCIAL
SECURITY MEXICAN INSTITUTE
González-Díaz B1, Contreras-Hernandez I1, Castaño-Guerra R2, Farell-Campa J2, Arguero-Sànchez R2, Morales-Cisneros G1, Estrada-Gallegos J1, Garduño-Espinosa J1, 1Social Security Mexican Institute, Mexico City, Mexico, 2Hospital de Cardiologia Centro Medico Nacional Siglo XXI, Mexico City, Mexico
pgA384 PCV12 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF ARBS VS. ACE INHIBITORS
Sharplin P1, Televantou F2, Beckham C3, Chamberlain G1
1
CRC, Cardiff, UK, 2Sanofi-Aventis, Guildford, UK, 3Bristol-Myers Squibb, Uxbridge, UK
pgA384 PCV13 ATTAINMENT OF MULTIPLE RECOMMENDED LIPID LEVELS FOLLOWING LIPID MODIFYING TREATMENT IN HIGH RISK PATIENTS. PRIMULA STUDY, SPAIN
Suarez C1, Maiques A2, Ambegaonkar B3, Melero M4, Nocea G5, Zhang Q3, Sazonov V3, 1H. de La Princesa, Madrid, Spain, 2Centro de Salud de Manises, Valencia, Spain, 3Merck & Co., Inc, Whitehouse Station, NJ, USA, 4Merck Sharp & Dohme, Madrid, Spain, 5MSD Spain, Madrid, Spain
pgA385 PCV14 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS
(CEPHEUS-GREECE)
Elisaf M1, Daskos G2, Nikas N2, 1University Hospital of Ioannina, Ioannina, Greece, 2AstraZeneca SA, Athens, Greece
pgA385 PCV15 CORONS STUDY: EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY
Kieffer A1, Turbelin C1, Rabeharimanana F1, Flahault A2, 1INSERM, Paris, France, 2EHESP, Paris, France
pgA385 PCV16 MONITORING POTENTIAL DRUG-DRUG INTERACTIONS – AN APPLICATION FOR PRESCRIPTION CLAIMS DATABASES
Foley K1, Chang S2, Misra A2, Hansen LG3, 1Thomson Reuters, Philadelphia, PA, USA, 2Thomson Reuters, Washington, DC, USA, 3Thomson Reuters, Northwood,
NH, USA
pgA386 PCV17 COLD AND INACTIVITY: THE ULTIMATE FACTORS FOR HEART ATTACK
Horváth L1, Vadász R1, Bódis J1, Boncz I1, Sebestyen A2, Temesvári B1, Koppán Á1, Kriszbacher I1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA386 PCV18 EFFECT OF ENVIRONMENTAL TEMPERATURE AND WORKDAYS ON HEART ATTACK FIGURES
Vadász R1, Bódis J1, Boncz I1, Sebestyen A2, Temesvári B1, Horváth L1, Koppán Á1, Kriszbacher I1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA386 PCV19 THE TIME OF SUNRISE AND HOURS WITH DAYLIGHT MAY HAVE AN EFFECT ON THE SEASONALITY AND DIURNAL VARIATION OF A HEART ATTACK
Kriszbacher I1, Bódis J1, Sebestyen A2, Koppán Á1, Boncz I1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA386 PCV20 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT
Sorensen SV1, Webb SF2, Burge RT2, 1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA
pgA387 PCV21 EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY
Kriszbacher I1, Boncz I1, Sebestyen A2, Vas G1, Bódis J1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA387 PCV22 TOLERABILITY OF ROSUVASTATIN 40MG COMPARED TO 20MG IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA: EVIDENCE FROM RANDOMISED CONTROLLED TRIALS
Edwards SJ, Kingslake SL, AstraZeneca UK Ltd, Luton, UK
CARDIOVASCULAR DISORDERS - Cost Studies
pgA388 PCV24 BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY
Neubauer AS1, Zeymer U2, Blankenfeld H3, Marschall D1, Ehlken B3, Plesnila-Frank C3, Berger K3, 1Bristol-Myers Squibb, Munich, Germany, 2Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 3IMS Health, Munich, Germany
pgA388 PCV25 BUDGET IMPACT ANALYSIS OF THROMBOLYSIS FOR STROKE: A DISCRETE EVENT SIMULATION MODEL
Mar J1, Arrospide A2, Comas M3, 1Hospital ‘Alto Deba’, Mondragon, Spain, 2Hospital Alto Deba, Mondragon, Spain, 3Hospital del Mar (IMAS), Barcelona, Spain
pgA388 PCV26 TREATING TO LOWER LDL-C TARGETS: ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES
IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND
Kingslake SL, AstraZeneca UK Ltd, Luton, UK
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
38
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA389 PCV27 MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING
Miller JD1, Denevich S1, McGarry MJ2, Albano MP2, Caloyeras JP1, Russell MW1, 1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Lantheus Medical Imaging, Inc, North Billerica, MA, USA
pgA389 PCV29 ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP
OR KNEE REPLACEMENT SURGERY: AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK
Robinson P1, Zah V2, 1Boehringer Ingelheim Ltd, Bracknell, UK, 2ZRx Outcomes Research Inc, Toronto, ON, Canada
pgA390 PCV30 COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN
Rodriguez Barrios JM1, Cairols M2, Brosa M3, Crespo C4, Brasseur P5, 1Medtronic Iberia, Madrid, Spain, 2Bellvitge Hospital, Barcelona, Spain, 3Oblikue Consulting, Barcelona, Spain, 4Barcelona University, Barcelona, Spain, 5Medtronic Sarl, Tolochenaz, Switzerland
pgA390 PCV31 ORAL ANTICOAGULATION AFTER MAJOR HIP OR KNEE REPLACEMENT SURGERIES
Wilke T, University of Wismar, Wismar, Germany
pgA390 PCV32 ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG
DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL
Beamer B1, Frial T1, Farahani P2, 1AstraZeneca Canada, Mississauga, ON, Canada, 2McMaster University, Hamilton, ON, Canada
pgA391 PCV33 COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY - COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA
Ivanova AD1, Lakic D2, Andric V3, Petrova GI1, 1Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 2Belgrade University, Faculty of Pharmacy, Belgrade,
Serbia and Montenegro, 3Republic Institute for Health Insurance, Belgrade, Serbia and Montenegro
pgA391 PCV34 COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL
ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA
Choi SE, Choi YG, Lim EA, Seoul National University, Seoul, South Korea
pgA391 PCV35 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA
O’Prinsen AC1, Redekop WK2, 1Philips Research Asia, Shanghai, China, 2Erasmus Medical Center, Rotterdam, The Netherlands
pgA391 PCV36 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND
Kawalec P1, Lis J2, Glasek M2
1
Centrum HTA, Krakow, Poland, 2Sanofi-Aventis sp. z o.o, Warsaw, Poland
pgA392 PCV37 ENOXAPARIN IS COST-SAVING AS PROPHYLACTIC THERAPY VERSUS UNFRACTIONATED HEPARIN OR NO PROPHYLAXIS IN HOSPITALISED MEDICAL PATIENTS
Feng J1, Yuen C2, Jackson D3, 1IMS Health Australia, St Leonards, Australia, 2Sanofi-Aventis Australia, Macquarie Park, Australia, 3IMS Health Australia, St
leonards, Australia
pgA392 PCV38 EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY: A PHARMACOECONOMIC STUDY
Capri S1, Ageno W2, Moia M3, Imberti D4, Palareti G5, Piovella F6, Scannapieco G7, Bamfi F8, Pitrelli A8, Cattaneo-LIUC University, Castellanza, (Varese), Italy,
2
University of Insubria, Varese, Italy, 3Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy, 4Piacenza Hospital, Piacenza, Italy, 5University Hospital of
Bologna, Bologna, Italy, 6Fondazione IRCCS Policlinico, Pavia, Italy, 7Azienda ULSS N°9 Treviso, Treviso, Italy, 8GlaxoSmithKline Spa, Verona, Italy
pgA393 PCV39 COST-EFFECTIVENESS OF NIASPAN® VERSUS ZETIA® AS ADD-ON TREATMENT TO STATIN THERAPY IN HIGH-RISK PATIENTS
Sorensen SV1, Webb SF2, Burge R, 1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA
pgA393 PCV40 COST-EFFECTIVENESS OF TARGETING MULTIPLE LIPID PARAMETERS (LDL-C, HDL-C, TG) WITH NIASPAN® VERSUS A SINGLE LIPID PARAMETER (LDL-C)
WITH ZETIA® IN PATIENTS RECEIVING ON-GOING STATIN THERAPY
Sorensen SV1, Webb SF2, Burge RT2, 1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA
pgA393 PCV41 COST EFFECTIVENESS OF IMPLANTABLE LOOP RECORDER SYSTEM (REVEAL DX®) FROM THE SPANISH NHS PERSPECTIVE
Garcia-Baena I1, Rodriguez-Barrios JM2, García García FJ3, 1Universitat Pompeu Fabra, Barcelona, Spain, 2Medtronic Ibérica SA, Madrid, Spain, 3Hospital Insular
de Gran Canaria, Las Palmas de Gran Canaria, Spain pgA393 PCV42 COST-EFFECTIVENESS OF POPULATION-BASED ‘SCREEN-AND-TREAT’ STRATEGIES DIRECTED AT ALBUMINURIA
Boersma C1, Gansevoort RT2, Visser ST1, De Jong-van den Berg L1, de Jong PE2, Postma M1, 1University of Groningen, Groningen, The Netherlands, 2University
Medical Center Groningen, Groningen, Groningen, The Netherlands
pgA394 PCV43 MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETS WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN
Webb SF1, Burge RT2, Sorensen SV3, 1Abbott Laboratotires, Abbott Park, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3United BioSource Corporation,
Bethesda, MD, USA
pgA394 PCV44 COST-EFFECTIVENESS MODEL OF IMPLANTABLE CARDIAC MONITORS (ICM) FOR PATIENTS TREATED WITH RADIOFREQUENCY CATHETER ABLATION FOR
ATRIAL FIBRILLATION (PAAF) IN SPAIN
Tsintzos S1, Brosa M2, Murthy A1, Rodriguez JM3, 1Medtronic International, Tolochenaz, Switzerland, 2Oblikue Consulting, Barcelona, SC, Spain, 3Medtronic
Iberia, Madrid, Spain
pgA394 PCV45 COST-EFFECTIVENESS OF EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION
Martí-Sánchez D1, Martí B2, Sánchez-Maestre C2, 1Cardiology Deparment, Hospital Ramón y Cajal, Madrid, Spain, 2Health Outcomes Research, Pfizer, Spain
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
39
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA395 PCV46 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: A SPANISH MODEL BASED ON THE CLARITY AND
COMMIT TRIALS
Brosa M1, Abadía C2, Betegón L2, 1Oblikue Consulting, Barcelona, SC, Spain, 2Sanofi-Aventis, Madrid, Spain
pgA395 PCV47 ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM
Giardina S1, Di Stasi F1, Palombo D2, Pane B2, Spinella G2, Brasseur P3, 1Medtronic Italia, Sesto San Giovanni (MI), Italy, 2San Martino Hospital, Genova, Italy,
3
Medtronic International SA, Tolochenaz, Switzerland pgA395 PCV48 ENHANCING SYNCOPE DIAGNOSTICS: COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF
CARE
Van Genugten M1, Tsintzos S2, 1Medtronic Trading NL B.V, Heerlen, DA, The Netherlands, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland
pgA396 PCV49 COST-EFFECTIVENESS OF ATORVASTATIN 80 MG VS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN
Sánchez Maestre C1, Martí B1, Webb K2, Soto J1, 1Health Outcomes Research, Pfizer, Spain, 2Pfizer Inc, Tadworth, Surrey, UK
pgA343EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS : A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN
DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
Marbaix S1, Vandenberghe H1, Van Gaal L2, 1Pfizer WPO Belgium, Brussels, Belgium, 2Antwerp University Hospital, Edegem, Belgium
pgA396 PCV50 COST-EFFECTIVENESS OF RULING OUT DEEP VENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL
ten Cate - Hoek AJ1, Toll DB2, van der Velde EF3, Buller H3, Hoes AW2, Moons KG2, Oudega R2, Prins MH1, Stoffers HE1, van Weert HC3, Joore MA4, 1Maastricht
University, Maastricht, The Netherlands, 2University Medical Center Utrecht, Utrecht, The Netherlands, 3Amsterdam Medical Centre, Amsterdam, The Netherlands, 4University Hospital Maastricht, Maastricht, The Netherlands
pgA396 PCV51 SINGLE PILL AMLODIPINE/ATORVASTATIN IS COST-EFFECTIVE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA
Liew D1, Park HJ2, Ko S2, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Pfizer Korea, Seoul, South Korea
pgA397 PCV52 COST-UTILITY ANALYSIS OF HOME TELEMONITORING IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
Stafylas P1, Dafoulas G2, Aletras V3, Lashos V4, Raptis O2, 1AHEPA University Hospital, Thessaloniki, Greece, 2Telecare Center, Municipality of Trikala, Trikala,
Greece, 3University of Macedonia, Thessaloniki, Greece, 4General Hospital of Trikala, Trikala, Greece
pgA397 PCV53 DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS
Moriarty J, Daniels P, Manning D, McBane R, Naessens J, Mayo Clinic, Rochester, MN, USA pgA397 PCV54 A EUROPEAN MULTI-COUNTRY COMPARISON OF THE COST-EFFECTIVENESS OF IODIXANOL VERSUS IOHEXOL BASED ON THE RESULTS OF THE NEPHRIC
CLINICAL TRIAL
Patel P1, Zyczynski T2, Beard S3, Earnshaw SR4, McDade CL4, Zimovetz E3, 1GE Healthcare, Barrington, IL, USA, 2GE Healthcare, Princeton, NJ, USA, 3RTI Health
Solutions, Manchester, UK, 4RTI Health Solutions, Research Triangle Park, NC, USA
pgA398 PCV55 PHARMACOECONOMIC EVALUATION OF TREATMENT WITH PROCORALAN® PREPARATION COMPARED TO INVASIVE TREATMENT
Filipiak KJ, Jaworski R, Medical University of Warsaw, Warsaw, Poland
pgA398 PCV56 AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND EXPECTANT MANAGEMENT IN WOMEN WITH PREGNANCY- INDUCED HYPERTENSION OR PREECLAMPSIA AT TERM (HYPITAT TRIAL)
Vijgen SM1, Opmeer BC1, Mol B1, Bijlenga D1, Burggraaff JM2, van Loon AJ3, Huisjes AJ4, Roumen FJ5, Papatsonis DN6, van Pampus MG7, 1Academic Medical
Centre, Amsterdam, The Netherlands, 2Scheper Hospital, Emmen, The Netherlands, 3Martini Hospital, Groningen, The Netherlands, 4Gelre Hospital, Apeldoorn, The
Netherlands, 5Atrium Medical Center, Heerlen, The Netherlands, 6Amphia Hospital, Breda, The Netherlands, 7University Medical Center, Groningen, The Netherlands
pgA398 PCV57 ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED BY TREATING TO ALTERNATIVE LDL-C TARGETS: IS LOWER BETTER?
Kingslake SL, AstraZeneca UK Ltd, Luton, UK
pgA399 PCV58 COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND
Banasiak W1, Jaworski R2, Pachocki R2, 14th Military Hospital, Wroclaw, Poland, 2Servier Polska, Warsaw, Poland
pgA399 PCV59 INPATIENT RESOURCE USE ASSOCIATED WITH THE TREATMENT OF SECONDARY ATRIAL FIBRILLATION Spalding JR1, Exuzides A2, Adams S2, Colby C2, Noe L2, 1Astellas Pharma US, Deerfield, IL, USA, 2ICON Clinical Research, San Francisco, CA, USA
pgA399 PCV60 TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE
REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
Mahoney EM1, Lei Y1, Wang K1, Bruggenjurgen B2, Mosse F3, Parhofer KG4, Zeymer U5, Roether J6, 1Mid America Heart Institute of Saint Luke’s Hospital,
Kansas City, MO, USA, 2Alpha Care, Celle, Germany, 3Sanofi-Aventis, Paris, France, 4University Munich, Munich, Germany, 5Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 6Johannes Wesling Klinikum Minden, Minden, Germany
pgA400 PCV61 INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKE TO POPULATION SETTING AND IN CLINICAL PRACTICE
Sicras-Mainar A1, Navarro-Artieda R2, Sánchez Maestre C3, Fernández de Bobadilla J4, 1Badalona Serveis Assistencials, Barcelona, Spain, 2Hospital Germans
Trias y Pujol, Barcelona, Spain, 3Pfizer Spain, Madrid, Spain, 4Hospital de la Paz, Madrid, Spain
pgA400 PCV62 THE BURDEN OF ACUTE CORONARY SYNDROMES IN AUSTRALIA
Liew D1, Price N2, 1The University of Melbourne, Melbourne, Australia, 2Sanofi-Aventis Australia Pty Ltd, Sydney, Australia
pgA400 PCV63 CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING
Sicras A1, Navarro-Artieda R2, Sánchez Maestre C3, Martí B3, 1Badalona Servicios Asistenciales, Barcelona, Spain, 2Hospital Germans Trias y Pujol, Badalona,
Barcelona, Spain, 3Health Outcomes Research, Pfizer, Spain Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
40
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA401 PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS
CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL
Mahoney EM1, Wang K2, Lei Y2, Arnold SV2, McCollam PL3, Riesmeyer J4, Plat F5, Cohen DJ2, 1Mid Americ Heart Institute of Saint Luke’s Hospital, Kansas City,
MO, USA, 2Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly & Co, Indianapolis, IN, USA, 5Daiichi Sankyo, Edison, NJ, USA
pgA401 PCV65 COSTS OF BLEEDS ASSOCIATED WITH TREATING ACUTE CORONARY SYNDROME PATIENTS IN GERMANY
Bufe A1, Briswalter S2, Brown R3, 1Universitätsklinik der Universität Witten/Herdecke, Wuppertal, Wuppertal, Germany, 2GlaxoSmithKline, Munich, Germany,
3
United BioSource Corporation, Bethesda, MD, USA
pgA402 PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
Ondrackova B1, Miklik R2, Parenica J2, Spinar J2, Pavlik T1, Tomcikova D1, 1Masaryk University, Brno, Czech Republic, 2Faculty Hospital Brno, Brno, Czech Republic
pgA402 PCV68 IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND ECONOMIC OUTCOMES IN AN UNSELECTED INTERVENTIONAL PRACTICE
Rihal CS, Singh M, Bresnahan JF, Liesinger J, Gersh BJ, Long KH, Mayo Clinic, Rochester, MN, USA
pgA402 PCV69 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: NON-RUPTURED INFRARENAL ABDOMINAL AORTIC
ANEURYSM IN AN ELECTIVE SETTING
Hayes P1, Ryan J2, Jensen M2, Harrison L2, Wyatt M3, Bradbury A4, Brasseur P5, 1Addenbrooke’s Hospital, Cambridge, UK, 2Abacus International, Bicester, UK,
3
Freeman Hospital, Newcastle upon Tyne, UK, 4University of Birmingham, Birmingham, UK, 5Medtronic Europe Sàrl, Tolochenaz, Switzerland
pgA403 PCV70 COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA
Liew D1, Cordony A2, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Sanofi-Aventis Australia, Macquarie Park, NSW, Australia
pgA403 PCV71 COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT ATRIAL FIBRILLATION IN SPAIN
López Gude MJ1, Rodríguez Bezos D2, Rodríguez Barrios JM2, Serrano Contreras D2, 1Hospital 12 Octubre, Madrid, Spain, 2Medtronic Iberia, Madrid, Spain
pgA403 PCV72 COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL
Pradelli L, Iannazzo S, Zaniolo O, AdRes Srl, Turin, Italy
pgA404 PCV73 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM
IN AN EMERGENCY SETTING
Hayes P1, Ryan J2, Jensen M2, Harrison L2, Brasseur P3, 1Addenbrooke’s Hospital, Cambridge, UK, 2Abacus International, Bicester, UK, 3Medtronic Europe Sàrl,
Tolochenaz, Switzerland pgA404 PCV74 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL
HIP OR TOTAL KNEE REPLACEMENT SURGERY Wolowacz S1, Roskell N1, Maciver F1, Beard S1, Robinson P2, Plumb J3, 1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd, Bracknell, UK, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
pgA404 PCV75 THE IMPACT OF POSTPRANDIAL PEAKS ON CARDIOVASCULAR COMPLICATIONS BEYOND THE HBA1C LEVEL - A HEALTH ECONOMIC ASSESSMENT
Neeser K, Heister F, Weber C, Institute for Medical Informatics and Biostatistics, Basel, Switzerland
pgA405 PCV76 THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)
Liew D1, Ko S2, Kang HY3, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Pfizer Korea, Seoul, South Korea, 3Yonsei University, Seoul, South
Korea
pgA405 PCV77 COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK
Thurston SJ1, Thompson RP2, Ong S2, van Hout BA1, 1Pharmerit Ltd, York, North Yorkshire, UK, 2Pfizer Ltd, Tadworth, Surrey, UK
pgA405 PCV78 ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE: A COST-UTILITY ANALYSIS
Koffijberg H1, Buskens E2, Rinkel G1, 1University Medical Center Utrecht, Utrecht, The Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
pgA405 PCV79 ECONOMIC EVALUATION OF IRBESARTAN IN GREECE
Maniadakis N1, Fragoulakis V2, Papagiannopoulou V3, Yfantopoulos I3, 1University of Piraeus, Drosia, Greece, 2National Social Insurance Institute, Athens,
Greece, 3University of Athens, Athens, Greece
pgA406 PCV80 TISSUE ENGINEERING OF VALVED VENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY
(CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A PRE-MARKETING
TECHNOLOGY ASSESSMENT APPROACH WITH GERMAN DATA
Dintsios CM1, Hagen A2, Gerhardus A3, Krauth C4, 1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 2Hannover Medical Scholl, Hannover, Germany, 3University of Bielefeld, Bielefeld, Germany, 4Hannover Medical School, Hannover, Germany
pgA406 PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
Balu S1, Simko RJ1, Burge RT1, Cziraky MJ2, Quimbo R2, 1Abbott Labs, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA
pgA406 PCV82 CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY
Simko RJ1, Burge RT1, Balu S1, Tunceli O2, Quimbo R2, Cziraky MJ2, 1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
41
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA407 PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-
DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY
Balu S1, Simko RJ2, Burge RT2, Cziraky MJ3, Quimbo R3, 1Abbott Labs, Abbott Park, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3HealthCore, Inc, Wilmington, DE, USA
pgA407 PCV84 HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
Ferrieres J1, Tcherny-Lessenot S2, Sartral M3, Pentel J2, Delahais V2, 1CHU Rangueil, Toulouse, France, 2Lilly France, Suresnes, France, 3Eli Lilly and Company
Ltd, Suregnes, France
pgA407 PCV85 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND RESULTS FROM THE ATHENS
STROKE REGISTRY
Payne K1, Caro JJ2, Lordan N2, Huybrechts KF2, Ishak KJ1, Rylander A3, Vemnos K4, 1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource
Corporation, Concord, MA, USA, 3AstraZeneca Sweden AB, Sodertalje, Sweden, 4University of Athens School of Medicine; Alexandra Hospital, Athens, Greece
CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes Studies
pgA408 PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY
SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS
Bae JP1, Zhu B1, McCollam PL1, Ramaswamy K2, Johnston JA1, Cohen DJ3, Effron MB1, 1Eli Lilly and Company, Indianapolis, IN, USA, 2Daiichi Sankyo Inc, Parsippany, NJ, USA, 3Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, USA
pgA408 PCV87 PERSISTENCE WITH AMIODARONE OR SOTALOL AND ITS IMPACT ON ATRIAL FIBRILLATION-RELATED HOSPITALIZATIONS AND CARDIOVERSIONS
Ishak KJ1, Proskorovsky I2, Guo S3, Lin J4, Caro JJ3, 1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Dorval, Quebec,
Canada, 3United BioSource Corporation, Concord, MA, USA, 4Sanofi-Aventis US, Bridgewater, NJ, USA
pgA409 PCV88 IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE: A CZECH PILOT PROJECT ON MEDICATION ADHERENCE
Cerna V, Skoupá J, Pharma Projects, Prague, Czech Republic
pgA409 PCV89 THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT
Jorgensen E1, Paulsson T2, 1AstraZeneca Norway, Oslo, Norway, 2AstraZeneca, Södertälje, Sweden
pgA409 PCV90 THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS’ ADHERENCE TO LONG-TERM TREATMENTS.
RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA®: A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMACOEPIDEMIOLOGICAL SURVEYS
Saussier C1, Van Ganse E2, Augé-Caumon MJ3, Chamba G4, Marrel A1, Benmedjahed K5, Longin J1, 1MAPI, Lyon, France, 2Pierre Wertheimer Hospital, Bron,
France, 3USPO, Paris, France, 4Pharmakeion, Lyon, France, 5Mapi Values, Lyon, France
pgA410 PCV91 IMPACT OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUGS ON QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION
Bulkova V1, Fiala M2, Wichterle D1, Haman L3, Chovancik J2, Simek J1, Parizek P3, Wojnarova D2, Havranek S1, 1Department of Cardiology and Angiology, First
Faculty of Medicine Charles University School in Prague, Prague, Czech Republic, 2Department of Cardiology, Hospital Podlesi, Trinec, Czech Republic, 3Department of Cardiology, University Hospital, Hradec Kralove, Hradec Kralove, Czech Republic
pgA410 PCV92 DERIVING UTILITY VALUES FOR ACUTE CORONARY SYNDROMES FROM THE GENERAL POPULATION IN AUSTRALIA
Cordony A, Price N, Gonzalo F, Yuen C, Sanofi-Aventis Australia, Macquarie Park, NSW, Australia
pgA410 PCV93 FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION
Berg J1, Lindgren P1, Nieuwlaat R2, Bascle S3, Crijns H4, 1i3 Innovus, Stockholm, Sweden, 2Population Health Research Institute, Hamilton, ON, Canada, 3SanofiAventis, Paris, France, 4University Hospital Maastricht, Maastricht, The Netherlands
pgA411 PCV94 PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONIST- OR AN ATENOLOL-LED HYPERTENSION STRATEGY
IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)
Ried LD, Gandhi PK, Bibbey A, University of Florida, Gainesville, FL, USA
pgA411 PCV95 SOCIODEMOGRAPHIC AND CARDIOVASCULAR RISK FACTORS INFLUENCES ON EQ-5D SOCIAL PREFERENCES SCORES AND SELF-REPORTED HEALTH: A
GENERAL POPULATION SURVEY IN ARGENTINA
Augustovski FA, Irazola V, Caporale JE, Rubinstein A, Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
pgA411 PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE
van Til JA, IJzerman MJ, University of Twente, Enschede, The Netherlands
pgA412 PCV97 TREATMENTS FOR VARICOSE VEIN DISEASE: EXPECTATIONS AND EXPERIENCES OF PATIENTS
Spijkers CJ1, Dirksen CD1, Krabbe PFM2, Dellaert BGC3, Severens JL1, Sommer A1, Joore MA1, 1University Hospital Maastricht, Maastricht, The Netherlands,
2
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands
pgA412 PCV98 MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UK
Barwell T1, Patel P2, Marelli C3, 1Abacus International, Bicester, UK, 2GE Healthcare, Barrington, IL, USA, 3GE Healthcare, Chalfont St Giles, UK
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
42
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies
pgA412 PCV99 A CROSS-NATIONAL COMPARISON ON PRICES OF PHARMACEUTICAL PRODUCT
Sakamaki H, Meijo University, Nagoya, Japan
pgA413 PCV100 METFORMIN FOR THE TREATMENT OF METABOLIC DISTURBANCES AND CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
Bouza C, Lopez T, Ruiz M
Carlos III Health Institute, Madrid, Spain
pgA413 PCV101 PROSPECTIVE STUDY TO EVALUATE THE IMPACT OF A DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK CONTROL IN HYPERTENSION Galera J1, Salazar J1, Armario P2, Segura J3, 1Novartis Farmacéutica S.A, Barcelona, Spain, 2Hospital General de L’Hospitalet, L’Hospitalet de Llobregat (Barcelona), Spain, 3Hospital 12 de Octubre, Madrid, Spain
pgA413 PCV102 COST-EFFECTIVENESS OF MANAGING ORAL ANTICOUAGULATION (OAC) AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION (PAAF) WITH IMPLANTABLE CARDIAC MONITORS (ICMS)
Tsintzos S1, Murthy A2, 1Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, 2Medtronic International, Tolochenaz, Vaud, Switzerland
pgA413 PCV103 TECHNOLOGICAL INNOVATION AND THE DECISION-MAKING PROCESS IN ITALIAN HOSPITALS
Bartoli S1, Tarricone R1, Benussi S2, Stefano P3, Marinelli G4, 1Bocconi University, Milan, Italy, 2S Raffaele University Hospital, Milan, Italy, 3Careggi UniversityHospital, Firenze, Italy, 4Sant’Orsola-Malpighi University-Hospital, Bologna, Italy
pgA414 PCV104 EVALUATION OF THE PRESCRIPTION PATTERNS OF STATINS THROUGH APPROPRIATE INDICATORS IN TWO ITALIAN LOCAL HEALTH UNITS IN 2004-2006
Lopatriello S1, Salvato C2, Maccari D2, Palcic S3, Broussard P3, Negrini C4, 1Pbe Consulting, Verona, Italy, 2ASL 7 Pieve di Soligo (TV), Pieve di Soligo, Italy,
3
A.S.S. 1 “Triestina”, S.C. Assistenza farmaceutica, Trieste, Italy, 4Pbe Consulting, Milano, Italy
pgA414 PCV105 STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001-2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
ŠTimac D, Culig J, Zagreb institute of Public Health, Zagreb, Croatia
pgA414 PCV106 PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY
Fraeman KH1, Reynolds MW2, Vaughn B3, De Lissovoy G1, 1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corp, Medford, MA, USA,
3
ETHICON, Inc, Somerville, NJ, USA
pgA415 PCV107 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES
McCollam PL1, Bae JP1, Nasuti P2, Anger C3, 1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Hospital Group Ltd, Sittingbourne, UK, 3IMS Health, Kent, UK
pgA415 PCV108 RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAÏVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY
Mathes J1, Kostev K2, Gabriel A1, Pirk O1, Schmieder RE3, 1IMS HEALTH, Nuremberg, Germany, 2IMS HEALTH, Frankfurt am Main, Germany, 3Friedrich-AlexanderUniversity Erlangen-Nürnberg, Erlangen, Germany
pgA415 PCV109 PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD
Khan N1, Kaestner R2, 1University of New Mexico, Albuquerque, NM, USA, 2University of Illinois at Chicago, Chicago, IL, USA
pgA416 PCV110 THE POTENTIAL ECONOMIC IMPACTS OF RECONFIGURING TIA CARE IN THE UK
Jackson D1, Begg A2, Moshinsky J2, 1GE Healthcare, Bucks, UK, 2Medaxial Group, London, UK
pgA416 PCV111 COST- ANALYSIS OF DYSLIPOPROTEINAEMIA TREATMENTS WITHIN THE SLOVAK REPUBLIC
Tesar T1, Foltan V1, Ilavska A2, 1Comenius University, Bratislava, Slovak Republic, 2Railway Hospital, Bratislava, Slovak Republic
pgA416 PCV112 STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE : RESULTS FROM THE STROKE ANALYZER DATABASE
Nasuti P, Belilty J, Hamad B, IMS Health, London, UK
pgA417 PCV113 PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION: WHO ARE THE “UNTREATED PATIENTS” IN HOSPITALS WITH CATH LAB?
Hamad B, Nasuti PI, Belilty J, IMS Health, London, UK
pgA417 PCV114 SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH – THE CASE OF CHOLESTEROL LOWERING IN SWEDEN
Martikainen JA1, Soini EJ1, Paulsson T2, 1ESiOR Oy, Kuopio, Finland, 2AstraZeneca, Södertälje, Sweden
pgA417 PCV115 ASSESSING THE POTENTIAL BENEFITS OF CHANGING REIMBURSEMENT CRITERIA FOR LIPID LOWERING THERAPY IN KOREA
Kang HY1, Liew D2, Ko S3, Kim J4, 1Yonsei University, Seoul, South Korea, 2The University of Melbourne, Melbourne, Victoria, Australia, 3Pfizer Korea, Seoul,
South Korea, 4Konyang University, Chungnam, South Korea
pgA418 PCV116 THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD
Vitezic D1, Buble T2, Matana Kastelan Z3, Kovacevic M4, Mrsic Pelcic J5, 1University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka,
Croatia, 2Croatian National Health Insurance, Zagreb, Croatia, 3University of Rijeka School of Medicine, Rijeka, Croatia, 4University Hospital Centre Rijeka and
University of Rijeka School of Medicine, Rijeka, Croatia, 5University of Rijeka Medical School, Rijeka, Croatia
pgA418 PCV117 COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS (HTA) OF DRUG ELUTING STENTS (DES)
Hurry MV1, Bending MW1, Trueman P1, Hutton J1, Brasseur P2, 1University of York, York, North Yorkshire, UK, 2Medtronic Europe Sàrl, Tolochenaz, Switzerland
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
43
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA418 PCV118 ADVANCING SYNCOPE DIAGNOSIS THROUGH IMPLANTABLE LOOP RECORDERS (ILRS) IN SWEDEN: COST-EFFECTIVENESS ANALYSIS OF NEW DIAGNOSTIC
STRATEGIES
Gadler F1, Murthy A2, Sohlberg A3, Tsintzos S4, 1Karolinska Hospital, Stockholm, Sweden, 2Medtronic International, Tolochenaz, Vaud, Switzerland, 3Medtronic
International, Stockholm, Sweden, 4Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland
pgA419 PCV120 GLYCOPROTEIN INHIBITOR USE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL
STUDY (APTOR) Zeymer U1, Leidreiter K2, Bakhai A3, Iniguez Romo A4, Ferrieres J5, 1Klinikum Ludwigshafen, Ludwigshafen, Germany, 2Eli Lilly Export S.A, Vernier/Geneva, Switzerland, 3Barnet & Chase Farm NHS Trust, Barnet, UK, 4Hospital Meixoeiro, Vigo, Spain, 5CHU Rangueil, Toulouse, France
pgA419 PCV121 LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY: RESULTS OF DYSIS-GERMANY Gitt AK1, Smolka W2, Bestehorn K2, 1University of Heidelberg, Ludwigshafen, Germany, 2MSD Germany, Haar, Germany
CARDIOVASCULAR DISORDERS - Conceptual Papers & Research on Methods
pgA420 PCV122 MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS
Lowy A1, Nixon R1, Ong SH1, Munk V1, Turk F1, Keefe D2, Vincze G1, 1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA
pgA410 PCV123 THE CARDIOVASCULAR PREVENTION MODEL (CPM), A GENERICALLY APPLICABLE MODEL FOR UNDERTAKING COST-EFFECTIVENESS ANALYSES OF PREVENTIVE INTERVENTIONS
Liew D1, Nanayakkara S2, Webb K3, Grobler M4, Delahoy PJ5, Magliano DJ6, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Monash University,
Melbourne, Victoria, Australia, 3Pfizer Inc, Tadworth, Surrey, UK, 4Pfizer Australia Pty Ltd, Sydney, NSW, Australia, 5Pfizer Australia Pty Ltd, West Ryde, NSW,
Australia, 6International Diabetes Institute, Melbourne, Victoria, Australia
INDIVIDUAL’S HEALTH - Clinical Outcomes Studies
pgA420 PIH1 CHANGES IN PELVIC FLOOR MUSCLE STRENGTH, ITS DURATION AND ITS RELAXATION ABILITY DURING PREGNANCY
Hock M1, Kránicz J1, Kivés Z1, Kriszbacher I1, Sebestyen A2, Boncz I1, Bódis J1, 1University of Pecs, Pecs, Hungary, 2National Health Insurance Fund Administration, Pecs, Hungary
pgA421 PIH2 ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS
Droupy S1, Giuliano F2, Cuzin B3, Costa P4, Vicaut E5, Levrat F6, 1CHU de Bicêtre, le Kremlin Bicêtre, France, 2AP-HP, hôpital Raymond Poincaré, Garches,
France, 3Groupement Hospitalier E Herriot, Lyon, France, 4CHU Carémeau, Nîmes, France, 5Lariboisière St Louis, Hôpital F. Widal, Paris, France, 6Pfizer, Paris,
France
pgA421 PIH3 EPIDEMIOLOGICAL SURVEILLANCE OF CONGENITAL MALFORMATIONS IN 52,744 BIRTHS COLOMBIAN BETWEEN APRIL 2001 AND JANUARY 2008
Zarante I, Fernandez N, Franco L, Pontificia Universidad Javeriana, Bogota, Colombia
pgA422 PIH5 INCIDENCE OF MAJOR MALFORMATIONS IN INFANTS FOLLOWING ANTIDEPRESSANT EXPOSURE IN PREGNANCY: RESULTS OF A LARGE PROSPECTIVE
COHORT STUDY
Einarson A1, Choi J1, Einarson TR2, Koren G1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada
INDIVIDUAL’S HEALTH - Cost Studies
pgA422 PIH6 SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES IN OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE
Vijgen SM, Opmeer BC, Mol B, Academic Medical Centre, Amsterdam, The Netherlands
pgA422 PIH7 ECONOMIC ANALYSIS OF TREATMENT WITH IUI-COH VERSUS 6 MONTHS DELAY OF TREATMENT IN COUPLES WITH UNEXPLAINED SUBFERTILITY
Mol B1, Van Rumste M1, Custers I1, Steures P1, Van der Steeg J1, Hompes P2, Eijckemans R3, Mochtar M1, Bossuyt P1, Van der Veen F1, 1Academic Medical
Centre, Amsterdam, The Netherlands, 2Vrije Universiteit, Amsterdam, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands
pgA423 PIH8 COST-EFFECTIVENESS OF PLANNED CAESAREAN SECTION VERSUS PLANNED VAGINAL DELIVERY IN BREECH-PRESENTATION PREGNANCIES AT TERM
Vijgen SM, Opmeer BC, Mol BW, Academic Medical Centre, Amsterdam, The Netherlands
pgA423 PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
Lete I1, Cristóbal I2, Febrer L3, Crespo C4, Hernández FJ3, Arbat A3, Serrano D5, Brosa M6, 1Hospital Santiago Apóstol, Álava, Spain, 2Hospital Sanitas La Zarzuela, Madrid, Spain, 3Bayer HealthCare, SJD (Barcelona), Catalunya, Spain, 4Oblikue Consulting, Barcelona, Spain, 5Oblikue Consulting, Barcelona, Catalunya,
Spain, 6Oblikue Consulting, Barcelona, Spain
pgA423 PIH10 THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHN’S DISEASE IN
SCOTLAND
Punekar YS1, Sunderland T2, Morris J3, 1Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 2Sheffield University, Sheffield, UK, 3Schering-Plough,
Welwyn Garden City, UK
pgA423 PIH11 COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN
Justo N, Jönsson L, Ekman M, Berg J, i3 Innovus, Stockholm, Sweden
pgA424 PIH12 INPATIENT LENGTH OF STAY AND TOTAL COSTS OF ILLNESSES OF PRESSING CONCERN FOR ASIAN-AMERICAN AND PACIFIC ISLANDER WOMEN IN THE
UNITED STATES
Candrilli SD1, Davis KL2, Balkrishnan R1, 1The Ohio State University, Columbus, OH, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
44
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA424 PIH13 ASSESSING THE INCREASED MATERNAL AND NEONATAL HEALTH CARE COSTS ASSOCIATED WITH PREECLAMPSIA
Chawla A1, White LA2, Mitchell D3, Chang E2, Gorin B2, Woelkers D4, Vargo J5, Rahman M5, 1Analysis Group, Menlo Park, CA, USA, 2Analysis Group, Boston, MA,
USA, 3Analysis Group, Montreal, QC, Canada, 4University of California, San Diego, San Diego, CA, USA, 5Ortho Clinical Diagnostics, Raritan, NJ, USA
pgA424 PIH14 COSTS AND OUTCOMES ASSOCIATED WITH IN VITRO FERTILISATION (IVF) OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH)
Holman AJ1, Irwin DE2, Ledger W3, Anderson P1, Wiebinga CJ4, Lloyd AC1, 1IMS Health, London, UK, 2University of North Carolina, Chapel Hill, NC, USA, 3University of Sheffield, Sheffield, UK, 4N.V. Organon, Oss, The Netherlands
INDIVIDUAL’S HEALTH - Patient-Reported Outcomes Studies
pgA425 PIH15 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME
Sintonen H1, Viita AM2, Leinonen ES2, Apajasalo M3, Sipilä I4, 1University of Helsinki, Helsinki, Finland, 2Oy Eli Lilly Finland Ab, Vantaa, Finland, 3Hospital for
Children and Adolescents, Helsinki, Finland, 4Mehiläinen Medical Center, Helsinki, Finland
pgA425 PIH16 PSYCHOMETRIC PERFORMANCE OF THE CHILDREN’S DERMATOLOGY QUALITY OF LIFE INDEX Malhan S1, Oksuz E1, Tulunay FC2, 1Baskent University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey
pgA425 PIH17 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
Malhan S1, Oksuz E1, Tulunay FC2, 1Baskent University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey
pgA426 PIH18 RELIABILITY, AND VALIDITY OF THE FATIGUE SYMPTOM INVENTORY
Oksuz E1, Malhan S1, Tulunay FC2, 1Baskent University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey
pgA426 PIH19 THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND
Søltoft F1, Hammer M2, Kragh N2, 1University of Copenhagen, Frederiksberg C, Denmark, 2Novo Nordisk A/S, Bagsværd, Denmark
pgA426 PIH20 WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY
Hainsworth KR1, Drendel AL1, Stevens MW2, 1Medical College of Wisconsin, Milwaukee, WI, USA, 2Medical College of Wisconsin; Children’s Hospital of Wisconsin, Milwaukee, WI, USA
pgA426 PIH21 EFFICACY OF TREATMENT AND PATIENT SATISFACTION IN TREATMENT OF CLIMACTERIC DISORDERS WITH SOY ISOFLAVONES: FRENCH APPROCH
Mares P1, Bruel P2, Boussetta S3, Taieb C4, 1Gynecologist Dpt, Nimes, France, 2Plantes et Médecines, Castres, France, 3Pierre Fabre, Boulogne Billancourt,
France, 4Pierre Fabre, Boulogne, France
INDIVIDUAL’S HEALTH - Health Care Use & Policy Studies
pgA427 PIH22 PRICE-ELASTICITY OF DEMAND FOR INFERTILITY SERVICES IN GERMANY
Connolly M1, Ledger WL2, 1Global Market Access Solutions, St Prex, Switzerland, 2University of Sheffield, Sheffield, UK
pgA427 PIH23 MEDICATION COSTS IN ELDERLY PATIENTS
Mendes Z1, Guedes S2, Batel Marques F3, Miranda A2, 1Cefar, Lisbon, Portugal, 2Infosaude, Lisbon, Portugal, 3University of Coimbra, Lisbon, Portugal
pgA427 PIH24 ASSESSMENT OF CURRENT CLINICAL PRACTICE AMONG PHYSICIANS AND SEX THERAPISTS REGARDING ERECTILE DYSFUNCTION (ED) TREATMENT
INITIATION WITH PHOSPHODIESTERASE-5 INHIBITORS (PDE5I)
Schnetzler G1, Marfatia A2, Symonds T3, Chambers R2, Muniain J4, 1Pfizer International Operations, Paris, France, 2Pfizer Inc, New York, NY, USA, 3Pfizer Global
Research & Development, Sandwich, UK, 4Surfernet, Rutherford, NJ, USA
INFECTION - Clinical Outcomes Studies
pgA428 PIN1 A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND
SOFT-TISSUE INFECTIONS (CSSTIS)
Logman JFS1, Treur MJ1, Verheggen BG1, Heeg BMS1, Stephens J2, Spiesser J3, Simoneau D3, Haider S4, Nathwani D5, Van Hout BA1, 1Pharmerit Europe, Rotterdam, The Netherlands, 2Pharmerit North America LLC, Bethesda, MD, USA, 3Pfizer PIO, Paris Cedex 14, France, 4Pfizer Inc, Groton, CT, USA, 5Ninewells Hospital
& Medical School, Dundee, UK
pgA428 PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN
AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS
Logman JFS1, Treur MJ1, Verheggen BG1, Heeg BMS1, Stephens JM2, Haider S3, Cappelleri J3, Nathwani D4, Tice A5, Van Hout BA1, 1Pharmerit Europe, Rotterdam, The Netherlands, 2Pharmerit North America LLC, Bethesda, MD, USA, 3Pfizer Inc, Groton, CT, USA, 4Ninewells Hospital & Medical School, Dundee, UK,
5
University of Hawaii, Honolulu, HI, USA
pgA428 PIN3 A SIMULATION-BASED APPROACH TO MODELING THE EFFECTS OF INTERVENTION STRATEGIES ON THE SPREAD OF MENINGOCOCCAL MENINGITIS
Smolen HJ1, Einterz RM2, 1Medical Decision Modeling Inc, Indianapolis, IN, USA, 2Indiana University, Indianapolis, IN, USA
pgA429 PIN4 A MARKOV MODEL TO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMAL TRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY
Deuffic-Burban S1, Moser A2, Cartier V2, Deltenre P3, Canva-Delcambre V3, Dharancy S3, Louvet A3, Roudot-Thoraval F4, Mathurin P3, 1INSERM U795, Lille,
France, 2Roche Pharma, Neuilly sur Seine Cedex, France, 3CHRU de Lille, Lille Cedex, France, 4Hopital Henri-Mondor, Creteil, France
pgA429 PIN5 IMPACT OF MASS VACCINATION WITH MMRV VERSUS MMR IN FRANCE ON THE EPIDEMIOLOGY OF VARICELLA AND HERPES ZOSTER, USING A DYNAMIC
TRANSMISSION MODEL
Vissers D1, Ouwens M1, Littlewood K1, Jansen JP2, 1Mapi Values, Houten, The Netherlands, 2Mapi Values, Boston, MA, USA
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
45
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA430 PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS®) AND RIBAVIRIN IN PA-
TIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING
Fagnani F1, Moser A2, Pinta A2, Hayem C2, Bourlière M3, Ouzan D4, Deffoel M5, Marcellin P6, Vray M7, 1Cemka-Eval, Bourg-la-Reine, France, 2Roche Pharma,
Neuilly sur Seine cedex, France, 3Saint Joseph Hospital, Marseille, France, 4Institut, Saint-Laurent-du-Var, France, 5CHU Strasbourg, Strasbourg, France, 6Hôpital
Beaujon, Clichy, France, 7Institut Pasteur, Paris, France
pgA430 PIN7 PHARMACOGENOMICS: RELEVANCE AND APPLICABILITY IN POST-GENOMIC ERA (HIV-THERAPY)
Chawla A, Kumar R, Aneja G, Bhanderi M, Sehgal M, Heron Health Private Ltd, Chandigarh, India pgA430 PIN8 PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND
Das R, Edwards SJ, Emmas C, AstraZeneca UK Ltd, Luton, UK
INFECTION - Cost Studies
pgA431 PIN9 BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE VACCINATION WITH A QUADRIVALENT HPV-VACCINE IN NORWAY
Kristensen FKO, Sverre JM, Nyhus K, PharmEcon, Asker, Akershus, Norway
pgA431 PIN10 THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES
Ho J, Becker RV, Dymaxium Inc, Toronto, ON, Canada
pgA431 PIN11 COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND
Väänänen JJP1, Herse F1, Korkeamäki J2, Parvinen PMT1, Remy V3, 1Nordic Healthcare Group, Helsinki, Finland, 2Sanofi Pasteur MSD Oy, Helsinki, Finland,
3
Sanofi Pasteur MSD, Lyon, France
pgA431 PIN12 COST-EFFECTIVENESS OF CERVARIXTM, A PROPHYLACTIC CERVICAL CANCER VACCINE, IN SPAIN
Gauthier A1, Moore L1, Martín-Escudero V2, Peterson C1, Pérez I2, de Sanjosé S3, 1i3 Innovus, Uxbridge, UK, 2GlaxoSmithKline, Madrid, Spain, 3ICO-CIBERESP,
Barcelona, Spain
pgA432 PIN13 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN ITALY
Viale P1, Sidhu M2, van Engen A3, Schoeman O3, 1Policlinico Universitario di Udine, Udine, Italy, 2Astellas Pharma Europe Ltd, Staines, UK, 3Quintiles Consulting,
Hoofddorp, The Netherlands
pgA432 PIN14 USING A DECISION SIMULATION MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE
CHB PATIENTS IN ITALY WITH ENTECAVIR AND TENOFOVIR Zammit DC1, Yuan Y2, Intorcia M3, Hay JW4, 1Bristol-Myers Squibb, Braine l-A’lleud, Belgium, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb,
Rome, Italy, 4University of Southern California, Los Angeles, CA, USA
pgA432 PIN15 COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV: RESULTS OF A DECISION MODEL WITH LOCAL DATA
García-Altés A1, Paladio N2, Pons J2, Tebé C2, 1Fundación Instituto de Investigación en Servicios de Salud, Barcelona, Spain, 2Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain
pgA433 PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS
Westra TA1, Rogoza R2, Ferko N2, Tamminga JJ3, Drummond MF4, Wilschut JC1, Postma MJ5, 1University Medical Centre Groningen, Groningen, The Netherlands,
2
i3 Innovus, Burlington, ON, Canada, 3GlaxoSmithKline BV, Zeist, The Netherlands, 4University of York, York, Heslington, UK, 5University of Groningen, Groningen, The Netherlands
pgA433 PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR
Littlewood K1, Vissers D1, Ouwens M1, Jansen JP2, Postma M3, 1Mapi Values, Houten, The Netherlands, 2Mapi Values, Boston, MA, The Netherlands, 3University
of Groningen, Groningen, The Netherlands
pgA433 PIN18 ANALYSIS OF COST-EFFECTIVENESS OF ITRACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN TURKISH SETTING
Kanbur B, Sarioz F, Tatar F, Janssen-Cilag, Istanbul, Turkey
pgA434 PIN19 PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING
Kanbur B, Sarioz F, Tatar F, Janssen-Cilag, Istanbul, Turkey
pgA434 PIN20 COST-EFFECTIVENESS OF SURGICAL INTERVENTION FOR THERAPY-INDUCED FACIAL LIPOATROPHY IN HIV-INFECTED PATIENTS
Massella M1, Scalone L2, Ivanovic J3, Narciso P3, Bellagamba R3, Fragola V1, Tozzi V3, 1Istituto Superiore di Sanità, Rome, Italy, 2Università degli Studi di Milano,
Milan, Italy, 3INMI L. Spallanzani, Rome, Italy pgA434 PIN21 ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS
Avxentyeva M, Vorobyev P, Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia
pgA435 PIN22 COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST ROTAVIRUS WITH RIX4414 IN FRANCE
Standaert BA1, Parez N2, Tehard B3, Colin X4, Detournay B5, 1GlaxoSmithKline Biologicals, Rixensart, Belgium, 2Assistance Publique, Hôpital Armand Trousseau,
Paris, France, 3GlaxoSmithKline, Marly-le-Roi, France, 4Cemka-Eval, Bourg-La-Reine, France, 5CEMKA-EVAL, Bourg-la-Reine, France
pgA435 PIN23 COST-EFFECTIVENESS ANALYSIS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN: TRANSMISSION DYNAMIC MODEL-BASED EVALUATIONS
Fann CS1, Wu D2, Huang YC3, Chang CJ4, 1Academia Sinica, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3Chang-Gung Memorial Hospital,
Taoyuan, Taiwan, 4Chang Gung University, Taoyuan, Taiwan
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
46
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA435 PIN55COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAÏVE, PI-RESISTANT, HIV-INFECTED ADULTS IN
THE UK, BELGIUM, ITALY AND SWEDEN
Moeremans K1, Hemmett LC2, Hjelmgren J3, Allegri G4, Smets E5, 1IMS Health HEOR, Brussels, Belgium, 2Tibotec, a division of Janssen-Cilag Ltd, Buckinghamshire, UK, 3Janssen-Cilag AB, Sollentuna, Sweden, 4Tibotec, a division of Janssen-Cilag S.p.A, Cologno Monzese - Milano b, Italy, 5Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium
pgA436 PIN24 ECONOMIC AND CLINICAL IMPACT OF IMPLEMENTATION OF AN ACELLULAR PERTUSSIS VACCINE IN CANADA
Iskedjian M1, Walker J1, De Serres G2, Einarson TR1, 1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2Université Laval, Québec, QC, Canada
pgA436 PIN25 COST-EFFECTIVENESS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) INCLUDING HERD PROTECTION IN TURKEY
Türel Ö1, McIntosh D2, Bakir M1, 1Marmara University, Istanbul, Turkey, 2Wyeth Europe, Berkshire, UK
pgA436 PIN26 COST-EFFECTIVENESS OF TREATMENT WITH PEGASYS/COPEGUS IN HIV/HCV CO-INFECTED PATIENTS IN PORTUGAL
Macedo A1, Monteiro I2, Nunes S1, Farinha S2, Pereira C2, 1KeyPoint, Consultoria Científica Lda, Lisbon, Portugal, 2Roche Farmacêutica Química, Lda, Amadora,
Portugal
pgA437 PIN27 COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE
CANDIDIASIS
Verheggen BG1, Heeg BMS1, Vos CBJ2, Van Hout BA1, 1Pharmerit Europe, Rotterdam, The Netherlands, 2Merck Sharp & Dohme BV, Haarlem, The Netherlands
pgA437 PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY: A COST-EFFECTIVENESS ANALYSIS
O’Sullivan AK1, Buti M2, Delong K1, Prasad M3, Sabater FJ4, Esteban R2, Weinstein MC5, 1i3 Innovus, Medford, MA, USA, 2Hospital General Universitario Valle de
Hebrón, Barcelona, Spain, 3Schering-Plough Corporation, Kenilworth, NJ, USA, 4Schering-Plough S.A, Alcobendas, Spain, 5Harvard University, Boston, MA, USA
pgA437 PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING – A SYSTEMATIC REVIEW
Sroczynski G1, Esteban E1, Conrads-Frank A1, Schwarzer R1, Mühlberger N1, Wright DR2, Zeuzem S3, Siebert U1, 1UMIT - University for Health Sciences, Medical
Informatics and Technology, Hall, Tirol, Austria, 2Harvard School of Public Health, Boston, MA, USA, 3Johann Wolfgang Goethe-University, Frankfurt a.M, Germany
pgA438 PIN30 COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA (ACTIVATED; DAA) AS A TREATMENT FOR SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE
(MOF) IN POLAND
Kuzma J1, Kawalec P1, Bochenski P2, 1Centrum HTA, Krakow, Poland, 2Ely Lilly, Warsaw, Poland
pgA438 PIN31 COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS
Martin SC, Johnson & Johnson Pharmaceutical Services, LLC, Mechelen, Belgium
pgA438 PIN32 COSTS OF INTERMITTENT VERSUS CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH CONTROLLED HIV INFECTION. A SUBSTUDY OF THE ANRS
106 WINDOW TRIAL
Charreau I1, Jeanblanc G2, Tangre P1, Marchou B3, Aboulker JP1, Molina JM4, Durand-Zaleski I2, 1Paul Brousse Hospital, Villejuif, France, 2Henri Mondor Hospital,
Créteil, France, 3Purpan Hospital, Toulouse, France, 4Hôpitaux de Paris, Paris, France
pgA439 PIN33 COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR
Bueno RLP1, Prismich G2, Suzuki C2, 1FEI, São Paulo, Brazil, 2Novartis Biociências S/A, São Paulo, Brazil
pgA439 PIN34 COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY
Malhan S1, Oksuz E1, Tulunay FC2
1
Baskent University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey
pgA439 PIN35 HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY
Postma MJ1, Williams P2, Neurohr C3, Welte R3, 1University of Groningen, Groningen, The Netherlands, 2Navitas BioPharma Consulting, Buckinghamshire, UK,
3
GlaxoSmithKline, Munich, Germany pgA439 PIN36 SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH RISK COUNTRIES
Arora M, Srivastava K, Siddiqui MK, Verma J, Ahuja M, Sharma S, Heron Health Private Ltd, Chandigarh, India
pgA440 PIN37 GENITAL WARTS IN ITALY: A COST OF ILLNESS ANALYSIS
Bamfi F1, Marocco A1, Capri S2, Sideri M3, 1GlaxoSmithKline Spa, Verona, Italy, 2Cattaneo-LIUC University, Castellanza, (Varese), Italy, 3European Institute of
Oncology, Milano, Italy
pgA440 PIN38 THE ECONOMIC BURDEN OF HCV AND HBV CO-INFECTION: EVIDENCE FROM UNITED STATES MANAGED CARE DATA
Mitra D1, Davis KL1, Medjedovic J2, Beam C3, Rustgi V4, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA
pgA440 PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED
STATES
Mitra D, Candrilli SD, RTI Health Solutions, Research Triangle Park, NC, USA
pgA441 PIN40 MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN
SPANISH HOSPITALS SETTINGS
Ruíz-Antorán B1, Hernández-Novoa B2, Galvez-Mújica M2, De-Pablo-López I2, Sánchez M3, Mazarrasa C3, Alonso M4, Castillo J5, Martí B6, Soto J6, 1Hospital Universitario Puerta de Hierro, Madrid, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 3Hospital Universitario “Marqués de Valdecilla”, Santander, Spain, 4Hospital
de la Santa Creu I Sant Pau, Barcelona, Spain, 5Hospital Universitario “Virgen del Rocio”, Sevilla, Spain, 6Health Outcomes Research, Pfizer, Spain
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
47
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA441 PIN41 DEVELOPING AN ECONOMIC MODEL OF GRAM+ COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREAT-
MENT SETTINGS
Stephens JM1, Treur MJ2, Heeg BMS2, Haider S3, Nathwani D4, Tice A5, 1PharMerit North America LLC, Bethesda, MD, USA, 2Pharmerit Europe, Rotterdam, The
Netherlands, 3Pfizer Inc, New London, CT, USA, 4Ninewells Hospital & Medical School, Dundee, UK, 5Infections Limited Hawaii, Honolulu, HI, USA
pgA441 PIN42 DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER
Chen S1, Schafer V1, Ottino JA1, Bharmal M2, Gemmen E2, Choe Y1, 1ConvaTec, Skillman, NJ, USA, 2Quintiles Inc, Falls Church, VA, USA
pgA352 IN4 ACHIEVING SUSTAINED VIROLOGIC RESPONSE WITH CHRONIC HEPATITIS C TREATMENT IS ASSOCIATED WITH IMMEDIATE HEALTH CARE UTILIZATION
BENEFITS IN EUROPE Zhang H1, Narayanan S2, 1Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, 2TNS Healthcare, New York, NY, USA
pgA442 PIN43 DIFFERENCE IN HEALTHCARE UTILIZATION IN EUROPE BETWEEN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTS WHO FAILED
PRIOR THERAPY
Zhang H1, Narayanan S2, 1Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, 2TNS Healthcare, New York, NY, USA
INFECTION - Patient-Reported Outcomes Studies
pgA442 PIN45 IMPACT OF PATIENT-HEALTH CARE PROVIDER COMMUNICATION: THE HIV/AIDS PATIENTS’ PERSPECTIVES
Layton MR1, Kerr SJ2, Chetchotisakd P3, 1Khon Kaen University, Khon Kaen, Thailand, 2University of New South Wales, Sydney, New South Wales, Australia,
3
Khon Kaen University, Khon Kaen, Khon Kaen, Thailand
pgA443 PIN46 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER
Chen S1, Schafer V1, Ottino JA1, Bharmal M2, Gemmen E2, Choe Y1, 1ConvaTec, Skillman, NJ, USA, 2Quintiles Inc, Falls Church, VA, USA
pgA443 PIN47 VALIDATION OF THE SINONASAL OUTCOME TEST-16 (SNOT-16) IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
Lloyd A1, Uhl-Hochgraber K2, Piccirillo JF3, 1Oxford Outcomes Ltd, Oxford, UK, 2Bayer Schering Pharma, Berlin, Germany, 3Washington University School of Medicine, St. Louis, MO, USA
pgA443 PIN48 VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
Lloyd A1, Uhl-Hochgraber K2, Keating K3, 1Oxford Outcomes Ltd, Oxford, UK, 2Bayer Schering Pharma, Berlin, Germany, 3Bayer HealthCare Pharmaceuticals,
West Haven, CT, USA
pgA444 PIN49 INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS – PROQOL HIV STUDY
Duracinsky M1, Acquadro C2, Berzins B3, Hermann S4, Le Coeur S5, Fournier I6, Diouf A7, Kohli R8, Chassany O9, 1Centre Hospitalier Universitaire de Bicetre, Le
Kremlin-Bicetre, France, 2AP HP, Paris, France, 3Northwestern University, Chicago, Chicago, IL, USA, 4Royal Perth Hospital, Perth, Australia, 5Institut National
d’Etudes Démographiques (INED), Chiang Mai, Thailand, 6Institut Pasteur, Phnom Penh, Cambodia, 7Centre de Recherche Clinique de Fann (CRCFP), Dakar,
Senegal, 8National AIDS Research Institute, Pune, India, 9Assistance Publique - Hopitaux de Paris, Paris, France
INFECTION - Health Care Use & Policy Studies
pgA444 PIN50 A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES
De Abreu Lourenco R, Strizek A, Covance, North Ryde, New South Wales, Australia
pgA444 PIN51 EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT A LARGE INNER-CITY ACADEMIC MEDICAL CENTER IN THE SURVIVING SEPSIS CAMPAIGN ERA
Ohuabunwo CJ1, Fotzeu C1, Heisler M2, VanDenBerg C3, 1Morehouse School of Medicine, Atlanta, GA, USA, 2Emory UNiversity, Atlanta, GA, USA, 3Grady Health
System, Atlanta, GA, USA
pgA445 PIN52 UTILIZATION ANALYSIS AND IMPACT OF ANTIBACTERIAL AGENTS IN TWO LEADING UNIVERSITY HOSPITALS IN NEIGHBORING COUNTRIES WITH DIFFERENT GDP AND HEALTH CARE SYSTEM
Francetic I1, Gavrankapetanovic F2, Begovic B2, Bielen L3, Bolanca S4, 1University Hospital Center Zagreb, Zagreb, Croatia, 2Clinical Center University of Sarajevo, Sarajevo, Bosnia, 3Medical School University of Zagreb, Zagreb, Croatia, 4Pfizer Croatia, Zagreb, Croatia
pgA445 PIN53 PHARMACY-IMPLEMENTED GUIDELINES ON SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS : A PROSPECTIVE STUDY IN A TEACHING HOSPITAL
Briquet C1, D’Hoore W2, Bisot-Locard S3, Simon A1, Tilleul P3, 1Cliniques Universitaires Saint Luc, Brussels, Belgium, 2Université Catholique de Louvain (UCL),
Brussels, Belgium, 3Université Paris Descartes, Paris, France
INFECTION - Conceptual Papers & Research on Methods
pgA445 PIN54 ADAPTATION & CALIBRATION OF A UK MODEL OF MENINGOCOCCAL DISEASE TO THE US SETTING
Aballéa S1, McGarry LJ2, Taylor DC2, Hill G2, Pawar V2, Clements KM2, Thompson D2, 1i3 Innovus, Uxbridge, Middlesex, UK, 2i3 Innovus, Medford, MA, USA
RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies
pgA446 PRS1 SMOKING, ASTHMA AND COPD IN ADULTS: A TOO FREQUENT RELATION
Sicras A1, Navarro-Artieda R2, 1Badalona Servicios Asistenciales, Barcelona, Spain, 2Hospital Germans Trias i Pujol, Barcelona, Spain
pgA446 PRS2 RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN
Blais L1, Kettani FZ1, Lemière C2, Beauchesne MF1, Perreault S1, Elftouh N1, 1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
48
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA446 PRS3 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES
Citarella A, Menditto E, Cammarota S, De Portu S, Riegler S, Mantovani LG, University of Naples, Federico II, Naples, Italy
pgA447 PRS4 SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR OF ASTHMA EXACERBATION IN A MANAGED CARE POPULATION
Stephenson JJ1, Quimbo RA1, Dai D1, Gutierrez B2, 1HealthCore Inc, Wilmington, DE, USA, 2AstraZeneca, Wilmington, DE, USA
pgA447 PRS5 ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE ATOPIC CONDITIONS IN UK: COHORT STUDY USING THE GENERAL PRACTICE RESEARCH
DATABASE
Punekar YS1, Gibbons CJ1, Sheikh A2, 1Schering-Plough Ltd, Welwyn Garden City, UK, 2University of Edinburgh, Edinburgh, UK
RESPIRATORY-RELATED DISORDERS - Cost Studies
pgA448 PRS7 THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN: AN ECOMIC MODEL TO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL
Darba J1, Restovic G2, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain
pgA448 PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS
OF RESISTANCE
Cure S1, Quilici S1, Martin M1, Evers T2, Schaberg T3, Mitfessel H4, 1i3 Innovus, Uxbridge, Middlesex, UK, 2Bayer Schering Pharma, Wuppertal, Germany, 3Lungenklinik Unterstedt - Zentrum für Pneumologie, Rotenburg(Wümme), Germany, 4Private practice, Remscheid, Germany
pgA449 PRS11 COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE + RELIEVER THERAPY
Kuna P1, Aubier M2, Buhl R3, 1Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, 2Hôpital Bichat Claude Bernard, Paris, France, 3Mainz University Hospital, Mainz, Germany
pgA449 PRS12 COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART® VERSUS FIXED COMBINATION TREATMENTS IN FINLAND
Tamminen K1, Laine J1, Soini EJ2, Martikainen JA2, Kankaanranta H3, 1AstraZeneca, Espoo, Finland, 2ESiOR Oy, Kuopio, Finland, 3Seinäjoki Central Hospital,
Seinäjoki, AL, Finland
pgA450 PRS13 THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK
Poulsen PB1, Dollerup J1, Keiding H2, 1Pfizer Denmark, Ballerup, Denmark, 2University of Copenhagen, Copenhagen, Denmark
pgA450 PRS14 COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS IN MEXICO
Del-Rio Navarro B1, Reyes-Lopez A1, Lemus A2, 1Federico Gomez” Mexican Children Hospital, Mexico City, Mexico, 2Sanofi aventis de México, Mexico City, D.F,
Mexico
pgA450 PRS15 ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES WITH MILD COPD – RESULTS FROM THE KORA F3 STUDY
Menn P1, John J1, Heinrich J2, Döring A2, Brüske-Hohlfeld I2, Holle R1, 1Institute of Health Economics & Health Care Management, Helmholtz Center Munich,
Neuherberg, Germany, 2Institute of Epidemiology, Helmholtz Zentrum Munich, Neuherberg, Germany
pgA450 PRS16 THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE
Hatzikou M1, Ravikalis V2, Steiropoulos P3, Geitona M1, Bouros D3, 1University of Thessaly, Volos, Greece, 2University of Alexandroupolis, Alexandroupolis,
Greece, 3University Hospital of Alexandroupolis, Alexandroupolis, Greece
pgA451 PRS17 COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007
Jahnz-Rózyk K, Targowski T, Mierzejewska MJ, From S, Military Institute of Health Service, Warsaw, Poland
pgA451 PRS18 DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI
Ohsfeldt R1, Summers KH2, Lage MJ3, Brooks JM4, Brewster C5, 1Texas A&M Health Science Center, College Station, TX, USA, 2Purdue University, West Lafayette, IN, USA, 3HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 4USRDS Economic Special Study Center, The University of Iowa, Iowa City, IA, USA,
5
Teva Neuroscience/Teva Specialty Pharmaceuticals, Kansas City, MO, USA
RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes Studies
pgA451 PRS19 RATES OF DISCONTINUATION AMONG COMMONLY PRESCRIBED MEDICATIONS IN THE US
Vanelli MR, Pedan A, Messier D, Hoar J, Liu N, Kiarsis K, Adheris, Inc, Burlington, MA, USA
pgA452 PRS20 SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS AND UNIT-OF-USE PACKAGING IN PATIENTS WITH HYPERTENSION, DYSLIPIDEMIA, AIDS, ASTHMA
AND DIABETES TYPE 2
Paladio N, Almazan C, Moharra M, Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain
pgA452 PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?
Williams AE1, Frith L2, Gul N2, Agier L3, Juniper E4, 1GlaxoSmithKline R&D, Uxbridge, UK, 2GlaxoSmithKline R&D, London, UK, 3ENSAI Engineering School, Bruz,
France, 4McMaster University, Hamilton, ON, Canada
pgA452 PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?
Juniper E1, Agier L2, Williams AE3, Frith L4, Gul N4, 1McMaster University, Hamilton, Ontario, Canada, 2ENSAI Engineering School, Bruz, France, 3GlaxoSmithKline
R&D, Uxbridge, UK, 4GlaxoSmithKline R&D, London, UK
pgA453 PRS23 IS THE EQ-5D RESPONSIVE TO RECOVERY FROM A MODERATE COPD EXACERBATION?
Goossens L1, Rutten-van Molken M1, Nivens C2, 1Erasmus MC, Rotterdam, The Netherlands, 2Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT, USA
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
49
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION I – SUNDAY, 9 NOVEMBER 2008: DISPLAY HOURS: 12:00 – 19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30 – 18:30
pgA453 PRS24 QUALITY OF LIFE RESULTS USING THE EUROQOL QUESTIONNAIRES AND DIRECT MEDICAL COSTS IN ASTHMATIC PATIENTS. CHAS STUDY
Tafalla M, Nuevo J, Cordero L, Hernandez R, AstraZeneca, Madrid, Spain
pgA453 PRS25 THE PUBLIC’S WILLINGNESS TO PAY FOR A QALY IN THAILAND
Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Health Intervention and Technology Assessment Program (HITAP), Nontaburi, Thailand
pgA454 PRS26 THE EXACT-PRO INITIATIVE: DEVELOPMENT AND VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME MEASURE FOR EVALUATING EXACERBATIONS
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Leidy NK, Wilcox TK, Roberts L, Winnette RM, Murray L, United BioSource Corporation, Bethesda, MD, USA
pgA454 PRS27 INTERPRETING SCORES ON THREE PATIENT-REPORTED OUTCOME MEASURES FOR ASTHMA
Meads DM1, Twiss J1, McKenna SP1, Revicki D2, Pokrzywinski R3, Gale R4, 1Galen Research, Manchester, UK, 2United BioSource Corporation, Bethesda, MD,
USA, 3United Biosource Corporation, Pittsburgh, PA, USA, 4Novartis AG, Horsham, UK
pgA454 PRS28 HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES
Gueron B1, Freedman D2, Annunziata K2, Poterre M1, 1GSK, Marly le Roi, France, 2Consumer Health Sciences, Princeton, NJ, USA
pgA454 PRS29 SOCIOECONOMIC ANALYSIS OF SMOKER’S PROFILE WHO INTENDS TO QUIT
Ramón JM1, Bruguera E2, Sanz de Burgoa V3, Ramírez E4, 1Hospital de Bellvitge, Barcelona, Spain, 2Hospital Vall d’Hebron, Barcelona, Spain, 3Laboratorios
Pfizer, Alcobendas, Madrid, Spain, 4Infociencia S.L, Barcelona, Spain
pgA455 PRS30 HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS OF ASTHMA CONTROL? – PRELIMINARY FINDINGS FROM A QUALITATIVE STUDY
Ruedell K1, Bonner N2, Arbuckle R2, Abetz L3, Hareendran A4, Gilbert C4, 1Pfizer Ltd, Sandwich, UK, 2Mapi Values Ltd, Bollington, UK, 3Mapi Values, Bollington,
UK, 4Pfizer, Ltd, Sandwich, UK
pgA455 PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE
Gueron B1, Canonica GW2, Bousquet J3, Mullol J4, Scadding G5, Virchow JC6, 1GSK, Marly le Roi, France, 2University of Genova, Genova, Liguria, Italy, 3INSERM,
Montpellier, MT, France, 4Institut D’investigacions Biomediques August Pi I Sunyer, Barcelona, Spain, 5Royal National Throat, Nose and Ear Hospital, London,
UK, 6Universitatsklinik Rostock, Rostock, Germany
pgA455 PRS32 SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY ASTHMA PATIENTS
Williams A1, Jacques L1, Rofail D2, Heelis R2, 1GlaxoSmithKline R&D, Uxbridge, UK, 2Mapi Values, Bollington, Cheshire, UK
pgA456 PRS33 FACTORS AFFECTING QUALITY OF LIFE OF ASTHMATIC AND COPD PATIENTS
Meszaros A, Orosz M, Mesko A, Semmelweis University, Budapest, Hungary
pgA456 PRS34 QUALITY OF LIFE DURING ACUTE EXACERBATIONS OF COPD: COMPARING EQ-5D, SF-12 AND SGRQ
Menn P1, Weber N2, Häußinger K2, Holle R1, 1Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany,
2
Asklepios Fachkliniken, Gauting, Germany
pgA456 PRS35 CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA A TURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS
RELIEF, AND IT’S INFLUENCE ON ASTHMA CONTROL AND PATIENTS’ WELL-BEING IN GREECE
Rasidakis A1, Kostagiolas L2, Daskos G2, 1Metropolitan Hospital, Athens, Greece, 2AstraZeneca SA, Athens, Greece
pgA457 PRS36 WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA
Park D1, Ko S2, 1Seoul National University, Seoul, South Korea, 2Pfizer Korea, Seoul, South Korea
RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies
pgA457 PRS37 RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUG THERAPY
Vaidya V1, Hufstader MA2, 1University of Tennessee, Memphis, TN, USA, 2University of Tennessee Health Science Center, Memphis, TN, USA
pgA457 PRS38 DEVELOPMENT OF EXPLICIT APPROPRIATENESS CRITERIA FOR THE INDICATION OF ADMISSION FROM PATIENTS WITH ACUTE COPD EXACERBATION
Quintana JM1, Escobar A2, Esteban C3, Aguirre U3, Garcia S3, Gonzalez N3, 1Hospital de Galdakao-Usansolo, Galdakao, Spain, 2Hospital de Basurto, Bilbao,
Spain, 3Hospital Galdakao-Usansolo, Galdakao, Vizcaya, Spain
pgA458 PRS39 GIVING-UP SMOKING: PREDICTIVE FACTORS OF SMOKING CESSATION AND ATTEMPTS TO STOP IN A FRENCH COHORT
Thomas D, Cardiology Institut, Paris, France
pgA458 PRS40 DECISION-MAKING IN HEALTH CARE USING COST-EFFECTIVENESS EVIDENCE - SMOKING CESSATION COMPARED TO TREATMENT OF SMOKING-RELATED
DISEASES
Poulsen PB1, Dollerup J1, Randskov HJ1, Pedersen KM2, 1Pfizer Denmark, Ballerup, Denmark, 2University of Southern Denmark, Odense, Denmark
RESPIRATORY-RELATED DISORDERS - Conceptual Papers & Research on Methods
pgA458 PRS41 USE OF AN ELECTRONIC DIARY IN 55 COUNTIRES: WHAT ARE THE CHALLENGES?
Muller S1, Kaschinski D2, 1Mapi Research Institute, Lyon, France, 2Boehringer Ingelheim International GMBH, Ingelheim/Rhein, Germany
pgA459 PRS42 SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS
Vemer P, Rutten-van Molken M, Erasmus MC, Rotterdam, The Netherlands
Sunday, 9 November – Research Poster Presentations – Session I includes the following topics:
PHP – HEALTH POLICY
PCV – CARDIOVASCULAR DISORDERS (Stroke, Other Cardiovascular)
PIH – INDIVIDUAL’S HEALTH (Children’s, Elderly, Men’s, Women’s)
PIN – INFECTION
PRS – RESPIRATORY-RELATED DISORDERS (Allergy, Asthma, Smoking, Other Respiratory)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
50
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
research poster presentations
research poster presentationS - SESSION II
< < <
< < < < < <
< < <
PDB
PGI
PHC
< < <
PMS
< < <
< < <
< < <
< < <
PGI
PGI
< < < < < <
< < <
< < <
PCN
< < <
PDB
< < < < < <
< < <
< < <
PDB
PMS
PCN
< < <
Hesperides
< < <
PCN
PMS < < <
< < < < < <
< < <
PMS
< < < < < <
To Hesperides
< < <
PCN
< < < < < < <
Hesperides Foyer
PCASE
< < < < < <
PCN
< < < < < <
< < < < < <
PCN
< < < < <
< < < < <
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
PMS
HEALTH CARE DECISION-MAKER’S CASE STUDIES
pgA657PCASE 1ESTABLISHMENT OF A COST-EFFECTIVENESS (CE) THRESHOLD AT KING HUSSEIN CANCER CENTER: IMATINIB IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
Jabr MF, Treish IM, King Hussein Cancer Center, Amman, Amman, Jordan
pgA658PCASE 2 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF CETUXIMAB AT A MAJOR ACADEMIC CANCER CENTER
Miller LA, Lal LS, Arbuckle R, University of Texas - MD Anderson Cancer Center, Houston, TX, USA
pgA658PCASE 3 USING IN-HOUSE STRATEGIES TO OVERCOME INCONSISTENCIES BETWEEN EXPENDITURES AND BUDGETING
Oren M, Schwartzberg E, Ben-Moshe A, Haspel J, Hillel Yaffe Medical Center, Hadera, Israel
pgA659PCASE 4BRIDGING THE GAP OF EVIDENCE AND COST-EFFECTIVENESS: THE PRAGMATIC APPROACH USING ECONOMIC MODELLING TO ASSESS THE COST-EFFECTIVENESS FOR ASSISTIVE TECHNOLOGIES (AT) IN THE UK- BOTH PRE-AND POSTMARKETED
Retsa MP1, Down K2, Guhl A1, Ferguson-Pell M3, 1NHS Innovations London Ltd, London, UK, 2Foundation for Asssitive Technologies (F.A.S.T), London, UK, 3University of Alberta, Edmonton, AB, Canada
CANCER - Clinical Outcomes Studies
pgA459 PCN1 THIRD-GENERATION AROMATASE INHIBITORS VS TAMOXIFEN IN THE TREATMENT OF EARLY AND ADVANCED BREAST CANCER: A SYSTEMATIC REVIEW
OF RANDOMISED CONTROLLED TRIALS
von Maltzahn R, Edwards SJ, AstraZeneca UK Ltd, Luton, UK
pgA459 PCN2 EFFICACY OF LEUPRORELIN 3.75MG COMPARED TO 7.5MG IN THE TREATMENT OF PROSTATE CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS
Payne HA1, Edwards SJ2, 1University College London Hospitals, London, UK, 2AstraZeneca UK Ltd, Luton, UK
pgA460 PCN4 EFFICACY OF OPIOIDS IN THE TREATMENT OF BREAKTHROUGH CANCER PAIN: A BAYESIAN MIXED TREATMENT COMPARISON
Stam W1, Lenre M2, Jansen JP3, 1Mapi Values, Houten, The Netherlands, 2Nycomed, Taastrup, Denmark, 3Mapi Values, Boston, MA, USA
pgA460 PCN5 TREATMENT EFFECT OF RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE (R-FC) VERSUS FC IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN AN
OBSERVATIONAL SETTING: AN INVESTIGATION OF PROGNOSTIC FACTORS AND LIFETIME HEALTH OUTCOMES
Keating MJ1, Lerner S1, Weisgerber-Kriegl U2, 1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
51
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA461 PCN6 MODELING LUNG AND BREAST CANCER INCIDENCE IN SPAIN: A ZERO INFLATED NEGATIVE BINOMIAL REGRESSION APPROACH
Villa G, Cuervo J, Rebollo P, BAP Health Outcomes Research, Oviedo, Asturias, Spain
pgA461 PCN7 ANALYSIS AND CATEGORISATION OF DRUG-RELATED PROBLEMS ASSOCIATED WITH SYSTEMIC BREAST CANCER THERAPY
Reineking N, Glasmacher A, Kühr M, Braun M, Kuhn W, Jaehde U, University of Bonn, Bonn, NRW, Germany
pgA461 PCN8 QUALITY OF LIFE-ADJUSTED SURVIVAL FOR FIRST LINE TREATMENT WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE AND VINCRISTINE (CVP) VERSUS CVP
ALONE FOR PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
Aultman R1, Jost F1, Marcus R2, 1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2Kings College Hospital, London, UK
CANCER - Cost Studies
pgA462 PCN9 COST OF MANAGEMENT VERSUS REIMBURSEMENT COST OF THE MANAGEMENT OF PATIENTS WITH SOLID TUMORS PRESENTING A FEBRILE NEUTROPENIA
Borget I1, Bailllot S1, Schwarzinger M1, Bogillot O2, Antoun S1, Merad M1, 1Institut de Cancérologie Gustave Roussy, Villejuif, France, 2Amgen S.A, Paris, France
pgA462 PCN11 BUDGET IMPACT ANALYSIS OF DIFFERENT TREATMENT PROTOCOLS FOR TRASTUZUMAB
Purmonen T1, Auvinen P2, Martikainen JA1, 1University of Kuopio, Kuopio, Finland, 2Kuopio University Hospital, Kuopio, Finland
pgA463 PCN12 BUDGETARY IMPACT OF XELOX IN COLORECTAL CANCER IN ITALY
Nuijten MC1, Giuliani G2, de Reydet de Vulpillières F3, 1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Roche S.p.A, Milano, Italy, 3F. Hoffman-La
Roche, Basel, Switzerland
pgA463 PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST
CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND
Walczak J1, Gebus E1, Lasota K1, Semeniuk A1, Malczak I1, Pawlik D1, Lis J2, Glasek M2, Nogas G1, 1Arcana Institute, Cracow, Poland, 2Sanofi-Aventis sp. z o.o,
Warsaw, Poland
pgA463 PCN14 A MODEL TO DEMONSTRATE THE COMPARATIVE COSTS BETWEEN PANITUMUMAB AND CETUXIMAB FOR THIRD-LINE METASTATIC COLORECTAL CANCER
PATIENTS IN ITALY
Lamarque H1, Fitzgibbon JW2, Farrimond BJ2, Lavelle RJB2, Eggington SG3, Bracco A1, 1AMGEN (Europe) GmbH, Zug, Switzerland, 2IMS Consulting, Cambridge,
Cambridgeshire, UK, 3IMS Health, London, UK
pgA464 PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT A TERTIARY CANCER CENTER
Lal LS, Maewal I, Miller LA, Smith WD, Arbuckle R, University of Texas MD Anderson Cancer Center, Houston, TX, USA
pgA464 PCN16 ANALYSIS OF COSTS AND CONSEQUENCES IN CANCER PATIENTS RECEIVING CAPECITABINE
Roth S1, Lehmann S1, Simons S1, Dietrich ES2, Ko Y3, Kuhn W4, Ruberg K5, Schwindt P6, Wolter H6, Jaehde U1, 1University of Bonn, Bonn, Germany, 2TK Scientific Institute for Benefit and Efficiency in Health Care, Hamburg, Germany, 3Johanniter Hospital, Bonn, Germany, 4University Hospital Bonn, Bonn, Germany,
5
Kronen Apotheke Marxen, Wesseling, Germany, 6Oncology Practice, Bonn, Germany
pgA464 PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC)
PATIENTS RECEIVING PANITUMUMAB IN GREECE
Papagianopoulou V1, Christodoulopoulou A2, Bracco A3, Yfantopoulos I1, 1University of Athens, Athens, Greece, 2Amgen Hellas, Athens, Greece, 3Amgen (Europe) GmbH, Zug, Switzerland
pgA465 PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER
Durbecq V, Veys I, Majjaj S, Schobbens JC, Noterman D, Filippov V, Sirtaine N, Bourgeois P, Nogaret J, Larsimont D, Institut Jules Bordet, Bruxelles, Belgium
pgA465 PCN19 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A MODELLING APPROACH FOR THE UK
Garrell D1, Griebsch I2, Samyshkin Y3, 1Merck Serono UK, Feltham, UK, 2Merck KGaA, Darmstadt, Germany, 3IMS Health, London, UK
pgA465 PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN
SETTING
AlOmar H1, Zazaa AS2, AlFayyadh M1, Ray JA3, 1Healthcare Experts, Riyadh, Saudi Arabia, 2F. Hoffmann-La Roche Ltd, Jeddah, Saudi Arabia, 3F. Hoffmann-La
Roche, Basel, Switzerland
pgA466 PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FOR WOMEN WITH HER2+ METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND
Färkkilä N1, Torvinen S1, Bergius S1, Delea T2, Sofrygin O2, Walker M3, 1GlaxoSmithKline Oy, Espoo, Finland, 2Policy Analysis Inc. (PAI), Brookline, MA, USA,
3
GlaxoSmithKline, London, UK
pgA466 PCN22 AN ECONOMIC EVALUATION OF CAPECITABINE/CISPLATIN PLUS 5-FU/CISPLATIN REGIMENS IN TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN
Darba J1, Restovic G2, Ramírez de Arellano A3, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona,
Spain, 3Roche Farma SA, Madrid, Spain
pgA466 PCN23 COST EFFECTIVENESS OF CLODRONATE AND ZOLENDRONATE FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BRAZIL: PUBLIC HEALTH
PERSPECTIVE
Fonseca M1, Machado M2, Araujo G1, Cruz LS3, 1Axia.Bio Consulting, São Paulo, Brazil, 2University of Toronto, Toronto, ON, Canada, 3Pacific Gateway International College, Toronto, ON, Canada
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
52
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA467 PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA - A COST-EFFEC-
TIVENESS STUDY FOR SCOTLAND
Gibbons CJ1, Yong K2, Roberts G3, 1Schering-Plough, Welwyn Garden City, UK, 2Royal Free and University College Medical School, London, UK, 3Oxford Outcomes
Ltd, Oxford, UK
pgA467 PCN25 COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS: THE BRAZILIAN PUBLIC HEALTH
CARE SYSTEM CASE
Santos EA, Saggia MG, Nasciben VD, Roche Brazil, Sao Paulo, SP, Brazil
pgA467 PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
Darba J1, Restovic G2, Ramiez de Arellano A3, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona,
Spain, 3Roche Farma SA, Madrid, Spain
pgA468 PCN27 ECONOMIC EVALUATION OF A TOBACCO CESSATION PROGRAM AT A MAJOR CANCER CENTER
Miller LA, Karam-Hage MA, Lal LS, Mallen M, Feng C, Blalock J, Cinciripini P, University of Texas - MD Anderson Cancer Center, Houston, TX, USA
pgA468 PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER-2 POSITIVE BREAST
CANCER
Polanco C1, Carulla M1, Badia X1, Ramirez-Arellano A2, 1IMS Health, Barcelona, Spain, 2Roche Farma, S.A, Madrid, Spain
pgA468 PCN29 ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMA VERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB
+ INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING
Munir U1, Benedict Á1, Borgman B2, Sandin R2, Harmenberg U3, Ullén A3, Sandström P3, 1United BioSource Corporation, Budapest, Hungary, 2Pfizer AB, Sollentuna, Sweden, 3Karolinska University Hospital, Stockholm, Sweden
pgA469 PCN30 COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY
Nagy L1, Erdesz D1, Lovas K2, Wisniewski T3, 1Merck Sharpe & Dohme, Budapest, Hungary, 2LK RO, Budapest, Hungary, 3Merck& Co., Inc, Whitehouse Station,
NY, USA
pgA469 PCN31 ECONOMIC EVALUATION OFCLODRONATE AND ZOLENDRONATE IN PATIENTS DIAGNOSED WITH METASTATIC BONE DISEASE FROM THE PERSPECTIVE OF
THIRD PARTY PAYORS IN BRAZIL
Machado M1, Araujo G2, Cruz LS3, Fonseca M2, 1University of Toronto, Toronto, ON, Canada, 2Axia.Bio Consulting, São Paulo, Brazil, 3Pacific Gateway International College, Toronto, ON, Canada
pgA469 PCN32 ECONOMIC ANALYSIS OF CHEMO RADIOTHERAPY IN HEAD AND NECK CANCER
Brentani A1, Federico M2, 1Faculdade de Medicina da universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da universidade de Sao
Paulo, São Paulo, Brazil
pgA469 PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) + BEVACIZUMAB
OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
Torrecillas L1, Vargas J2, 1Medical Center “20 de Noviembre”, ISSSTE, México, DF, Mexico, 2Econopharma Consulting SA de CV, Mexico, DF, Mexico
pgA470 PCN34 PHARMAECONOMIC EVALUATION OF THE USE OF ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC) WITH FAILURE TO PREVIOUS CHEMOTHERAPY
Tenorio C1, Vargas J2, Pacheco MI3, González-Michaca L3, 1Instituto Nacional de Cancerología, Mexico, DF, Mexico, 2Econopharma Consulting SA de CV, Mexico,
DF, Mexico, 3Roche México, México, DF, Mexico
pgA470 PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT
RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA
Soini EJ1, Martikainen JA1, Nousiainen T2, 1ESiOR, Kuopio, Finland, 2Kuopio University Hospital and University of Kuopio, Kuopio, Finland
pgA470 PCN36 PHARMACOECONOMIC COMPARISON OF TWO PROTOCOLS FAC VS. CMF IN THE TREATMENT OF EARLY BREAST CANCER
Ilic M1, Horvat O2, Sabo A2, Muzikravic L1, Jovanovic D1, Tomic Z3, 1Oncology Institute of Vojvodina, Sremska Kamenica, Serbia and Montenegro, 2University of
Novi Sad, Novi Sad, Serbia and Montenegro, 3University of Novi Sad, Sremska Kamenica, Serbia and Montenegro
pgA471 PCN38 COST-EFFECTIVENESS OF EXTENDED ADJUVANT TREATMENT WITH LETROZOLE IN SWEDEN
Lundkvist J1, Lindman H2, 1Novartis Sweden, Täby, Sweden, 2Akademiska Hospital, Uppsala, Sweden
pgA471 PCN39 EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE
Ducournau P1, Latimer N2, Sabate E3, Walzer S1, 1F. Hoffmann-La Roche, Basel, Switzerland, 2Roche Products Ltd, Welwyn Garden City, UK, 3F. Hoffmann–La
Roche, Basel, Switzerland
pgA472 PCN40 COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE
Macedo A1, Monteiro I2, Ray JA3, Cirrincione A3, Andrade S1, Pereira C2, 1KeyPoint, Consultoria Científica Lda, Lisbon, Portugal, 2Roche Farmacêutica Química,
Lda, Amadora, Portugal, 3F.Hoffmann-La Roche Ltd, Basel, Switzerland
pgA472 PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN The Netherlands
Essers BA1, Tjan Heijnen V1, Severens JL1, Novák A2, Oron U3, Pompen M4, Joore MA1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2AnovákServices, Apeldoorn, The Netherlands, 3Roche, Woerden, The Netherlands, 4Roche Netherland BV, Woerden, The Netherlands
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
53
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA472 PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF
METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE
Ducournau P1, Lewis G2, McDonald A3, Millar DR2, Sabate E1, Walzer S1, 1F. Hoffmann-La Roche, Basel, Switzerland, 2Roche Products, Welwyn Garden City, UK,
3
Western Infirmary, Glasgow, UK
pgA473 PCN43 MODELING THE COST-EFFECTIVENESS OF PROSTATE CANCER TREATMENT WITH PARTICLE THERAPY
Peeters A1, Joore MA2, Pijls-Johannesma M1, De Ruysscher D1, Dekker AL1, Grutters JP1, Reimoser S3, Severens JL2, Lambin P1, 1Maastro Clinic, Maastricht,
The Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands, 3Turner & Townsend, Munchen, Germany
pgA473 PCN44 COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCER TREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS
IN POLISH SETTING
Kawalec P1, Szawlowski A2, Federowicz I2, Szkultecka-Debek M3, Russel-Szymczyk M3, 1Centrum HTA, Krakow, Poland, 2M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Warsaw, Poland, 3Roche Polska, Warsaw, Poland
pgA473 PCN45 ECONOMIC ANALYSIS OF THE CLINICAL OUTCOMES OF SURGICAL THERAPY (COST) TRIAL COMPARING LAPAROSCOPICALLY-ASSISTED COLECTOMY
(LAC) WITH OPEN COLECTOMY (OC) FOR COLON CANCER
Weeks JC1, Nelson H2, Romanus D1, Long KH2, Sargent D2, 1Dana-Farber Cancer Institute, Boston, MA, USA, 2Mayo Clinic, Rochester, MN, USA
pgA474 PCN46 COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN
BRAZIL
Saggia MG1, Nasciben VD1, Santos EA1, Stefani S2, 1Roche Brazil, Sao Paulo, SP, Brazil, 2UNIMED and Instituto do Câncer Mãe de Deus, Porto Alegre, Brazil
pgA474 PCN47 ECONOMIC EVALUATION IN THE POSTOPERATIVE MANAGEMENT OF COLORECTAL CANCER PATIENTS IN GREECE
Maniadakis N1, Fragoulakis V2, Pectasides D3, Foutzilas G4, 1University of Piraeus, Piraeus, Greece, 2National Social Insurance Institute, Athens, Greece, 3Medical School, University of Athens, Haidari Athens, Greece, 4Helenic Cooperative Oncology Group, Athens, Greece
pgA474 PCN48 COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL
Caponero R1, Saggia MG2, Nasciben VD2, Santos EA2, Stefani S3, 1Hospital Brigadeiro, São Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, Brazil, 3UNIMED and
Instituto do Câncer Mãe de Deus, Porto Alegre, Brazil
pgA475 PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG
CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC
Suchankova E, Dolezal T, Charles University, Prague, Czech Republic
pgA475 PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICS TECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
Redekop WK1, Vietor H2, Lowenberg B3, Uyl-de Groot CA4, 1Erasmus Medical Center, Rotterdam, The Netherlands, 2Skyline Diagnostics BV, Rotterdam, The
Netherlands, 3Erasmus MC, Rotterdam, The Netherlands, 4IMTA, Rotterdam, The Netherlands
pgA476 PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL
LUNG CANCER
Negreiro F1, Pereira C2, Pereira H2, Silva C1, 1Eurotrials - Consultores Científicos, Lisbon, Portugal, 2Roche Farmacêutica Química, Lda, Amadora, Portugal
pgA476 PCN53 COST IMPACT OF CAPECITABINE THERAPY INTRODUCTION IN BREAST CANCER PATIENTS
Camacho F1, Anderson RT1, Wei W2, Kimmick G3, Balkrishnan R4, 1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2Roche, Nutley, NJ,
USA, 3Duke University Medical Center, Durham, NC, USA, 4The Ohio State University, Columbus, OH, USA
pgA476 PCN54 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH
BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UK (UK)
Oglesby A1, Pockett RD2, McEwan P2, Chung K1, 1Amgen, Inc, Thousand Oaks, CA, USA, 2Cardiff Research Consortium, Cardiff, UK
pgA477 PCN55 MANAGAMENT COSTS OF PATIENTS WITH VULVAR AND VAGINAL CANCER IN FRANCE
Remy V1, Mathevet P2, Largeron N1, Vainchtock A3, 1Sanofi Pasteur MSD, Lyon, France, 2Hôpitla Edouard Herriot, Lyon, France, 3HEVA, Lyon, France
pgA477 PCN56 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH
BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN
Oglesby A1, Pockett RD2, McEwan P2, Chung K1, 1Amgen, Inc, Thousand Oaks, CA, USA, 2Cardiff Research Consortium, Cardiff, Wales, UK
pgA477 PCN57 PALLIATIVE CARE FOR CANCER PATIENTS IN BRAZIL: A COST-OF-ILLNESS STUDY
Fernandes RA1, Teich V1, Marinho T1, Pereira M2, 1MedInsight, Rio de Janeiro, Brazil, 2Janssen Cilag, Sao Paulo, Brazil
pgA477 PCN58 MEDICAL RESOURCE CONSUMPTION RELATED TO THE TREATMENT OF IRINOTECAN REFRACTORY ADVANCED COLORECTAL CANCER PATIENTS
Strens D1, Lamotte M2, 1IMS HEOR, Brussels, Belgium, 2IMS Health, Brussels, Belgium
pgA478 PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY
Schulz-Holstege O1, Hampl M1, Huppertz E2, Schmitter S3, Bönte M3, Kok P4, 1University of Düsseldorf, Düsseldorf, Germany, 2Sanofi Pasteur MSD, Niedererbach, Germany, 3Sanofi Pasteur MSD, Berlin, Germany, 4University of Düsseldorf, Düsseldorf, Germany
pgA478 PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES – RESULTS OF A PILOT STUDY
Berger K1, Ehlken B1, Krämer M2, Kettner E3, Lordick F4, 1IMS Health, Munich, Germany, 2Fresenius Biotech, Munich, Germany, 3Magdeburg Hospital, Magdeburg, Germany, 4National Center for Tumor Diseases (NCT), Heidelberg, Germany
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
54
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA478 PCN61 INVASIVE FUNGAL INFECTION (IFI) IN PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) – TREATMENT
COST FROM HOSPITAL PERSPECTIVE
Berger K1, Cornely OA2, Hoppe-Tichy T3, Kiehl M4, Knoth H5, Rieger C6, Thalheimer M3, Schuler U5, Ullmann AJ7, Ostermann H6, 1IMS Health, Munich, Germany,
2
Cologne University Hospital, Köln, Germany, 3University Hospital Heidelberg, Heidelberg, Germany, 4Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany, 5University Hospital Dresden, Dresden, Germany, 6University Hospital Munich, Munich, Germany, 7Johannes Gutenberg-University Mainz, Mainz, Germany
pgA479 PCN62 ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH SALVAGE TREATMENT IN ADVANCED AND METASTATIC BREAST CANCER
Kowal-Podmore S1, Munakata J1, Tencer T2, Smith TW1, 1IMS Consulting, Falls Church, VA, USA, 2Eisai Corporation of North America, Woodcliff Lake, NJ, USA
pgA479 PCN63 METASTATIC COLORECTAL CANCER: MEDICAL COSTS OF FIRST LINE INFUSIONAL 5-FLUOROURACIL OR ORAL CAPECITABINE IN ITALIAN PATIENTS
Lopatriello S1, Negrini C2, Amoroso D3, Donati S3, Alabiso O4, Fornasiero A5, Smergo A5, Iacono C6, Lucenti A7, Lalli AM8, 1Pbe Consulting, Verona, Italy, 2Pbe
Consulting, Milano, Italy, 3Istituto Toscano Tumori, Firenze and Ospedale Versilia, Lido di Camaiore, Italy, 4Azienda Ospedaliera-Universitaria Maggiore della
Carità, Novara, Italy, 5Ospedale Immacolata Concezione, Piove di Sacco, Italy, 6Azienda Ospedaliera “ Civile-Maria Paternò Arezzo”, Ragusa, Italy, 7Azienda
Ospedaliera “ Civile-Maria Paternò Arezzo”, RAgusa, Italy, 8Ospedale Maria SS d. Splendore, Giulianova, Italy
pgA479 PCN64 SHIFT OF PUBLIC HEALTH CARE EXPENDITURES FOR PALLIATIVE CANCER PATIENTS FROM INPATIENT TO OUTPATIENT EFFECTED BY HOME CARE SUPPORT TEAMS PROVIDED BY A UNIVERSITY HOSPITAL IN AUSTRIA
Spat S1, Habacher W2, Rakovac I1, Baumgartner J3, Schippinger W4, Samonigg H4, Pieber TR1, 1Joanneum Research Forschungsgesellschaft mbH, Graz, Austria,
2
Joannuum Research Forschungsgesellschaft mbH, Graz, Austria, 3Coordination Palliative Care Steiermark, Graz, Austria, 4University Hospital Graz, Graz, Austria
pgA480 PCN65 A PHARMACOECONOMIC MODEL FOR THE MANAGEMENT OF CANCER PAIN: OPIOID MARKET WITH OR WITHOUT OROS HYDROMORPHINE IN TURKEY
Kanbur B1, Sahin A2, Sarioz F1, Tatar F1, 1Janssen-Cilag, Istanbul, Turkey, 2Hacettepe University, Ankara, Turkey
pgA480 PCN66 HOW COSTLY IS RADIOTHERAPY WITH PARTICLES? COST ANALYSIS OF EXTERNAL BEAM RADIOTHERAPY WITH CARBON IONS, PROTONS AND CONVENTIONAL PHOTONS
Peeters A1, Grutters JP1, Pijls-Johannesma M1, Reimoser S2, Severens JL3, Lambin P1, Joore MA3, 1Maastro Clinic, Maastricht, The Netherlands, 2Turner &
Townsend, Munchen, Germany, 3University Hospital Maastricht, Maastricht, The Netherlands
pgA480 PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC
LEUKEMIA IN THE UK
Lloyd AC1, Valderrama A2, Ferguson J3, Gilmour L3, Ravndal F1, 1IMS, London, UK, 2Bayer Healthcare Pharmaceuticals Inc, Pine Brook, NJ, USA, 3Bayer Healthcare Pharmaceuticals Inc, Newbury, Berkshire, UK
pgA481 PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND
Walczak J1, Gebus E1, Lasota K1, Semeniuk A1, Pawlik D1, Malczak I1, Lis J2, Glasek M2, Nogas G1, 1Arcana Institute, Cracow, Poland, 2Sanofi-Aventis sp. z o.o,
Warsaw, Poland
pgA481 PCN69 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH
ADVANCED FOLLICULAR LYMPHOMA
Rubio-Terrés C1, Gómez-Codina J2, Ríos Herranz E3, Castro AJ4, Varela C4, Ray JA5, 1Health Value, Madrid, Spain, 2Hospital Universitario La Fe, Valencia, Spain,
3
Hospital Universitario Virgen del Rocío, Seville, Spain, 4Roche Farma, Madrid, Spain, 5F. Hoffmann - La Roche, Basel, Switzerland
pgA481 PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN – AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA
Keating MJ1, Lerner S1, Aultman R2, 1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland
pgA482 PCN71 COST-EFFECTIVENESS OF ORAL TOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED
SMALL–CELL LUNG CANCER (SCLC) IN THE UK
Lykopoulos K1, Morris S2, Papo N1, O’Brien ME3, 1GlaxoSmithKline, Uxbridge, UK, 2Brunel University, Uxbridge, UK, 3Royal Marsden Hospital, Sutton, UK
pgA482 PCN72 THE IMPACT OF INITIAL TREATMENT CHOICE AND DISEASE PROGRESSION ON THE ECONOMIC BURDEN OF PATIENTS AND THEIR CAREGIVERS - A LONGITUDINAL STUDY OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
Romanus D1, Neumann PJ2, Earle C1, Weinstein MC3, Weeks JC1, 1Dana-Farber Cancer Institute, Boston, MA, USA, 2Tufts-New England Medical Center, Boston,
MA, USA, 3Harvard University, Boston, MA, USA
pgA482 PCN73 DEVELOPING A COMPREHENSIVE COSTS TOOLKIT TO FACILITATE ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE
Baffert S1, Coudray-Omnès C2, Livartowski A1, 1Institut Curie, Paris, France, 2Roche, Neuilly sur Seine, France
pgA483 PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Millar DR1, Corrie P2, Hill M3, Pulfer A4, 1Roche Products Ltd, Welwyn Garden City, UK, 2Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 3Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK, 4pH Associates, Marlow, UK
CANCER - Patient-Reported Outcomes Studies
pgA483 PCN75 AN UPDATED GEOGRAPHIC SUBPOPULATION ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) ENROLLED IN A PHASE III TRIAL OF SUNITINIB VERSUS INTERFERON-ALFA
Cella D1, Bushmakin AG2, Cappelleri JC2, Kim ST3, Motzer RJ4, Charbonneau C5, 1Evanston Northwestern Healthcare, Evanston, IL, USA, 2Pfizer Global Research
and Development, New London, CT, USA, 3Pfizer Global Research and Development, La Jolla, CA, USA, 4Memorial Sloan Kettering Cancer Center, New York, NY,
USA, 5Pfizer Global Research and Development, New York, NY, USA
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
55
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA483 PCN76 HEALTH-RELATED QUALITY OF LIFE EVALUATION IN ROMANIAN CANCER PATIENTS
Mihailov MD1, Serban M2, Arghirescu S2, 1University of Medicine and Pharmacy “Victor Babes”, Timisoara, Timis, Romania, 2University of Medicine and Pharmacy, Timis, Romania
pgA484 PCN77 DERIVING UTILITY VALUES FROM THE GENERAL POPULATION FOR INDUCTION CHEMOTHERAPY ADMINISTERED BEFORE CONCURRENT CHEMOTHERAPYRADIATION THERAPY IN THE TREATMENT OF HEAD AND NECK CANCER
Cordony A1, Yuen C1, Kovacs G2, Guarnieri C2, Adams J2, 1Sanofi-Aventis Australia, Macquarie Park, NSW, Australia, 2IMS Health, St Leonards, NSW, Australia
pgA484 PCN78 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN TREATMENT WITH PLACITAXEL WITH/WITHOUT BEVACIZUMAB,
RELATED WITH TREATMENT RESPONSE (REMISSION AND PROGRESSION)
Tenorio C1, Vargas J2, 1Instituto Nacional de Cancerología, Mexico, DF, Mexico, 2Econopharma Consulting SA de CV, Mexico, DF, Mexico
pgA484 PCN111 A STRUCTURED REVIEW OF STUDIES ON HEALTH-RELATED QUALITY OF LIFE IN KIDNEY CANCER, HEPATOCELLULAR CARCINOMA AND LEUKEMIA
Liu J1, Mittendorf T1, Chang J2, Von der Schulenburg JM1, 1Leibniz University of Hannover, Hannover, Germany, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne,
NJ, USA
pgA485 PCN79 HEALTH STATE PREFERENCE STUDY MAPPING THE CHANGE OVER THE COURSE OF THE DISEASE PROCESS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
Ferguson J1, Tolley K2, Gilmour L1, Priaulx J2, 1Bayer plc, Newbury, UK, 2Mapi Values, Macclesfield, UK
pgA485 PCN80 PATIENT REPORTED QUALITY OF LIFE IN CANCER PATIENTS ON OPIOID THERAPY IS INFLUENCED BY CONSTIPATION
Van der Linden MW1, van den Haak P1, Penning-van Beest FJA1, Klok RM2, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands, 2Wyeth Pharmaceuticals bv, Hoofddorp, The Netherlands
pgA485 PCN81 CROSS-CULTURAL ADAPTATION INTO SPANISH AND ITEM REDUCTION OF THE UCLA-PROSTATIC CANCER INDEX (UCLA-PCI): A SPECIFIC HEALTH RELATED
QUALITY OF LIFE (HRQOL) QUESTIONNAIRE FOR PROSTATIC CANCER
Vera-Donoso C1, Cuervo J2, Valero E3, Rebollo P2, 1Hospital Universitario La Fe, Valencia, Spain, 2BAP Health Outcomes Research, Oviedo, Asturias, Spain,
3
Astellas Pharma, Madrid, Spain
pgA485 PCN82 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EQ-5D
Lundy JJ, Coons SJ, University of Arizona, Tucson, AZ, USA
pgA486 PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY: THE CASE OF THE PERFORM
QUESTIONNAIRE
Baro E1, Rodríguez C2, Gascón P3, García-Mata J4, Colomer R5, Cassinello J6, Carulla J7, Valentín V8, Gasquet JA9, 13D Health Research, Barcelona, Spain, 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 3Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 4Hospital Santa Maria Nai, Orense,
Spain, 5Centro Oncológico MD Anderson, Madrid, Spain, 6Hospital Universitario de Guadalajara, Guadalajara, Spain, 7Hospital General Mateu Orfila, Menorca,
Spain, 8Hospital 12 de octubre, Madrid, Spain, 9AMGEN S.A, Barcelona, Spain
pgA486 PCN84 THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM CANCER PAIN ITEM BANK (PROMIS-CA PAIN)
Lai JS1, Garcia S1, Cella D1, George J2, 1ENH/NWU, Evanston, IL, USA, 2Evanston Northwestern Healthcare, Evanston, IL, USA
pgA486 PCN85 PATIENT PREFERENCES IN THE THERAPY OF MULTIPLE MYELOMA
Mühlbacher AC1, Berndt K2, Lincke HJ1, Nübling M1, 1Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany, 2Janssen-Cilag GmbH, Neuss,
Germany
pgA487 PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
Romanus D1, Oh WK1, Cook FE2, Weeks JC1, 1Dana-Farber Cancer Institute, Boston, MA, USA, 2Brigham and Women’s Hospital, Boston, MA, USA
pgA487 PCN87 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC: PANITUMUMAB PLUS BEST SUPPORTIVE
CARE (BSC) VS. BSC ALONE BY KRAS TUMOR STATUS
Odom D1, Devercelli G2, Bennett L1, Peeters M3, Wolf M2, Amado R2, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen, Thousand Oaks, CA, USA,
3
Ghent University Hospital, Ghent, Belgium
pgA487 PCN88 QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Garcia R1, Juan O2, Vázquez S3, Barneto I4, Cardenal F5, Varela C6, Perulero N7, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital Arnau de Vilanova, Valencia, Spain, 3Complexo Hospitalario Xeral Calde, Lugo, Spain, 4Hospital General Universitario Reina Sofía, Córdoba, Spain, 5ICO. Hospital
Duran i Reynals, L’Hospitalet de Llobregat, Barcelona, Spain, 6Roche Farma, Madrid, Spain, 7IHMS Health, Barcelona, Spain
pgA488 PCN89 RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS
Ramsey SD1, Zeliadt SB1, Moinpour CM1, Hall IJ2, Lee JW2, Ekwueme DU2, Thompson IM3, Keane TE4, Fedorenko CR1, Penson DF5, 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA, 3University of Texas Health Science Center at San Antonio, San
Antonio, TX, USA, 4Medical University of South Carolina, Charleston, SC, USA, 5University of Southern California / Norris Cancer Center, Los Angeles, CA, USA
pgA488 PCN90 DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE SYSTEM ADOPTING A MULTIDISCIPLINARY TEAM APPROACH – SATISFACTION OF THE PATIENTS’ FAMILY FOR THE DOMICILIARY PALLIATIVE CARE “OKAYAMA ” MODEL
Saito S1, Shimozuma K2, Yamaguchi M3, 1Kochi Women’s University, Kochi, Japan, 2Ritsumeikan University, Kusatsu, Shiga, Japan, 3Japanese Red Cross Hiroshima College of Nursing, Hatsukaichi, Japan
pgA488 PCN91 TREATMENT PREFERENCE AND WILLINGNESS-TO-PAY (WTP) FOR METHYLNALTREXONE, A NOVEL PERIPHERAL OPIOID ANTAGONIST FOR OPIOID INDUCED
CONSTIPATION
Wang M1, Iyer S2, Desjardins O3, Iskedjian M3, Einarson TR4, 1Wyeth Canada, Markham, ON, Canada, 2Wyeth Pharmaceuticals, Collegeville, PA, USA, 3PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 4University of Toronto, Toronto, ON, Canada
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
56
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA489 PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY : A WILLINGNESS TO PAY STUDY
Brignone M1, Bernard M2, Adehossi A3, Pefoura S4, Briquet C5, Fer AC6, Chouaid C7, Tilleul P6, 1Saint antoine Hospital, Paris, France, 2Pharmacy department,
hôpital Saint joseph, paris, France, 3Pharmacy Departement, Hôpital De Beauvais, beauvais, France, 4Universital Hospital of Saint Luc, Belgium, Brussels,
Belgium, 5Pharmacy department, hôpital saint luc, liege, Belgium, 6Hopital Saint antoine, APHP, PARIS, France, 7Hopital Saint antoine, APHP, Paris, France
pgA489 PCN93 THE IMPACT OF A COST ATTRIBUTE ON PREFERENCES
Essers BA1, van Helvoort-Postulart D1, Prins MH1, Neumann H2, Dirksen CD1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Erasmus Medical
Centre, Rotterdam, The Netherlands
CANCER - Health Care Use & Policy Studies
pgA489 PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER
Sibma TS1, Klaase J2, Siesling S3, Hans E1, Hummel JM1, IJzerman MJ1, 1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente, Enschede, The Netherlands, 3Comprehensive Cancer Centre North East, Groningen/Enschede, The Netherlands
pgA490 PCN95 POLICY-MAKING FOR EXPENSIVE INNOVATIVE DRUGS IN FRANCE: ECONOMIC IMPACT AND INFLUENCE ON STAKEHOLDERS’ BEHAVIOURS OF POTENTIAL
DECISIONS ABOUT TAXANES
Spath HM1, Favier B2, Carrère MO1, 1University of Lyon, Lyon, France, 2Centre Leon Berard, Lyon, France
pgA490 PCN96 ASSOCIATION BETWEEN RESPONDENT- AND PRACTICE-RELATED CHARACTERISTICS AND RADIATION ONCOLOGY STAFF-REPORTED BURDEN ON MUCOSITIS MANAGEMENT FOR HEAD AND NECK CANCER (HNC) PATIENTS
Xu X1, Barron RL2, Mautner B2, Goss TF1, 1Covance Market Access Services, Gaithersburg, MD, USA, 2Amgen, Inc, Thousand Oaks, CA, USA
pgA490 PCN97 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN THE UK WHO PROGRESS ON TRASTUZUMAB AND HAVE PREVIOUSLY RECEIVED
AN ANTHRACYCLINE AND A TAXANE: A NEED FOR EVIDENCE BASED THERAPIES?
Walker M1, Unwin J1, Relf C2, Browning D1, Amonkar M3, 1GlaxoSmithKline, London, UK, 2IMS Health, Kent, UK, 3GlaxoSmithKline, Collegeville, PA, USA
pgA491 PCN98 RACIAL DIFFERENCES IN MEDICATION-RELATED HEALTH CARE COSTS AND SERVICE UTILIZATION IN HORMONE RECEPTOR POSITIVE PRIMARY BREAST
CANCER PATIENTS
Bhosle MJ1, Kimmick G2, Anderson RT3, Balkrishnan R1, 1The Ohio State University, Columbus, OH, USA, 2Duke University Medical Center, Durham, NC, USA,
3
Wake Forest University School of Medicine, Winston Salem, NC, USA
pgA491 PCN99 AVAILABILITY AND SPATIAL DISTRIBUTION OF ONCOLOGY SPECIFIC RESOURCES IN GREECE
Souliotis K1, Athanasakis K2, Golna C3, Papadopoulou C2, Kyriopoulos J2, 1University of Peloponnese, Korinthos, Greece, 2National School of Public Health,
Athens, Greece, 3Roche (Hellas) S.A, Maroussi, Greece
pgA491 PCN100 CONSUMPTION AND ACCESS TO INNOVATIVE CANCER DRUGS IN SLOVAKIA
Tomek D1, Bielik J2, 1Slovak society for pharmacoeconomics, Bratislava, Slovak Republic, 2Trencin University, Trenčín, Slovak Republic
pgA492 PCN101 RELATIONSHIP BETWEEN HEALTH CARE SUPPLY AND MAMMOGRAPHY SCREENING?
Khan N1, Gutierrez B2, Salmon JW3, 1University of New Mexico, Albuquerque, NM, USA, 2NM Legislative Finance Committee, Santa Fe, NM, USA, 3University of
Illinois at Chicago, Chicago, IL, USA
pgA492 PCN102 THE BURDEN OF RENAL CELL CANCER: A RETROSPECTIVE LONGITUDINAL STUDY ON OCCURRENCE, OUTCOMES AND COST USING AN ADMINISTRATIVE
CLAIMS DATABASE
Mantovani LG1, Morsanutto A2, Tosolini F2, Mustacchi G3, Esti R2, Belisari A4, de Portu S1, 1University of Naples, Federico II, Naples, Italy, 2Friuli Venezia Giulia
Regional Health Authority, Trieste, Italy, 3ASS1 Oncology Center, Trieste, Italy, 4Center of Pharmacoeconomics, Univeristy of Milan, Milan, Italy
pgA492 PCN103 HETEROGENEITY IN THE APPROACH TAKEN TO CONDUCTING CHART AUDITS IN AUSTRALIAN HOSPITALS
O’Leary BA1, Colman S1, Ruth AJ2, Cook GA2, 1Covance Pty Ltd, Sydney, Australia, 2Bristol-Myers Squibb Pharmaceuticals, Melbourne, Australia
pgA493 PCN104 A BUDGET IMPACT MODEL FOR THE INTRODUCTION OF PANITUMUMAB, A NEW THERAPY FOR THE MANAGEMENT OF METASTATIC COLORECTAL CANCER
(MCRC) IN GREECE
Papagiannopoulou V1, Christodoulopoulou A2, Bracco A3, Yfantopoulos I1, 1University of Athens, Athens, Greece, 2Amgen Hellas, Athens, Greece, 3Amgen (Europe) GmbH, Zug, Switzerland
pgA493 PCN105 MEDICARE PART D’S MARKET IMPACT ON UTILIZATION, AVERAGE RETAIL PRICE AND OUT-OF-POCKET SPENDING FOR ORAL CHEMOTHERAPEUTICS AND
A COMPARATIVE MARKET BASKET OF DRUGS
Horowicz-Mehler N, Sepulveda B, Doyle JJ, Quintiles Global Consulting, Hawthorne, NY, USA
pgA493 PCN106 PROSTATE CANCER DIAGNOSIS IN SPAIN: HOW IS IT PERFORMED? HOW MUCH DOES IT COST FOR SPANISH NHS?
Herranz F1, Bovio H2, Cordero L2, Sobreviela E2, Ampudia R2, 1Gregorio Marañón General Hospital, Madrid, Madrid, Spain, 2AstraZeneca Farmacéutica Spain
S.A, Madrid, Spain
CANCER - Conceptual Papers & Research on Methods
pgA494 PCN107 NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN CANCER PATIENTS: VALIDATION OF THE LINKAGE OF THE EINDHOVEN CANCER REGISTRY
AND THE PHARMO RECORD LINKAGE SYSTEM
Sukel MPP1, Van de Poll-Franse LV2, Coebergh JWW2, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands, 2Eindhoven Cancer Registry, Eindhoven, The
Netherlands
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
57
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA494 PCN108 DEVELOPMENT OF AN INTERACTIVE MODEL OF FINANCIAL ACCESS TO CANCER THERAPY
Lines LM1, Lang K1, Wallace JF2, Neumann PJ3, Friedman M4, Menzin J1, 1Boston Health Economics, Inc, Waltham, MA, USA, 2Genentech, Inc, South San Francisco, CA, USA, 3Tufts Medical Center, Boston, MA, USA, 4Boston Health Economics, Waltham, MA, USA
pgA494 PCN109 DEALING WITH QUALITY OF LIFE MISSING DATA IN A SINGLE ARM STUDY. COMPARISON OF MULTIPLE IMPUTATION METHODS
Arnault A1, Ivanescu C2, van Engen A2, Peeters P1, 1Quintiles Consulting, Levallois-Perret, France, 2Quintiles Consulting, Hoofddorp, The Netherlands
pgA495 PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE
Mauer M, Coens C, Bottomley A, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studies
pgA495 PDB1 THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS: A
MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
Gschwend MH1, Aagren M2, Valentine WJ1, 1IMS Health, Allschwil, Switzerland, 2Novo Nordisk A/S, Virum, Denmark
pgA495 PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPH TO INSULIN GLARGINE: A RETROSPECTIVE OBSERVATIONAL STUDY
Gordon JP1, Sharplin P1, Peters J2, Tetlow AP1, Longman AJ1, McEwan P1, 1Cardiff Research Consortium, Cardiff, UK, 2Cardiff University, Cardiff, UK
pgA496 PDB3 SWITCHING FROM PREMIXED INSULIN TO INSULIN GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 1 OR TYPE 2
DIABETES: A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS
McEwan P1, Gordon JP1, Sharplin P1, Longman AJ1, Peters J2, Tetlow AP1, 1Cardiff Research Consortium, Cardiff, UK, 2Cardiff University, Cardiff, UK
pgA496 PDB4 GLYCEMIC CONTROL OF TYP-2 DIABETES IN MAKKAH SECURITY FORCES HEALTH CARE CENTER (MSFHCC), SAUDI ARABIA: A DISCRIPTIVE PILOT STUDY
Suliman MA1, Alkelya MA2, Al-Shareef MA1, 1Makkah Security Forces Health Care Center, Makkah, Saudi Arabia, 2King Abdullah International Medical Research
Center, Riyadh, Saudi Arabia
pgA496 PDB5 GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS
Levin P1, Danel A2, Bromberger L1, Choi JC3, Mersey J1, 1MODEL Clinical Research, Baltimore, MD, USA, 2Sanofi-Aventis, Paris, France, 3Rutgers University,
Piscataway, NJ, USA
pgA497 PDB6 EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES : A
META-ANALYSIS
Lee JK1, Lee EK2, 1Sookmyung Women’s University, Seoul, South Korea, 2Sook Myung Women’s University, Seoul, South Korea
pgA497 PDB7 LONG TERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NAïVE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN
CHINA: DATA FROM THE IMPROVE STUDY
White J1, Aagren M2, Jing L3, 1Novo Nordisk International Operations A/S, Zurich, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk (China) Pharmaceuticals Co. Ltd, Beijing, China
pgA497 PDB8 BURDEN OF DIABETES AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF SIX COUNTRIES
Narayanan S1, Potthoff P2, Guether B2, 1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Germany
pgA498 PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSISRELATED HIP FRACTURES
Bahia L1, Teich V2, 1Brazilian Society of Diabetes, Rio de Janeiro, Brazil, 2MedInsight, Rio de Janeiro, Brazil
pgA498 PDB10 COMPREHENSIVE LIPID PROFILE AMONG TYPE 2 DIABETES MELLITUS (T2DM) POPULATION IN SPAIN. RECAP-DM SPANISH COHORT STUDY
Nocea G1, Melero M2, Caloto MT2, 1MSD Spain, Madrid, Spain, 2Merck, Sharp & Dohme, Madrid, Spain
pgA498 PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION IN T2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY
Nocea G1, Melero M2, Caloto MT2, Yin D3, 1MSD Spain, Madrid, Spain, 2Merck, Sharp & Dohme, Madrid, Spain, 3Merck & Co., Inc, Whitehouse Station, NJ, USA
pgA499 PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS
(T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY
Caloto MT1, Nocea G2, Yin D3, 1Merck, Sharp & Dohme, Madrid, Spain, 2MSD Spain, Madrid, Spain, 3Merck & Co., Inc, Whitehouse Station, NJ, USA
DIABETES/ENDOCRINE DISORDERS - Cost Studies
pgA499 PDB13 “REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND: A BUDGT IMPACT ANALYSIS
Rys P1, Gasiorowski M1, Lis J2, Gierczynski J2, Plisko R1, 1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis sp. z o.o, Warszawa, Poland
pgA499 PDB14 LARGE IMPACT OF ANTIDIABETIC DRUG TREATMENT AND HOSPITALIZATIONS ON ECONOMIC BURDEN OF DIABETES MELLITUS IN The Netherlands
DURING 2000 TO 2004
Van der Linden MW1, Plat A1, Erkens JA1, Emneus M2, Herings RMC1
1
PHARMO Institute, Utrecht, The Netherlands, 2Novo Nordisk A/S, Bagsvaerd, Denmark
pgA500 PDB15 COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1
AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND
Walczak J1, Pawlik D1, Jasinska A1, Garbacka M1, Kedzior J1, Fundament T1, Malczak I1, Dardzinski W1, Skrzekowska- Baran I2, Czech M2, Nogas G1, 1Arcana
Institute, Cracow, Poland, 2Novo Nordisk Pharma Poland, Warsaw, Poland
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
58
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA500 PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA®) IN TYPE 2 DIABETES IN POLAND
Walczak J, Malczak I, Panasiuk A, Pawlik D, Lasota K, Stelmachowski J, Nogas G, Arcana Institute, Cracow, Poland
pgA500 PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE
Misurski DA1, Fabunmi R2, Boye K1, Lage M3, 1Eli Lilly and Company, Indianapolis, IN, USA, 2Amylin Pharmaceuticals, San Diego, CA, USA, 3HealthMetrics Outcomes Research, Groton, CT, USA
pgA501 PDB18 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED THERAPY WITH EXENATIDE OR SITAGLIPTIN
Lage M1, Misurski DA2, Fabunmi R3, Boye KS2, 1HealthMetrics Outcomes Research, Groton, CT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin
Pharmaceuticals, San Diego, CA, USA
pgA501 PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE
SHEFFIELD TYPE 2 DIABETES MODEL
Brennan A, Gillett M, Duenas A, University of Sheffield, Sheffield, UK
pgA501 PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES
USING A BASAL–BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
Gschwend MH1, Aagren M2, Valentine WJ1, 1IMS Health, Allschwil, Switzerland, 2Novo Nordisk A/S, Virum, Denmark
pgA502 PDB21 COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING
Minshall ME1, Sauriol L2, 1IMS Health, Noblesville, IN, USA, 2Sanofi-Aventis, Laval, QC, Canada
pgA502 PDB22 COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED TO INSULIN DETEMIR FOR TYPE 1 (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
IN THE CANADIAN PAYER SETTING
Minshall ME1, Tunis SL1, Sauriol L2, 1IMS Health, Noblesville, IN, USA, 2Sanofi-Aventis, Laval, QC, Canada
pgA502 PDB23 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A SWEDISH SETTING
Bech PG1, Buckland AG2, Bentley A2, Twena N3, Christensen T1, 1Novo Nordisk A/S, Bagsværd, Denmark, 2Abacus International, Bicester, UK, 3Novo Nordisk
Ltd, Crawley, UK
pgA503 PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE
Lee TJ1, Han DS2, Sohn HS3, 1Seoul National University, Seoul, South Korea, 2Yonsei University, Seoul, South Korea, 3Rutgers, The State University of New
Jersey, Piscataway, NJ, USA
pgA503 PDB68LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES
USING A BASAL–BOLUS REGIMEN IN SWEDEN
Valentine WJ1, Lammert M2, Aagren M3, Gschwend MH4, 1IMS Health, Basel, Switzerland, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 3Novo Nordisk
A/S, Virum, Denmark, 4IMS Health, Allschwil, Switzerland
pgA503 PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE
SECTOR IN SOUTH AFRICA
White J1, Stoustrup M2, Aagren M3, 1Novo Nordisk International Operations A/S, Zurich, Switzerland, 2Novo Nordisk Region Europe, Zurich, Switzerland, 3Novo
Nordisk A/S, Virum, Denmark
pgA504 PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC
Dolezal T1, Skoupá J2, Taylor MJ3, Whitehead S3, Rausova V4, Pavlikova P4, 1Charles University, Praha, Czech Republic, 2Pharma Projects, Prague, Czech Republic, 3University of York, York, UK, 4GlaxoSmithKline, Prague, Czech Republic
pgA504 PDB27 INSULIN GLARGINE AND NPH INSULIN-BASED REGIMENS REVEAL COMPARABLE TOTAL DIRECT TREATMENT COSTS IN TYPE 2 DIABETES PATIENTS. THE
LONG-ACTING INSULIN GLARGINE VS. NPH INSULIN COST EVALUATION STUDY IN GERMANY (LIVE-DE)
Scholten T1, Holle R2, Landgraf W3, Spiesecke A4, Hauner H5, 1University of Witten-Herdecke, Hagen, Germany, 2Institute of Health Economics & Health Care
Management, Helmholtz Center Munich, Neuherberg, Germany, 3Sanofi-Aventis Germany, Berlin, Germany, 4IMS Health HEOR, Nuremberg, Germany, 5Else
Kröner-Fresenius-Center for Nutritional Medicine, Technical University Munich, Munich, Germany
pgA504 PDB28 DIABETES MELLITUS BURDEN AND RELATIONSHIP WIH THE DEGREE OF PATIENTxS GLYCEMIC CONTROL
Banegas JR1, Franch J2, De Pablos PL3, Fernández S4, Díaz S4, 1Public Health and Preventive Medicine Department, UAM, Madrid, Spain, 2Raval Sud Primary
Care Centre, Barcelona, Spain, 3Service of Endocrinology & Nutrition, Hospital Universitario Dr. Negrín, Las Palmas, Spain, 4Pfizer Spain, Madrid, Spain
pgA505 PDB29 ESTIMATING THE DIRECT COST OF TYPE II DIABETES IN GREECE
Athanasakis K1, Ollandezos M1, Angeli A2, Gregoriou A1, Geitona M3, Kyriopoulos J1, 1National School of Public Health, Athens, Greece, 2Sanofi-Aventis, Athens,
Greece, 3University of Thessaly, Volos, Greece
pgA505 PDB30 INSTIGATE STUDY (INSULIN TITRATION; GAINING AN UNDERSTANDING OF THE BURDEN OF TYPE 2 DIABETES IN EUROPE): HEALTH CARE RESOURCE
UTILIZATION AND COSTS WITHIN THE FIRST 6 MONTHS OF INSULIN THERAPY - FRENCH DATA
Fagnani F1, Chartier F2, Salaun Martin C2, Tcherny S2, Pentel J2, T Smith H3, Charles M4, 1Cemka-Eval, Bourg-La-Reine, France, 2Lilly France, Suresnes, France,
3
Lilly UK, Windlesham, AL, UK, 4INSERM U780, Villejuif, France
pgA505 PDB31 THE COST OF TYPE 2 DIABETES MELLITUS IN CZECH REPUBLIC
Dolezal T, Pisarikova Z, Bartaskova D, Charles University, Prague, Czech Republic
pgA358 DB2 IMPACT OF OVERWEIGHT OR OBESITY ON TREATMENT COSTS IN PATIENTS WITH DIABETES IN THE USA: QUANTILE REGRESSION APPROACH
Suh DC1, Jang EJ1, Kim CM2, Nam EW1, Choi IS1, Barone JA1, 1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, South Korea
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
59
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA506 PDB32 MEDICAL COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH DIABETES MELLITUS AMONG U.S. ADULTS
Barone JA1, Jang EJ1, Lee DH2, Jung JC3, Suh DC1, 1Rutgers University, Piscataway, NJ, USA, 2Ewha Womans’ University Hospital, Seoul, South Korea, 3Korea
National Health Insurance Corporation, Mapo-gu, Seoul, South Korea
pgA506 PDB33 COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA: A TRIAL-BASED PROBABILISTIC MODEL
Pichon-Riviere A1, Caporale JE2, Augustovski FA1, von Schulz-Hausmann C3, Gagliardino JJ4, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma
de Buenos Aires, Argentina, 2CENEXA - Universidad Nacional de La Plata / Instituto de Efectividad Clínica y Sanitaria (IECS), La Plata / Ciudad Autónoma de
Buenos Aires, Argentina, 3Sanofi-Aventis Argentina, Buenos Aires, Argentina, 4CENEXA - Universidad Nacional de La Plata, La Plata, Argentina
pgA506 PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION: SOMATOSTATIN ANALOGUES FOR ACROMEGALY
Valentim J1, Passos V2, Calabró A3, 1University of São Paulo, São Paulo, Brazil, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3Novartis Biociências SA,
São Paulo, Brazil
pgA507 PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA: A LONG TERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY
White J1, Aagren M2, Jing L3, 1Novo Nordisk International Operations A/S, Zurich, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk (China) Pharmaceuticals Co. Ltd, Beijing, China
pgA507 PDB37 IS INSULIN GLARGINE A COST-EFFECTIVE OPTION FOR TREATMENT OF PATIENTS NAÏVE TO INSULIN TREATMENT WITH TYPE 2, BASELINE HBA1C ABOVE
8% AND AGE BELOW 65 YEARS IN COMPARISON TO NPH AND PREMIX IN POLAND?
McEwan P1, Woehl A1, Kawalec P2, Lis J3, Gierczynski J3, Walczak J4, 1Cardiff University, Cardiff, UK, 2Centrum HTA, Krakow, Poland, 3Sanofi-Aventis sp. z o.o,
Warszawa, Poland, 4Arcana Institute, Cracow, Poland
pgA508 PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENT THERAPY WITH GENOTROPIN® IN HYPOPITUITARY ADULT PATIENTS
Bolin K1, Jonsson B2, Koltowska-Häggström M3, Prütz C4, Sandin R4, 1Lund University, Lund, Sweden, 2Uppsala University, Uppsala, Sweden, 3Pfizer Endocrine
Care, Sollentuna, Sweden, 4Pfizer AB, Sollentuna, Sweden
pgA508 PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8% IN COMPARISON TO
NPH AND PREMIX IN POLAND?
McEwan P1, Woehl A1, Kawalec P2, Lis J3, Gierczynski J3, Walczak J4, 1Cardiff University, Cardiff, UK, 2Centrum HTA, Krakow, Poland, 3Sanofi-Aventis sp. z o.o,
Warszawa, Poland, 4Arcana Institute, Cracow, Poland
pgA508 PDB40 COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DM1 FROM A PUBLIC PAYER PERSPECTIVE IN POLAND
McEwan P1, Woehl A1, Kawalec P2, Lis J3, Gierczynski J3, Walczak J4, 1Cardiff University, Cardiff, UK, 2Centrum HTA, Krakow, Poland, 3Sanofi-Aventis sp. z o.o,
Warszawa, Poland, 4Arcana Institute, Cracow, Poland
pgA509 PDB41 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN ®) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A UK SETTING
Christensen T1, Buckland AG2, Bentley A2, Twena N3, Bech PG1, 1Novo Nordisk A/S, Bagsværd, Denmark, 2Abacus International, Bicester, UK, 3Novo Nordisk
Ltd, Crawley, UK
pgA509 PDB42 COST-UTILITY OF INSULIN GLARGINE COMPARED TO PRE MIX IN TYPE 2 FROM PUBLIC PAYER PERSPECTIVE IN POLAND
McEwan P1, Woehl A1, Kawalec P2, Lis J3, Gierczynski J3, Walczak J4, 1Cardiff University, Cardiff, UK, 2Centrum HTA, Krakow, Poland, 3Sanofi-Aventis sp. z o.o,
Warszawa, Poland, 4Arcana Institute, Cracow, Poland
DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes Studies
pgA509 PDB43 ADDING INSULIN GLARGINE TO ORAL THERAPY IN PATIENTS WITH TYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED
TO NPH INSULIN
Pfohl M1, Dippel FW2, Kostev K3, Kotowa W4, 1Evangelisches Bethesda-Johanniter-Klinikum GmbH, Duisburg, Germany, 2Sanofi-Aventis Germany GmbH, Berlin,
Germany, 3IMS HEALTH GmbH & Co. OHG, Frankfurt am Main, Germany, 4IMS HEALTH, Nuremberg, Germany
pgA510 PDB44 TREATMENT COMPLIANCE AND ILLNESS KNOWLEDGE IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES
Franch J1, De Pablos PL2, Banegas JR3, Fernández S4, Díaz S4, 1Raval Sud Primary Care Centre, Barcelona, Spain, 2Hospital Universitario Dr. Negrín, Las Palmas
Gran Canaria, Spain, 3Universidad Autónoma de Madrid, Madrid, Spain, 4Pfizer Spain, Madrid, Spain
pgA510 PDB45 SELF-MANAGEMENT AND PATIENT PERCEPTIONS OF CARE IN RELATION TO HEALTH AND COST-RELATED OUTCOMES IN TYPE 2 DIABETES: A SYSTEMATIC
REVIEW
Cobden D1, Niessen L2, Rutten F3, Redekop WK2, 1Roche Inc, Nutley, NJ, USA, 2Erasmus Medical Center, Rotterdam, The Netherlands, 3IMTA, Rotterdam, The
Netherlands
pgA510 PDB46 DIABETES RELATED QUALITY OF LIFE IN PORTUGUESE PATIENTS
Mendes Z1, Guedes S2, Guerreiro JP2, Miranda A2, Conde V3, Inês M3, 1CEFAR, Lisbon, Portugal, 2INFOSAUDE, Lisbon, Portugal, 3Laboratórios Pfizer, Lda,
Lisbon, Portugal
pgA511 PDB47 THE SUITABILITY OF POLYCYSTIC OVARY SYNDROME-SPECIFIC QUESTIONNAIRES FOR MEASURING THE IMPACT OF PCOS ON QUALITY OF LIFE IN CLINICAL TRIALS
Malik-Aslam A, Reaney MD, Speight J, AHP Research, Uxbridge, UK
pgA511 PDB48 NOT ALL ROADS LEAD TO ROME – A REVIEW OF QUALITY OF LIFE MEASUREMENT IN DIABETES
Speight J1, Reaney MD2, Barnard K3, 1AHP Research Ltd, Uxbridge, UK, 2AHP Research, Uxbridge, UK, 3University of Southampton, Southampton, UK
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
60
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA511 PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES
De Pablos PL1, Banegas JR2, Franch J3, Fernández S4, Díaz S4, 1Hospital Universitario Dr. Negrín, Las Palmas Gran Canaria, Spain, 2Universidad Autónoma de
Madrid, Madrid, Spain, 3Raval Sud Primary Care Centre, Barcelona, Spain, 4Pfizer Spain, Madrid, Spain
pgA512 PDB50 CONCEPTUAL DEVELOPMENT OF A PATIENT SELF-ASSESSMENT TOOL TO IMPROVE PATIENT-CLINICIAN COMMUNICATION ON THE DAILY MANAGEMENT
OF TYPE 2 DIABETES
Arnould B1, Vigneux M1, Seignobos E1, Penfornis A2, Varroud-Vial M3, Consoli SM4, Falissard B5, Grimaldi A6, 1Mapi Values, Lyon, France, 2Jean Minjoz University
Hospital, Besançon, France, 3Sud Francilien Hospital Center, Corbeil Essonnes, France, 4Georges Pompidou European Hospital, Paris, France, 5Maison de
Solenn, Cochin Hospital, Paris, France, 6Pitié-Salpêtrière University Hospital, Paris, France
pgA512 PDB51 UNDERSTANDING AND ASSESSING THE IMPACT OF DIABETES TREATMENT ACROSS MEDICATION DELIVERY SYSTEMS
Brod M1, Hammer M2, Christensen T2, 1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Bagsværd, Denmark
pgA512 PDB52 A SELF-MANAGEMENT PROFILE FOR PATIENTS WITH TYPE-2 DIABETES
Patrick D1, Martin M2, Best JH3, Ascoytia C2, Gilman P2, Kalsekar A4, Velez F3, 1University of Washington, Seattle, WA, USA, 2Health Research Associates,
Seattle, WA, USA, 3Amylin Pharmaceuticals, San Diego, CA, USA, 4Eli Lilly and Company, Indianapolis, IN, USA
pgA513 PDB53 VALIDATION OF THE HUMAN GROWTH HORMONE PREFERENCE AND SATISFACTION QUESTIONNAIRE (HGH-PSQ)
Stephens JM1, Gold KF2, Carpiuc KT1, Altman P3, Germack J3, Joshi AV3, 1PharMerit North America LLC, Bethesda, MD, USA, 2Harvard University, Cambridge,
MA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA
pgA513 PDB54 PSYCHOLOGICAL INSULIN RESISTANCE (PIR): PATIENT AND PHYSICIAN BELIEFS IMPACTING DIABETES MANAGEMENT
Kongsø JH1, Brod M2, Lessard S3, Christensen T4, 1Novo Nordisk A/S, Bagsvaerd, Denmark, 2The BROD GROUP, Mill Valley, CA, USA, 3The Brod Group, Mill Valley, CA, USA, 4Novo Nordisk A/S, Bagsværd, Denmark
pgA513 PDB55 PSYCHOMETRIC STRENGTH OF CURRENT TREATMENT SATISFACTION QUESTIONNAIRES IN NON-INSULIN TREATED TYPE 2 DIABETES
Howarth A, Speight J, AHP Research, Uxbridge, UK
pgA514 PDB56 IDENTIFYING FACTORS THAT AFFECT PATIENTS’ WILLINGNESS TO PAY FOR INHALED INSULIN
Pinto SL1, Holiday-Goodman M2, Black CD2, 1University of Toledo, Toledo, OH, USA, 2The University of Toledo, Toledo, OH, USA
pgA514 PDB57 EFFECT OF INSULIN GLARGINE OR NPH INSULIN ON TREATMENT SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Moock J1, Hessel F2, Kohlmann T1, 1University of Greifswald, Greifswald, Germany, 2Sanofi-Aventis Pharma GmbH Germany, Berlin, Germany
DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies
pgA514 PDB58 PREDICTION MODEL FOR BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENT
Auamnoy T1, Boondarick J1, Munprom C2, 1Chulalongkorn University, Bangkok, Thailand, 2Saraburi Hospital, Saraburi, Thailand
pgA515 PDB59 TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH TYPE 2 DIABETES
Wisloff TF, Kristiansen IS, Jenssen TG, University of Oslo, Oslo, Norway
pgA515 PDB60 A COMPARISON OF THE MANAGEMENT OF SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES: SIMILARITIES,
DIFFERENCES AND RESOURCE IMPLICATIONS
Lammert M1, Hammer M2, Frier BM3, 1Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Royal Infirmary of Edinburgh, Edinburgh, UK
pgA515 PDB61 CHART AUDIT OF THE DOSE AND EFFECTIVENESS OF LONG ACTING INSULIN ANALOGUES IN AUSTRALIAN CLINICAL PRACTICE
O’Leary BA1, Daja MM2, Adena MA3, 1Covance Pty Ltd, Sidney, Australia, 2Novo Nordisk Pharmaceuticals Pty Ltd, Sidney, Australia, 3Covance Pty Ltd, Canberra,
Australia
pgA516 PDB62 IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY OF CARE AND HEALTH CARE SERVICE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES
Pawaskar MD1, Burch SP2, Nahata MC1, Seiber E3, Balkrishnan R3, 1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithKline,
Research Triangle Park, NC, USA, 3The Ohio State University, Columbus, OH, USA
pgA516 PDB63 EFFECTS OF DOSING REGIMEN ON RESOURCE UTILIZATION AND COSTS IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS
Jayawant SS1, Arondekar B2, Seiber E3, Lacombe V3, Balkrishnan R3, 1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithKline,
Philadelphia, PA, USA, 3The Ohio State University, Columbus, OH, USA
pgA516 PDB64 EFFECTS OF DOSING REGIMEN ON MEDICATION USE BEHAVIOR IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS
Jayawant SS1, Arondekar B2, Lacombe V3, Seiber E3, Balkrishnan R3, 1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2GlaxoSmithKline,
Philadelphia, PA, USA, 3The Ohio State University, Columbus, OH, USA
pgA517 PDB65 A COMPARISON OF DIABETES KNOWLEDGE AMONG RESIDENTS IN BANGKOK AND OTHER CENTRAL PROVINCES OF THAILAND
Pongmesa T1, Li SC2, Wee HL1, 1National University of Singapore, Singapore, Singapore, 2University of Newcastle, Callaghan, Australia
pgA517 PDB66 INSULIN GLARGINE UTILIZATION IN REAL-LIFE – EFFICACY OF A REGIMEN BASED ON INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES PREVIOUSLY ON NPH INSULIN IN CLINICAL PRACTICE IN SPAIN
Delgado E, Hospital Central de Asturias, Oviedo, Spain
DIABETES/ENDOCRINE DISORDERS - Conceptual Papers & Research on Methods
pgA517 PDB67 PATIENT-CENTERED OUTCOMES IN THE ECONOMIC EVALUATION OF TYPE 2 DIABETES TREATMENT: A SYSTEMATIC REVIEW OF MODELING METHODS
Redekop WK1, Cobden D2, Niessen L1, Rutten F3, 1Erasmus Medical Center, Rotterdam, The Netherlands, 2Roche Inc, Nutley, NJ, USA, 3IMTA, Rotterdam, The
Netherlands
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
61
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies
pgA518 PGI1 THE DEVELOPMENT AND PERFORMANCE OF MODELS TO PREDICT RISK OF LIVER DISEASE DIAGNOSIS FOLLOWING LIVER FUNCTION TESTING IN PRIMARY CARE
McLernon DJ1, Dillon JF2, Sullivan FM2, Donnan PT2, 1University of Aberdeen, Aberdeen, UK, 2University of Dundee, Dundee, UK
pgA518 PGI2 UNCONTROLLED GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD): FINDINGS FROM A UK MULTICENTRE, CROSS-SECTIONAL STUDY
Borrill J1, Edwards SJ2, Patrikios T2, 1AstraZeneca UK Ltd, Luton, UK, 2AstraZeneca UK Ltd, Luton, Bedfordshire, UK
GASTROINTESTINAL DISORDERS - Cost Studies
pgA519 PGI4 BUDGET IMPACT OF METHYLNALTREXONE SC ON A PUBLIC DRUG PROGRAM FORMULARY
Wang M1, Iyer S2, Jeddi M3, 1Wyeth Pharmaceuticals, Markham, ON, Canada, 2Wyeth Pharmaceuticals, Collegeville, PA, USA, 3Innomar Strategies Inc, Burlington, ON, Canada
pgA519 PGI5 A BUDGET IMPACT ANALYSIS FOR DETERMINING THE COSTS OF INCREASED PANTOPRAZOL IV PRESCRIPTION FOR THE MANAGEMENT OF PEPTIC ULCER IN SPAIN
Darba J1, Restovic G2, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain
pgA519 PGI6 THE MANAGEMENT OF GASTRO OESOPHAGEAL REFLUX DISEASE IN SPAIN: A BUDGET IMPACT ANALYSIS TO ESTIMATE COSTS DUE TO A GREATER PANTOPRAZOL IV PENETRATION
Darba J1, Restovic G2, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain
pgA519 PGI7 AN ECONOMIC EVALUATION OF THE TWO LEADING ALGINTE THERAPIES IN THE UK: RESULTS FROM A LARGE LONGITUDINAL DATABASE
Connolly M1, Bhatt A2, 1Global Market Access Solutions, St Prex, Switzerland, 2Reckitt Benckiser (Healthcare), Hull, UK
pgA520 PGI8 A COST-EFFECTIVENESS EVALUATION - RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTS WHO HAVE
PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
Gibbons CJ1, Morris J1, O’Sullivan AK2, 1Schering-Plough, Welwyn Garden City, UK, 2i3 Innovus, Medford, MA, USA
pgA520 PGI9 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING: A DECISION-TREE MODEL WITH SPANISH COSTS
AND NEW CLINICAL DATA
Barkun A1, Adam V1, Sung JJY2, Kuipers E3, Mössner J4, Jensen D5, Stuart RC6, Lau JY2, Nauclér E7, Kilhamn J8, Granstedt H7, Liljas B7, Lind T7, 1McGill University Health Centre, Montreal, QC, Canada, 2The Chinese University of Hong Kong, Hong Kong, China, 3Erasmus University Medical Center, Rotterdam, The
Netherlands, 4University of Leipzig, Leipzig, Germany, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 6Glasgow Royal Infirmary, Glasgow, UK,
7
AstraZeneca R&D, Mölndal, Sweden, 8AstraZeneca R&D, Mölndal, Västra Götaland, Sweden
pgA521 PGI10 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE: AN ECONOMIC EVALUATION BASED
ON THE PODIUM RANDOMISED CONTROLLED TRIAL
Connolly M1, Nielsen SK2, Currie CJ3, Poole CD4, 1Global Market Access Solutions, St Prex, Switzerland, 2Ferring International Center, Saint-Prex, Switzerland,
3
Cardiff University, Cardiff, UK, 4Pharmatelligence, Cardiff, South Glamorgan, UK
pgA521 PGI11 A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHN’S DISEASE
Waters H1, McKenzie RS1, Tang B1, Piech CT1, Papandrikopoulou N2, 1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Centocor B.V, Ottobrunn, Germany
pgA521 PGI12 MODELING THE LONG-TERM COST-EFFECTIVENESS OF CRONIC HEP. B THERAPIES IN SPAIN
Buti M1, Brosa M2, Casado MA3, Rueda M4, Esteban R5, 1Hospital General Universitario Valle de Hebrón, Barcelona, Spain, 2Oblikue Consulting, Barcelona,
SC, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Gilead Sciences, Madrid, Spain, 5Hospital General Universitari Vall d’Hebrón,
Barcelona, Spain
pgA522 PGI13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS
De Pouvourville G1, Levesque K2, Nestrigue C2, Maurel F2, Brignone M3, Ménégaux F4, Buscail L5, Levesque E6, Tilleul P7, 1ESSEC Business School, Cergy-pontoise, France, 2IMS Health, Puteaux, France, 3Hopital Saint antoine, APHP, Paris, France, 4Pitié Salpêtrière Hospital, Paris, France, 5Rangueil Hospital, Toulouse,
France, 6Paul Brousse Hospital, Villejuif, France, 7St-Antoine Hospital, Paris, France
pgA522 PGI14 A HYPOTHETICAL ROAD MAP TO REDUCE ACID RELATED DISEASES COSTS MANAGEMENT
Cammarota S, De Portu S, Citarella A, Menditto E, Cuomo R, University of Naples, Naples, Italy
pgA522 PGI15 COSTS OF CROHN’S DISEASE WITHIN THE GERMAN STATUTORY HEALTH INSURANCE
Prenzler A1, Mittendorf T1, Conrad S2, von der Schulenburg JM1, Bokemeyer B3, 1Leibniz University of Hannover, Hannover, Germany, 2University of Luebeck,
Luebeck, Germany, 3Gastroenterology Practice, Minden, Germany
pgA523 PGI16 DIRECT MEDICAL COSTS OF GERD AND ASSOCIATED FACTORS
Tafalla M1, Gisbert JP2, Nuevo J1, Cordero L1, Hernandez R1, Jimenez J1, 1AstraZeneca, Madrid, Spain, 2Hospital de la Princesa, Madrid, Spain
pgA523 PGI17 REAL WORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHN’S DISEASE
Waters H1, Meekins T2, Bewtra A2, McKenzie RS1, Tang B1, Piech CT1, Papandrikopoulou N3, 1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Wolters Kluwer Health, Yardley, PA, USA, 3Centocor B.V, Ottobrunn, Germany
pgA523 PGI18 DIRECT MEDICAL COSTS OF CROHN’S DISEASE IN SPAIN: A MARKOV MODEL
Casellas F1, Panés J2, Barreiro M3, Bastida G4, García V5, Guinard D6, Gomollón F7, Herrera JM8, Hinojosa J9, Marín I10, Lindner L11, Gimenez E11, Vieta A11,
1
Hospital Vall dxHebron, Barcelona, Barcelona, Spain, 2Hosp. Clínico de Bcn, Barcelona, Spain, 3Hosp. Clínco Univ. De Santiago, Santiago de Compostela,
Spain, 4Hosp. Univ. La Fe, Valencia, Spain, 5Hosp Reina Sofia Avenida Menéndez Pidal S/N, Cordoba, Spain, 6Hospital Son Dureta, Palma de Mallorca, Spain,
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
62
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
Hosp. Clínico de Zaragoza, Zaragoza, Spain, 8Hosp. Virgen del Rocio, Sevilla, Spain, 9Hosp. De Sagunto, Sagunto, Spain, 10Hosp. Gregorio Marañon, Madrid,
Spain, 11IMS Health, Barcelona, Spain
pgA524 PGI19 THE COST-UTILITY OF LIVER DISEASE DIAGNOSIS: ASSESSING GP DECISIONS FOR PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS AND NO OBVIOUS
LIVER DISEASE
McLernon DJ1, Donnan PT2, Sullivan FM2, Dillon JF2, 1University of Aberdeen, Aberdeen, UK, 2University of Dundee, Dundee, UK
pgA524 PGI20 ASSESSING THE COST AND EFFECTIVENESS OF TERLIPRESSIN COMPARED WITH SOMATOSTATIN FOR THE TREATMENT OF BLEEDING OESOPHAGEAL
VARICES IN SPAIN
Darba J1, Restovic G2, 1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain
pgA524 PGI21 REDUCTION OF WORK PRODUCTIVITY ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND RELATED COSTS
Gisbert JP1, Nuevo J2, Tafalla M2, Cordero L2, Hernandez R2, Jimenez J2, 1Hospital de la Princesa, Madrid, Spain, 2AstraZeneca, Madrid, Spain
7
GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes Studies
pgA524 PGI22 ASSESSING THE PATIENT-REPORTED IMPACT OF USING BOWEL CLEANSING PREPARATIONS
Doward LC1, McKenna SP1, Leicester RJ2, Hedley V2, Epstein O3, Korala S3, Wilburn J1, Twiss J1, Jones D4, Geraint M4, 1Galen Research, Manchester, UK, 2St
George’s Healthcare NHS Trust, London, UK, 3Royal Free Hampstead NHS Trust, London, UK, 4Norgine Pharmaceuticals Ltd, Uxbridge, UK
pgA525 PGI23 QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MILD/MODERATE AND SEVERE RELAPSE: FINDINGS FROM THE PODIUM STUDY
Poole CD1, Nielsen SK2, Currie CJ3, Connolly M4, 1Pharmatelligence, Cardiff, South Glamorgan, UK, 2Ferring International Center, Saint-Prex, Switzerland, 3Cardiff University, Cardiff, UK, 4Global Market Access Solutions, St Prex, Switzerland
pgA525 PGI24 FURTHER VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) IN THE SPANISH POPULATION
Ruiz MA1, Suárez-Parga JM2, Pardo A1, Pascual V3, 1Universidad Autónoma de Madrid, Madrid, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Pfizer
Spain, Madrid, Spain
pgA526 PGI25 ESTABLISHING THE RELATIONSHIP BETWEEN THE ULCERATIVE COLITIS DISEASE ACTIVITY INSTRUMENT (UCDAI) AND PATIENT HEALTH RELATED QUALITY OF LIFE FROM A LARGE RANDOMISED CONTROLLED TRIAL
Poole CD1, Nielsen SK2, Currie CJ3, Connolly M4, 1Pharmatelligence, Cardiff, South Glamorgan, UK, 2Ferring International Center, Saint-Prex, Switzerland, 3Cardiff University, Cardiff, UK, 4Global Market Access Solutions, St Prex, Switzerland
pgA526 PGI26 DERIVING PREFERENCE BASED UTILITIES FOR CD AND UC PATIENTS: CONVERTING IBDQ INTO EQ-5D UTILITIES
Punekar YS1, Casellas F2, 1Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 2Hospital Vall dxHebron, Barcelona, Spain
pgA526 PGI27 PSYCHOMETRIC VALIDATION OF TRANSLATION TO SPANISH OF THE REFLUX DISEASE QUESTIONNAIRE (RDQ) AND GASTROINTESTINAL IMPACT SCALE IN
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Tafalla M, Nuevo J, Muñoz M, Zapardiel J, AstraZeneca, Madrid, Spain
pgA526 PGI28 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A NEW QUESTIONNAIRE MEASURING THE IMPACT OF CHILD GASTROENTERITIS ON PARENTS
Viala-Danten M1, Meunier J2, Arnould B2, 1Mapi Values France, Lyon, France, 2Mapi Values, Lyon, France
pgA527 PGI29 INDIVIDUAL AND SOCIETAL PREFERENCE SCORES BOTH IDENTIFY ACTIVE INFLAMMATORY BOWEL DISEASE (IBD) IN GERMANY
Stark R1, Reitmeier P1, Konig HH2, Leidl R1, 1Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg (by Munich), Germany, 2University of Leipzig, Leipzig, Germany
pgA527 PGI30 A EUROPEAN CROSS-SECTIONAL STUDY TO EVALUATE SYMPTOM BURDEN AND CLINICAL MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE
(RANGE-GREECE)
Karagiannis D1, Vaskantiras V2, Yourgioti G2, Daskos G2, Nikas N2, 1Athens Medical Center, Athens, Greece, 2AstraZeneca SA, Athens, Greece
pgA527 PGI31 GENDER, AGE AND BODY MASS-RELATED DIFFERENCES IN THE IMPACT OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOMS IN PRIMARY
CARE PATIENTS ASSESSED BY THE GASTROINTESTINAL IMPACT SCALE (GIS)
Ferrus J1, Zapardiel J2, Sobreviela E3, 1IMAS- CS Santa Mónica, Madrid, Spain, 2Astrazeneca Spain, Madrid, Spain, 3Quintiles Iberia, Madrid, Spain
pgA528 PGI32 CORRELATION BETWEEN THE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING
Papatheodoridis G1, Carvounis C2, Vaskantiras V3, Nikas N3, Daskos G3, 1Athens University Medical School, Athens, Greece, 2Blue Cross Hospital, Athens,
Greece, 3AstraZeneca SA, Athens, Greece
pgA528 PGI33 A POPULATION-BASED SURVEY TO ASSESS IMPACT OF TROUBLESOME SYMPTOMS IN GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY
Reimer C1, Malmberg I2, Bytzer P1, 1Køge University Hospital, Køge, Denmark, 2AstraZeneca, Albertslund, Denmark
pgA529 PGI34 PATIENT PREFERENCES FOR CROHN’S DISEASE MAINTENANCE THERAPY: A DISCRETE CHOICE EXPERIMENT
Darba J1, Restovic G2, Calvet X3, Taxonera C4, Ricart E5, Ginard D6, López-San Román A7, Gisbert JP8, Casellas F9, Sabater FJ10, 1Universitat de Barcelona,
Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain, 3Hospital Parc Tauli, Sabadel, Spain, 4Hospital Clínico San Carlos, Madrid, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Son Dureta, Palma Mallorca, Spain, 7Hospital Ramón y Cajal, Madrid, Spain, 8Hospital de la Princesa,
Madrid, Spain, 9Hospital Vall d’Hebron, Barcelona, Spain, 10Schering-Plough S.A, Alcobendas, Spain
pgA529 PGI35 PATIENT PREFERENCES FOR CROHN’S DISEASE FLARE-UP THERAPY: A DISCRETE CHOICE EXPERIMENT
Darba J1, Restovic G2, Calvet X3, Taxonera C4, Ricart E5, Ginard D6, López-San Román A7, Gisbert JP8, Casellas F9, Sabater FJ10, 1Universitat de Barcelona,
Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain, 3Hospital Parc Tauli, Sabadel, Spain, 4Hospital Clínico San Carlos, Madrid, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Son Dureta, Palma Mallorca, Spain, 7Hospital Ramón y Cajal, Madrid, Spain, 8Hospital de la Princesa,
Madrid, Spain, 9Hospital Vall d’Hebron, Barcelona, Spain, 10Schering-Plough S.A, Alcobendas, Spain
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
63
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies
pgA529 PGI36 SELF-DIAGNOSIS AND HEALTH SEEKING BEHAVIOUR OF WOMEN FOR MINOR BOWL AILMENTS IN A LARGE REPRESENTATIVE UK (UK) SAMPLE POPULATION
Connolly M1, Bhatt A2, Travis SP3, 1Global Market Access Solutions, St Prex, Switzerland, 2Reckitt Benckiser (Healthcare), Hull, UK, 3John Radcliffe Hospital,
Headington, UK
pgA530 PGI37 A COMPARISON OF TREATMENT FAILURE RATES BASED ON STARTING ALGINATE THERAPY OBSERVED IN A LARGE REPRESENTATIVE LONGITUDINAL UK
DATABASE
Connolly M1, Bhatt A2, 1Global Market Access Solutions, St Prex, Switzerland, 2Reckitt Benckiser (Healthcare), Hull, UK
pgA530 PGI38 RESULTS OF ALEGRIA, A REAL LIFE EVALUATION OF GERD IMPACT OF SYMPTOM ASSESSMENT IN BELGIUM
Louis E1, Tack J2, Taeter C3, Vandenhoven G4, 1Université libre de Liège, Liège, Belgium, 2Katholiek Universiteit Leuven, Leuven, Belgium, 3AstraZeneca, Brussels, Belgium, 4AstraZeneca Belgium, Brussels, Belgium
pgA530 PGI39 ALEGRIA, A REAL LIFE EVALUATION OF GERD (GASTROESOPHAGEAL REFLUX DISEASE) IMPACT OF SYMPTOM ASSESSMENT IN LUXEMBOUR
Fritz R1, Taeter C2, Vandenhoven G3, 1C.H. Emile Mayrisch, Esch-sur-Alzette, Luxembourg, 2AstraZeneca, Brussels, Belgium, 3AstraZeneca Belgium, Brussels,
Belgium
pgA531 PGI40 PROTON PUMP INHIBITORS MARKET IN PRIMARY CARE SETTING
Cammarota S, De Portu S, Citarella A, Menditto E, Cuomo R, University of Naples, Naples, Italy
HEALTH CARE INTERVENTIONS - Clinical Outcomes Studies
pgA531 PHC1 TREATMENT OF DISCOGENIC LOW BACK PAIN WITH INTRADISCAL ELECTROTHERMAL THERAPY [IDET], A MINIMALLY INVASIVE, LOW COST ALTERNATIVE
TO OPEN SURGERY: A PROSPECTIVE 24-MONTH OUTCOMES STUDY IN 50 CONSECUTIVE PATIENTS
Assietti R1, Morosi M1, Meani L1, Block JE2, Schultz M3, Rohan B4, 1Ospedale Fatebenefratelli e Oftalmico, Milano, Italy, 2Jon E Block PhD Inc, San Francisco,
CA, USA, 3Pharmaccess Inc, Westmount, QC, Canada, 4Smith&Nephew Inc, Memphis, TN, USA
HEALTH CARE INTERVENTIONS - Cost Studies
pgA531 PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET
Krysanov I, Kulikov A, Yagudina RI, Moscow Medical Academy, Moscow, Russia
pgA532 PHC3 COST AND QUALITY IMPROVEMENTS ASSOCIATED WITH MINIMALLY INVASIVE SURGERY (MIS) TOTAL HIP ARTHROPLASTY (THA)
Straumann D1, Kaufmann D1, Egli B1, Mills T2, Davies M3, 1Zimmer GmbH, Winterthur, Switzerland, 2Wolters Kluwer Health, Chester, UK, 3Wolters Kluwer Health,
London, UK
pgA532 PHC4 COST-EFFECTIVENESS OF HARMONIC SCALPEL USE VERSUS CONVENTIONAL TOTAL THYROIDECTOMY
Cicchetti A1, Lombardi C2, Raffaelli M2, Ruggeri M1, Di Bidino R2, Attinà G3, 1Catholic University of Sacred Heart, Rome, Italy, 2University Hospital “A.Gemelli”,
Rome, Italy, 3Johnson & Johnson Medical Holding, Rome, Italy
pgA532 PHC5 A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN The Netherlands
Van Genugten M1, Chhabra A2, Alt V3, 1Medtronic Trading NL B.V, Heerlen, DA, The Netherlands, 2Medtronic Europe SA, Tolochenaz, Switzerland, 3University
Hospital Giessen-Marburg , Brackenheim, Germany
pgA533 PHC6 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN
Diamantopoulos A1, Forster F1, Brosa M2, Lees M3, Piñol C4, Febrer L4
1
IMS Health, London, UK, 2Oblikue Consulting, Barcelona, Spain, 3Bayer HealthCare, Uxbridge, UK, 4Bayer HealthCare, Barcelona, Spain
pgA533 PHC7 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN CANADA
Diamantopoulos A1, Forster F1, Lees M2, McDonald HP3, 1IMS Health, London, UK, 2Bayer HealthCare, Uxbridge, UK, 3Bayer Inc, Toronto, ON, Canada
pgA533 PHC8 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT IN THE UK AND SPAIN
Diamantopoulos A1, Forster F1, Brosa M2, Lees M3, Gilmour L4, Ashley D4, Piñol C5, 1IMS Health, London, UK, 2Oblikue Consulting, Barcelona, SC, Spain, 3Bayer
HealthCare, Uxbridge, UK, 4Bayer Healthcare Pharmaceuticals Inc, Newbury, UK, 5Bayer HealthCare, Barcelona, Spain
pgA534 PHC9 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN THE UK
Diamantopoulos A1, Forster F1, Lees M2, Gilmour L3, Ashley D4, 1IMS Health, London, UK, 2Bayer HealthCare, Uxbridge, UK, 3Bayer Healthcare Pharmaceuticals
Inc, Newbury, Berkshire, UK, 4Bayer Healthcare Pharmaceuticals Inc, Newbury, UK
pgA534 PHC10 PROPHYLAXIS WITH RIVAROXABAN AGAINST VENOUS THROMBOEMBOLISM (VTE): A COST-CONSEQUENCE ANALYSIS FROM THE PERSPECTIVE OF THE
ITALIAN HEALTHCARE SERVICE
Negrini C1, Diamantopoulos A2, Forster F2, Lopatriello S3, Lees M4, Bianchi C5, Pedone MP5, 1PBE Consulting, Milano, Italy, 2IMS Health, London, UK, 3Pbe
Consulting, Verona, Italy, 4Bayer HealthCare, Uxbridge, UK, 5Bayer HealthCare, Milan, Italy
pgA534 PHC11 THE BURDEN OF ADHESIOLYSIS DURING LAPAROSCOPIC GYNECOLOGICAL SURGERY
Crowe AM1, Knight AD1, Krishnan S2, 1Corvus Communications Limited, Buxted, UK, 2Baxter BioSurgery, Westlake Village, CA, USA
pgA535 PHC12 COMPARING TIME AND SUPPLIES USAGE ASSOCIATED WITH A NEW SKIN CLOSURE DEVICE VS. STANDARD OF CARE WOUND CLOSURE FOR ABDOMINOPLASTY SURGERY IN The Netherlands
Van Nooten F1, De Cock E2, Fabré J3, Tan R4, 1United BioSource Corporation, Brussels, Flanders, Belgium, 2United BioSource Corporation, Barcelona, Spain,
3
UMC St. Radboud, Nijmegen, The Netherlands, 4Ethicon, Livingston, UK
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
64
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA535 PHC13 CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY: TIME AND SUPPLIES WITH PRINEO VS. STANDARD OF CARE FOR ABDOMINO-
PLASTY SURGERY IN GERMANY
De Cock E1, Van Nooten F2, Müller K3, Tan R4, 1United BioSource Corporation, Barcelona, Spain, 2United BioSource Corporation, Brussels, Flanders, Belgium,
3
ASKLEPIOS Klinik Wandsbek, Hamburg, Germany, 4Ethicon, Livingston, UK
HEALTH CARE INTERVENTIONS - Health Care Use & Policy Studies
pgA535 PHC14 ORGAN SHORTAGE IN TRANSPLANTATION MEDICINE: WHOSE VALUES AND ON WHAT BASIS SHOULD ORGAN PROCUREMENT BE ORGANISED?
Naujoks C, Novartis Pharma AG, Basel, Switzerland
MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies
pgA536 PMS1 COGNITIVE IMPAIRMENT IN PATIENTS WITH FIBROMYALGIA SYNDROME AS ASSESSED BY THE MINIMENTAL STATE EXAMINATION
Rodríguez-Andreu J1, Ibáñez-Bosch R2, Portero-Vázquez A3, Masramón X4, Rejas J5, 1Hospital Virgen de la Victoria, Málaga, Spain, 2Hospital de Navarra, Pamplona, Spain, 3Hospital Xeral-CALDE, Lugo, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain
pgA536 PMS2 DIAGNOSIS OF OSTEOPOROSIS BY DUAL X-RAY AND LASER (DXL) DENSITOMETRY – A HEALTH TECHNOLOGY ASSESSMENT
Beh JS, Luehmann D, University of Luebeck, Luebeck, Germany
pgA537 PMS3 A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS
Rys P1, Kucia K1, Pankiewicz O1, Rogoz A1, Lis J2, Nadzieja-Koziol A1, Gurda-Duda A1, 1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis sp. z o.o, Warszawa, Poland
pgA537 PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO
Carlos-Rivera F1, Aguirre-Granados A1, Manterola SOMC2, 1R A C Salud Consultores, S.A. de C.V, Mexico DF, Mexico, 2Economía de la Salud. Sanofi-Aventis,
Mexico City, Mexico
pgA537 PMS5 PREVALENCE OF FIBROMYALGIA IN GERMANY
Le Lay K1, Spaeth M2, Boussetta S1, Taieb C1, 1Pierre Fabre, Boulogne, France, 2-, Munich, Germany
pgA538 PMS6 PREVALENCE OF FIBROMYALGIA IN FRANCE
Le Lay K1, Bannwarth B2, Blotman F3, Boussetta S1, Taieb C1, 1Pierre Fabre, Boulogne, France, 2University Hospital Pellegrin, Bordeaux, France, 3Lapeyronie
Hospital, Montpellier, France
pgA538 PMS7 PREVALENCE OF FIBROMYALGIA: A LARGE-SCALE EUROPEAN SURVEY: EARLY RESULTS IN UNITED-KINGDOM
Le Lay K1, Boussetta S1, Taieb C1, Wessely S2, 1Pierre Fabre, Boulogne, France, 2Epidemiology-Psychiatry, London, UK
pgA538 PMS8 PREVALENCE OF FIBROMYALGIA IN ITALY
Le Lay K1, Boussetta S1, Matucci Cerinic M2, Taieb C1, 1Pierre Fabre, Boulogne, France, 2Univ. Firenze, Florence, Italy
pgA538 PMS9 PREVALENCE OF FIBROMYALGIA IN PORTUGAL
Le Lay K1, Boussetta S1, Branco J2, Taieb C1, 1Pierre Fabre, Boulogne, France, 2CHLO, EPE/Hospital Egas Moniz, Lisboa, Portugal
pgA539 PMS10 PREVALENCE OF FIBROMYALGIA IN SPAIN
Le Lay K1, Boussetta S1, Carbonell JA2, Failde I3, Taieb C1, 1Pierre Fabre, Boulogne, France, 2Hospital de la Esperanz, Barcelona, Spain, 3Universidad de Cadiz,
Cadix, Spain
pgA539 PMS11 PREVALENCE OF FIBROMYALGIA IN RUSSIA: EARLY RESULTS
Le Lay K1, Nasonov E2, Soldatov D3, Boussetta S1, Taieb C1, 1Pierre Fabre, Boulogne, France, 2Rheumatology Institute, Moscou, Russia, 3Pierre Fabre Laboratories, Moscou, Russia
pgA539 PMS12 THE ROLE OF DIFFERENT CO-MORBIDITIES IN THE EVALUATION OF CORRELATION BETWEEN CERTAIN RISK FACTORS AND THE ONE YEAR MORTALITY
FOLLOWING FEMORAL NECK FRACTURE
Sebestyen A1, Sándor J2, Kriszbacher I3, Betlehem J3, Boncz I2, 1National Health Insurance Fund Administration, Pecs, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pecs, Pecs, Hungary
pgA540 PMS13 IMPACT OF VIOXX WITHDRAWAL ON VOLUME OF TOTAL HIP AND KNEE REPLACEMENTS
Huse D1, Marder WD1, Hansen LG2, 1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Northwood, NH, USA
MUSCULAR-SKELETAL DISORDERS - Cost Studies
pgA540 PMS14 NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
Iannazzo S1, Giuliani G2, Zaniolo O1, Sacchi V1, Pradelli L1, 1AdRes Srl, Turin, Italy, 2Roche S.p.A, Milano, Italy
pgA540 PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND – A BUDGET IMPACT ANALYSIS
Golicki D1, Niewada M1, Lis J2, Tlustochowicz W3, 1Medical University of Warsaw, Warsaw, Poland, 2Sanofi-Aventis sp. z o.o, Warsaw, Poland, 3Military Institute
of the Health Services, Warsaw, Poland
pgA541 PMS16 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS – BUDGET IMPACT ANALYSIS ON POLISH NATIONAL
HEATH FUND
Macioch T1, Niewada M2, Wrona W1, Golicki D1, Hermanowski T1, 1Medical University of Warsaw, Department of Pharmacoeconomics, Warsaw, Poland, 2Medical
University of Warsaw, Department of Experimental and Clinical Pharmacology, Warsaw, Poland
pgA541 PMS17 THE ECONOMIC IMPLICATIONS OF ACHIEVING TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Taylor MJ1, Conway P2, Lebmeier M3, Batta R3, 1University of York, York, UK, 2Wyeth Europa, Berkshire, UK, 3Wyeth Pharmaceuticals, Maidenhead, UK
pgA541 PMS18 COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS
Rasmussen C1, Knudsen MS2, Hansen BB2, Lindkvist RM3, 1Vendsyssel Hospital, Hjørring, Denmark, 2COWI, Lyngby, Denmark, 3Wyeth Denmark, Glostrup, Denmark
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
65
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA541 PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
Miadi-Fargier H1, Fautrel B2, Maravic M3, Daures JP4, Ollivier AL5, Le Pen C6, Maurel F1, 1IMS Health, Puteaux, France, 2Groupe Hospitalier Pitié-Salpêtrière,
Paris, France, 3Hopital Leopold Bellan, Paris, France, 4CHU de Nimes, Nimes, France, 5Wyeth Pharmaceuticals, Paris La Defense, France, 6Dauphine University,
Paris, France
pgA542 PMS20 IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS
Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY , University of Liège, Liège, Belgium
pgA542 PMS21 COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
Gossec L1, Goupille P2, Saraux A3, Bregman B4, Boccard E4, Dupont D5, Beresniak A6, 1Cochin Hospital, Paris, France, 2CHRU de Tours - Université François
Rabelais, Tours, France, 3Hôpital de la Cavale Blanche, Brest, France, 4Bristol-Myers Squibb, Rueil-Malmaison, France, 5Bristol-Myers Squibb International
Corporation, Braine l’Alleud, Belgium, 6LIRAES, Descartes University, Paris, France and Data Mining International, Geneva, Switzerland
pgA543 PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS – COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS
Macioch T, Niewada M, Wrona W, Golicki D, Hermanowski T, Medical University of Warsaw, Warsaw, Poland
pgA543 PMS70 COST-EFFECTIVENESS OF ETANERCEPT VS. RITUXIMAB IN THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN COLOMBIA
Gao X1, Hwang S2, Carpiuc KT1, Stephens JM1, Sato R2, Singh A2 ,1Pharmerit North America LLC, Bethesda, MD, USA, 2Wyeth Research, Collegeville, PA, USA
pgA543 PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY: A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY
Ganz ML1, Prasad M2, Yeh YC1, Miller JD1, Russell MW1, 1Abt Bio-Pharma Solutions, Lexington, MA, USA, 2Schering-Plough Corporation, Kenilworth, NJ, USA
pgA544 PMS24 THE COST-EFFECTIVENESS OF SEQUENTIAL USE OF ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Taylor MJ1, Conway P2, Lebmeier M3, Ganderton M1, 1University of York, York, UK, 2Wyeth Europa, Berkshire, UK, 3Wyeth Pharmaceuticals, Maidenhead, UK
pgA544 PMS25 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
Plisko R1, Krzystek J1, Rys P1, Russel-Szymczyk M2, Szkultecka-Debek M2, Szamotulska K3, 1HTA Consulting, Krakow, Poland, 2Roche Polska, Warsaw, Poland,
3
National Research Institute of Mother and Child, Warsaw, Poland
pgA544 PMS26 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN The Netherlands
Van Genugten M1, Chhabra A2, Alt V3, 1Medtronic Trading NL B.V, Heerlen, The Netherlands, 2Medtronic Europe SA, Tolochenaz, Switzerland, 3University Hospital
Giessen-Marburg , Brackenheim, Germany
pgA544 PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL
Hammerman A1, Klang SH1, Liebermann N1, Birenboim-Gal T2, Shuali A2, Kfir M2, 1Clalit Health Services, Tel-Aviv, Israel, 2Roche Pharmaceuticals (Israel),
Petach-Tikva, Israel
pgA545 PMS28 COST OF RHEUMATOID ARTHRITIS MODEL PER LEVEL OF DISEASE ACTIVITY IN FRANCE
Beresniak A1, Gossec L2, Goupille P3, Saraux A4, Bamberger M5, Bregman B5, 1LIRAES, Paris Descartes University, Paris, France and Data Mining International,
Geneva, Switzerland, 2Cochin Hospital, Paris, France, 3CHRU de Tours - Université François Rabelais, Tours, France, 4Hôpital de la Cavale Blanche, Brest,
France, 5Bristol-Myers Squibb, Rueil-Malmaison, France
pgA545 PMS29 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN SPANISH PATIENTS
Lamotte M1, Maugars Y2, De Vos C1, Girard L3, Le Lay K4, Taieb C4, 1IMS Health, Brussels, Belgium, 2Hotel Dieu, Nantes, France, 3IMS Health, Nantes, France,
4
Pierre Fabre, Boulogne, France
pgA545 PMS30 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN FRENCH PATIENTS
Lamotte M1, Maugars Y2, De Vos C1, Girard L3, Le Lay K4, Taieb C4, 1IMS Health, Brussels, Belgium, 2Hotel Dieu, Nantes, France, 3IMS Health, -, France, 4Pierre
Fabre, Boulogne, France
pgA546 PMS31 OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS: EVIDENCE FROM U.S. NATIONAL SURVEY DATA
Kotlarz H1, Gunnarsson C2, Rizzo J3, 1DePuy Orthopaedics, Warsaw, IN, USA, 2S2 Statistical Solutions, Inc, Cincinnati, OH, USA, 3Stony Brook University, Stony
Brook, NY, USA
pgA546 PMS32 THE DIRECT HEALTH CARE COSTS OF OSTEOARTHRITIS: EVIDENCE FROM US NATIONAL SURVEY DATA
Kotlarz H1, Gunnarsson C2, Rizzo J3, 1DePuy Orthopaedics, Warsaw, IN, USA, 2S2 Statistical Solutions, Inc, Cincinnati, OH, USA, 3Stony Brook University, Stony
Brook, NY, USA
pgA546 PMS33 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN SPAIN
Lamotte M1, Maugars Y2, De Vos C1, Girard L3, Le Lay K4, Taieb C4, 1IMS Health, Brussels, Belgium, 2Hotel Dieu, Nantes, France, 3IMS Health, -, France, 4Pierre
Fabre, Boulogne, France
pgA547 PMS34 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN FRANCE
Lamotte M1, Maugars Y2, De Vos C1, Girard L3, Le Lay K4, Taieb C4, 1IMS Health, Brussels, Belgium, 2Hotel Dieu, Nantes, France, 3IMS Health, Paris, France,
4
Pierre Fabre, Boulogne, France
pgA547 PMS35 RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND
Lacki J1, Rys P2, Plisko R2, Szamotulska K3, Szkultecka-Debek M4, Russel-Szymczyk M4, 1Institute of Rheumatology, Warsaw, Poland, 2HTA Consulting, Krakow,
Poland, 3National Research Institute of Mother and Child, Warsaw, Poland, 4Roche Polska, Warsaw, Poland
pgA547 PMS36 COST OF THERAPY OF TUMOR NECROSIS FACTOR BLOCKING AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
Fiocco U1, Cantini F2, Matucci Cerinic M3, Ferri C4, Botsios C1, Intorcia M5, Bombardieri S6, 1University of Padova, Padova, Italy, 2Ospedale Misericordia e Dolce,
Prato, Italy, 3University of Florence, Florence, Italy, 4Università di Modena, Modena, Italy, 5Bristol-Myers Squibb, Rome, Italy, 6Università di Pisa, Pisa, Italy
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
66
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA548 PMS37 A MICROSIMULATION-BASED COST-UTILITY ANALYSIS OF RITUXIMAB (MABTHERA®) IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN
Fernández I1, Varela C1, Badia X2, Carreño Á2, Polanco C2, 1Roche Farma, Madrid, Spain, 2IMS Health, Barcelona, Spain
pgA548 PMS38 COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
Kobelt G1, Lindgren P2, 1European Health Economics, Speracedes, France, 2i3 Innovus, Stockholm, Sweden
pgA548 PMS39 COST-UTILITY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INSUFFICIENT RESPONSE OR INTOLERANCE TO ANTI-TNF THERAPY IN
ITALY: A PROBABILISTIC SENSITIVITY ANALYSIS
Mantovani LG1, De Portu S1, Intorcia M2, Olivieri I3, 1University of Naples, Federico II, Naples, Italy, 2Bristol-Myers Squibb, Rome, Italy, 3San Carlo Hospital of
Potenza and Madonna delle Grazie, Potenza, Italy
pgA549 PMS40 COST-EFFECTIVENESS ANALYSIS OF ANNUAL DOSE OF ZOLEDRONIC ACID VERSUS ORALLY ADMINISTERED BISPHOSPHONATES IN PREVENTION OF OSTEOPOROTIC FRACTURES IN CZECH POST-MENOPAUSAL WOMEN
Tichopad A1, Kutscherauer P2
pgA549 PMS41 COST-EFFECTIVENESS OF CELECOXIB COMPARED TO CONVENTIONAL NSAIDS AND NSAID+PPI COMBINATION THERAPY IN RHEUMATOID ARTHRITIS
Inotai A, Meszaros A, Semmelweis University, Budapest, Hungary
pgA549 PMS42 COST-UTILITY EVALUATION OF THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS WITH INSAPONIFICATES OF AVOCADO AND SOY (PIASCLEDINE ®)
Ayala C1, Abud F2, Del angel Garcia G2, Brugada-Cruces C2, 1Epieconomics Research, Mexico City, DF, Mexico, 2IMSS, Mexico, DF, Mexico
pgA549 PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
Brodszky V1, Borgström F2, Arnetorp S2, Péntek M3, Gulácsi L1, 1Corvinus University of Budapest, Budapest, Hungary, 2I3 Innovus, Stockholm, Sweden, 3Flor
Ferenc County Hospital, Kistarcsa, Hungary
pgA550 PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID
ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3 STUDIES
Buchanan J1, Emery P2, Keystone EC3, Smolen J4, Doyle MK5, Hsia EC5, Rahman MU5, Gathany T1, Han C1, Parasuraman S1, 1Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 2University of Leeds, Leeds, UK, 3University of Toronto/ Mount Sinai Hospital, Toronto, ON, Canada, 4Medical University
of Vienna, Vienna, Austria, 5Centocor Research and Development, Inc./ U Penn Medical School, Malvern/ Philadelphia, PA, USA
pgA550 PMS44 PARAMEDICAL OR ALTERNATIVE TREATMENTS AND ASSOCIATED COSTS FOR THE MANAGEMENT OF FIBROMYALGIA IN FRANCE
Maugars Y1, Lamotte M2, Van Vlaenderen I3, Le Lay K4, Taieb C4, 1Hotel Dieu, Nantes, France, 2IMS Health, Brussels, Belgium, 3IMS Health Belgium, Brussels,
Belgium, 4Pierre Fabre, Boulogne, France
pgA550 PMS45 OUTPATIENT MEDICAL MANAGEMENT OF FIBROMYALGIA IN FRANCE COMPARED TO THE UK
Maugars Y1, Lamotte M2, Van Vlaenderen I2, Le Lay K3, Taieb C3, 1Hotel Dieu, Nantes, France, 2IMS Health, Brussels, Belgium, 3Pierre Fabre, Boulogne, France
MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes Studies
pgA551 PMS46 DEVELOPMENT OF A SPECIFIC TOOL TO EVALUATE WOMEN’S ADHERENCE TO OSTEOPOROSIS TREATMENT
Roborel de Climens A1, Cotte FE2, Dias-Barbosa C1, Breuil V3, Cortet B4, Legrand E5, Gaudin AF2, Arnould B1, 1Mapi Values France, Lyon, France, 2GlaxoSmithKline France, Marly le Roi, France, 3CHU de Nice, Nice, France, 4CHRU Lille, Lille, France, 5CHU, Angers, France
pgA551 PMS47 USING HAQ TO ESTIMATE HUI3 AND EQ-5D UTILITY VALUES IN SPANISH RHEUMATOID ARTHRITIS PATIENTS
Fernández I1, Varela C1, Layola M2, Ruiz MD3, Navarro F3, 1Roche Farma, Madrid, Spain, 2IMS Health, Barcelona, Spain, 3Hospital Universitario Virgen Macarena, Sevilla, Spain
pgA551 PMS48 PATIENT EXPECTATIONS IN HEALTH RELATED QUALITY OF LIFE OUTCOMES IN TOTAL JOINT REPLACEMENT
González M1, Escobar A1, Herrera C2, Garcia L3, Sarasqueta C4, Quintana JM5, Aizpuru F6, Linertova R7, Reyes E8, 1Hospital de Basurto, Bilbao, Spain, 2Hospital
Virgen de las Nieves, Granada, Spain, 3Servicio Canario de la Salud, Santa Cruz de Tenerife, Spain, 4Hospital Donostia, Donostia-San Sebastian, Spain, 5Hospital de Galdakao-Usansolo, Galdakao, Spain, 6Hospital de Txagorritxu, Vitoria-Gasteiz, Spain, 7Servicio de Evaluación y Planificación, Santa Cruz de Tenerife,
Spain, 8Subdirección de Investigación, Granada, Spain
pgA552 PMS49 HEALTH-RELATED QUALITY OF LIFE (HRQL) OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN GREECE: PRELIMINARY RESULTS FROM
THE HEOR STUDY
Papagiannopoulou V1, Latsou D1, Boumpas D2, Drosos A3, Floros A4, Yfantopoulos I1, 1University of Athens, Athens, Greece, 2University of Crete, Crete, Greece,
3
University of Ioannina, Ioannina, Greece, 4Abbott Hellas, Athens, Greece
pgA552 PMS50 FRACTURE INCIDENCE AND CHANGES IN QUALITY OF LIFE AND BACK PAIN IN WOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE: EUROPEAN
FORSTEO OBSERVATIONAL STUDY (EFOS) 18 MONTH RESULTS FROM PATIENTS ENROLLED IN FRANCE
Rajzbaum G1, Tcherny S2, Liu-Leage S2, Jamonneau I3, 1Saint Joseph Hospital, Paris, France, 2Lilly France, Suresnes, France, 3Lilly France, suresnes, France
pgA552 PMS51 MAJOR DETERMINANTS OF EUROQOL (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON A LARGE JAPANESE COHORT IORRA
Igarashi A1, Hoshi D2, Orihara S1, Inoue E2, Momohara S2, Hara M2, Kamatani N2, Yamanaka H2, Tsutani K1, 1The University of Tokyo, Bunkyo, Tokyo, Japan,
2
Tokyo women’s medical university, Shinjyuku, Tokyo, Japan
pgA553 PMS52 THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS: THE IMPACT OF TREATMENT
Taieb C1, Roche R2, 1Pierre Fabre, Boulogne, FRANCE, France, 2PFS, Castres, France
pgA553 PMS53 PUBLIC HEALTH OBJECTIVE: THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS FINALLY TAKEN INTO CONSIDERATION
Taieb C1, Roche R2, 1Pierre Fabre, Boulogne, FRANCE, France, 2PFS, Castres, France
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
67
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION II – MONDAY, 10 NOVEMBER 2008: DISPLAY HOURS: 8:00-19:30 / POSTER AUTHOR DISCUSSION HOUR: 17:30-18:30
pgA553 PMS54 RELIEF OF PAIN AND SYMPTOMS IN KNEE CARTILAGE DEFECT IS ASSOCIATED WITH HIGHER SF-36 UTILITY SCORES: DATA FROM A PROSPECTIVE RAN-
DOMIZED TRIAL OF CHONDROCELECT®
Gerlier L1, Lamotte M1, Van Lommel N2, Wille M3, Vanlauwe JJ4, 1IMS Health, Brussels, Belgium, 2TiGenix NV, LEUVEN, Belgium, 3TiGenix NV, Leuven, Belgium,
4
University Hospitals Leuven, Pellenberg, Belgium
pgA554 PMS55 EURO QOL (EQ-5D) BASED QOL (QUALITY OF LIFE) IN 5,023 JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) PATIENTS IN AN OBSERVATIONAL
COHORT IORRA
Hoshi D1, Igarashi A2, Orihara S2, Tsutani K2, Inoue E1, Momohara S1, Hara M1, Kamatani N1, Yamanaka H1, 1Tokyo women’s medical university, Shinjyuku,
Tokyo, Japan, 2The University of Tokyo, Bunkyo, Tokyo, Japan
pgA554 PMS56 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): VALIDATION OF A TOOL TO AID DIAGNOSIS
Le Lay K1, Moldofsky H2, Boussetta S1, Taieb C1
1
Pierre Fabre, Billancourt, France, 2Centre for Sleep and Chronobiology, Toronto, ON, Canada
pgA554 PMS57 VALIDITY AND RESPONSIVENESS OF THE WORK PRODUCTIVITY SURVEY: A NOVEL DISEASE-SPECIFIC INSTRUMENT ASSESSING WORK PRODUCTIVITY
WITHIN AND OUTSIDE THE HOME IN SUBJECTS WITH RHEUMATOID ARTHRITIS Osterhaus J1, Purcaru O2, Richard L3, 1Wasatch Health Outcomes, Park City, UT, USA, 2UCB, Braine l’Alleud, Belgium, 3UCB Celltech, Slough, UK
pgA555 PMS58 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): USE OF A TOOL TO AID DIAGNOSIS
Le Lay K1, Boussetta S2, Moldofsky H3, Taieb C4, 1Pierre Fabre, Boulogne-billancourt, France, 2Pierre Fabre, Boulogne Billancourt, France, 3Centre for Sleep and
Chronobiology, Toronto, ON, Canada, 4Pierre Fabre, Boulogne, France
pgA555 PMS59 RESTORATIVE EFFECT OF SLEEP: VALIDATION OF THE SQA (SLEEP QUALITY ASSESSMENT)
Le Lay K1, Boussetta S1, Moldofsky H2, Taieb C1, 1Pierre Fabre, Boulogne, France, 2Centre for Sleep and Chronobiology, Toronto, ON, Canada
pgA555 PMS60 QUALITATIVE STEPS FOR THE DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF FIBROMYALGIA ON PATIENTS’ DAILY LIVES
Arnould B1, Benmedjahed K2, Barnes N1, Carbonell JA3, Serra E4, Spaeth M5, Boussetta S6, Le Lay K7, Taieb C8, 1Mapi Values, Lyon, France, 2Mapi Values
France, Lyon, France, 3Hospital de la Esperanz, Barcelona, Spain, 4Amiens University Hospital, Amiens, France, 5-, Munich, Germany, 6Pierre Fabre, Boulognebillancourt, -, France, 7Pierre Fabre, Boulogne-billancourt, France, 8Pierre Fabre, Boulogne, France
pgA556 PMS61 SHORT-TERM OUTCOMES AND HRQOL AFTER PEDIATRIC EMERGENCY DEPARTMENT (PED) TREATMENT OF MINOR INJURY: A PILOT STUDY
Stevens MW1, Drendel AL2, Hainsworth KR2, 1Medical College of Wisconsin; Children’s Hospital of Wisconsin, Milwaukee, WI, USA, 2Medical College of Wisconsin, Milwaukee, WI, USA
pgA556 PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTOR THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
Punzi L1, Cantini F2, Matucci Cerinic M3, Ferri C4, Fiocco U5, Intorcia M6, Bombardieri S7, 1Azienda Ospedaliera di Padova, Padova, Italy, 2Ospedale Misericordia
e Dolce, Prato, Italy, 3University of Florence, Florence, Italy, 4Università di Modena, Modena, Italy, 5University of Padova, Padova, Italy, 6Bristol-Myers Squibb,
Rome, Italy, 7Università di Pisa, Pisa, Italy
pgA556 PMS63 PATIENT REPORTED OUTCOMES OF DIFFERENT SURGICAL PROCEDURES IN PATIENTS WITH CARTILAGE DEFECTS OF THE KNEE AFTER 1 TO 5 YEARS
Brüggenjürgen B1, Berger H2, Willich SN1, 1Charite University Medical Center, Berlin, Germany, 2Fachhochschule Osnabrück, Osnabrück, Germany
pgA557 PMS64 DIFFERENCES IN QUALITY OF LIFE ACCORDING TO THE REPLACED JOINT
Escobar A1, Quintana JM2, González M1, Sarasqueta C3, Aizpuru F4, Herrera C5, Garcia L6, 1Hospital de Basurto, Bilbao, Spain, 2Hospital de Galdakao-Usansolo,
Galdakao, Spain, 3Hospital Donostia, Donostia-San Sebastian, Spain, 4Hospital de Txagorritxu, Vitoria-Gasteiz, Spain, 5Hospital Virgen de las Nieves, Granada,
Spain, 6Servicio Canario de la Salud, Santa Cruz de Tenerife, Spain
pgA557 PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3 STUDIES
Buchanan J1, Fleischmann R2, Genovese MC3, Kay J4, Hsia EC5, Doyle MK5, Rahman MU5, Han C1, Parasuraman S1, 1Johnson and Johnson Pharmaceutical
Services, LLC, Malvern, PA, USA, 2Univeristy of Texas Southwestern Medical Center, Dallas, TX, USA, 3Stanford University, Palo Alto, CA, USA, 4Massachussetts
General Hospital/ Harvard Medical School, Boston, MA, USA, 5Centocor Research and Development, Inc./ U Penn Medical School, Malvern/ Philadelphia, PA, USA
pgA557 PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTED WAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN: AN APPLICATION TO BALLOON KYPHOPLASTY
Anton E1, Corugedo I2, Hidalgo A3, Martin M2, 1Medtronic Iberica, Madrid, Spain, 2Complutense University, Madrid, Spain, 3Castilla la Mancha University, Toledo,
Spain
MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies
pgA558 PMS67 HEALTH GAINS FOREGONE DUE TO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS: THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
Storz P1, Gothe H1, Klein S1, Marx P2, Häussler B1, 1IGES Institut GmbH, Berlin, Germany, 2Pfizer GmbH, Karlsruhe, Germany
pgA558 PMS68 ANTI-TUMOUR NECROSIS FACTOR-&ALPHA; INHIBITOR DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN A PROSPECTIVE PATIENT REGISTRY SETTING
Kievit W1, Tatt ID2, Van Riel P1, 1Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2F.Hoffmann-La Roche Ltd, Basel, Switzerland
pgA558 PMS69 PATTERNS OF MORBIDITY AND DIRECT COSTS ASSOCIATED IN THE OSTEOPOROSIS SPANISH POPULATION SETTING
Sicras A1, Navarro R1, Rejas J2, 1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain
Monday, 10 November – Research Poster Presentations – Session II includes the following topics:
PCASE – HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCN – CANCER
PDB – DIABETES/ENDOCRINE DISORDERS
PGI – GI DISORDERS
PHC – HEALTH CARE INTERVENTIONS (Dental, Surgery, Veterinary Medicine)
PMS – MUSCULAR-SKELETAL DISORDERS (Arthritis, Osteoporosis, Other Muscular-Skeletal)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
68
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
research poster presentations
research poster presentationS - SESSION III
< < <
< < < < < <
PSS
PSS
PSY
< < <
< < <
< < <
PSY
PMH
< < <
< < <
< < <
PSS
PSY
< < < < < <
< < <
< < <
< < < < < <
PUK
< < <
PND
PMH
< < <
< < <
PND
< < <
PUK
< < <
Hesperides
< < <
PMH
< < < < < <
< < <
PUK
< < < < < <
To Hesperides
< < <
PMH
< < < < < < <
Hesperides Foyer
PMC
< < < < < <
PMC
< < < < < <
< < < < < <
PMC
< < < < <
< < < < <
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
PSY
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Clinical Outcomes Methods
pgA559 PMC1 COLLECTING REAL DATA FROM REAL PATIENTS
Wade AG, Crawford G, Patients Direct, Glasgow, UK
pgA559 PMC2 HAS THE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME: AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS?
Proudfoot CW1, Stoddart SD1, Muston D2, 1Heron Evidence Development Ltd, Letchworth Garden City, UK, 2Heron Evidence Development Ltd, Letchworth, UK
pgA559 PMC3 OVERCOMING THE FINAL HURDLE: COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG
Shannon PR, Beard S, RTI Health Solutions, Manchester, UK
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Cost Methods
pgA560 PMC4 FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY
Calgan Z1, Ozer A2, 1Hacettepe University, Ankara, Turkey, 2Social Security Institution, Ankara, Turkey
pgA560 PMC5 A MISSING DATA THRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA: DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS
Bush S, CRC/Cardiff Research Consortium, Cardiff, Glamorgan, UK
pgA560 PMC6 SOCIAL DISCOUNTING IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES
Valentim J1, Prado Jr JM2, 1University of São Paulo, São Paulo, SP, Brazil, 2IMT Lucca Institute for Advanced Studies, Lucca, Toscana, Italy
pgA561 PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS
Hoogendoorn M1, van Wetering CR2, Schols AM3, Rutten-van Mölken MP1, 1Erasmus MC, Rotterdam, The Netherlands, 2Maxima Medical Centre, Veldhoven, The
Netherlands, 3Maastricht University, Maastricht, The Netherlands
pgA561 PMC8 DESIGN AND REPORTING TRENDS IN PIGGY-BACK ECONOMIC TRIALS
Ubhadiya BS1, Gautam C1, Narvilkar P2, Singh N2, Bhanderi M2, Dimri S2, 1Heron Health Pvt Ltd, Chandigarh, India, 2Heron Health Private Ltd, Chandigarh, India
pgA561 PMC9 DISCOUNTING COSTS AND BENEFITS OF HEALTH CARE PROGRAMMES: PROBLEMS OF THE SOCIAL TIME PREFERENCE APPROACH
John J, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
69
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA562 PMC10 PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS
Hoyle M, Anderson R, University of Exeter, Exeter, England
pgA562 PMC11 IMPROVING PROBABILISTIC SENSITIVITY ANALYSIS (PSA) IN THE TREATMENT OF UNCERTAINTY COSTS USING MCMC
Monleon-Getino A1, Crespo C2, Rodriguez JM3, Ocaña J1, 1University of Barcelona, Barcelona, Spain, 2Oblikue Consulting, Barcelona, Spain, 3Medtronic Iberia,
Madrid, Spain
pgA562 PMC12 MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE: A STOCHASTIC APPLICATION IN DIABETES CARE
Hoomans T1, Abrams K2, Evers SMAA1, Ament AJHA1, Severens JL3, 1Maastricht University, Maastricht, The Netherlands, 2University of Leicester, Leicester, UK,
3
University Hospital Maastricht, Maastricht, The Netherlands
pgA563 PMC13 ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS: AN ALTERNATIVE TO THE SMEARING APPROACH
Exuzides A1, Colby C1, Spalding JR2, 1ICON Clinical Research, San Francisco, CA, USA, 2Astellas Pharma US, Deerfield, IL, USA
pgA563 PMC14 A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS
Grutters JP1, Joore MA2, 1Maastro Clinic, Maastricht, The Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands
pgA563 PMC15 IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS
Tilling CJ1, Krol M2, Tsuchiya A3, Brazier JE3, Brouwer W2, 1Sheffield University, Sheffield, UK, 2The institute for Medical Technology Assessment, Rotterdam, The
Netherlands, 3The University of Sheffield, Sheffield, South Yorkshire, UK
pgA564 PMC16 EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS
Schlander M, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Databases & Management Methods
pgA564 PMC17 VALIDITY OF ELECTRONIC PRECRIPTION CLAIMS RECORDS: A COMPARISON OF ELECTRONIC PBM CLAIMS RECORDS WITH PHARMACY PROVIDER DERIVED RECORDS
Martin BC1, Cox E2, 1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2Express Scripts Inc, Maryland Heights, MO, USA
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Modeling Methods
pgA564 PMC18 CONCEPTUALISING DISEASE: BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE
STUDY IN ALZHEIMER’S DISEASE (AD)
Wild D1, Nixon A1, Sculpher M2, Lloyd A1, Briggs A3, Mealing S1, Gallop K1, 1Oxford Outcomes Ltd, Oxford, UK, 2University of York, York, UK, 3University of Glasgow, Glasgow, UK
pgA565 PMC19 COST-EFFECTIVENESS ANALYSES OF BEHAVIORAL INTERVENTIONS: TOWARDS A MORE REALISTIC COST-EFFECTIVENESS RATIO BY INCLUDING INTERMEDIATE OUTCOME MEASURES
Prenger R1, Braakman-Jansen LM1, Pieterse ME1, van der Palen J2, Seydel ER1, 1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente
Hospital, Enschede, The Netherlands
pgA565 PMC20 QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS
Bolle M1, Mukku SR2, Sparrowhawk K2, Tutt S2, 1University of Cambridge, Cambridge, UK, 2PriceSpective, London, UK
pgA565 PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN
DIABETES CARE
Gordon JP1, Bergenheim K2, Yuan Y3, Tetlow AP1, McEwan P1, 1Cardiff Research Consortium, Cardiff, UK, 2AstraZeneca, Mölndal, Sweden, 3Bristol-Myers
Squibb, Princeton, NJ, USA
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Patient-Reported Outcomes Studies
pgA566 PMC22 THE IMPACT OF COMORBIDITY BURDEN AND AGE ON PREFERENCE-BASED HRQL IN THE UNITED STATES
Sullivan PW, Ghushchyan VH, University of Colorado Denver, Aurora, CO, USA
pgA566 PMC24 SELF-ASSESSED HEALTH STATUS IN POLAND: EQ-5D FINDINGS FROM POLISH VALUATION STUDY
Golicki D1, Niewada M2, Jakubczyk M1, Wrona W1, Dwojak A3, Gasiewska A3, Holownia M3, Koltowski L3, Macioch T1, Hermanowski T1, 1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw,
Poland, 3Medical University of Warsaw, Warsaw, Poland
pgA567 PMC26 PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36
Chen T1, Li L2, 1Zhejiang University, Hangzhou, China, 2Zhejiang University, Hangzhou, Zhejiang, China
pgA567 PMC27 DO LIKERT-TYPE SCALE AND VISUAL ANLOGUE SCALE MEASURE THE SAME QUALITY OF LIFE?
Hsiao YY1, Yao G2, 1National Taiwan University, Taipei, Taiwan, Taiwan, 2National Taiwan University, Taipei, Taiwan
pgA568 PMC29 PATIENT REPORTED OUTCOMES RESEARCH IN A REAL TIME PRACTICE NETWORK
Barr JT1, Schumacher GE1, Myers E2, Snetselaar L3, 1Northeastern University, Boston, MA, USA, 2American Dietetic Association, Chicago, IL, USA, 3University of
Iowa, Iowa, IA, USA
pgA568 PMC30 THE IMPACT OF INITIAL DISEASE SEVERITY: AN APPLICATION TO EXISTING HEALTH ECONOMICS MODELS
Taylor MJ, Whitehead S, Stelemekas M, University of York, York, UK
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
70
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA568 PMC31 VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION
Golicki D1, Jakubczyk M1, Niewada M1, Wrona W1, Busschbach JJ2, Jablonska A1, Jawoszek A1, Mozenska O1, Kaminski B3, Hermanowski T1
1
Medical University of Warsaw, Warsaw, Poland, 2Erasmus Medical Center, Rotterdam, The Netherlands, 3Warsaw School of Economics, Warsaw, Poland
pgA569 PMC32 METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES: BEST PRACTICE GUIDELINES FOR
DECISION-MAKING AND TRANSLATION OR ADAPTATION
Eremenco S1, Houchin C2, Gawlicki M3, Chong LY4, 1United BioSource Corporation, Bethesda, MD, USA, 2Oxford Outcomes Ltd, Oxford, Oxon, UK, 3Corporate
Translations, Inc, East Hartford, CT, USA, 4NCC-AC, Royal College of Surgeons, London, UK
pgA569 PMC33 THE ROLE OF RANKING DATA IN HEALTH VALUATION
Chuang LH, Kind P, Zarate V, Weatherly H, University of York, York, UK
pgA569 PMC34 METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES
RESEARCH
Nixon A, Wild D, Oxford Outcomes Ltd, Oxford, UK
pgA570 PMC36 AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION - THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS
THROUGH STRUCTURAL EQUATION MODELLING
Chuang LH, Kind P, University of York, York, UK
pgA570 PMC37 CHALLENGES OF TRANSLATING AND LINGUISTICALLY VALIDATING PRO MEASURES INTO SLAVIC LANGUAGES
Merry R, Houchin C, Wild D, Oxford Outcomes Ltd, Oxford, UK
pgA570 PMC38 INFLUENCE OF DEMOGRAPHIC AND CULTURAL PREDICTORS ON EQ-5D VALUE SET IN THE POLISH POPULATION
Wrona W, Golicki D, Jakubczyk M, Niewada M, Orłowski K, Gaczkowska A, Zawodnik S, Medical University of Warsaw, Warsaw, Poland
pgA571 PMC39 WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES
Marant C1, Longin J2, Spizak C1, Patrick DL3, Saussier C2, Arnould B1, Van Ganse E4, 1Mapi Values France, Lyon, France, 2MAPI, Lyon, France, 3University of
Washington, Seattle, WA, USA, 4Neuroepidemiology and Pharmacoepidemiology unit, Bron, France
pgA571 PMC40 STABILITY OF TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) STRUCTURE IN DIFFERENT PATHOLOGY SAMPLES Ruíz MÁ1, Rejas J2, Pardo A1, Soto J2, 1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain
pgA571 PMC41 METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES
Salas M1, Zuluaga A1, Hughes D2, Cowell W3, Lebmeier M4, Vardeva K5, Pisu M1, Shinogle J6, 1University of Alabama at Birmingham, Birmingham, AL, USA, 2University of Bangor, Bangor, UK, 3Roche, Welwyn Garden City, UK, 4University of Sheffield, Sheffield, -, UK, 5Bristol-Myers Squibb, Uxbridge, UK, 6RTI International,
Washington, DC, USA
pgA572 PMC42 PATIENT AND POPULATION HEALTH-STATE VALUES ARE COMPARABLE WHEN DERIVED BY ELEMENTARY MEASUREMENT METHODS
Krabbe P1, Tromp N2, Ruers T3, Van Riel P1, 1Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2Radboud University Medical Centre
Nijmegen, Nijmegen, The Netherlands, 3Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
pgA572 PMC43 USE OF AND COMPLIANCE WITH ELECTRONIC PATIENT REPORTED OUTCOMES WITHIN CLINICAL DRUG TRIALS
Wenzel KW1, O’Gorman H2, 1ClinPhone, Bradenton, FL, USA, 2ClinPhone, Nottingham, UK
pgA572 PMC44 THE SIGNIFICANCE OF PATIENT-REPORTED OUTCOMES TO FACILITATE MARKET ACCESS DURING A PRODUCT LIFECYCLE
Rofail D1, Abetz L1, Heelis R1, Brown C2, 1Mapi Values, Bollington, UK, 2Mapi Values France, Lyon, France
pgA573 PMC45 WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR?
Proudfoot CW, Alnwick K, Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA573 PMC46 SHOULD WE BE CONSIDERING COMPONENTS OF SOCIAL COGNITION MODELS TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSION MEDICATION?
Reaney MD1, Martin C2, Speight J1, 1AHP Research, Uxbridge, UK, 2University of the West of Scotland, Ayr, UK
pgA573 PMC47 A STUDY OF THE KEY FACTORS INFLUENCING THE PATIENT SATISFACTION IN INPATIENT AND OUTPATIENT SETTINGS
Tsai SF, Yeh GC, Taipei Medical University Hospital, Taipei, Taiwan
pgA574 PMC48 UPDATE OF TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA
Caron M1, Emery MP1, Marquis P2, Piault E2, 1Mapi Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA
pgA574 PMC49 COMPARISON OF HEALTH LOCUS OF CONTROL BETWEEN PHYSICIANS AND THE GENERAL PUBLIC: MULTI-GROUP STRUCTURAL EQUATION MODELING
Tokuda Y1, Ohde S2, Takahashi O3, Omata F1, Jacobs J1, Hinohara S2, Fukui T3, 1St. Luke’s Life Science Institute, Chuo City, Tokyo, Japan, 2St. Luke’s Life Science Institute, Chuo, Tokyo, Japan, 3St. Luke’s International Hospital, Chuo, Tokyo, Japan
pgA574 PMC50 THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS
Houchin C1, Nixon A1, Herdman M2, Juárez DM3, Labuschagne LA4, Manuel C5, Manuel F5, Wan Mahmud WMR6, 1Oxford Outcomes Ltd, Oxford, Oxon, UK,
2
Insight Consulting & Research, Mataró, Spain, 3Independent consultant, Mexico city, Mexico, 4Leona Labuschagne & Associates, Port Elizabeth, South Africa,
5
Independent consultant, Chennai, India, 6Kedah Medical Centre, Kedah, Malaysia
pgA575 PMC51 UTILITIES OF THE EQ-5D: TRANSFERABLE OR NOT? INFLUENCE OF THE NATIONAL VALUE SETS OF THE EQ-5D ON THE INCREMENTAL UTILITIES OF TWO
HEALTH STATES
Knies S1, Evers SMAA1, Severens JL2, Candel MJJM1, Ament AJHA1, 1Maastricht University, Maastricht, The Netherlands, 2University Hospital Maastricht, Maastricht, The Netherlands
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
71
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
CONCEPTUAL PAPERS & RESEARCH ON METHODS - Study Design
pgA575 PMC52 LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION
(WPAI:GH)
McKown S1, Handa ML1, Gawlicki M2, Stankey C1, 1Corporate Translations, Inc, Chicago, IL, USA, 2Corporate Translations, Inc, East Hartford, CT, USA
pgA575 PMC54 THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES – DO WE NEED AN INDUSTRY STANDARD METHODOLOGY?
Reaney MD, Howarth A, Khagram L, Speight J, AHP Research, Uxbridge, Middlesex, UK
pgA576 PMC55 THE C-STATISTIC AND THE EFFICIENCY OF THE PROPENSITY SCORES MODEL: EVIDENCE FROM SIMULATED DATA
Kiri VA1, Feudjo-Tepie M2, 1PAREXEL International, London, UK, 2GlaxoSmithKline R&D, London, UK
pgA576 PMC56 THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE
Knies S1, Ament AJHA1, Evers SMAA1, Severens JL2, 1Maastricht University, Maastricht, The Netherlands, 2University Hospital Maastricht, Maastricht, The
Netherlands
pgA576 PMC57 DISCONTINUOUS COST MEASUREMENT: HOW TO FILL IN THE GAPS?
Hendriks MRC1, Evers SMAA2, Bleijlevens MHC2, van Haastregt JCM2, Crebolder HFJM2, van Eijk JTM2, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The Netherlands
pgA577 PMC58 THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS: EVIDENCE FROM SIMULATED DATA
Kiri VA1, Feudjo-Tepie M2, 1PAREXEL International, London, UK, 2GlaxoSmithKline R&D, London, UK
pgA577 PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES
Eckermann S1, Coory M2, Willan AR3,1Flinders University, Adelaide, South Australia, Australia, 2University of Queensland, Brisbane, Queensland, Australia, 3SickKids Research Insitute, Toronto, ON, Canada
pgA578 PMC61 THE IMPLICIT VALUE OF STATISTICAL LIFE: ESTIMATES DERIVED FROM PUBLIC INTERVENTIONS IMPLEMENTED IN The Netherlands
Goebbels AFG1, Ament AJHA1, Novák A2, Veraart CPWM3, Severens JL4, 1Maastricht University, Maastricht, The Netherlands, 2Anovák-Services, Apeldoorn, The
Netherlands, 3Roche Nederland BV, Woerden, The Netherlands, 4University Hospital Maastricht, Maastricht, The Netherlands
pgA578 PMC62 UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN
Herzberg T, Arnold B, Evanston Northwestern Healthcare, Evanston, IL, USA
pgA578 PMC63 SYSTEMATIC REVIEW RELIABILITY: SENSITIVITY AND SPECIFICITY OF ONE VS. TWO REVIEWS
Muston D, Alnwick K, Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK
MENTAL HEALTH - Clinical Outcomes Studies
pgA579 PMH1 PREVALENCE OF TIC DISORDERS AND COEXISTENCE WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN A GERMAN COMMUNITY SAMPLE
Schlander M1, Schwarz O1, Viapiano M2, Bonauer N2, Rothenberger A3, Roessner V3, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn,
Germany, 2Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany, 3University of Göttingen, Göttingen, Germany
pgA579 PMH2 DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER: A STATISTICAL MEDIATION MODEL ANALYSIS
Bollu V1, Cappelleri J2, Bushmakin AG3, Mychaskiw M4, Feltner D1, 1Pfizer Global Research and Development, New London, CT, USA, 2Pfizer Inc, Groton, CT,
USA, 3Pfizer, Inc, Groton, CT, USA, 4Pfizer Inc, New York, NY, USA
pgA579 PMH3 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC
SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA
Lyubov E1, Dzhatdoeva A2, Zhao Z3, Cain J4, 1Moscow Institute of Psychiatry, Moscow, Russia, 2Janssen-Cilag Russia, Moscow, Russia, 3J&J Worldwide Health
Economics & Pricing, Raritan, NJ, USA, 4Janssen Pharmaceutica, Beerse, Belgium
pgA580 PMH4 EFFICACY AND SAFETY OF ORAL ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE Jones MP1, Nicholl D2, Trakas K3, 1Macquarie University, North Ryde, Australia, 2Johnson & Johnson, Raritan, NJ, USA, 3Johnson & Johnson, Toronto, ON,
Canada
pgA580 PMH5 COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION
Kreilick C1, Seal B2, Tangirala M3, 1PRO Unlimited, Bridgewater, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Smith Hanley Consulting Group LLC, Lake
Mary, FL, USA
pgA580 PMH6 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE
Fajutrao L1, Locklear JC2, Priaulx J3, Heyes A4, 1AstraZeneca R&D, Sodertalje, Sweden, 23AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3Mapi Values,
Macclesfield, UK, 4Mapi Values Ltd, Cheshire, UK
pgA581 PMH7 PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY
Mehnert A1, Hargarter L1, Diels J2, 1Janssen-Cilag GmbH, Neuss, NRW, Germany, 2Johnson & Johnson Pharmaceutical Services, Beerse, Belgium
pgA581 PMH8 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER: AN ADJUSTED INDIRECT COMPARISON
Edwards SJ, Korim F, AstraZeneca UK Ltd, Luton, UK
pgA581 PMH9 TOLERABILITY OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
Edwards SJ1, Smith CJ2, 1AstraZeneca UK Ltd, Luton, UK, 2Guy’s Hospital and Maudsley Hospital, London, UK
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
72
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA582 PMH10 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE: A META-ANALYSIS OF RANDOMISED
CONTROLLED TRIALS IN SCHIZOPHRENIA
Edwards SJ, Korim F, AstraZeneca UK Ltd, Luton, UK
MENTAL HEALTH - Cost Studies
pgA582 PMH11 DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE: THE BUDGET IMPACT OF ILLEGAL DRUGS
Prieto L, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal
pgA582 PMH12 BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION - A DATABASE ANALYSIS IN GERMANY
Rudolph I, Sindern J, Janssen-Cilag GmbH, Neuss, Germany
pgA583 PMH13 COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND
Walczak J, Dardzinski W, Pawlik D, Nogas G, Arcana Institute, Cracow, Poland
pgA583 PMH14 THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST
EPISODE SCHIZOPHRENIA
Meier G, AstraZeneca, Luton, Bedfordshire, UK
pgA583 PMH15 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
Fajutrao L1, Locklear JC2, Liu S3, Paulson OB4, 1AstraZeneca R&D, Sodertalje, Sweden, 23AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA, 4AstraZeneca Pharmaceuticals, Södertälje, Sweden
pgA584 PMH16 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY
Kanbur B1, Karamustafalioglu O2, Dilbaz N3, Turkcan S4, Sarioz F1, Tatar F1, 1Janssen-Cilag, Istanbul, Turkey, 2Sisli Etfal Training and Research Hospital, Istanbul, Turkey, 3Ankara Numune Training and Research Hospital, Ankara, Turkey, 4Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey
pgA584 PMH17 TREATMENT OF OPIATE DEPENDENT PATIENTS IN WALES WITH BUPRENORPHINE/NALOXONE - A COST-EFFECTIVENESS EVALUATION
Gibbons CJ, Schering-Plough, Welwyn Garden City, UK
pgA584 PMH18 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY
Sarioz F1, Dilbaz N2, Karamustafalioglu O3, Turkcan S4, Kanbur B1, Tatar F1, 1Janssen-Cilag, Istanbul, Turkey, 2Ankara Numune Training and Research Hospital,
Ankara, Turkey, 3Sisli Etfal Training and Research Hospital, Istanbul, Turkey, 4Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey
pgA585 PMH19 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY
Mæhlum E1, Hansen K2, Sapin C2, 1Lundbeck, Lysaker, Norway, 2Lundbeck SAS, Paris, France
pgA585 PMH20 ECONOMIC EVALUATION OF PALIPERIDONE ER FOR THE TREATMENT OF SCHIZOPHRENIA IN THE CONTEXT OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Araujo D1, Souza CPR2, Passos RBF3, Pereira M4, 1State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2MedInsight, Rio de Janeiro, Brazil, 3Medinsight, Rio
de Janeiro, Brazil, 4Janssen Cilag, Sao Paulo, Brazil
pgA585 PMH21 COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA: 12 MONTH DATA FROM CZECH REPUBLIC
Skoupá J1, Cerna V1, Dolezal T2, 1Pharma Projects, Prague, Czech Republic, 2Charles University, Praha, Czech Republic
pgA586 PMH62ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS
FLUOXETINE TREATMENT ALONE
Snedecor SJ1, Botteman MF1, Schaefer K2, Sarocco P2, Barry N2, Pickard AS3, 1Pharmerit North America LLC, Bethesda, MD, USA, 2Sepracor Inc, Marlborough,
MA, USA, 3College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
pgA586 PMH22 IMPACT ON SCHIZOPHRENIA INPATIENT RESOURCE USE FOLLOWING SWITCH TO LONG-ACTING RISPERIDONE IN FINLAND
Seppälä N1, Hakala M2, Willis M3, Asseburg C3, Svensson M3, Persson U3, Löthgren M4, 1Harjavalta Hospital, Harjavalta, Finland, 2Janssen-Cilag Nordic, Espoo,
Finland, 3IHE - The Swedish Institute for Health Economics, Lund, Sweden, 4Janssen-Cilag AB, Sollentuna, Sweden
pgA586 PMH23 THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR – THE ECONOMIC VALUE
OF A NEW DRUG FORMULATION
Laine J1, Järbrink K2, 1AstraZeneca, Espoo, Finland, 2AstraZeneca, Mölndal, Sweden
pgA587 PMH24 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION
Camacho F1, Joish VN2, Drake C3, Asche CV4, 1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA,
3
Henry Ford Hospital Sleep Center, Detroit, MI, USA, 4University of Utah College of Pharmacy, Salt Lake City, UT, USA
pgA587 PMH25 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ELDERLY DEPRESSED MANAGED CARE POPULATION
Camacho F1, Joish VN2, Drake C3, Asche CV4, 1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA,
3
Henry Ford Hospital Sleep Center, Detroit, MI, USA, 4University of Utah College of Pharmacy, Salt Lake City, UT, USA
pgA587 PMH26 ONE YEAR PROSPECTIVE HEALTH CARE AND NON-HEALTHCARE RESOURCES USE AND COST STUDY IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE:
A SPANISH PERSPECTIVE
Coduras A1, Rabasa I1, Frank A2, Bermejo F3, López-Pousa S4, López Arrieta J1, Del Llano J1, León T5, Rejas J6, 1Gaspar Casal Foundation, Madrid, Spain, 2University Hospital La Paz, Madrid, Spain, 3University Hospital 12 de Octubre, Madrid, Spain, 4Hospital Santa Caterina, Girona, Spain, 5Pfizer Global Pharmaceuticals, New York, NY, USA, 6Pfizer Spain, Madrid, Spain
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
73
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA588 PMH27 HEALTH SERVICE EXPENDITURES FOR PATIENTS WITH A DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY – AN AGE
AND GENDER SPECIFIC ANALYSIS
Schlander M1, Schwarz O1, Trott GE2, Viapiano M3, Bonauer N3, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University
of Wuerzburg, Aschaffenburg, Germany, 3Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany
pgA588 PMH28 THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT
Bergman A, Hjalte F, Persson U, The Swedish Institute for Health Economics, IHE, Lund, Sweden
pgA588 PMH29 HEALTHCARE RESOURCE UTILIZATION AND COSTS OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES
Birnbaum HG1, Kessler R2, Joish VN3, Kelley D1, Hsieh M1, Ben-Hamadi R1, Greenberg P1, 1Analysis Group, Inc, Boston, MA, USA, 2Harvard Medical School,
Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA
pgA589 PMH30 ANTIDEPRESSANT THERAPY DURING PREGNANCY: AN INSIGHT ON ITS POTENTIAL HEALTH CARE COSTS
Ramos E, Bérard A, University of Montreal, Montreal, QC, Canada
pgA589 PMH31 A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE
Wade AG1, Milea D2, Despiégel N2, Guelfucci F3, Toumi M4, 1CPS Research, Glasgow, UK, 2Lundbeck SAS, Paris, France, 3Altipharm, Paris, France, 4Université
Lyon I, Villeurbanne, France
pgA589 PMH32 A GPRD STUDY OF HEALTH CARE COST ASSOCIATED WITH DIFFERENT FIRST-LINE ANTIDEPRESSANT TREATMENTS IN SEVERE DEPRESSION
Wade AG1, Saragoussi D2, Despiégel N2, Guelfucci F3, François C2, 1CPS Research, Glasgow, UK, 2Lundbeck SAS, Paris, France, 3Altipharm, Paris, France
pgA590 PMH33 COST-UTILITY ANALYSIS OF DULOXETINE VERSUS VENLAFAXINE IN THE MANAGEMENT OF MAJOR DEPRESSION IN PORTUGAL
Pinto CG1, Barbosa A2, Miguel LS3, Feio M2, 1Technical University of Lisbon, Lisboa, Portugal, 2Hospital de Santa Maria, Lisbon, Portugal, 3Research Centre on
the Portuguese Economy - CISEP, Lisboa, Portugal
pgA590 PMH34 WORKPLACE BURDEN OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES
Birnbaum HG1, Kessler R2, Seal B3, Kelley D1, Hsieh M1, Ben-Hamadi R1, Greenberg P1, 1Analysis Group, Inc, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA
pgA590 PMH35 COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980-2004
Saz-Parkinson Z, Cediel-García P, Rubio B, Amate JM, Medel-Herrero Á, Instituto de Salud Carlos III, Madrid, Spain
MENTAL HEALTH - Patient-Reported Outcomes Studies
pgA591 PMH36 WHAT DO PATIENTS WITH SCHIZOPHRENIA WANT OUT OF THEIR MEDICATION? IDENTIFYING PATIENT REPORTED “PROCESSES” IN MENTAL HEALTH
Schmeding A1, Bridges JF2, Rudolph I1, 1Janssen-Cilag GmbH, Neuss, Germany, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
pgA591 PMH37 SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW: RESULTS OF A QUANTITATIVE PATIENT SURVEY
Schmeding A1, Bormann L2, Klose N1, Ibach B1, 1Janssen-Cilag GmbH, Neuss, Germany, 2GfK AG, Nürnberg, Germany
pgA591 PMH38 CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY
Bridges JF, Kinter ET, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
pgA592 PMH39 RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS’ REPORTED OUTCOMES IN SCHIZOPHRENIA: THE CONTRIBUTION OF THE EQ-5D
Scalone L1, Pirfo E2, Mencacci C3, Ferrannini L4, Berto P5, Sturkenboom MC6, Bernareggi M7, Giustra MG7, Mantovani LG8, 1Centre of Pharmacoeconomics, Milan, Italy, 2Mental Health Department G. Maccacaro, Torino, NA, Italy, 3Mental Health Department, Milan, NA, Italy, 4Mental Health Department ASL 3, Genova,
Italy, 5PBE consulting, Verona, Italy, 6Erasmus University Medical Center, Soest, The Netherlands, 7Janssen-Cilag SpA, Cologno Monzese, Milan, NA, Italy,
8
University of Naples, Federico II, Naples, Italy
pgA592 PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY: RESULTS FROM ADORE STUDY IN FRANCE
Le Heuzey MF1, Tcherny-Lessenot S2, Raimond C2, 1Robert Debre Hospital, Paris, France, 2Lilly France, Suresnes, France
pgA592 PMH41 SAD BLUE DEPRESSED DAYS, HEALTH–RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONG WOMEN IN A UNIVERSITY COMMUNITY
Bastardo YM, Central University of Venezuela, Caracas, Venezuela
pgA593 PMH42 HEALTH-RELATED QUALITY OF LIFE OF MARRIED, WORKING WOMEN WITH CHILDREN (SUPERWOMAN SYNDROME) IN KOREA
Kim S1, Park S2, Park H3, 1Kyung Hee University, Seoul, South Korea, 2Kyung Hee University, Yongin, Gyeonggi-Do, South Korea, 3Pochon CHA University, Sungnam, Gyeonggi-Do, South Korea
pgA593 PMH43 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND
BIPOLAR PATIENTS
Maurino J1, Cordero L1, Montejo A2, Rebollo P3, Cuervo J3, Diez T1, Tafalla M1, Hernandez R1, 1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2Salamanca
University, Salamanca, Spain, 3BAP Health Outcomes Research, Oviedo, Spain
pgA593 PMH44 LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE “DEPRESSION IN THE MEDICALLY ILL-18”
Las Hayas C, Padierna JA, Quintana JM, Orive M, Vrotsou K, Madrazo A, Aristegui E, Silva M, Hospital Galdakao-Usansolo, Galdakao, Spain
pgA594 PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY
Rudolph I1, Bridges JF2, Schmeding A1, 1Janssen-Cilag GmbH, Neuss, Germany, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD,
USA
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
74
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA594 PMH46 PATIENT PREFERENCES IN ADHD - DISCRETE CHOICE EXPERIMENT
Mühlbacher AC1, Rudolph I2, Lincke HJ1, Nübling M1, 1Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany, 2Janssen Cilag GmbH,
Neuss/Germany, D-41470 Neuss, Germany
pgA594 PMH47 QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA
Wagner S, Kannan H, Bolge SC, Consumer Health Sciences, Princeton, NJ, USA
pgA595 PMH48 TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER
Ciesla JR, Northern Illinois University, DeKalb, IL, USA
pgA595 PMH49 INTERNATIONAL INVESTIGATION INTO DEPRESSION BASED ON THE STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON DEPRESSION RATING SCALE
(SIGH-D) AND THE CLINICIAN RATED INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (IDS-C)
Caire P1, Bowers B2, Williams BW J3, Rush A J4, 1Mapi Research Institute, Lyon, France, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3MedAvante, Inc,
Hamilton, NJ, USA, 4University of Texas Southwestern Medical Center, Dallas, TX, USA
pgA595 PMH50 THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION
Gerhards SAH, Goossens MEJB, Huibers MJH, de Graaf LE, Evers SMAA, Maastricht University, Maastricht, The Netherlands
MENTAL HEALTH - Health Care Use & Policy Studies
pgA596 PMH51 DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANT WARNINGS
Libby AM, Orton HD, Valuck RJ, University of Colorado Denver, Aurora, CO, USA
pgA596 PMH52 PILOT SURVEY OF ADVERSE EVENT MANAGEMENT ASSOCIATED WITH ANTIPSYCHOTIC USE: THE NEGLECTED DIMENSION IN RESOURCE USE IMPLICATIONS (A UK PERSPECTIVE)
Meier G, Malcolm B, AstraZeneca, Luton, Bedfordshire, UK
pgA596 PMH53 PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN: A PROSPECTIVE COHORT STUDY BASELINE ASSESSMENT
Tafalla M1, Vieta E2, de Dios C3, Goikolea J2, Saiz-Ruiz J4, González-Pinto A5, Montes JM6, Diez T1, 1AstraZeneca, Madrid, Spain, 2Hospital Clínic de Barcelona,
Barcelona, Spain, 3Centro de Salud Mental Fuencarral-El Pardo, Madrid, Spain, 4Hospital Ramón y Cajal, Madrid, Spain, 5Hospital de Santiago Apóstol, Vitoria,
Spain, 6Hospital del Sureste, Arganda del Rey, Spain
pgA597 PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION – A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A
GERMAN SICKNESS FUND
Gothe H1, Hagenmeyer EG1, Höer A1, Runge C2, Volmer T2, Häussler B1, 1IGES Institut GmbH, Berlin, Germany, 2Wyeth Pharma GmbH, Münster, Germany
pgA597 PMH55 A COMPARISON OF PERSISTENCE AND HEALTH CARE COSTS RELATED TO DIFFERENT TREATMENT STRATEGIES AFTER INITIAL ESCITALOPRAM 10MG IN
MAJOR DEPRESSIVE DISORDER
Sanglier T1, Milea D2, Saragoussi D2, Toumi M1, 1Université Lyon I, Villeurbanne, France, 2Lundbeck SAS, Paris, France
pgA597 PMH56 PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN: A NATIONWIDE STUDY, 2006
Chou LF1, Chen TJ2, 1National Chengchi University, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan
pgA598 PMH57 SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER: A CLAIMS DATA ANALYSIS
Pikalov A1, Whitehead R1, Werner C2, Kim E3, 1Otsuka America Pharmaceuticals Inc, Rockville, MD, USA, 2Otsuka Pharma GmbH, Frankfurt, Hessen, Germany,
3
Bristol-Myers Squibb, Plainsboro, NJ, USA
pgA598 PMH58 BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMER’S DISEASE IN GERMANY: A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS
Gaudig M, Janssen-Cilag, Neuss, Germany
pgA598 PMH59 MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES
Pechlivanoglou P, Boersma C, Visser ST, Postma MJ, University of Groningen, Groningen, The Netherlands
pgA599 PMH60 DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE: PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UK
Saragoussi D1, Milea D1, Despiégel N1, Guelfucci F2, Toumi M3, 1Lundbeck SAS, Paris, France, 2Altipharm, Paris, France, 3Université Lyon I, Villeurbanne, France
pgA599 PMH61 ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY - PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN
PRACTICE
Slawik L, Rudolph I, Janssen Cilag GmbH, Neuss, Germany
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies
pgA599 PND1 INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING
Zachry III WM1, Doan QD1, Smith BJ2, Clewell JD1, Griffith JM1, 1Abbott Laboratories, Abbott Park, IL, USA, 2Henry Ford Hospital, Detroit, MI, USA
pgA600 PND2 HUNTINGTON’S DISEASE: WHERE HAVE WE BEEN?
Samuels E, Stoddart SD, Lock K, Karia R, Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA600 PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND
INPATIENT EVENTS)
Mann TA, Rascati KL, Richards KM, Johnsrud M, The University of Texas at Austin, Austin, TX, USA
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
75
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
NEUROLOGICAL DISORDERS - Cost Studies
pgA600 PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS
Castelli-Haley J1, Oleen-Burkey M1, Lage M2, Johnson K3, 1Teva Neuroscience, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Groton, CT, USA,
3
University of Maryland, Baltimore, MD, USA
pgA601 PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS
Castelli-Haley J1, Oleen-Burkey M1, Lage M2, Johnson K3, 1Teva Neuroscience, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Groton, CT, USA,
3
University of Maryland, Baltimore, MD, USA
pgA601 PND7 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN The Netherlands
Nuijten MJ1, Pais BR2, Liedgens H3, van Wijck AJ4, 1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Grunenthal BV,
Bunnik, The Netherlands, 3Grünenthal GmbH, Aachen, Germany, 4University Utrecht - UMCU, Utrecht, The Netherlands
pgA602 PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY
Nuijten MJ1, Mittendorf T2, Jäcker A3, Osowski U4, 1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Leibniz University of
Hannover, Hannover, Germany, 3Serono GmbH, Darmstadt, Germany, 4Merck Pharma GmbH, darmstadt, Germany
pgA602 PND9 WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE
(STAR)
King D1, Knapp M1, Kan HJ2, Pugner K3, van Baardewijk M3, 1London School of Economics, London, UK, 2Bristol-Myers Squibb, Wallingford, CT, USA, 3BristolMyers Squibb, Braine-l’Alleud, Belgium
pgA602 PND10 BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY)
Collar JM1, Porta-Etessam J2, Tobaruela JL3, Rabes C1, Casado MA4, 1Grünenthal Group Spain, Madrid, Spain, 2Hospital Clinico San Carlos, Madrid, Spain,
3
Hospital Virgen de la Poveda, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
pgA602 PND11 EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED
Birnbaum H1, Ivanova J2, Kidolezi Y1, Caleo S3, 1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, New York, NY, USA, 3Janssen Pharmaceutica N.V,
Beerse, Belgium
pgA603 PND12 COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE
Bénard S1, Pinchinat S2, Gallais JL3, Mick G4, Simon F5, Beillat M6, 1StèVe Consultants, Lyon, France, 2Biostatem, Castries, France, 3Société Française de Médecine Générale, Paris, France, 4Groupe d’Experts Douleurs Neuropathiques, Voiron, France, 5Instituto de Salud Carlos III, Madrid, Spain, 6sanofi pasteur MSD,
Lyon, France
pgA603 PND13 ALZHEIMER’S DISEASE PRESCRIPTION MEDICATION COSTS: 2004-2005
Anderson K, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
pgA603 PND14 MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY
Eidt D, Mittendorf T, von der Schulenburg JM, Leibniz University of Hannover, Hannover, Germany
pgA604 PND15 THE INDIRECT COST BURDEN OF EPILEPSY IN THE UNITED STATES
Birnbaum H1, Ivanova J2, Kidolezi Y1, Caleo S3, 1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, New York, NY, USA, 3Janssen Pharmaceutica N.V,
Beerse, Belgium
pgA604 PND16 INDIRECT COSTS OF ALZHEIMER’S DISEASE IN THE UNITED STATES
Anderson K, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
pgA604 PND17 ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO: RATIONAL OR NOT?
Duborija-Kovacevic N1, Vujisic S2, 1University of Montenegro Medical School, Podgorica, Serbia and Montenegro, 2Clinical Centre of Montenegro, Podgorica,
Montenegro, Serbia and Montenegro
pgA605 PND18 RUFINAMIDE IN THE ADJUNCTIVE TREATMETN OF LENNOX-GASTAUT SYNDROME (LGS): A COST EFFECTIVENESS ANALYSIS
Yi Y1, Verdian L2, Jansen JP3, 1Mapi Values, Cheshire, UK, 2Eisai Europe Limited, Hatfield, Herthfordshire, UK, 3Mapi Values, Houten, The Netherlands
pgA605 PND19 NATALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS OF HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
O’Day K1, Meyer K1, Rajagopalan K2, 1Xcenda, Palm Harbor, FL, USA, 2Biogen Idec Pharmaceuticals, Cambridge, MA, USA
NEUROLOGICAL DISORDERS - Patient-Reported Outcomes Studies
pgA605 PND20 MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE: A SYSTEMATIC REVIEW
Khagram L, Reaney MD, AHP Research, Uxbridge, UK
pgA606 PND21 SYMPTOM SEVERITY IN PARKINSON’S DISEASE SCALE (SSPDS): A NEW PATIENT-REPORTED OUTCOME MEASURE OF PARKINSON’S DISEASE SEVERITY
Schröder S, Schaefer M, Martus P, Charité University Medicine, Berlin, Germany
pgA606 PND22 ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
Yi Y1, Verdian L2, Oyee J3, Tolley K3, Heyes A4, 1Mapi Values, Cheshire, UK, 2Eisai Europe Limited, Hatfield, UK, 3Mapi Values, Bollington, UK, 4Mapi Values Ltd,
Bollington, UK
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
76
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA606 PND23 RELATIONSHIP BETWEEN CHANGES IN EQ-5D DERIVED UTILITY SCORES AND CHANGES IN IRLS SUM SCORES FROM A MAPPING EXERCISE IN TWO
PHASE III CLINICAL TRIALS
Tan SC1, Brabant Y2, Grosset D3, Briggs A4, 1UCB, Slough, Berkshire, UK, 2UCB S.A, Braine, Belgium, 3Institute of Neurological Sciences, Glasgow, UK, 4University of Glasgow, Glasgow, UK
pgA607 PND24 CAN THE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY?
de La Loge C1, Yang H2, Schiemann J2, Hunter SJ3, 1UCB Pharma SA, Braine l’Alleud, Belgium, 2UCB Inc, Smyrna, GA, USA, 3University of Chicago, Chicago, IL,
USA
pgA607 PND25 EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSON’S DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING
Andrés I1, Kulisevsky J2, Balañá M1, Pagonabarraga J2, Llebaria G2, Gobartt AL3, Arranz J4, 1NOVARTIS FARMACEUTICA S.A, Barcelona, Spain, 2Hospital de Sant
Pau, Barcelona, Spain, 3Novartis Pharmaceuticals, Barcelona, Spain, 4Laboratorios Esteve, Barcelona, Spain
pgA607 PND26 ARE THERE DIFFERENCES IN PATIENT SATISFACTION WITH INSOMNIA MEDICATIONS? PILOT RESULTS FROM A NOVEL REGISTRY
Bharmal M1, Cascade EF2, Gemmen EK1, 1Quintiles, Falls Church, VA, USA, 2iGuard Inc, Falls Church, VA, USA
NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies
pgA608 PND27 UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS: AN ITALIAN PRESCRIPTION DATABASE ANALYSIS
Menditto E, De Portu S, Cammarota S, Citarella A, Riegler S, Mantovani LG, University of Naples, Federico II, Naples, Italy
pgA608 PND28 TRENDS IN RESEARCH INTO CENTRAL NERVOUS SYSTEM DISORDERS: THE INFLUENCE OF AN AGING POPULATION
Lock K, Samuels E, Heron Evidence Development Ltd, Letchworth Garden City, UK
pgA608 PND29 EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS: USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS
Sicras-Mainar A1, Navarro-Artieda R2, Velasco-Velasco S1, Llopart-Lopez JR1, Rejas J3, 1Badalona Serveis Assistencials SA, Barcelona, Spain, 2Germans Trias i
Pujol Hospital, Badalona, Barcelona, Spain, 3Pfizer Spain, Madrid, Spain
pgA609 PND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH: AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET
IMPACT
Bueno RLP, Pereira MF, FEI, São Paulo, Brazil
pgA609 PND31 DESCRIPTIVE STUDY OF THE PHARMACOLOGICAL TREATMENTS USED IN PATIENTS WITH DEPRESSION IN PARKINSON’S DISEASE (PD)
Sunderland TJ, Lee S, Das Gupta R, Boehringer Ingelheim, Bracknell, UK
SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies
pgA609 PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS
Han C1, Zhao N2, Waters H2, Schenkel B1, 1Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 2Centocor Ortho Biotech Services, LLC,
Horsham, PA, USA
pgA610 PSS2 EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES
Berdeaux G1, Feneron D2, Meunier J3, Viala-Danten M3, Arnould B3, Maurel F4, 1Alcon France, Rueil-Malmaison, France, 2IMS Health, Puteaux, France, 3Mapi
Values, Lyon, France, 4Aremis, Neuilly sur Seine, France
pgA610 PSS3 VISION WITH RESTOR® , ARRAY® SA40 AND A MONOFOCAL INTRA-OCULAR LENS (IOL) AFTER CATARACT SURGERY
De vries N1, Lafuma A2, Laurendeau C3, Berdeaux G4, Nuijts R1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Cemka eval, Bourg-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France, 4Alcon France, Rueil-Malmaison, France
pgA610 PSS4 RESTOR® VERSUS ACRILISA® ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY
Gauthier L1, Lafuma A2, Laurendeau C2, Berdeaux G3, 1Polyclinique Côte Basque Sud, Saint jean de Luz, France, 2Cemka-Eval, Bourg-la-Reine, France, 3Alcon
France, Rueil-Malmaison, France
pgA611 PSS5 IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE (IOP) CONTROL IN GLAUCOMA PATIENTS
Lafuma A1, Laurendeau C1, Jeanbat V1, Berdeaux G2, 1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France
pgA611 PSS6 EFFECTIVENESS OF MOXIFLOXACIN IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS IN ADULTS
Lafuma A1, Koshnood B1, Laurendeau C1, Berdeaux G2, 1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France
pgA611 PSS7 A MIXED TREATMENT COMPARISON OF TOPICAL OCULAR HYPOTENSIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
Orme M1, Loftus J2, Collins S1, Kelly S2, 1Abacus International, Bicester, Oxfordshire, UK, 2Pfizer Ltd, Walton on the Hill, Surrey, UK
pgA612 PSS8 ATOPIC DERMATITIS IN CHILDHOOD: WHAT “DERMATOLOGICAL FUTURE” FOR THESE CHILDREN?
Misery L1, Boussetta S2, Taieb C2, 1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
pgA612 PSS9 SENSITIVE SCALP: AN EPIDEMIOLOGICAL APPROACH
Misery L1, Boussetta S2, Taieb C2, 1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
pgA612 PSS10 SENSITIVE SKIN IN EUROPE : AN EPIDEMIOLOGICAL APPROACH
Misery L1, Boussetta S2, Taieb C2, 1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
pgA612 PSS11 SENSITIVE SKINS IN FRANCE: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA613 PSS12 SENSITIVE SKINS IN PORTUGAL: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
77
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA613 PSS13 HAIR LOSS: AN EPIDEMIOLOGICAL APPROACH
Misery L1, Boussetta S2, Taieb C2, 1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France
pgA613 PSS14 DRY SKIN: AN EPIDEMIOLOGICAL APPROACH
Boussetta S1, Taieb C2, 1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, France
pgA614 PSS15 SENSITIVE SKINS IN SPAIN: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA614 PSS16 SENSITIVE SKINS IN GERMANY: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA614 PSS17 SENSITIVE SKINS IN BELGIUM: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA614 PSS18 SENSITIVE SKINS IN SWITZERLAND: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA615 PSS19 SENSITIVE SKINS IN GREECE: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA615 PSS20 SENSITIVE SKINS IN ITALY: AN EPIDEMIOLOGICAL APPROACH
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA615 PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY
Schlander M1, Schwarz O1, Viapiano M2, Bonauer N2, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Kassenaerztliche
Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany
pgA616 PSS22 FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN
Arias A1, Schargel K2, Ussa F3, Canut MI4, Robles A4, Martí B5, 1Hospital de Alcorcón, Alcorcón, Madrid, Spain, 2Hospital de Torrevieja, Torrevieja, Alicante,
Spain, 3Instituto Universitario de Oftalmobiología Aplicada, Valladolid, Spain, 4Centro de Oftalmología Barraquer, Barcelona, Spain, 5Universidad Autónoma de
Madrid, Madrid, Spain
pgA616 PSS23 TOPICAL TACROLIMUS FOR THE TREATMENT OF ATOPIC DERMATITIS: A SYSTEMATIC REVIEW WITH META-ANALYSES
Svensson Å1, Gånemo A1, Chambers C2, Mitchell S3, 1University of Lund, Malmö, Sweden, 2Astellas Pharma Europe Ltd, Staines, UK, 3Abacus International,
Bicester, UK
pgA616 PSS24 SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS REGARDING THE COMPARATIVE INCIDENCE OF HYPERAEMIA OF PROSTAGLANDIN TOPICAL GLAUCOMA MEDICATIONS
Lee CW1, Stoddart SD2, Muston D2, Buckley F2, Costello S2, Kelly S1, 1Pfizer, Tadworth, Surrey, UK, 2Heron Evidence Development Ltd, Letchworth Garden City,
Hertfordshire, UK
SENSORY SYSTEMS DISORDERS - Cost Studies
pgA617 PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
Ortonne JP1, Feneron D2, Daures JP3, Ollivier AL4, Thiriet C4, Maurel F5, Le Pen C6, 1Hopital Archet II, Nice, France, 2IMS health, Puteaux, France, 3CHU de
Nimes, Nimes, France, 4Wyeth Pharmaceuticals, Paris La Defense, France, 5IMS Health, Puteaux, France, 6Dauphine University, Paris, France
pgA617 PSS26 PHARMACOECONOMIC EVALUATION OF RANIBIZUMAB IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN AUSTRIA
Walter E1, Brennig C1, Moeremans K2, Thomas V3, 1IPF - Institute for Pharmaeconomic Research, Vienna, Austria, 2IMS HEOR, Brussels, Belgium, 3Novartis
Pharma AG, Basel, Switzerland
pgA617 PSS27 COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN The Netherlands: RESTOR®, ARRAY-SA40® AND A MONOFOCAL
De vries N1, Lafuma A2, Laurendeau C2, Berdeaux G3, Nuijts R1, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Cemka-Eval, Bourg-la-Reine,
France, 3Alcon France, Rueil-Malmaison, France
pgA618 PSS28 VENOUS LEG ULCER. COSTS-OF-ILLNESS OF IN GERMANY. A NATIONAL CROSS-SECTIONAL STUDY
Purwins S1, Augustin M1, Herberger K1, Debus S2, Rustenbach SJ1, 1University Clinics of Hamburg, Hamburg, Germany, 2Asklepios Klinik Harburg, Hamburg,
Germany
pgA618 PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY
Hieke K1, Diepgen T2, 1NEOS Health, Binningen, Switzerland, 2University Hospital Heidelberg, Heidelberg, Germany
pgA618 PSS30 COST OF SPECTACLES AFTER CATARACT SURGERY IN The Netherlands
De vries N1, Nuijts R1, Lafuma A2, Jeanbat V2, Laurendeau C2, Berdeaux G3, 1University Hospital Maastricht, Maastricht, The Netherlands, 2Cemka-Eval, Bourgla-Reine, France, 3Alcon France, Rueil-Malmaison, France
pgA618 PSS31 ACUTE OTITIS MEDIA: A MAJOR SOURCE OF PRODUCTIVITY LOSS
Stolk E1, Wolleswinkel-van den Bosch J2, Laplante S3, 1Erasmus Medical Center, Rotterdam, The Netherlands, 2Pallas Health Research and Consultancy B.V,
Rotterdam, The Netherlands, 3GlaxoSmithKline Biologicals, Rixensart, Belgium
pgA619 PSS32 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10
EUROPEAN COUNTRIES
Hommer AB1, Wickstrom J2, Walt JG3, Buchholz P4, 1Krankenhaus Hera Vienna, Vienna, Austria, 2Muusmann Research & Consulting A/S, Kolding, Denmark,
3
Allergan Inc, Irvine, CA, USA, 4Allergan Europe, Ettlingen, Germany
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
78
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA619 PSS33 THE COST OF UVEITIS TREATMENT IN FRANCE: A ONE-YEAR RETROSPECTIVE ANALYSIS
Kobelt G1, Bodaghi B2, Richard B1, Plesnilla C3, Buchholz P4, Brézin AP5, Heron E6, Labetoulle M7, Sahel J6, 1European Health Economics, Speracedes, France,
2
Pitié Salpêtrière, Paris, France, 3Medical Economics Research Group, Munich, Germany, 4Allergan Europe, Ettlingen, Germany, 5Hôpital Cochin-Université Paris
5, Paris, France, 6CHNO des XV-XX, Paris, France, 7CHU de Bicêtre, Le Kremlin-Bicêtre, France
pgA619 PSS34 MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Orme M1, Loftus J2, Collins S1, 1Abacus International, Bicester, UK, 2Pfizer Ltd, Walton on the Hill, UK
pgA620 PSS35 COST UTILITY OF BILATERAL COCHLEAR IMPLANT
Callejo D, López-Pedraza MJ, Llorente C, Maeso S, Martín C, Blasco JA, Agencia Laín Entralgo, Madrid, Spain
pgA620 PSS36 THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UK
Conway P1, Currie CJ2, 1Wyeth Europa, Berkshire, UK, 2Cardiff University, Cardiff, UK
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes Studies
pgA620 PSS37 IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA
TREATMENT
Regnault A1, Viala M1, Vigneux M2, Berdeaux G3, 1Mapi Values France, Lyon, France, 2Mapi Values, Lyon, France, 3Alcon France, Rueil-Malmaison, France
pgA621 PSS38 RELATION BETWEEN SELF REPORTED GLAUCOMA SYMPTOMS AND COMPLIANCE
Ruiz MA1, Pardo A1, Martínez de la Casa JM2, Polo V3, Esquirol J4, Soto J5, 1Universidad Autónoma de Madrid, Madrid, Spain, 2Hospital Clínico San Carlos,
Madrid, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Centro Médico Tecnón, Barcelona, Spain, 5Outcomes Research, Pfizer, Spain
pgA621 PSS39 QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
Puig L1, Sánchez-Carazo JL2, Daudén E3, Vanaclocha F4, Toribio J5, Pujol R6, Casado MA7, Sabater FJ8, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,
2
Hospital General de Valencia, Valencia, Spain, 3Hospital La Princesa, Madrid, Spain, 4Hospital 12 de Octubre, Madrid, Spain, 5Complejo Hospitalario de
Santiago, Santiago de Compostela, Spain, 6Hospital del Mar, Barcelona, Spain, 7Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 8ScheringPlough S.A, Alcobendas, Spain
pgA621 PSS40 RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOW VISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY
Shimozuma K1, Yamaguchi T2, Fujita K3, Yuzawa M3, Suzukamo Y4, Takahashi N5, Takahashi K6, Morita S7, Fukuhara S8, 1Ritsumeikan University, Kusatsu,
Japan, 2University of Tokyo, Tokyo, Japan, 3Surugadai Nihon University Hospital, Tokyo, Japan, 4Tohoku University, Sendai, Japan, 5Japan Council for Quality
Health Care, Tokyo, Japan, 6Kansai Medical University Hirakata Hospital, Hirakata, Japan, 7Yokohama City University Medical Center, Yokohama, Japan, 8Kyoto
University, Kyoto, Japan
pgA622 PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
Lebwohl M1, Schenkel B2, Han C3, Yeilding N4, Wang Y4, Papp KA5, Krueger GG6, 1Mount Sinai School of Medicine, New York, NY, USA, 2Johnson and Johnson
Pharmaceutical Services, LLC, Horsham, PA, USA, 3Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5Probity Medical Research, Waterloo, ON, Canada, 6University of Utah Health Sciences Center, Salt Lake City, UT, USA
pgA622 PSS42 PSORIASIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE
Boussetta S1, Taieb C2, 1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, France
pgA622 PSS43 ATOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE
Boussetta S1, Taieb C2, 1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, France
pgA622 PSS44 ATOPIC DERMATITIS & PSORIASIS: CROSS-EVALUATION OF QUALITY OF LIFE
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA623 PSS45 ATOPICAL DERMATITIS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE
Boussetta S1, Taieb C2, 1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, France
pgA623 PSS46 MELANOTIC TUMOURS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE
Boussetta S1, Taieb C2, 1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, France
pgA623 PSS47 ATOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION IN CHILDREN UNDER 15
Boussetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA624 PSS48 HOSPITAL DERMATOLOGY CONSULTATION TYPES: A FRENCH ASSESSMENT
Bousetta S, Taieb C, Pierre Fabre, Boulogne, France
pgA624 PSS49 A DISEASE MODEL ILLUSTRATING THE IMPACT OF PSORIASIS ON PATIENTS’ LIVES
Marant C1, Emery MP2, Dias-Barbosa C1, Swensen A3, Staniek V2, Arnould B1, 1Mapi Values France, Lyon, France, 2Mapi Research Trust, Lyon, France, 3Novartis
Pharmaceuticals Corp, East Hanover, NJ, USA
pgA624 PSS50 DEVELOPMENT OF AN INSTRUMENT FOR ASSESSING HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA
Garcia A1, Ortiz de Frutos J2, Peyri J3, Serra E4, Rosales M5, Sabater FJ6, Badia XB7, 1Hospital de La Princesa, Madrid, Spain, 2Hospital 12 de octubre, Madrid,
Spain, 3Hospital Universitari de Bellvitge, L’Hospitalet Llobregat, Barcelona, Spain, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Schering-Plough
S.A, Alcobendas, Madrid, Spain, 6Schering-Plough S.A, Alcobendas, Spain, 7IMS Health, Barcelona, Spain
pgA625 PSS51 SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)
Meunier J1, Berdeaux G2, Arnould B1, Viala-Danten M3, 1Mapi Values, Lyon, France, 2Alcon France, Rueil-Malmaison, France, 3Mapi Values France, Lyon, France
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
79
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA625 PSS52 SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ)
Regnault A1, Vigneux M2, Viala M1, Berdeaux G3, 1Mapi Values France, Lyon, France, 2Mapi Values, Lyon, France, 3Alcon France, Rueil-Malmaison, France
pgA625 PSS53 ATOPIC DERMATITIS IN PAEDIATRIC PATIENTS: COMMON CAREGIVER BEHAVIOUR WHEN FACING THE DIFFERENT DISEASE PRESENTATIONS OR LESION
SEVERITY. ELIBROT STUDY
Lahoz R1, Torrelo A2, Febrer I3, Lleonart M1, 1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Niño Jesús, Madrid, Spain, 3Hospital General Universitario
de Valencia, Valencia, Spain
pgA626 PSS54 EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS: A PATIENT SURVEY ACROSS NINE
EUROPEAN COUNTRIES
Conway P1, Dixon S2, Currie CJ3, 1Wyeth Europa, Berkshire, UK, 2University of Sheffield, Sheffield, UK, 3Cardiff University, Cardiff, UK
pgA626 PSS55 USTEKINUMAB REDUCES WORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS
WITH MODERATE TO SEVERE PSORIASIS
Reich K1, Schenkel B2, Han C2, Szapary P3, Li S3, Lebwohl M4, Langley R5, 1Dermatologikum Hamburg, Hamburg, Germany, 2Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Centocor Research and Development, Inc, Malvern, PA, USA, 4Mount Sinai School of Medicine, New York, NY, USA,
5
Dalhousie University, Halifax, NS, Canada
SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies
pgA626 PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA
Jayawant SS1, Feldman SR2, Balkrishnan R3, 1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine,
Winston Salem, NC, USA, 3The Ohio State University, Columbus, OH, USA
pgA627 PSS57 RETROSPECTIVE CHART REVIEW TO ASSESS IMPLEMENTATION OF NICE GUIDANCE ON THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH CHRONIC
PLAQUE PSORIASIS
Chauhan D1, Drakard M2, Velangi S3, Ralston SJ1, 1Merck Serono, Feltham, UK, 2Interface Clinical Services, Burley in Wharfdale, UK, 3City Hospital, Birmingham, UK
pgA627 PSS58 A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION. A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN NORTH GERMANY
Augustin M1, Grams L1, Herberger K1, Franzke N1, Debus S2, Rustenbach SJ1, 1University Clinics of Hamburg, Hamburg, Germany, 2Asklepios Klinik Harburg,
Hamburg, Germany
pgA627 PSS59 IMPACT OF HEALTH CARE REGULATION ON PROSTAGLANDIN ANALOGUE PRESCRIBING IN 5 EUROPEAN COUNTRIES
De Natale R1, Berdeaux G2, 1Padova Hospital, Padova, Italy, 2Alcon France, Rueil-Malmaison, France
SENSORY SYSTEMS DISORDERS - Conceptual Papers & Research on Methods
pgA628 PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS
WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL
Lebwohl M1, Schenkel B2, Han C2, Papp KA3, Krueger GG4, 1Mount Sinai School of Medicine, New York, NY, USA, 2Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Probity Medical Research, Waterloo, ON, Canada, 4University of Utah Health Sciences Center, Salt Lake City, UT, USA
SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies
pgA628 PSY1 A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE
(APCC) IN THE ON-DEMAND TREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBITORS
Knight C1, Dano AM2, Kennedy-Martin T3, 1RTI Health Solutions, Manchester, UK, 2Novo Nordisk A/S, Virum, Denmark, 3KMHO, Brighton, UK
pgA628 PSY2 CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE
Clarke J1, Beck M2, Giugliani R3, Sunder-Plassmann G4, Elliott P5, Hernberg-Stahl E6, Mehta A7, 1Hospital for Sick Children, Toronto, Ontario, Canada, 2University
of Mainz, Mainz, Germany, 3Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, 4Medical University Vienna, Vienna, Austria, 5Heart Hospital, London, UK,
6
Shire HGT, Danderyd, Sweden, 7Royal Free Hospital, London, UK
pgA629 PSY3 PREVALENCE OF METABOLIC ABNORMALITIES AMONG OBESE ADULTS IN KOREA
Lee SY1, Kim SJ1, Kim Y-K2, Choi Y3, Jung SH4, 1Ajou University College of Medicine, Suwon, South Korea, 2Kyunghee University, Seoul, South Korea, 3sanofiaventis Korea, Seoul, South Korea, 4Ehwa Womans University, Seoul, South Korea
pgA629 PSY4 EPIDEMIOLOGY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS
Gerlier L1, De Vos C1, Lamotte M1, Malfait M2, Poitrinal P3, 1IMS Health, Brussels, Belgium, 2Amgen NV, Brussels, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland
pgA629 PSY5 FACTORS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY
Thaipanich A, Wongchinsri J, Hemachudha A, Auamnoy T, Chulalongkorn University, Bangkok, Thailand
pgA630 PSY6 PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12-17
Sias S1, Hufstader MA1, White-Means SI2, Gourley D1, Vaidya V2, 1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee,
Memphis, TN, USA
SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
pgA630 PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE
ADULTS IN A MANAGED CARE POPULATION
Campbell J1, McGarry LJ1, Gilmore K1, Hale B2, Weinstein MC3, Shikora S4, 1i3 Innovus, Medford, MA, USA, 2Allergan Pharmaceuticals, Irvine, CA, USA, 3Harvard
University, Boston, MA, USA, 4Tufts-New England Medical Center, Boston, MA, USA
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
80
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA630 PSY8 BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETA THALASSAEMIA IN VENETO
REGION, ITALY
Venturini F, Adami S, Alberti C, Scroccaro G, Veneto Regional Drug Information Center, Verona, Italy
pgA631 PSY9 BUDGET IMPACT OF THE USE OF OROS® HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM
Fleischmann J1, Bergman G2, Verkuijlen G3, Lam A4, 1Janssen-Cilag GmbH, Neuss, Germany, 2Mapi Values, Houten, The Netherlands, 3Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA, 4Johnson & Johnson Pharmaceutical Services, Toronto, ON, Canada
pgA631 PSY10 ESTIMATION OF THE COSTS FOR A HEREDITARY HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME PER 100.000 INDIVIDUALS UNDER 30 YEARS
OF AGE IN SPAIN
Saz-Parkinson Z1, Amate JM1, Ayuso C2, 1Instituto de Salud Carlos III, Madrid, Spain, 2Fundación Jiménez Díaz, Madrid, Spain
pgA631 PSY11 EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN
THE UK
Webber JM1, Lloyd AC1, Lebmeier M2, Conway P3, Warburton J2, 1IMS Health, London, UK, 2Wyeth Pharmaceuticals, Maidenhead, UK, 3Wyeth Europa, Berkshire, UK
pgA632 PSY12 COST-EFFECTIVENESS OF FOOD FOR SPECIAL MEDICAL PURPOSES RELATIVE TO STANDARD CARE IN PATIENTS UNDERGOING ABDOMINAL SURGERY
Nuijten MJ1, Freyer K2, Ceri Green J3, 1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Nutricia Advanced Medical Nutrition, Zoetermeer, The Netherlands, 3Danone Medical Nutrition, Schiphol, The Netherlands
pgA632 PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN
LYMPHOMA (NHL) STAGES III AND IV: TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER INSTITUTE (MEX-INCAN)
Cervera-Ceballos E1, Meneses A1, Vargas J2, 1National Institute of Cancer, México, DF, Mexico, 2Econopharma Consulting SA de CV, Mexico, DF, Mexico
pgA633 PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME
Migliaccio-Walle K1, Baladi JF2, 1United BioSource Corporation, Concord, MA, USA, 2Novartis Pharmaceuticals Corp, Florham Park, NJ, USA
pgA633 PSY16 THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS: THE CASE OF USING ACTIVATED
RECOMBINANT FACTOR VII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS
Odeyemi IA1, Dano AM2, 1Novo Nordisk A/S, Pinner, UK, 2Novo Nordisk A/S, Virum, Denmark
pgA633 PSY17 PRECISE STUDY: BASELINE ANALYSIS OF A COST EFFECTIVENESS STUDY ON FAILED BACK SURGERY SYNDROME
Beccagutti G1, Zucco F2, Lavano A3, De Rose M3, Poli P4, Fortini G5, De Martini L6, De Simone E7, Menardo V8, Cisotto P9, Meglio M10, Costantini A11, 1Medtronic Italy, Sesto San Giovanni, Italy, 2Azienda Ospedaliera, Garbagnate Milanese, Milano, Italy, 3Campus Universitario di Germaneto, Catanzaro, Italy, 4Azienda
Ospedaliera Universitaria Pisana, Pisa, Italy, 5Ospedale di Circolo e Fondazione Macchi, Varese, Italy, 6Fondazione Maugeri, Pavia, Italy, 7Ospedale Maffucci,
Avellino, Italy, 8Ospedale S. Croce e Carle, Cuneo, Italy, 9Ospedale Regionale S. M. dei Battuti, Treviso, Italy, 10Azienda Universitaria Policlinico A. Gemell, Roma,
Italy, 11Policlinico SS Annunziata, Chieti, Italy
pgA634 PSY18 COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT: A FINNISH HOSPITAL PERSPECTIVE ANALYSIS
Van den Steen D1, Van Bellinghen LA1, Liwing J2, Van Vlaenderen I1, Lamotte M1, Lothgren M2, Annemans L3, 1IMS Health, Brussels, Belgium, 2Janssen-Cilag AB,
Sollentuna, Sweden, 3University of Ghent, Brussels University, Ghent, Belgium
pgA634 PSY19 MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTH
TECHNOLOGY ASSESSMENT
Vauth C1, Stöber Y1, Bockelbrink A2, Greiner W3, 1Leibniz University Hannover, Hannover, Germany, 2Charité University Medical Center, Berlin, Germany, 3University of Bielefeld, Bielefeld, Germany
pgA635 PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND
Beard S1, Roskell N1, Garcia-Cebrian A2, Maas G3, Das Gupta R4, Le TK5, 1RTI Health Solutions, Manchester, UK, 2Eli Lilly and Company Limited, Basingstoke,
UK, 3Boehringer Ingelheim GmbH, Ingelheim, Germany, 4Boehringer Ingelheim, Bracknell, Berkshire, UK, 5Eli Lilly and Company, Indianapolis, IN, USA
pgA635 PSY21 COST-MINIMIZATION ANALYSIS OF ORAL VS. INTRAVENOUS FLUDARABINE (BENEFLUR®) IN SPAIN
Delgado J1, Febrer L2, Nieves D3, Piñol C2, Brosa M3, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Bayer HealthCare, Barcelona, Spain, 3Oblikue
Consulting, Barcelona, Spain
pgA635 PSY22 PROCESS STUDY: A 6-MONTHS COST-CONSEQUENCE ANALYSIS IN CHRONIC PAIN FROM THE SPANISH PERSPECTIVE
Molet J1, Solivera J1, Rodriguez JM2, González P2, Baena M2, 1Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 2Medtronic Iberia, Madrid, Spain
pgA636 PSY24 MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM: A COST OF ILLNESS STUDY
Caekelbergh K1, Lamotte M1, Muchada JP2, 1IMS Health, Brussels, Belgium, 2Sanofi Pasteur MSD, Brussels, Belgium
pgA636 PSY25 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF SYSTEMIC LUPUS ERYTHEMATOSUS
Richard L, Brown M, Tan SC, UCB Celltech, Slough, UK
pgA637 PSY26 COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006
Chrzanowski M1, Czech M1, Hermanowski T1, Sykut-Cegielska J2, 1Medical University of Warsaw, Warsaw, Poland, 2Children’s Memorial Health Institute, Warsaw,
Poland
pgA637 PSY27 HEALTHCARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK
PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
Morera Domínguez C1, Ceberio Balda F2, Flórez García M3, Masramón X4, Freire O5, Rejas J5, 1Hospital Mutua de Terrasa, Barcelona, Spain, 2Hospital de Urbamin, Pamplona, Spain, 3Foundation Hospital Alcorcón, Madrid, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
81
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA637 PSY28 HEALTH CARE AND NON-HEALTHCARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK
PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
Rejas J1, Morera Domínguez C2, Ceberio Balda F3, Flórez García M4, Masramón X5, Freire O1, 1Pfizer Spain, Madrid, Spain, 2Hospital Mutua de Terrasa, Barcelona, Spain, 3Hospital de Urbamin, Pamplona, Spain, 4Foundation Hospital Alcorcón, Madrid, Spain, 5European Biometrics Institute, Barcelona, Spain
pgA638 PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE
Ehlken B1, Berger K1, Leithäuser M2, Koester U3, Schmid C4, Thalheimer M5, Plesnila-Frank C1, Freund M2, Junghanss C2, 1IMS Health, Munich, Germany,
2
University Hospital Rostock, Rostock, Germany, 3Asklepios proresearch, Hamburg, Germany, 4Hospital Augsburg, Augsburg, Germany, 5University Hospital
Heidelberg, Heidelberg, Germany
pgA638 PSY30 HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY:
IS INITIAL DOSING A SIGNIFICANT FACTOR?
Zhao Y1, Boulanger L2, Wu N2, Lamothe K2, Russell MW2, 1Eli Lilly and Company, Indianapolis, IN, USA, 2Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA
pgA638 PSY31 ECONOMIC IMPACT OF THE FABRY-ANDERSON DISEASE TREATMENT
De Portu S, Pisani A, Scalzone A, Cianciaruso B, Mantovani LG, University Federico II, Naples, Italy
pgA639 PSY32 COSTS OF A BLOOD TRANSFUSION IN HEMATO-ONCOLOGIC PATIENTS IN A PORTUGUESE HOSPITAL
Brilhante D1, Macedo A2, Santos A2, Pereira C3, 1Instituto Português de Oncologia de Lisboa, Francisco Gentil, EPE, Lisbon, Portugal, 2KeyPoint, Consultoria
Científica Lda, Lisbon, Portugal, 3Roche Farmacêutica Química, Lda, Amadora, Portugal
pgA639 PSY33 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLOOD TRANSFUSION DURING INPATIENT HOSPITALIZATION: AN ANALYSIS OF THE 2004
HEALTH CARE COST AND UTILIZATION PROJECT NATIONWIDE INPATIENT SAMPLE DATABASE
Patel ST1, Anastassopoulos K1, Lerner J1, Ryan K1, Dodd SL2, Goss TF1, Morton J3, 1Covance Market Access Services, Gaithersburg, MD, USA, 2Ethicon, Inc,
Silesia, MT, USA, 3Stanford University School of Medicine, Stanford, CA, USA
pgA639 PSY34 COSTS AND PATIENT-REPORTED OUTCOMES (PRO) IN GERMAN PATIENTS WITH CHRONIC KNEE AND HIP PAIN
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1, 1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany
pgA640 PSY35 COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY
RESULTS (ONVIDA GROUP)
Camps C1, Casas A2, Barón F3, Colmenarejo A4, Jara C5, Lobo F6, Massuti B7, Poveda JL8, Rifá J9, Rubio-Terrés C10, 1Hospital General Universitario de Valencia,
Valencia, Spain, 2Hospital Universitario Virgen del Rocio, Seville, Spain, 3Hospital Universitario Santiago de Compostela, Santiago de Compostela, La Coruña,
Spain, 4Hospital Central de la Defensa, Madrid, Spain, 5Hospital Unversitario de Alcorcón, Alcorcón, Madrid, Spain, 6Hospital Fundcaión Jiménez Díaz, Madrid,
Spain, 7Hospital General de Alicante, Alicante, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital Son Dureta, Palma de Mallorca, Balearic Islands,
Spain, 10Health Value, Madrid, Spain
pgA640 PSY36 EUROPEAN ECONOMIC EVALUATION OF OROS® HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN
Hauber AB1, Lam A2, Fleischmann J3, Wilson MR1, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson Pharmaceutical Services,
Toronto, ON, Canada, 3Janssen-Cilag GmbH, Neuss, Germany
pgA640 PSY37 HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII
Asukai Y1, Lloyd AC1, Ghatnekar O2, Hutchings AS3, 1IMS Health, London, UK, 2The Swedish Institute for Health Economics, Lund, Sweden, 3Baxter Healthcare,
Newbury, Berkshire, UK
pgA641 PSY38 IMPACT OF TENSION HEADACHE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT
Bolge SC, Kannan H, Wagner S, Consumer Health Sciences, Princeton, NJ, USA
pgA641 PSY39 IMPACT OF HIGH WAIST CIRCUMFERENCE ON PRODUCTIVITY IN US AND GERMAN OVERWEIGHT/OBESE SUBJECTS
Caterson I1, Hauner H2, Amand C3, Sherrill B4, Wolf A5, 1University of Sydney, Camperdown, Australia, 2Klinik Für ErnährungsmedizinKlinikum Rechts der,
München, Germany, 3Sanofi-Aventis, Paris, France, 4RTI Health Solutions, Research Triangle Park, NC, USA, 5University of Virginia, Charlottesville, VA, USA
pgA641 PSY40 BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS)
Lister S, Pfizer Limited, Tadworth, Surrey, UK
pgA642 PSY41 REVIEW OF HOME READINESS INSTRUMENTS TO ASSESS RECOVERY POST-SURGERY
Asmussen M1, Wendicke K1, Heyes A2, Priaulx J2, Goad C2, 1Nycomed, Roskilde, Denmark, 2Mapi Values, Macclesfield, UK
SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes Studies
pgA642 PSY42 E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES
Marino B, Platko J, Raymond S, PHT Corporation, Boston, MA, USA
pgA642 PSY43 THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D)
Sanz M1, Aledort L2, Danese M3, Guo M4, Isitt J4, 1University Hospital La Fe, Valencia, Spain, 2Mount Sinai Hospital, New York, NY, USA, 3Outcomes Insights,
Inc, Newbury Park, CA, USA, 4Amgen, Thousand Oaks, CA, USA
pgA642 PSY44 UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUES Brod M1, Hammer M2, Lessard S3, Kragh N2, 1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3The Brod Group, Mill Valley, CA,
USA
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
82
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA643 PSY45 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS
Molta CT, Boggs R, Singh A, Yang S, Wyeth Pharmaceuticals, Inc, Collegeville, PA, USA
pgA643 PSY46 PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF MIGRAINE IN GERMANY
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1, 1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany
pgA644 PSY47 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF
PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
Flórez García M1, Morera Domínguez C2, Ceberio Balda F3, Masramón X4, Freire O5, Rejas J5, 1Foundation Hospital Alcorcón, Madrid, Spain, 2Hospital Mutua de
Terrasa, Barcelona, Spain, 3Hospital de Urbamin, Pamplona, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain
pgA644 PSY48 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA: PATIENT-REPORTED DATA. INTERMEDIATE RESULTS. PART 2
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4, Telnova E5, Tonoyan A2, 1Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, 2Russian
Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow, Russia, 4Hematological Research Center,
Moscow, Russia, 5Roszdravnadzor, Moscow, Russia
pgA644 PSY49 PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH
NEUROPATHIC PAIN: A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL PRACTICE
Pérez C1, Navarro A2, Saldaña MT3, Masramón X4, Rejas J5, 1Hospital University La Princesa, Madrid, Spain, 2Primary Care Centre “Puerta del Ángel”, Madrid,
Spain, 3Primary Care Centre “Raíces”, Castrillón, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain
pgA645 PSY50 ASSESSING THE VALUE OF 24-HOUR CHRONIC PAIN CONTROL FROM THE PATIENT PERSPECTIVE: DO EXISTING PATIENT-REPORTED OUTCOMES INSTRUMENTS ADEQUATELY COVER THE RELEVANT CONCEPTS RELATED TO 24-HOUR CHRONIC PAIN CONTROL?
Guillemin I1, Lam A2, Richarz U3, Kavanagh S4, Emery MP5, Benmedjahed K1, Dubois D4, Arnould B1, 1Mapi Values, Lyon, France, 2Johnson & Johnson Pharmaceutical Services, Toronto, ON, Canada, 3Johnson & Johnson Pharmaceutical Services, Baar, Switzerland, 4Johnson & Johnson Pharmaceutical Services,
Beerse, Belgium, 5Mapi Research Trust, Lyon, France
pgA645 PSY51 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN: A POST-HOC ANALYSIS OF THE EFFECT
OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
Ceberio Balda F1, Flórez García M2, Morera Domínguez C3, Masramón X4, Freire O5, Rejas J5, 1Hospital de Urbamin, Pamplona, Spain, 2Foundation Hospital
Alcorcón, Madrid, Spain, 3Hospital Mutua de Terrasa, Barcelona, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain
pgA645 PSY52 QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES. INTERMEDIATE RESULTS
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4, Telnova E5, Tonoyan A2, 1Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, 2Russian
Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow, Russia, 4Hematological Research Center,
Moscow, Russia, 5Roszdravnadzor, Moscow, Russia
pgA646 PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD
Rofail D1, Abetz L1, Heelis R1, Baladi JF2, 1Mapi Values, Bollington, Cheshire, UK, 2Novartis Pharmaceuticals Corp, Florham Park, NJ, USA
pgA646 PSY54 UNDERSTANDING PATIENT PERCEPTION OF THE BIOENTERICS INTRAGASTRIC SYSTEM FOR WEIGHT REDUCTION
Hale B1, Stern L2, Ogbonnaya A2, Walt JG1, Buchholz P3, 1Allergan Pharmaceuticals, Irvine, CA, USA, 2Analytica International, New York, NY, USA, 3Allergan Ettlingen, Ettlingen, Germany
pgA646 PSY55 PAIN MANAGEMENT IN THAILAND: IMPLICATION FOR BETTER PATIENT EDUCATION
Layton MR1, Chadbunchachai S1, Kerr SJ2, 1Khon Kaen University, Khon Kaen, Thailand, 2University of New South Wales, Sydney, Australia
pgA647 PSY56 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS
Brown TM1, Lee WC2, Joshi AV3, Pashos CL1, 1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Abt Bio-Pharma Solutions, Inc, Bethesda, MD, USA, 3Novo
Nordisk Inc, Princeton, NJ, USA
SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies
pgA647 PSY57 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS
ECONOMIC BURDEN IN FRANCE
Vainchtock A1, Bogillot O2, Divine M2, Durand-Zaleski IS3, 1HEVA, Lyon, France, 2Amgen France, Neuilly-Sur-Seine, France, 3APHP Henri Mondor hospital, Créteil,
France
pgA647 PSY58 RETROSPECTIVE ANALYSIS OF FACTOR VIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII
Epstein JD1, Woo P1, Hutchings AS2, Li-McLeod J1, 1Baxter BioScience, Westlake Village, CA, USA, 2Baxter Healthcare, Newbury, Berkshire, UK
pgA648 PSY59 A POPULATION STUDY ON THE AGE-SPECIFIC RELATIONSHIP BETWEEN BODY MASS INDEX, METABOLIC DISORDERS, AND UTILIZATION OF AMBULATORY
SERVICES
Chang HY1, Liu WL1, Chu NF2, Hsiao CF1, 1National Health Research Institutes, Zhunan, Maoli, Taiwan, 2National Defense Medical Center, Taipei, Taiwan
pgA648 PSY60 PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12-17 YEARS OF AGE
Sias S1, Hufstader MA1, White-Means S1, Gourley D1, Vaidya V2, 1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee,
Memphis, TN, USA
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
83
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA648 PSY61 INCREMENTAL SAVINGS ASSOCIATED WITH A DECREASE IN ANTIDEPRESSANT MEDICATIONS FOLLOWING BARIATRIC SURGERY IN WESTERN NEW YORK
Purdy CH1, Hayward A1, Magar RS2, Iskedjian M3, 1PharmIdeas Research and Consulting, Buffalo, NY, USA, 2PharmIdeas Research and Consulting, Raleigh, NC,
USA, 3PharmIdeas Research and Consulting, Oakville, ON, Canada
pgA648 PSY62 A NATURAL EXPERIMENT TO ESTIMATE THE IMPACT OF A PREFERRED DRUG LIST POLICY FOR LONG ACTING NARCOTIC ANALGESICS ON COSTS AND
UTILIZATION
Flannagin KR, Martin BC, University of Arkansas for Medical Sciences, Little Rock, AR, USA
pgA649 PSY63 PATIENT-REPORTED OUTCOMES (PRO’S) AND ECONOMICS OF NEUROPATHIC PAIN IN GERMANY
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1, 1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany
pgA649 PSY64 PATIENT-REPORTED OUTCOMES (PRO’S) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1, 1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies
pgA649 PUK1 CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION: THE ICEBERG STUDY
Font B1, Saval N1, Gatell S1, Andrés I1, Grinyó JM2, Campistol JM3, 1Novartis Farmacéutica S.A, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Hospitalet
de Llobregat, Spain, 3Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
URINARY/KIDNEY DISORDERS - Cost Studies
pgA650 PUK2 IN GREECE, INCREASING THE UTILIZATION OF PERITONEAL DIALYSIS THERAPY MAY REDUCE OVERALL DIALYSIS EXPENDITURES
Walker DR, Just PM, Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA
pgA650 PUK3 THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY
Bademlioglu C1, Guloksuz Y1, Hisarli C1, Walker DR2, Just PM2, 1Baxter Healthcare Corporation, Instanbul, Turkey, 2Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA
pgA650 PUK4 PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY
Pradelli L, Iannazzo S, AdRes Srl, Turin, Italy
pgA651 PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS
Borghetti F1, Scalone L1, Brancati B1, Sottini L2, Brunori G2, Viola BF2, Cancarini G2, Mantovani LG3, 1Centre of Pharmacoeconomics, University of Milan, Milan,
Italy, 2Spedali Civili, Brescia, Italy, 3University of Naples, Federico II, Naples, Italy
pgA651 PUK6 COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION (SNM) FOR PATIENTS WITH OVERACTIVE BLADDER (OAB) IN The Netherlands
Van Genugten M1, Leong R2, Brosa M3, Stauble F4, 1Medtronic Trading NL B.V, Heerlen, DA, The Netherlands, 2Academic Medical Centre Maastricht, Maastricht,
The Netherlands, 3Oblikue Consulting, Barcelona, SC, Spain, 4Medtronic International Trading Sarl, Tolochenaz, Switzerland
pgA651 PUK7 A TEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS OF THE SPANISH INTEGRATED RENAL REPLACEMENT THERAPY PROGRAM
Villa G1, Cuervo J1, Ortiz LF1, Sánchez JE2, Rebollo P1, 1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Hospital Universitario Central de Asturias,
Oviedo, Asturias, Spain
pgA652 PUK8 FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF AN ECONOMIC MODEL
Kelleher C1, Snedecor SJ2, Botteman MF2, Lee R3, Najib H4, Weinstein D5, Trocio J6, 1St. Thomas’ Hospital, London, UK, 2Pharmerit North America, LLC,
Bethesda, MD, USA, 3Weill Medical College of Cornell University, New York, NY, USA, 4Pfizer Ltd, Surrey, UK, 5Pfizer France, Paris, France, 6Pfizer Inc, New York,
NY, USA
pgA652 PUK9 COST OF OVERACTIVE BLADDER IN THE UNITED STATES
Ganz ML1, Smalarz AM1, Anger JT2, Krupski TL3, Hu JC4, Wittrup-Jensen KU5, Pashos CL1, 1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2David Geffen
School of Medicine, UCLA, Los Angeles, CA, USA, 3Duke Medical Center, Raleigh, NC, USA, 4Brigham and Women’s Hospital, Boston, MA, USA, 5Bayer Schering
Pharma AG, Berlin, Germany
pgA652 PUK10 ECONOMIC IMPACT OF A LOW-PROTEIN DIET AIMING TO DELAY THE HAEMODIALYSIS TREATMENT IN PATIENTS WITH CHRONIC-RENAL-FAILURE
de Portu S1, Cianciaruso B2, Pota A2, di Miccio L2, Di Palma A1, Pisani A2, Mantovani LG1, 1Faculty of Pharmacy, University Federico II, Naples, Italy, 2School of
Medicine, University Federico II, Naples, Italy
pgA653 PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5MG AND SOLIFENACIN 10MG VERSUS TOLTERODINE ER 4MG IN THE PHARMACOLOGICAL TREATMENT OF
PATIENTS WITH OVERACTIVE BLADDER (OAB)
Cardozo L1, Thorpe A2, Grishchenko M3, Sidhu MK4, 1Kings College Hospital, London, UK, 2Freeman Hospital, Newcastle, UK, 3Abacus International, Bicester,
UK, 4Astellas Pharma Europe Ltd, Staines, UK
pgA653 PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5MG AND 10MG VERSUS FESOTERODINE 4MG AND 8MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
Cardozo L1, Thorpe A2, Grishchenko M3, Sidhu MK4, 1Kings College Hospital, London, UK, 2Freeman Hospital, Newcastle, Tyne and Wear, UK, 3Abacus International, Bicester, Oxon, UK, 4Astellas Pharma Europe Ltd, Staines, Middlesex, UK
pgA653 PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION: RESULTS OF ECONOMIC EVALUATION
Ortega T, Ortega F, Baltar JM, Valdés C, Diaz-Corte C, Gómez E, Hospital Universitario Central de Asturias, Oviedo, Spain
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
84
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SESSION III – TUESDAY, 11 NOVEMBER 2008: DISPLAY HOURS: 8:00-16:00 / POSTER AUTHOR DISCUSSION HOUR: 11:00-12:00
pgA654 PUK14 A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH
HAEMODIALYSIS
Van Bellinghen LA1, Lamotte M2, Malfait M3, 1IMS HEOR, Brussels, Belgium, 2IMS Health, Brussels, Belgium, 3Amgen NV, Brussels, Belgium
pgA654 PUK15 ASSESSMENT OF THE BENEFITS OF TIME SAVINGS ACHIEVED BY ONCE MONTHLY INJECTION OF ERYTHROPOIETIN STIMULATING AGENTS (ESA) ON ANAEMIA MANAGEMENT IN HAEMODIALYSIS CENTRES
Allard B1, Grégoire M2, Ferrandini C3, Ollivier C4, Vrtovsnik F5, Zambrowski JJ6, Lamure E7, Baillon N8, 1ECHO de Nantes, Rezé, France, 2AURA Paris, Paris,
France, 3CRAT, Tassin La Demi Lune, France, 4CHR Caen, Caen, France, 5CH Bichat, Paris, France, 6Université René Descartes - Paris V, Paris, France, 7IMS
Health, Puteaux, France, 8Roche, Neuilly, France
URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes Studies
pgA654 PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES
Hollingworth W1, Campbell JD2, Kowalski J3, Ravelo A3, Girod I4, Briggs A5, Sullivan SD2, 1University of Bristol, Bristol, UK, 2University of Washington, Seattle,
WA, USA, 3Allergan, Inc, Irvine, CA, USA, 4Allergan Limited, Marlow, UK, 5University of Glasgow, Glasgow, UK
pgA655 PUK17 ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND
OVERACTIVE BLADDER
Verheggen BG1, Treur MJ1, Heeg BMS1, Botteman MF2, Van Hout BA1, Trocio JN3, 1Pharmerit Europe, Rotterdam, The Netherlands, 2PharMerit North America
LLC, Bethesda, MD, USA, 3Pfizer Inc, New York, NY, USA
pgA655 PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)
Coyne KS1, Margolis MK1, Jumadilova Z2, Vats V2, Hsieh R1, 1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer Inc, New York, NY, USA
pgA655 PUK19 PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES
Coyne KS1, Margolis MK1, Weinstein D2, Ebel-Bitoun C2, 1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer France, Paris, France
pgA656 PUK20 VALIDATION OF THE SPANISH VERSION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL QUESTIONNAIRE-SHORT FORM (PISQ-12)
Rebollo P1, Espuña PM2, Puig-Clota M2, Gonzalez A2, Zardain PC1, 1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Institut Clínic de Ginecología
Obstetricia i Neonatología. Hospital Clínic. Universidad de Barcelona, Barcelona, Spain
pgA656 PUK21 CONTENT VALIDITY OF THE SUBJECT’S ASSESSMENT OF CONDITION, SUBJECT’S ASSESSMENT OF TREATMENT SATISFACTION, KING’S HEALTH QUESTIONNAIRE, AND INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE – SHORT FORM IN PATIENTS WITH OAB
Margolis MK1, Coyne KS1, Vats V2, 1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA
pgA656 PUK22 FACTORS ASSOCIATED WITH PERCEIVED SATISFACTION IN HEMODYALISIS PATIENTS
Valdes C1, Miguel M1, Artos Y1, Alvarez M2, Portero E2, Ortega T1, Ortega F1, 1Hospital Universitario Central de Asturias, Oviedo, Spain, 2Cruz Roja de Oviedo,
Oviedo, Spain
Tuesday, 11 November – Research Poster Presentations – Session III includes the following topics:
PMC – METHODS & CONCEPTS
PMH – MENTAL HEALTH PND – NEUROLOGICAL DISORDERS
PSS – SENSORY SYSTEMS DISORDERS (Ear, Eye, Skin)
PUK – URINARY/KIDNEY DISORDERS
PSY – SYSTEMIC DISORDERS/CONDITIONS (Auto-Immune Disorders, Hematological Disorders, Metabolic Disorders, Obesity, Pain)
The page number to the left of each poster presentation refers to the abstract published in Value in Health Volume 11, Issue 6
85
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
Issue PanELs
ISSUE PANELS – SESSION I: Monday, 10 November 2008 – 10:15-11:15
ECONOMIC OUTCOMES RESEARCH ISSUES
IP1: DISCRETE EVENT SIMULATION OR MARKOV MODEL: WAR OF THE WORLDS
OR EXPANDING THE GALAXY? Thalia 3-4
Moderator: Bengt Jönsson PhD, Professor of Health Economics, Stockholm School
of Economics, Stockholm, Sweden
Panelist(s): J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President Health
Economics, United BioSource Corporation, Lexington, MA, USA; Mark J. Sculpher
PhD, Professor, University of York, York, UK; Andrea Manca PhD, Research Fellow,
University of York, York, UK
ISSUE: Markov models have dominated the pharmacoeconomics field but discrete
event simulation is making inroads. Which technique should be used? When? Should
Agencies consider both?
OVERVIEW: For more than 20 years, the predominant modeling technique for health
economic models has been one based on depicting the problem in terms of the
states the population can be in and the transitions among those states (i.e. the
‘Markov’ approach). By combining this structure with estimates of the value of the
states weighted average net value(s) can be derived and these can be used to guide
resource allocation decisions. The state-based concept implies various methodological choices and feasibility of implementation requires several assumptions but this
approach is well-tested and the data demands are well within what most health economic problems pose. An alternative approach based on depiction of the problem in
terms of the events that can occur has been proposed, borrowing heavily from the
fields of engineering and operations research. Discrete-event simulations consider
what can happen in a disease process and its management and what the consequences of these events might be. This approach requires fewer technique-driven
assumptions but poses greater data demands and computational time. Orthogonal
to the choice of state vs. event-based modeling is the decision to model a population as a cohort in the aggregate or rather as individuals. This panel will present the
pro, con and neutral positions and stoke the audience into discussion of the merits
of each approach.
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES
IP2: PATIENT-REPORTED OUTCOME (PRO) AND UTILITY DATA IN MARKET ACCESS
DECISION-MAKING Galaxy
Moderator: Anne Heyes MBA, Research Manager, Mapi Values, Cheshire, UK
Panelist(s): Jan J. Busschbach PhD, Senior Research Associate, Erasmus Medical
Center, Rotterdam, The Netherlands; Chloë Brown PhD, Director, Mapi Values, Lyon,
France
ISSUE: To demonstrate and discuss the ways PROs, including utilities, are taken into
account in appraisal of new pharmaceuticals seeking market access in Europe and
Asia.
OVERVIEW: PRO is an umbrella term for a measurement of any aspect of a patient’s
health status derived directly from the patient without interpretation by a third party.
It includes a variety of concepts from disease-related symptoms, functioning and
satisfaction to multi-dimensional measures such as Health Related Quality of Life.
Utilities, needed to calculate Quality Adjusted Life Years (QALYs), can be patientderived in a variety of ways, often from instruments such as EQ-5D. Utility data are
used by some national level market access decision-makers in those countries (e.g.
UK, NL) where there are formal requirements for a cost-effectiveness assessment
in the form of cost per QALY, although there may be no clear guidance on interpretation. However market access decision-makers in other countries, with their variety
of health care systems and processes, have different perspectives on the role and
importance of PRO data in determination of pricing and reimbursement.
In this issue panel we will discuss the position of market access decision-makers
regarding the use of PRO assessments; the importance of these relative to core
clinical information and their use in assessing cost-effectiveness. We will use
evidence to provide insights into decisions that have been taken in Japan, UK, NL
86
and France, and will present and contrast how utility and non-utility data have been
evaluated in reaching pricing/reimbursement decisions for recent products, using
examples in iron chelation therapy, sleep disorders, allergy, anemia and diabetes.
We will then discuss with the audience options for how the data can be derived and
presented optimally to show the added value of new products and support the payer
in the decision-making process.
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP3: ADVANCING METHODS IN PERSONALIZED MEDICINE FOR CLINICAL
DECISION-MAKING (Speakers at this panel were invited) Thalia 1-2
Moderator: Uwe Siebert MD, MPH, MSc, ScD, Professor/Chair, Department of
Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
Panelists: M.J. Finley Austin PhD, Director, US External Science Policy, F. HoffmannLa Roche Ltd., Basel, Switzerland; David L. Veenstra PharmD, PhD, Associate
Professor, Department of Pharmacy, School of Pharmacy, University of Washington,
Seattle, WA, USA; Adrian Towse MA, MPhil, Director, Office Health Economics,
London, UK
ISSUE: Personalized medicine has the potential to revolutionize the practice of medicine, but despite significant scientific advances, very few genomics-based tests or
treatments have reached consumers and – as with all new technologies – there may
be some risk associated with this approach.
OVERVIEW: Personalized medicine is the use of a patient’s genetic or clinical data
to stratify a disease and select a preventive, diagnostic or therapeutic procedure,
which is particularly suited to that patient. Personalized medicine makes it possible
to give: “the appropriate drug, at the appropriate dose, to the appropriate patient,
at the appropriate time”. David Veenstra will present “Risks and Benefits from
Personalized Medicine for the Patient”. M.J. Finley Austin will present “The Role of
Personalized Medicine in Drug Development,” and Adrian Towse will present “Value
and Cost-Effectiveness of Personalized Medicine”.
IP4: ISPOR GREECE CHAPTER PANEL: IS ECONOMIC EVALUATION IN THE GREEK
HEALTH CARE CONTEXT A FEASIBLE TARGET OR AN INTANGIBLE DREAM?
Santorini 1-3
Moderator: Mary Geitona PhD, Assistant Professor, University of Thessaly, Volos,
Greece
Panelist(s): Sotiria Papanicolaou MSc, MBA, Health Economics Manager, JanssenCilag Pharmaceutical SACI, Athens, Greece; Vassilis Kontozamanis MSc, MBA,
President, National Organization for Medicines, Athens, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus, Dresia, Greece
ISSUE: To investigate whether it is possible and feasible to incorporate cost-effectiveness analysis in the pharmaceutical decision making process in Greece and to
determine the necessary steps in order to create the appropriate environment in
which HTA can be performed efficiently.
OVERVIEW: Greece is one of the very few European countries which do not take
into account economic evaluation criteria in the health care policy decision making.
Therefore, pharmaceutical pricing and reimbursement decisions do not incorporate
cost-effectiveness criteria but have traditionally been based on the daily cost of
treatment, rather than on the relative cost per additional unit of benefit.
Based on other European countries’ experience, we need to specify what is
necessary to be done in order to ensure a credible and efficient method of health
economic evaluation. We need to examine what other countries do and whether we
can incorporate this in our framework and how. We need to evaluate the opportunities that currently exist, the weaknesses of our system and the hurdles that need to
be tackled before implementing health economic evaluations in Greece. We further
need to answer to the following questions: Can HTA ensure a more effective alloca-
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
ISSUE PANELs SESSION I: Monday, 10 November – 10:15-11:15 / SESSION II: Tuesday, 11 November – 10:00-11:00
tion of resources in the Greek market, without restricting market access to the most
innovative medicines? Is this even possible given the situation in Greece? What
would the immediate benefits be?
IP5: WHAT IS THE ROLE OF HTA IN INTERNATIONAL DECISION-MAKING?
Terpsichore AB
Moderator: Mark JC Nuijten MD, PhD, MBA, Physician and Health Economist, Erasmus University, Rotterdam, The Netherlands
Panelist(s): Wolfgang Greiner PhD, Professor for Health Economics and Health Care
Management, University of Bielefeld, Bielefeld, North Rhine-West, Germany; Peter
J. Neumann ScD, Professor, Tufts-New England Medical Center, Boston, MA, USA;
Gerry Oster PhD, Vice-President, PAI, Brookline, MA, USA
ISSUE: Information on the cost-effectiveness (CE) of medical interventions is becoming increasingly important in decision-making processes. Clinical innovations may
not be reimbursed—and thus access to them effectively denied—because their CE
ratio is deemed to exceed a pre-specified threshold. Economic data thus may have
considerable consequences in terms of the range of medical interventions from
which clinicians may choose and the quality of patient care. The uses of CE information therefore should be subjected to careful scrutiny.
OVERVIEW: The panel will discuss theoretical and practical issues regarding the use
of CE data as a determining criterion in decisions regarding healthcare reimbursement decisions. Particular attention will be paid to methodological issues in the use
of CE ratios and threshold values, and the extent to which the use of such criteria
also reflect other potentially important decision-making criteria, such as equity and
patient preferences. The panel also will address broader societal concerns that may
conflict with the narrow application of CE criteria, including inequality and the value
of innovation. Differences in the use of CE criteria in Europe and the United States
also will be discussed.
ISSUE PANELS – SESSION II: Tuesday, 11 November 2008 – 10:00-11:00
PATIENT-REPORTED OUTCOMES RESEARCH ISSUES
IP6: PUBLIC-PRIVATE PARTNERSHIPS IN PRO INSTRUMENT DEVELOPMENT:
AN IDEA WHOSE TIME HAS COME? Santorini 1-3
Moderator: Nancy Kline Leidy PhD, Senior Vice President Scientific Affairs, United
BioSource Corporation, Bethesda, MD, USA
Panelist(s): Laurie B. Burke RPh, MPH, Director, FDA/CDER/OND-IO, Silver Spring,
MD, USA; Asha Hareendran PhD, Senior Director, Global Outcomes Research,
Pfizer, Ltd, UK & Chair, COPD PRO Working Group of the EFPIA Innovative Medicines
Initiative (IMI) Respiratory calls, Sandwich, UK; Ingela Wiklund PhD, Director, Global
Health Outcomes, GlaxoSmithKline, UK & Co-Chair, COPD PRO Working Group of the
EFPIA Innovative Medicines Initiative (IMI) Respiratory calls, Uxbridge, Middlesex, UK
ISSUE: The development of different patient-reported outcome (PRO) instruments
to measure the same concept across multiple products is expensive and inefficient.
This panel will address independent versus collaborative instrument development,
comparing and contrasting two new approaches to pre-competitive public-private
collaboration.
OVERVIEW: Measuring the effects of treatments within clinical trials using endpoints
that reflect patients’ perspectives is a key component of successful drug evaluation programs. The development and validation of new PRO instruments can be
expensive and time consuming. A collaborative approach for the development of
instruments to capture endpoints that are common across products will save time
and resources for industry and regulatory agencies and facilitate treatment decision
making. This panel will address issues around independent versus collaborative
efforts in the development of PRO instruments. Two approaches to public-private collaborative instrument development will be discussed: 1) A case-specific need-driven
collaborative programs with multiple private sponsors and involvement of regulatory
authorities, and 2) public-private partnerships with joint public-private funding. Each
of these approaches will be discussed using examples from two currently active collaborative programs in the U.S. and Europe: 1) The EXACT-PRO Initiative, a program
involving multiple pharmaceutical sponsors, international experts in clinical research
and members of the U.S. Food & Drug Administration (FDA) to develop a single
tool to evaluate exacerbation outcomes in international trials of COPD. This tool is
currently undergoing translation for use in international trials, and 2) The Innovative
Medicines Initiative (IMI), a partnership between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations
(EEPIA) and the European Communities represented by the European Commission.
The first call for proposals for the IMI is now underway, including a call for studies of
PROs in COPD. These approaches will be compared and contrasted with an opportunity for the audience to ask questions and participate in discussion.
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP7: IS THE PURSUIT OF QALY MAXIMIZATION A NOBLE CAUSE?
(Speakers at this panel were invited) Terpsichore AB
Moderator: Adrian Towse MA, MPhil, Director, Office Health Economics, London, UK
Panelist(s): Mark J. Sculpher PhD, Professor, University of York, York, UK; Erik
Nord PhD, Senior Researcher, Norwegian Institute of Public Health, Oslo, Norway;
Georg Marckmann MD, MPH, Professor, Department of Medical Ethics, University of
Tübingen, Tübingen, Germany
ISSUE: To discuss the merits of “QALY maximization” as a theoretical basis for the
evaluation of healthcare technologies and to consider research opportunities associated with wider or alternative principles of health care decision-making.
OVERVIEW: As NICE approaches its 10th anniversary, the application of such formal
cost-utility methods to inform reimbursement and pricing decisions still represents
the minority methodology within Europe. However a large proportion of current pharmacoeconomic research focuses upon the methods of evaluating new health care
technologies assuming the principle of maximising health gain from a fixed budget.
Contrasting perspectives will be put forward from panelists on the advantages and
disadvantages of utilising QALY maximization as the basis for health care decision
making. Specific issues that will be discussed include whether maximising health
gain from a fixed budget should be the primary focus of payers and HTA agencies,
if not what is the correct “maximand”? The panel will consider whether population
preferences between equity of access, the rule of rescue and technical efficiency
are accounted for within HTA systems and if so how can this be practically achieved?
Also what are the possible longer term consequences for patient access and innovation of new technologies from the strict application of QALY maximisation? Consideration of the role and weight formal quantitative methods should receive within
the broader decision making framework will be discussed. The question of whether
it is ethical to primarily focus on QALY maximisation will also be considered by the
panel. Finally if alternative principles for HTA assessment are identified, the panel
will discuss whether current HTA methods are sufficiently capable to support such
alternative principles or are new theories of health care decision making required?
IP8: FAST IS BEST! IS RAPID HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT
MARKET ACCESS DECISION-MAKING A GOOD THING? Galaxy
Moderator: Jeanni Van Loon MSc, Development Director - Europe, Mapi Values,
Houten, The Netherlands
Panelist(s): Keith H. Tolley MPhil, Director, Tolley Health Economics Limited, Buxton, Derbyshire, UK; Meindert Boysen MSc, Associate Director Single Technology
Appraisals, National Institute for Health and Clinical Excellence (NICE), Manchester,
UK; Andrew Walker PhD, Senior Lecturer, University of Glasgow, Glasgow, UK
87
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
ISSUE PANELS SESSION II: Tuesday, 11 November – 10:00-11:00
ISSUE: What are the advantages and limitations of rapid health technology assessment when used to support decisions on market access for new pharmaceuticals in
Europe?
Panelist(s): Christoph Vauth MSc, Head Health Technology Unit, Leibniz University
Hannover, Hannover, Germany; John Hutton PhD, Professor of Health Economics,
University of York, York, UK
OVERVIEW: The use of health technology assessment (HTA) and formal cost-effectiveness analysis by bodies such as NICE and Scottish Medicines Consortium (SMC)
has become well established in the UK to support market access decision making
for new pharmaceuticals. While SMC has always performed rapid HTA on single
drugs based primarily on company submissions of clinical and cost-effectiveness
evidence, NICE has traditionally conducted detailed technology appraisals of one or
more drugs in a therapy area with clinical reviews and economic modeling conducted
by independent academic institutions. However, under pressure to produce guidance
faster and closer to drug launch, in the last two years NICE has also begun performing rapid single technology appraisals based on company submissions of evidence.
The approaches of NICE and SMC to performing rapid HTA and pharmacoeconomics
differ in important ways, in terms of process and methodology. The issues panel
will explore the advantages and limitations of alternative England and Scotland
approaches to rapid appraisal and investigate whether this is better in terms of
granting access to cost-effective medicines than a slower ‘more rigorous’ process
of appraisal with independent assessment. The panelists from NICE and SMC will
therefore present the advantages and limitations of the rapid appraisal processes
and methods for their respective bodies. Before opening to audience debate the
third panelist will explore (primarily from a pharma industry/consulting agency perspective) the rigour and value for decision making of the rapid approaches described
and the transferability of key principles and methods from the UK model to other
European countries to support pricing, reimbursement and market access decisions.
ISSUE: Cost-effectiveness data is becoming increasingly a formal requirement for
reimbursement submissions in Europe and the incremental cost-effectiveness ratio
is becoming an essential decision criterion in health care reimbursement decisions. Most of the European countries have similar health economic guidelines. The
recent IQWiG guidelines for Germany shows a substantial difference with the other
guidelines in Europe, which may have important consequences for the development
of health economics as a science and its relevance and role in health care decision
making processes.
IP9: MARKET ACCESS OF MEDICAL DEVICES IN EUROPE: HAVE METHODOLOGICAL APPROACHES BECOME A HINDRANCE OR HELP? Thalia 1-2
Moderator: Stacey J. Ackerman MSE, PhD, Vice President, Covance Market Access
Services Inc, San Diego, CA, USA
Panelist(s): Uwe Siebert MD, MPH, MS, ScD, Professor/Chair, Department of
Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria;
Arne Heissel PhD, Director, Reimbursement & Health Economics, Spinal & Biologics,
Medtronic International, Tolochenaz, Switzerland; Inger Natvig Norderhaug PhD,
Research Director, Norwegian Knowledge Center for the Health Services,
Oslo, Norway
ISSUE: Will European authorities and decision-making bodies routinely embrace
methodological approaches, such as meta-analysis of diagnostic tests and adaptive
clinical trials of therapeutic devices?
OVERVIEW: European authorities and decision-making bodies appraise diagnostic
and therapeutic medical devices, in addition to drugs, to inform market access decisions. The distinguishing characteristics of medical devices and drugs explain the
inherent differences in research approach, including study design and analysis. The
Agency for Healthcare Research and Quality (AHRQ) is currently developing and discussing the frameworks, principles, and guidance for evaluation of diagnostic tests.
In addition, the ISPOR book entitled, Medical Device and Diagnostics Outcomes
Research: Issues and Good Research Practices is nearing completion. During this
issue panel, several analytical approaches will be presented, such as meta-analysis
of diagnostic tests, adaptive clinical trials of therapeutic devices, and decision
modeling to link test performance (sensitivity and specificity) to patient-relevant
outcomes. Methodologists and decision makers on the panel will present contrasting perspectives. There will be discussion about whether these methodological
approaches are likely to be increasingly adopted for guideline development or reimbursement purposes in European countries. The role of medical device companies in
generating evidence and influencing the regulatory and reimbursement environments
will be a topic for audience debate.
IP10: FUTURE SCIENTIFIC AND POLICY CONSEQUENCES OF THE IQWiG
APPROACH FOR EUROPE Thalia 3-4
Moderator: Mark JC Nuijten MD, PhD, MBA, Consultant, Ars Accessus Medica/
Erasmus University Rotterdam, Amsterdam, The Netherlands
88
OVERVIEW: The panel will discuss theoretical and conceptual discrepancies
between the German and other guidelines, especially the NICE guidelines, which can
be considered the most influential guidance in Europe. An important discrepancy is
the difference in outcomes assessment: cost-effectiveness vs. cost-utility. This and
other conceptual differences will be explained from a legal and historical perspective in the respective countries. The scientific consequences of the current IQWiG
guidelines will be addressed. In a broader view the current methodological debates
on discounting, utilities and costing seem minor issues compared with substantial
conceptual differences of the IQWiG guideline, illustrated by the concept of a costeffectiveness frontier. On the other hand the cost-effectiveness approach seems
more in line with AMCP guidelines in the United States, justifying also the question,
if the use of health economic data by decision makers in Germany will become
comparable to the United States. Panel members represent the relevant countries
(Germany, UK, US). Key topics will include: will IQWiG guidelines lead to a split in
different health economics schools? Will IQWiG guidelines prevent central European
reimbursement decision and health economic standards? Will other countries, who
currently have no formal requirement (e.g. France), follow NICE or IGWiG guidance?
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
workshops
WORKSHOPS – SESSION I: Monday, 10 November 2008 - 15:15-16:15
CLINICAL OUTCOMES RESEARCH
W1: TIME-DEPENDENT SURVIVAL MODELS IN HEALTH OUTCOMES STUDIES:
POTENTIAL PITFALLS AND HOW TO AVOID THEM Thalia 3
Discussion Leaders: Victor A. Kiri MSc, PhD, CStat, Professor & Director of Pharmacoepidemiology, PAREXEL International, Uxbridge, London, UK; Maurille FeudjoTepie MSc, PhD, Medical Statistician, GlaxoSmithKline R&D, London, UK; David
Todem MSPH, PhD, Assistant Professor, Michigan State University, East Lansing,
MI, USA; Gilbert MacKenzie MSc, PhD, CStat, Professor & Director of Centre of
Biostatistics, University of Limerick, Limerick, Ireland
PURPOSE: The validity of treatment-effect assessments carried out with time-dependent survival models rests on certain fundamental assumptions some of which are
not so easy to satisfy in general practice or health care claims settings. However
these assumptions are often ignored in observational studies involving datasets
generated from such settings. Participants will learn about the conditions for appropriate application of the time-dependent versions of the Cox regression model. The
workshop should benefit researchers who encounter problems of immortal time bias
or time-varying treatment exposure in outcomes studies.
DESCRIPTION: Measuring the effectiveness of treatment is generally not easy,
and the difficulty manifests itself more clearly when we attempt casual interpretation of observational studies of therapeutic agents. To handle this problem, we
use models to adjust for differences in the characteristics of treatment groups.
However the validity of such models is dependent not only on whether the relevant
variables used have been measured without error, but also whether the model has
been specified correctly. The latter is often largely ignored, even though satisfaction
of assumptions, which underpin appropriate application of the model, is a critical
caveat in any subsequent interpretation of its results. Recent observational studies
have given rise to debate on how best to handle the problem of immortal-time bias,
which is only one aspect of the problem of time-dependency. However, the use of
such models in this area often raises more issues than solutions and some recent
applications appear to marginalise the role of good study design. The workshop will
describe the issues involved in time-dependent survival models. The pitfalls and possible solutions associated with these models will be illustrated in two case studies
involving: 1) the classical Stanford Heart Transplant data, and 2) a cohort of COPD
patients in the UK GPRD. Audience participation will be encouraged through interactive discussions
ECONOMIC OUTCOMES RESEARCH
W2: CHALLENGES OF DEVELOPING ECONOMIC EVALUATIONS FOR ORPHAN
DRUGS Santorini 1-3
Discussion Leaders: Michael F. Drummond PhD, Professor of Health Economics,
Centre for Health Economics, University of York, York, UK; Aline Gauthier MSc,
Lead Analyst, i3 Innovus Research Inc, Uxbridge, UK; Tsveta Milanova MSc, Health
Outcomes Manager, GlaxoSmithKline R&D, Greenford, UK
PURPOSE: This workshop aims to highlight the challenges of developing economic
evidence for orphan drugs (OD), examining both the perspectives of the manufacturer and payer.
DESCRIPTION: Over the last few years the number of OD evaluated by regulatory
and pricing and reimbursement bodies has increased substantially, with 44 OD
having received a market authorization under the European orphan designation. This
trend is expected to increase. The nature of the underlying diseases has sparked a
debate as to whether these new drugs should be evaluated in a similar manner as
non-orphan drugs. This workshop will not dwell on this debate but will focus on the
practical implications of developing economic evidence for a new OD drawing upon
the experiences of both consultants and manufacturers. The workshop will start by
identifying the main issues associated with the evaluation of OD, such as ethical
issues in relation to clinical controlled trials and equity-related issues, and will dis-
cuss how these could affect the development of economic evidence and subsequent
evaluations by decision makers.
During a second part of the workshop we will provide practical solutions via an interactive discussion around a case study, to aid those having to use imperfect available
data on OD to develop sound economic evidence for submission to reimbursement
agencies. Some of the issues being addressed will be how to handle the lack of data,
as evidenced by the small clinical trials, lack of general epidemiological evidence
and absence of utility data, either from clinical trials or free-standing studies. In the
third part of this workshop the perspective of the manufacturer will be provided. Here
would be discussed how their current experiences with the clinical development of an
OD have changed their perspective on these drugs and how this would affect future
clinical and economic development programmes of new orphan drugs.
W3: THRESHOLD PRICING ANALYSIS: AN ECONOMISTS’ CONTRIBUTION TO PHARMACEUTICAL PRICING Terpsichore AB
Discussion Leaders: Deirdre Mladsi BA, Global Head, RTI Health Solutions,
Research Triangle Park, NC, USA; Hediyyih Narula BS, Health Outcomes Scientist,
RTI Health Solutions, Research Triangle Park, NC, USA; W. Neil Palmer BA, Vice
President, RTI Health Solutions, Ottawa, ON, Canada; David W. Miller PhD, President, Miller Pharma Consulting, London, UK
PURPOSE: The aim of this workshop is to explore the application of economic analysis in generating threshold estimates of a new product’s price and efficacy.
DESCRIPTION: In many countries, for a pharmaceutical to be adopted and reimbursed, it must be demonstrated to be good value for money, offering health gains
at a reasonable incremental cost. Many countries evaluate a product’s cost-effectiveness against a standard threshold as one component in making an adoption
and reimbursement decision or recommendation. Because these thresholds are
explicit and known, it is possible for a manufacturer to develop an economic model
that estimates threshold levels of price, given an expected level of health gain
with the new product, and threshold levels of health gain that society is likely to
require, given a manufacturer’s target price. A threshold pricing model can provide
an objective, data-driven input to the pricing decision, a framework for anticipating
data weaknesses and payers’ responses, and may serve to set internal manufacturer expectations regarding product commercial performance. Although theoretically straightforward, an economic threshold pricing model can be complicated
when model inputs vary across countries, e.g., cost-effectiveness threshold levels,
standards of care. Because the measure of effectiveness most often employed is
the QALY, a manufacturer must pay careful attention to estimating gains in health
in terms of utilities based on clinical trial endpoints, particularly in the absence of
head-to-head data. This workshop will focus on leading participants through the math
behind the threshold calculations, the factors that drive a “spread” of threshold
results, and simple hypothetical models using example pricing data in oncology and
ophthalmology. Participants will be invited to make a pricing recommendation for a
hypothetical product in each therapeutic area based on a threshold pricing model
and to anticipate “weaknesses” in an eventual economic argument in support of the
product to payers.
PATIENT-REPORTED OUTCOMES RESEARCH
W4: HEALTH-BELIEFS – WHAT ROLE DO THEY PLAY IN OUTCOMES RESEARCH?
Thalia 1-2
Discussion Leaders: Matthew D. Reaney MSc, PGDip, Senior Scientist, Health
Psychology, AHP Research, Uxbridge, UK; Aysha Malik-Aslam BSc, Scientist, AHP
Research, Uxbridge, UK; Colin Martin RN, BSc, PhD, YC, Chair in Mental Health,
University of the West of Scotland, Ayr, Scotland, UK; Jane Speight MSc, PhD, Director, AHP Research, Uxbridge, UK
PURPOSE: Health beliefs can be categorised in many ways, but the underlying
assumption is that they drive corresponding health behaviours. This workshop
89
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION I: Monday, 10 November 2008 - 15:15-16:15
explores the role of health beliefs as predictors of important health-related behavioural outcomes, and discusses the psychological methods, theories and models
that may be applied to identify and influence health beliefs.
DESCRIPTION: Lay beliefs about health and illness are individual and social, influenced by prevailing social and medical ideologies. Health beliefs clearly influence
self-care motivation and have an effect on health-promoting behaviour (e.g. attendance at a screening program, food choices, adherence to prescribed medication).
Further, the beliefs and attributions that people hold can directly affect physiological
systems (e.g. the immune system). Health beliefs have been shown to influence a
variety of patient-reported outcomes, including medication adherence, satisfaction
and health-related quality of life. It is widely acknowledged that when the patient’s
beliefs are acknowledged and incorporated, rather than ignored, optimal biomedical
patient-reported outcomes are more likely to be achieved. Several psychological
models have been developed to predict health behaviours and may be utilised to
identify the beliefs that inform such behaviours. These models consider the social
milieu, personality, demographic, political and economic predictors of health beliefs.
They demonstrate the impact of beliefs such as the causes of illness, effectiveness
of health care and acceptability of health services, and how manipulating these can
result in actual or intended behaviour change. This workshop will introduce health
beliefs and discuss the psychological models that underpin the translation of belief
into behaviour. The session is interactive, with participants defining health beliefs
and their impact on behaviour. Participants will be invited to critique the models and
apply their chosen model to a health indication of their choice.
W5: PATIENT-REPORTED OUTCOME – VALUE BEYOND THE LABEL CLAIM Galaxy
Discussion Leaders: Ari Gnanasakthy MSc, Director, Novartis Pharmaceuticals, East
Hanover, NJ, USA; Lynda C. Doward MRes, Associate Director of Research, Galen
Research, Manchester, UK; Mary G. Baker MBE, President, European Federation of
Neurological Associations, Firenze, Italy
PURPOSE: To examine possibilities for maximizing value messages derived from
patient reported outcomes (PRO) data and to demonstrate ways of communicating
PRO value messages to stakeholders other than the regulatory authorities.
DESCRIPTION: Pharmaceutical companies routinely incorporate PRO assessments
in clinical trial programs and health care providers and patients are increasingly
considering PRO information to make decisions on treatment choices. PROs are
essential for providing an understanding of the impact of treatment from the patient
perspective. Ultimately, they are crucial to the development of patient-centric strategies; both facilitating a dialogue with patient support organizations and demonstrating company commitment to patient care. However, use of PRO data by the
pharmaceutical industry is generally restricted to the pursuit of the PRO-related label
claim. Despite the wealth of data generated by PRO use in clinical trials, companies
do not always utilize such data beyond these registration activities. This workshop
will highlight the value of PROs beyond the label claim. Examples will be presented
of how some companies are beginning to utilize PRO data to demonstrate the value
of their products to patients and health care providers. However, the aim is for the
workshop to be participatory and it is anticipated that participants will take an active
part in the discussion. The workshop will address the following questions: What are
the hurdles for obtaining label claims from PRO data? How does the situation in
Europe compare to the USA? What are the market segments for PRO data? How can
value messages be communicated with each segment? What are the barriers? How
can they be overcome? How will the changing technology and the social trends influence the future of communication of PRO value messages?
USE OF REAL WORLD DATA
W6: THE ROLE OF OBSERVATIONAL STUDIES IN DEMONSTRATING PRODUCT
VALUE AND BENCHMARKING PRODUCT SAFETY Thalia 4
Discussion Leaders: Thomas Goss PharmD, Vice President, Boston Healthcare
Associates, Washington, DC, USA; Gergana Zlateva PhD, Director, Global Outcomes
Research, Pfizer Inc, New York, NY, USA
PURPOSE: The purpose of this workshop is to learn to design and utilize observational studies to develop real-world data to define product value.
90
DESCRIPTION: Numerous stakeholders (payers, providers, policymakers and
manufacturers) are increasingly reliant on the use of evidence-based data to evaluate the role of innovative therapies relative to current standard-of-care practices.
Manufacturers frequently include outcomes-based endpoints in investigational trials,
but traditional randomized clinical trials often have limited generalizability to routine
clinical practice because of the size and homogeneity of the clinical trial population.
Thus, the landscape of pre- and post-approval research has shifted dramatically, with
more emphasis on scientific rigor and monitoring patient safety. In addition, the use
of observational studies is being integrated with health economics and outcomes
research to facilitate demonstration of the value of new products in real-world
populations during introduction into the marketplace and at various times during
the post-approval product life cycle. These data are useful to meet the increasing
needs of decision-makers, including patients, providers, payers, policymakers and
manufacturers, to increase commercial impact. While the use of observational
designs has limitations, observational studies can often be used to generate
hypotheses, and to assess a number of potential endpoints; the best such programs
usually have a defined (a priority) goal and purpose. We will review these strengths
and limitations in this context. In this session, speakers representing manufacturer,
CRO, and payer perspectives will review challenges with evaluating real-world safety
and demonstrating product value: 1) Decision-maker needs for data to benchmark
emerging therapies relative to standards of care; 2) Operational considerations when
implementing observational studies; 3) Strengths/limitations of observational data;
and 4) Specific case studies will address how data are used to address key questions from the provider and payer perspectives.
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W7: WHY IS IT SO DIFFICULT TO IMPLEMENT COST CONTAINMENT REFORMS
AND MAKE VALUE-BASED DECISIONS IN THE GREEK HEALTH CARE SYSTEM?
Terpsichore C
Discussion Leaders: Antonis Karokis MSc, Government and Public Affairs Manager,
Wyeth, Athens, Greece; John Yfantopoulos PhD, Professor of Health Economics,
University of Athens and President of the National Centre for Social Research, Athens, Greece; Nikolaos Maniadakis PhD, Assistant Professor, University of Piraeus,
Piraeus, Greece; Kyriakos Souliotis PhD, Lecturer, University of Peloponnese,
Maroussi, Greece
PURPOSE: The workshop purpose is to explore why implementing cost containment
health care reforms and making value based decisions is so difficult in the Greek
health care system, emphasizing the pharmaceuticals and medical devices sectors.
DESCRIPTION: The cost-escalation problem has been discussed intensively in the
Greek health policy debate over the past 15 years. A number of issues continuously remain as hot discussion topics despite legislative attempts to initiate cost
containment measures and enhance efficiency in health care decision making. Most
health reform laws have not been implemented at all, hospital debts are rising and
health care expenditures are, now, among the highest priorities in the government
efforts to meet its European Union Stability Program and related objectives, regarding government deficit limits and public sector debt. We try to explore why solutions
proposed over the past 15 years have not been implemented successfully and also
identify the basic factors which hinder more efficient resource allocation and health
care decision making. We focus on discussing the impact of excess health care supply on health care demand, the impact of a silo-tripartite financial structure (taxationhospitals, health insurance-pharmaceuticals, private expenditures-primary health
care) on the difficulty to coordinate containment efforts and the strong entitlementlegal framework which hinders clinical behavior controls and is used as an alibi to
alienate coverage decisions from efficiency considerations. Inherent features of the
Greek public sector bureaucracy pose additional (perceived/real) obstacles in installing value based decision making mechanisms. The workshop will be illuminating
for various audiences including public sector decision makers, pharmaceutical and
medical devices industry and academics as it will try to link the discussion on the
obstacles for more wider use of H.T.A. approaches with the theory of implementing
health care reforms, using a very appropriate case study as the Greek health care
system as an appropriate case-study
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION II: Monday, 10 November 2008 - 16:30-17:30
CLINICAL OUTCOMES RESEARCH
W8: OPTIMIZING POSTMARKETING VACCINE EFFECTIVENESS STUDIES Thalia 3
Discussion Leaders: Jeffrey Stoddard MD, Vice President, Medical and Scientific
Affairs, Risk Management and Post Marketing Programs, Covance Periapproval Services, Conshohocken, PA, USA; James C. King Jr MD, Professor of Pediatrics, Chief,
Division of General Pediatrics, University of Maryland School of Medicine, Baltimore,
MD, USA
PURPOSE: Examine study designs pertinent to vaccine effectiveness assessment
and review methodological approaches to herd immunity and/or indirect protection.
DESCRIPTION: Vaccines are unique inasmuch as they both directly and indirectly
impact incidence, prevalence and disease burden. Whereas other biopharmaceutical
interventions treat, ameliorate or cure disease processes in individual patients, they
rarely measurably impact disease incidence or prevalence. As new vaccines’ uptake
expands, tracking the impact of their widespread use (i.e. population level benefit)
becomes crucial from various perspectives. Multiple stakeholders (manufacturers,
policymakers, providers, and consumers) all have an interest in understanding the
population level benefits of vaccine uptake. This session will explore populationbased effectiveness assessment from multiple perspectives. The presentation
will frame, within a historical perspective, the importance of post marketing study
designs that have been used to ascertain effectiveness at the population level,
stressing the impact that these studies have had on vaccine development and
societal vaccine acceptance. A scientifically oriented and methodologically focused
perspective will describe community intervention trials, randomized cluster trials,
and other prospective, interventional approaches to ascertaining indirect protection.
Case studies will be used to highlight successful research designs. The presentation will employ a structured audience participation component to highlight available
population-based datasets. Analytic approaches designed to track disease incidence
and disease burden using these sources will also be discussed interactively. Case
studies from recent vaccine launches will be described. Finally, implications of the
research findings from large-scale, post marketing vaccine effectiveness studies will
be explored. This segment will focus on the potential for translation of this body of
research into policy and practice, including public health recommendations, clinical
practice impacts, reimbursement policies, and product lifecycle management. Translational case studies of effectiveness research will also be reviewed. The session
will present a balanced positioning of the issues that affect all stakeholders in the
vaccine arena.
ECONOMIC OUTCOMES RESEARCH
W9: TRIVIAL OR IMPORTANT? THE NEEDS, BENEFITS AND IMPLICATIONS OF
VARIABILITY Santorini 1-2
Discussion Leaders: Denis Getsios BA, Graduate Student, College of Pharmacy,
Dalhousie University, Halifax, NS, Canada; Kristen Migliaccio-Walle BS, Director
& Research Scientist, Health Economics, United BioSource Corporation, Concord,
MA, USA; Duygu Bozkaya MSc, MBA, Researcher, United BioSource Corporation,
Concord, MA, USA
PURPOSE: Is the extent to which we account for variability in pharmacoeconomics
evaluation trivial or important? The impact of choosing different degrees at which
to incorporate variability in aspects of modeling such as treatment response will be
discussed. The implications of these choices for reaching conclusions about the
pharmacoeconomics value of interventions will be highlighted.
DESCRIPTION: The potential effects of applying variability in key input variables
such as treatment response, patient characteristics, and adherence with treatment
and provider behaviour on resulting outcomes will be explored. The importance of
considering variability will be illustrated with an example using an individual level
simulation, by incorporating variability at different levels of detail and comparing the
results of corresponding scenarios. Key messages will be communicated on: variability as a necessary and valuable component of pharmacoeconomics evaluation,
the challenges in designing pharmacoeconomics evaluations that properly account
for variability and the utility of individual level simulation as a framework for doing
so. While geared towards researchers involved in designing health economic evalua-
tions, the workshop will also be of interest to a more general audience, who can use
the concepts identified in the workshop to evaluate the validity of pharmacoeconomics studies.
W10: GUIDELINES FOR APPROPRIATE SELECTION OF MODELING APPROACH IN
PHARMACOECONOMIC EVALUATION Terpsichore AB
Discussion Leaders: David Thompson PhD, Vice President, i3 Innovus Research,
Inc, Medford, MA, USA; Andreas Maetzel MD, MSc, PhD, Associate Director/Assistant Professor, Amgen (Europe) GmbH/University of Toronto, Health Economics &
Reimbursement, Zug, Switzerland; Monique Martin MSc, MBA, Vice-President UK
Operations, i3 Innovus Research Inc, Uxbridge, UK; Peter Lindgren PhD, Director,
i3 Innovus Research Inc, Stockholm, Sweden
PURPOSE: To discuss methodological differences across alternative modeling
approaches, and to offer practical guidance for selecting the most appropriate
approach under a range of circumstances.
DESCRIPTION: Recent years have witnessed continuous refinement in available
tools and techniques for health economic modeling. Workshops and short courses
are frequently offered at ISPOR and other venues to provide opportunities to learn
how to use the traditional methodologies, such as decision tree and Markov modeling, as well as advanced ones, such as patient-level simulation. Less frequently
offered are opportunities for researchers to learn how to be pragmatic in selecting
the most appropriate methodological approach when faced with the task of modeling
a given disease area and set of treatments under the typical constraints imposed
by time, budget, and data availability. Yet, practical guidance along these lines is
crucially important to ensure that pharmacoeconomics models are “fit for purpose”,
answering the right questions with appropriate scientific rigor so as to facilitate
informed decision making. In this workshop, we will provide a broad overview of the
most widely employed methodologies in cost-effectiveness analysis, including:
1) decision-analytic models; 2) state-transition models; and 3) patient-level simulation models, including discrete-event simulation. Particular attention will be paid to
outlining their relative strengths and limitations vis-à-vis a range of criteria, including
amenability to alternative disease types (acute, chronic, infectious) and medical
interventions (preventive, curative, palliative); transparency of model structures;
difficulty of fulfilling data requirements for parameter estimation; adaptability to
multiple settings and/or users; need for specialized software; and others. Real-world
case studies will be introduced to illustrate how these criteria shaped the presenters’ decision making in adopting a particular modeling approach. The importance of
being pragmatic—as opposed to dogmatic—in selecting the appropriate modeling
approach will be emphasized. Participants will share their thoughts and experiences
in selecting appropriate modeling approaches for pharmacoeconomics evaluation.
PATIENT-REPORTED OUTCOMES RESEARCH
W11: MISSING DATA – IMPLICATIONS FOR OUTCOMES RESEARCH AND STRATEGIES TO MAXIMISE DATA INTEGRITY Thalia 1-2
Discussion Leaders: Colin Martin RN, BSc, PhD, YC, Chair in Mental Health, University of the West of Scotland, Ayr, Scotland, UK; Matthew D. Reaney MSc, PGDip,
Senior Scientist, Health Psychology, AHP Research, Uxbridge, UK; Jane Speight
MSc, PhD, Director, AHP Research, Uxbridge, UK
PURPOSE: Missing data is a common issue in clinical trials, particularly in patientreported outcomes (PRO), potentially threatening the integrity of a study. The impact
of missing data (from reducing statistical power to detect treatment effects to
distortion of treatment effects) depends on the extent of the problem and how it is
handled. The FDA draft guidance for industry alludes to the problem but does not
propose a standardised strategy. It recommends that the statistical analysis plan
(SAP) includes plans for how missing data will be handled at an item and a domain/
measurement level. A number of approaches have been adopted to deal with missing data, but the suitability of alternative approaches is seldom discussed in an
evidenced-based manner. Clearly, however, the best strategy is to avoid missing data
wherever possible. This workshop explores the impact of missing data and strategies for minimising and handling missing data in relation to the specific attributes of
the study design, in line with the FDA’s current thinking.
91
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION II: Monday, 10 November 2008 - 16:30-17:30
DESCRIPTION: The workshop will firstly provide an overview of the problems
associated with missing data within the context of clinical trials and how to minimise these. Missing data will be explored by modeling the impact on a number of
datasets. This approach will be invaluable in highlighting how alternative methods for
controlling for missing data impact differentially on the interpretation of study findings. Popular strategies involve options based on an assessment of the percentage
of missing data. More innovative approaches to the management of missing data
(e.g. based upon reliability analyses) will be explored and evaluated and the role of
the most popular methods of data management explored in several study designs
beyond those of the classic randomised controlled trial. Participants will have the
opportunity to appraise and debate existing methods of missing data handling.
W12: RAISING THE VALUE OF DIRECT UTILITY MEASUREMENT APPROACHES FOR
PHARMACEUTICAL MARKET ACCESS DECISION MAKING: IS IT POSSIBLE?
Galaxy
Discussion Leaders: Keith H. Tolley MPhil, Director, Tolley Health Economics Limited, Buxton, Derbyshire, UK; Jan J. Busschbach PhD, Senior Research Associate,
Erasmus Medical Center, Rotterdam, The Netherlands; Jane Scott PhD, Research
Director, Mapi Values, Macclesfield, Cheshire, UK
PURPOSE: To present and debate the use and value of direct measurement utility
methods for QALY calculations used to support reimbursement and market access
decisions for new pharmaceuticals.
DESCRIPTION: QALYs are used as part of pharmacoeconomics evaluations in a
number of countries in Europe to support pricing, reimbursement and market access
decision making for new pharmaceuticals. These include UK (NICE and SMC), The
Netherlands, Sweden and its use could spread further to become an explicit part
of decision making in other countries. UK and Dutch guidance on pharmacoeconomics evaluations recommend use of a generic validated utility instrument such
as the EQ-5D as the primary source of utility data. The use of direct measurement approaches based on health state vignettes have been considered relatively
less robust and open to bias, but have nonetheless been used in NICE and SMC
technology appraisals based on either time trade-off or standard gamble valuation
approaches. Therefore, in this workshop we will present examples of its use in previous NICE, SMC and other technology appraisals in Europe and present links with
associated decision outcomes. We will explore potential specific advantages of the
approach, for example for generating utilities associated with specific drug features
such as mode of administration or adverse events, compared to other methods
of utility elicitation. We will then further explore limitations and criticisms of direct
measurement approaches especially relating to the way health state descriptions
are generated. The workshop will discuss how patient experiences can be better captured in health state vignettes to improve their rigour and value for decision making.
The workshop will include an interactive session to obtain the views of the audience
regarding the use of TTO or standard gamble based direct measurement approaches
within pharmacoeconomics models designed for market access decision making.
USE OF REAL WORLD DATA
W13: HEALTH TECHNOLOGY ASSESSMENT RESEARCH IN EUROPE: GATHERING
THE DATA Thalia 4
Discussion Leaders: Carl V. Asche PhD, Research Associate Professor, University
of Utah College of Pharmacy, Salt Lake City, UT, USA; William C. Maier MPH, PhD,
Scientific Advisor, MAPI Research Trust, Lyon, France
PURPOSE: The purpose of this workshop is to increase the awareness of the
databases available in Europe that are applicable in doing health technology assessment research. The participants will gain an understanding of European health care
databases to enable important types of health care related research in Europe.
DESCRIPTION: The field of health technology assessment research has attained an
advanced level of formality and standardization over the last fifteen years through
the world. Instrumental guidelines have been developed to provide investigators with
useful tools and approaches for conducting health technology assessment research
within the European market. This has, in turn, led to increased data for health technology assessment research through health care databases being made available
92
to researchers. The combination of guidelines, research and availability of data in
Europe will have major implications in terms of further enabling health technology
assessment research by various stakeholders in Europe. The aim of this workshop
is to allow the participants to understand the availability of databases associated
with doing health technology assessment research in Europe. The ISPOR Digest
classification of international databases initiative will be summarized, with particular
emphasis on those available to researchers in Europe. Examples will be given on
benefits and challenges for the use of such data by health technology assessment
researchers in Europe. The workshop will conclude with an opportunity to engage
workshop participants to comment on the information provided as well as their own
feedback on the European health care databases that should be considered as part
of the ISPOR Digest inventory of databases.
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W14: DECISION CRITERIA BY HEALTH INSURERS: WHAT DO THEY WANT FROM
US? Terpsichore C
Discussion Leaders: Eline Kogels MSc, Consultant, Kogels Consultancy Network,
Amsterdam, The Netherlands; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars
Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
PURPOSE: The purpose of this workshop is to explore the critical data, which are
relevant for health care decision makers in health insurers (third party payers) in
Europe. The conflicting incentives for health insurers in this process will be discussed as well: cost containment versus competitive differentiation. We will present
an overview of current situation in main European countries, including some case
studies, where health insurers played a crucial role in obtaining market access for
new pharmaceuticals.
DESCRIPTION: Decisions on reimbursement of new pharmaceuticals have been
central decisions based on traditional registration data (efficacy, safety). Now also
other data are required, which relate to the use of the drug in real daily practice:
cost-effectiveness and budget impact. A positive reimbursement decision used to
be sufficient for market access and the target audience for prescription was the
physician. However the introduction of market mechanisms and the decentralisation
of the health care decision making process resulted in an additional hurdle for new
pharmaceuticals: the requirement of listing on local formularies of health insurers. The physicians’ freedom of prescribing new pharmaceuticals has been rather
limited by these local formularies. On the other hand, health insurers may decide
to reimburse a new drug after negative central reimbursement decision and absorb
the additional costs. The decision criteria for central reimbursement are explicitly
described in official policy documents and research guidelines, and the process has
been embedded in a legal framework. Contrary to the decision criteria, which are
applied by health insurers, are not explicitly stated and the process lacks transparency. A more profound understanding of this decision making process of health
insurers will allow a more proactive development of a dossier for health insurers
during the drug program phase and faster access on formularies.
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION III: Tuesday, 11 November 2008 - 14:45-15:45
CLINICAL OUTCOMES RESEARCH
W15: MAXIMISING CLINICAL TRIAL PARTICIPATION – HOW IMPORTANT IS THE
SOCIAL CONTEXT? Thalia 1
Discussion Leaders: Matthew D. Reaney MSc, PGDip, Senior Scientist, Health
Psychology, AHP Research, Uxbridge, UK; Jane Speight MSc, PhD, Director, AHP
Research, Uxbridge, UK; Colin Martin RN, BSc, PhD, YC, Chair in Mental Health,
University of the West of Scotland, Ayr, UK
for depicting the frontier band and for projecting it in a consistent way. In the workshop, we will describe and demonstrate these techniques using various case studies. Given the topic’s developmental nature, strong discussion will be fostered and
the presenters look forward to a vigorous and illuminating debate on what should be
done. The decision by IQWiG to implement the efficiency frontier in Germany as the
method of choice for economic evaluations means these methodological discussions
will have a strong impact on pharmacoeconomics in general.
PURPOSE: Participation rates for clinical trial research continue to drop in the UK
and much of Europe. Reasons for this are multiple and include clinical concerns and
misunderstandings, political and regulatory guidelines, socioeconomic and historical
restrictions, cultural, and practical issues. This workshop focuses on one of the
social determinants of participation. Presenters will discuss ways in which social
barriers to clinical participation can be overcome.
W17: PRACTICAL ISSUES IN THE EXECUTION OF A BUDGET IMPACT ANALYSIS: A
CASE STUDY Thalia 2
Discussion Leaders: Stefan Walzer MA, International Economic Strategy Manager,
F. Hoffmann-La Roche Pharmaceuticals AG, PBSE - Economic Value Strategy, Basel,
Switzerland; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars Accessus Medica/
Erasmus University Rotterdam, Amsterdam, The Netherlands
DESCRIPTION: Individuals participate in clinical research for a variety of reasons,
dependant not only on the trial phase and their own clinical status but also their
sense of optimism, altruism, clinician influence, or financial gain. Practical factors
influencing participation may include geographical access, motivation, availability,
and language spoken. Widely-used health psychology models (e.g. the Theory of
Reasoned Action, the Health Belief Model) demonstrate that, in addition to these
factors, the primary reason for non-participation in clinical research is social
perception of risk. These models detail how beliefs and attitudes toward clinical research develop within, and are influenced by, an individual’s social context.
Perceived social benefits and barriers toward participation are considered alongside
perceived susceptibility and severity of side-effects from participation, or symptoms
of disease. A major factor in such models is the subjective norm i.e. individuals’
beliefs that important others expect or wish him/her to perform this behaviour, and
the motivation to act in accordance with their expectations or wishes. This includes,
but is not limited to, the role of the media, peers and family members, clarification
of risk associated with trial participation and discussion of comparative risk, and risk
equivalence between trials and same treatment outside trials.
PURPOSE: The aim of this workshop is to present practical issues in the execution
of a budget impact analysis and to show potential solutions in order to optimally
communicate the economic impact of a new innovative drug to the relevant health
care decision makers.
The workshop will involve a 30-minute presentation from the discussion leaders
and a 30-minute group-work session to explore how an understanding of the social
context of participation in clinical research can maximise appropriate clinical trial
participation.
ECONOMIC OUTCOMES RESEARCH
W16: QUANTIFYING AND DISPLAYING UNCERTAINTY AROUND AN EFFICIENCY
FRONTIER Galaxy
Discussion Leaders: Isao Kamae MD, DrPH, Professor, Keio University Graduate
School of Health Management, Fujisawa, Kanagawa, Japan; J. Jaime Caro MDCM,
FRCPC, FAC, Senior Vice President Health Economics, United BioSource Corporation, Lexington, MA, USA
PURPOSE: An efficiency plot with an explicit frontier conveys information about the
efficiency of interventions in a therapeutic area clearly and directly. It allows decision
makers to consider each intervention’s value in relation to its net costs; projection
of the frontier can provide guidance for decisions about newer interventions lying
beyond the existing frontier’s reach. In this workshop, we will address quantification
of uncertainty surrounding the frontier and its projection. Concepts will be illustrated
using various examples.
DESCRIPTION: In analyses relating the value of an intervention’s benefits to its
cost, relative to those of other interventions in that therapeutic area, there are many
sources of uncertainty in both dimensions. For example, effectiveness of each intervention is derived from efficacy studies, which are imprecise given sample size and
follow-up, and (hopefully!) from data on how efficacy translates to actual effects in
practice, which are also imprecise. Proper depiction of the efficiency frontier requires
incorporating this uncertainty. As imprecision also extends to costs and valuation of
benefits, depiction of efficiency requires a more diffuse representation than a single
point. This less precise understanding of efficiency leads to an efficiency band on
the frontier and a projection fan beyond it. Special techniques are then required both
DESCRIPTION: As budget impact is gaining in importance in the overall decision
making process, it is important to explore the appropriate execution of a budget
impact analysis in more detail, especially because no formal guidelines exist like
for a cost-effectiveness analysis. Although some methodological guidance has been
published, there are some specific practical issues in a budget impact analysis,
which are not covered by this guidance. Contrary to the input data for cost-effectiveness, a budget impact analysis also requires forecasts, for example the prediction
of diffusion (or uptake). As there is no generally accepted guidance on how to handle
diffusion and other critical input data, the purpose of this workshop is to present
potential solutions for a number of practical issues in the execution of a budget
impact analysis, which will be illustrated by a case study for an innovative drug in
rheumatology.
Key topics will include: diffusion, choice of comparator mix, assessment of distribution of comparator mix and the impact of new drug on distribution of comparator mix.
PATIENT-REPORTED OUTCOMES RESEARCH
W18: A CHECKLIST FOR GOOD RESEARCH PRACTICES FOR THE APPLICATION OF
CONJOINT ANALYSIS IN HEALTH – FINAL REPORT Thalia 3
Discussion Leaders*: John FP Bridges PhD, Assistant Professor, Johns Hopkins
University, Bloomberg School of Public Health, Baltimore, MD, USA; A. Brett Hauber
PhD, Senior Economist and Head, RTI Health Solutions, Research Triangle Park, NC,
USA; Maarten J. Ijzerman PhD, Professor of Clinical Epidemiology & HTA, University
of Twente, Enschede, The Netherlands
PURPOSE: To present the ISPOR Patient Preference Methods – Conjoint Analysis
Working Group’s final report, Good Research Practices for the Application of Conjoint
Analysis. The focus is a checklist for outcomes researchers who want to measure
health preferences using these methods.
DESCRIPTION: Conjoint analysis, discrete-choice experiments, and other statedpreference methods are grounded in economic theory and have long been standard
methods in transportation and environmental economics. While these methods are
often applied in most other sectors of the economy, they have only recently gaining
prominence in outcomes research, and hence the quality of the existing applications
of these methods in outcomes research has been rather mixed. Conjoint analysis
measures the relative value of specific components of health and health-care choice
alternatives and may provide more detailed and potentially more valid information
compared to alternative approaches to evaluating preferences. Moreover, understanding how patients perceive and value different aspects of health and health-care
interventions and incorporating these values into decision-making can ultimately
result in clinical and policy decisions that better reflect individuals’ preferences.
The report provides an overview of current practices in conjoint analysis, identifies
study design and analysis issues researchers should consider when conducting such
93
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION III: Tuesday, 11 November 2008 - 14:45-15:45
studies, and recommends items that researchers should address when describing
their research in peer-reviewed journals with the goal to improve consistency and
comparability of published conjoint studies in outcomes research.Participants will be
invited to comment on the group’s findings and recommendations.
* Discussion Leaders represent the ISPOR PRO SIG: Patient Preference Methods
– Conjoint Analysis Working Group. A list of members is available on the ISPOR
website.
W19: ADDRESSING CROSS-CULTURAL ISSUES WITH PATIENT-REPORTED OUTCOMES ASSESSMENTS TO STRENGTHEN EVIDENCE OBTAINED IN AN INTERNATIONAL CONTEXT Thalia 4
Discussion Leaders: Antoine Regnault PhD, Associate Statistician, Mapi Values France, Lyon, France; Isabelle Mear MA, Managing Director, Mapi Research
Institute, Lyon, France; Shalaka Marfatia MS, MPH, Manager Global Outcomes
Research, Pfizer Inc, New York, NY, USA; Patrick Mollon MD, ESSEC, MBA, Associate Director, Pfizer Ltd, Sandwich, UK
PURPOSE: To demonstrate how to handle cross-cultural issues to take full advantage of Patient-Reported Outcomes (PRO) in international studies.
DESCRIPTION: PRO instruments are commonly used in international clinical studies, notably in pivotal trials intended for marketing authorisation. The consideration
of cross-cultural issues related to the use of different language versions of an
instrument allows the conclusions resulting from PRO to be strengthened and must
be addressed appropriately at two stages of the study. Firstly, before starting the
study, methods to optimize the cross-cultural equivalence of the versions of the PRO
instrument must be implemented: appropriate development in the case of a new
instrument and translatability assessment and rigorous linguistic validation in case
of the development of new versions of a pre-existing instrument. Secondly, when the
study database is available, the application of appropriate quantitative methods (e.g.
Confirmatory Factor Analysis or Differential Item Functioning detection) allows the
performance of the different versions to be compared and the cross-cultural validity
of the instrument to be supported. Addressing the cross-cultural issues at these
two stages is essential to increase the confidence in the conclusions drawn from
the use of PRO instruments in international studies. This approach demands active
collaboration of individuals from different fields of expertise (linguists, statisticians,
outcomes research specialists…). The workshop will address both aspects using
examples from the presenters’ experience and from the literature. In particular, a
comprehensive case study describing the consideration of the cross-cultural issues
related to a symptom scale included in an international HIV clinical trial will allow
the critical points to be discussed. The participation of the audience will be actively
encouraged based on examples and their own experience dealing with cross-cultural
issues within international studies.
W26: THE NEW CHILD-FRIENDLY EUROQOL VERSION: EQ-5D-Y Terpsichore C
Discussion Leaders: Wolfgang Greiner PhD, Professor for Health Economics and
Health Care Management, University of Bielefeld, Faculty of Public Health, Bielefeld,
North Rhine-West, Germany; Luciana Scalone PharmD, DSc, Researcher, Centre
of Pharmacoeconomics, University of Milan, Milan, Italy; Paul Kind, Professor,
University of York, Outcomes Research Group, York, UK; Frank T. De Charro PhD,
Health Economist, Erasmus University Rotterdam, Centre for Health Policy and Law,
Rotterdam, The Netherlands.
PURPOSE: The aim of this workshop is to introduce a new instrument for the
measurement of quality of life in children. As it was based on the traditional EQ-5D
questionnaire with, the modification process with regard to phrasing of the questionnaire, the translation procedure and the qualitative and quantitative testing of the
questionnaire as well as first results from different population studies in Europe will
be discussed.
DESCRIPTION: Health-related quality of life (HRQoL) of children and adolescents
is increasingly considered a relevant topic for research. Since studies in this field
require measuring procedures, which are appropriate to the stage of development
of the young respondent, instruments to assess generic as well as disease-specific
quality of life in children and adolescents were developed and increasingly applied
in epidemiological surveys, clinical studies, quality assurance and health economics
94
in recent years. Due to its 81 officially approved language versions, its briefness,
its applicability to a wide range of health conditions and its ability to provide a
descriptive profile, as well as an index value, the use of EQ-5D has internationally
spread into many different settings. Against the background of the rising importance to measure HRQoL in children and adolescents, the need of a well-validated
child-friendly version of the EQ-5D became obvious as a central precondition for
cross-cultural use of EQ-5D in health status measurement in children and adolescents. In the recent years, the EuroQol Group supported increasing research on this
topic. After an accumulated body of research and experiences with the application of
(partly modified versions of) EQ-5D in several countries was available, researchers
from seven different countries working on the application of the EQ-5D in younger
age-groups met in order to harmonise and integrate the results of this preparatory
work and to coordinate further development and validation of a new child-friendly
EQ-5D version.
USE OF REAL WORLD DATA
W20: USE OF REAL WORLD DATA: CHALLENGES IN THE ANALYSIS OF PATIENT
REGISTRY DATA Santorini 1-2
Discussion Leaders*: Christopher M. Blanchette PhD, MS, MA, Associate Scientist
and Director, Lovelace Respiratory Research Institute, Albuquerque, NM, USA; Shital
Kamble BPharm, MMS, MS, Doctoral Student-Research Assistant, The University of
North Carolina at Charlotte, Charlotte, NC, USA; Alex Exuzides PhD, Director, ICON
Clinical Research, San Francisco, CA, USA; Carl J. Gibbons BsC, (Psych), Research
Analyst, Schering-Plough, Welwyn, Garden City, UK
PURPOSE: To provide recommendations for strategies on analyzing patient registry
data. Topics will include considerations in developing a statistical analysis plan, challenges to and the value of patient registry analysis.
DESCRIPTION: Patient registries are an important source of data that can aid in
the development and evaluation of access and reimbursement strategies. However,
the analysis and interpretation of registry data can be challenging, due in part to
the often non-randomized, non-controlled, hypothesis-generating nature of registry
designs, large sample sizes, and varying follow-up time points. We will discuss how
analytical approaches can be applied to extract critical information for regulatory and
payer requirements. We will use examples from disease, product and exposure registries to illustrate our recommendations. Key elements of our Analysis Team Plan*
include sample size and power estimation, estimation of treatment effect/ effect
size, statistical inference and hypothesis testing, timing of analyses, variable types,
main analysis techniques, severity adjustment techniques, treatment of selection
bias, re-sampling techniques for statistical modeling, treatment of missing observations, statistical significance under large sample sizes, multiplicity adjustments,
and systematic reviews/ meta-analysis. This workshop will interest health outcomes
researchers who develop and conduct statistical analysis plans for registries and
those who consider strategies in post-hoc analysis. Participants are encouraged to
bring their registry analysis challenges up in the interactive discussion section of the
workshop.
* Discussion Leaders represent the ISPOR Patient Registry SIG Classification, Strategy & Design Working Group. A list of members is available on the ISPOR website.
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W21: VALUE BASED PRICING IN GERMANY – OLD WINE IN NEW BOTTLES?
Terpsichore AB
Discussion Leaders: Olaf Pirk MD, PhD, Principal, IMS Health, Nuremberg, Germany;
Frank-Ulrich Fricke PhD, MSc, Principal, IMS Health, Nuremberg, Germany; Christian Krauth PhD, Head of Working Group Health Economy, Hannover Medical School,
Epidemiology, Social Medicine and Health System Research, Hannover, Germany
PURPOSE: The objective of this workshop is to demonstrate how to optimize reimbursement in Germany for selected drugs and how to demonstrate value during this
new process of value based pricing.
DESCRIPTION: The latest health care reform in Germany introduced a kind of value
based pricing for all new non-orphan drugs not fitting into the reference pricing
system but not being the first ones within a treatment option. These drugs have to
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION III: Tuesday - 14:45-15:45 / SESSION IV: Tuesday - 16:00-17:00
undergo an IQWiG (Institute for Quality and Efficiency in Health Care) assessment.
Assessed as better than the comparator based on IQWiG’s cost-benefit assessment
the Federal Association of Sick funds (GKV-Spitzenverband) in Germany will define
a maximum reimbursement price for the new drug. During the first part of the workshop (led by Christian Krauth) the basic principles of the cost-benefit methodology
and the assessment process will depicted. In the second part of the workshop (led
by Olaf Pirk and Frank-Ulrich Fricke), drugs which might be affected by a maximum
reimbursement price will be discussed.
discussing with German Sickness Fund associations or single German Sick Funds.
Implications for the drug development process and the product life cycle of a drug
will be elaborated.
Overall, the attendees will develop a notion on what are the requirements derived
from IQWiG methodologies and how to fulfill these requirements during the development process of their respective product.
Activities by the affected parties during the assessment process and based on the
methodology will be delineated. Attendees will learn how to demonstrate value when
WORKSHOPS – SESSION IV: Tuesday, 11 November 2008 - 16:00-17:00
CLINICAL OUTCOMES RESEARCH
W22: STATISTICAL MEASURES OF TREATMENT EFFECT IN ONCOLOGY: WHAT ARE
WE MISSING? Thalia 3
Discussion Leaders: Deirdre Mladsi BA, Global Head, RTI Health Solutions,
Research Triangle Park, NC, USA; William D. Irish PhD, Global Head, Biometrics,
RTI Health Solutions, Research Triangle Park, NC, USA; Kati Copley-Merriman MBA,
MS, Global Head, Regulatory and Health Outcomes Strategy, RTI Health Solutions,
Ann Arbor, MI, USA; Durgesh Bhandary, Health Economics & Outcomes Research,
AstraZeneca, Wilmington, NC, USA
PURPOSE: The aims of this workshop are to explore the limitations of commonly
used methods for conveying the efficacy of new drugs for advanced cancer and to
discuss the merits of including supplemental methods in clinical trial analysis plans.
The workshop is targeted toward clinicians, statisticians, and health outcomes
researchers who may be required to understand and communicate to providers and
payers the value of new cancer drugs.
DESCRIPTION: Decision-makers may be well-versed in traditional measures of treatment effect for drugs for advanced cancer, where prolongation of life is paramount;
however, even these well-accepted measures have inherent limitations. KaplanMeier curves offer a statistically sound and visually intuitive manner of comparing
treatments, but interpretation for patients’ benefit is less clear when the curves do
not separate until after the first few months of treatment, or when the curves cross.
Median survival, in and of itself, conveys information for half of the patients—those
with the shorter survival. Nothing is conveyed about the longer living half. Also, differences in median survival are most impressive when the survival curves are intersected at the point of greatest separation. What is the meaning of the separation if
it occurs at the 25% survival duration? At 75%? The hazard ratio offers a measure
of overall difference; however, is the inclusion of it on a survival graph statistically
correct? How easy is the hazard ratio to interpret? This workshop will use examples
from the websites and journal advertisements for current drugs for cancer to review
common statistical methods of conveying efficacy. Participants will be asked to provide their interpretation of the data, their conclusion regarding drug superiority, and
their ideas for supplementing the traditional methods. New ideas for data analysis
and presentation will be discussed and their merits debated.
ECONOMIC OUTCOMES RESEARCH
W23: COLLABORATIVE MULTI-NATIONAL HEALTH ECONOMIC AND PRO DATA
GATHERING: A CASE STUDY HIGHLIGHTING THE ATHENS STROKE REGISTRY
Santorini 1-2
Discussion Leaders: Krista Payne MEd, Director & Research Scientist, United
BioSource Corporation, Montreal, QC, Canada; Kostas Vemnos MD, Professor,
University of Athens School of Medicine, Alexandra Hospital, Athens, Greece; Liberty
Fajutrao MD, MSc, Senior Health Economics and Outcome Research Scientist,
AstraZeneca R&D, Sodertalje, Sweden
PURPOSE: To describe, using a research collaboration featuring the Athens Stroke
Registry as a case study, an adaptable design and electronic data capture methodology that is practical and efficient for collecting multi-national clinical, resource
utilization and patient-reported outcome data to populate economic models or other
burden of illness evaluations.
DESCRIPTION: In support of pricing and reimbursement submissions, countryspecific economic evaluations are required. As modeling methods evolve, and given
the growing emphasis on the inclusion of patient-reported outcomes in these evaluations, there is an increasing need for tailored multi-national data gathering. The
practical challenges to collecting these data under time and resource constraints,
while maintaining quality control, are formidable. Innovative study designs and data
capture methodologies provide a solution to these challenges. Using an international
research collaboration with the Athens (Greece), Erlangen (Germany), South London
(UK), and Melbourne (Australia) stroke registries as a case study, this workshop will
present one complete approach to gathering multi-national health economic, or QOL,
data electronically; managed by remote study monitoring. The goal of the workshop
is to provide participants with practical knowledge and lessons learned related to
effective study planning and design, electronic data capture methodology, cohort
identification, sampling, data entry, monitoring, project management, and quality
control processes. Opportunities and challenges associated with this approach will
be delineated. Perspectives of the scientific consultant, the clinician expert, and the
industry sponsor will be shared. In small group format, participants will be given
the opportunity to apply workshop content to the resolution of common challenges
described in hypothetical research scenarios.
W24: MODELING OF INFECTIOUS DISEASES AND THEIR TREATMENT FOR HEALTHECONOMIC ANALYSIS Thalia 2
Discussion Leaders: Mario Ouwens PhD, Research Consultant, Mapi Values,
Houten, The Netherlands; Debby Vissers MSc, Senior Research Associate, Mapi Values, Houten, The Netherlands; Thierry Van Effelterre PhD, Mathematical Modeller,
GlaxoSmithKline Biologicals, Rixensart, Belgium
PURPOSE: There is growing interest in the cost-effectiveness of vaccines and antimicrobial therapies for the control of infectious diseases. This workshop aims at providing an understanding of how the population dynamics of infectious diseases and
the (cost)-effectiveness of interventions can be adequately modeled. Key dynamic
modeling concepts will be introduced, with an emphasis on practical applications.
DESCRIPTION: Dynamic modeling approaches have become very important for
estimating the cost-effectiveness of infectious disease control interventions and
programs. One of the reasons is that traditional decision trees and Markov models
do not capture herd immunity, thereby underestimating the cost-effectiveness of
the intervention. Dynamic modeling is based on the nonlinear dynamics of infection
spread in a population. The models predict the transmission and spread of viral and
bacterial infections and can help identify the factors controlling the persistence, stability and epidemic periods of these. In this workshop participants will be introduced
step by step to basic dynamic modeling. The workshop starts with a formalization of
clinical descriptions of a few different infectious diseases. Then it will be shown how
this can be translated into a modeling environment. The audience is then asked to
select an appropriate model structure for a few not previously discussed infectious
diseases, including HPV, influenza, varicella and antibiotic resistance. The results
will be discussed and compared with peer-reviewed papers. The workshop proceeds
with the presentation of a model describing the transmission dynamics of the
rotavirus, accounting for direct and indirect “herd protection” effects. The model was
developed to better understand the transmission dynamics of rotavirus and evaluated the potential of rotavirus spread and the population-level impact of vaccination.
95
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
WORKSHOPS – SESSION IV: Tuesday, 11 November 2008 - 16:00-17:00
The workshop finishes by interactively evaluating the health economic effects of
different vaccination strategies for varicella with a generic model as example.
PATIENT-REPORTED OUTCOMES RESEARCH
W25: DISCRETE CHOICE MODELING FOR THE QUANTIFICATION OF HEALTH
STATES: THE CASE OF THE EQ-5D Terpsichore AB
Discussion Leaders: Paul Krabbe PhD, Senior Scientist, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands; Luciana Scalone PharmD,
DSc, Researcher, Centre of Pharmacoeconomics, Milan, Italy; Mark Oppe MSc,
Researcher, Erasmus Medical Center, Rotterdam, The Netherlands; Elly Stolk PhD,
Senior Research Associate, Erasmus Medical Center, Rotterdam, The Netherlands
PURPOSE: To present an overview of research strategies for and findings from the
explorative work on discrete choice models (DCM) as conducted by the EuroQol
Group to derive health state values.
DESCRIPTION: This workshop considers the application of discrete choice modeling (DCM) to derive values for the health states of the EQ-5D. These models were
developed to establish the relative merit of subjective phenomena. They are based
on specific judgmental tasks (e.g., ranking, paired comparisons) combined with
associated data analysis. The advantage of these models in quantifying health
states (i.e., values or utilities) lies in their uncomplicated and cognitively simple
judgment tasks, which guarantee response data of good quality. The main reason
for the EuroQol Group to investigate DCM was to explore the possible benefits of
this analytical framework. DCMs are powerful but complex. Consequently, the aim
was to determine which DCM research strategy is the most practical and efficient
for deriving health state values based on the EQ-5D classification. After considering
the various experimental design strategies (random selection, full factorial, fractional
factorial, Bayesian approach) the EuroQol Group arrived at an informative set of 60
pairs of health states for the discrete choice experiment (DCE) using a Bayesian
approach. Data were collected in a sample of the general population (n=400) and
a student sample (N=200). The students also completed a ranking, VAS, and a TTO
task to investigate comparability of the various valuation methods and to anchor the
DCE values on a scale from 0 (death) to 1 (full health). The Group also experimented
with a different way to anchor at death by including death as an option. In a satellite study “duration” was included as a separate attribute to test the effect of this
attribute on the valuations of health states.
USE OF REAL WORLD DATA
W27: NON-US DATA SOURCES FOR DISEASE AND HEALTH MANAGEMENT: WHAT
IS THERE, HOW ARE THEY USED LOCALLY AND HOW TO USE THEM FOR OTHER
RESEARCH Thalia 1
Discussion Leaders*: Oliver Mast MSc, Head of Global Reimbursement, Roche
Diagnostics, Mannheim, Germany; Tomas Sechser MD, PhD, Researcher, The Diabetes Centre, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
PURPOSE: To provide examples of non-US data sources and their use in the context
of their specific objective in the local health environment and to better understand
options for its use in other health care research projects.
DESCRIPTION: Most projects that involve health systems or disease modeling
depend on external data as assumptions on epidemiological figures, cost, effectiveness, etc. Often the challenge is to identify relevant data sources, especially outside
the U.S. Many countries face the need to do such projects – even in the absence
of local data or based on best available local data, regardless of quality. Or can you
just plug in data form abroad?
We will select several non-U.S. countries, including Central Europe and Greece to discuss: the current status of disease and health management in the country; the role
of local data sources for disease and health management; available data sources in
terms of their content and reliability / validity.
96
We will conclude with an interactive discussion on the adaptation of foreign data
for local analysis: what to do if you need data and there is no local data source and
pitfalls when using foreign data and ways to cope with these.
This workshop will interest researchers that need to adopt international research
findings to non-U.S. health systems and those who want to use non-U.S. data
sources for health care / health economic research.
* Discussion Leaders represent the ISPOR Disease & Health Management SIG:
International Section and their work on the forthcoming ISPOR book: Reliability and
Validity of Data Sources for Disease and Health Management. A list of members is
available on the ISPOR website.
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W28: FOOD FOR THOUGHT: SHOULD REIMBURSEMENT CRITERIA FOR PHARMACEUTICALS ALSO BE APPLIED TO NUTRITIONALS? Galaxy
Discussion Leaders: Eline Kogels MSc, Consultant, Kogels Consultancy Network,
Amsterdam, The Netherlands; Mark JC Nuijten MD, PhD, MBA, Consultant, Ars
Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands
PURPOSE: The objective of this workshop is to explore to what extent the reimbursement criteria for pharmaceuticals should be applied to nutritionals. The pros and
cons of using these decision criteria for nutritionals will be discussed using cases
studies from The Netherlands and the UK. Especially the use of cost-effectiveness
data will be addressed.
DESCRIPTION: Nutritionals traditionally belong to the consumer market and consequently market access has been different from pharmaceuticals. There is no third
party payer involved and the actual consumption depends on the willingness to pay
by a patient. Recently, nutritionals have been developed, which have proven efficacy
in a clinical trial setting in specific diseases. If nutritionals have become an alternative medical treatment for a specific disease, one may challenge the discrepancy in
the financing system between pharmaceuticals and nutritionals from a scientific, but
also from a medical and ethical point of view. Reimbursement of pharmaceuticals
is based on cost-effectiveness from a society perspective, whereas the use of a
nutritional is often based on willingness to pay by the hospitals. We will present an
overview of current situation in the main European countries. A case study will be
used to show that a standard cost-effectiveness analysis can be performed for nutritionals by applying the pharmacoeconomics research guidelines in The Netherlands.
Next, the appropriateness of using decision criteria for reimbursement for pharmaceuticals to nutritionals will be addressed. Specific topics will be the risk of off-label
use and potential budget impact.
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
SPONSORED SYMPOSIA
SATURDAY, 8 NOVEMBER 2008
18:00-20:00
Hesperides
Achieving Better Health Outcomes for the Benefit of Patients - An Update on EFPIA’s Key HTA Principles
Due to its rapidly growing impact on the prioritisation and rationing of health technologies Health Technology Assessment (HTA) is becoming one of
the most important and contentious subjects in current health care policy discussions. In health care systems largely driven by cost containment
considerations, there is considerable risk that HTA will run counter to its key objectives: identifying health technologies that bring the greatest benefit
to patients, ensuring early access, allowing choice among health technologies of value and ensuring efficient health care through objective high-quality
assessments.
In order to use the full potential of HTA for the benefit of patients and society, the European Federation of Pharmaceutical Industries and Associations
(EFPIA), has identified and actively supports a set of key HTA principles. These principles as well as latest research findings on HTA will be presented
and discussed at the symposium.
EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 32 national associations and 43 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 2,200 companies committed to researching, developing and bringing to patients new
medicines that improve health and the quality of life around the world.
EFPIA Position Paper: The Use Of Health Technology Assessments (HTA) To Evaluate Medicines - Key Principles.
http://www.efpia.org/content/default.asp?PageID=559&DocID=1350
Moderator: Adrian Towse MA, Mphil, Director, Office of Health Economics, London, UK
INTRODUCTORY PRESENTATION OF THE EFPIA PRINCIPLES
Jens Grueger PhD, DrPH, Head, Global Pricing & Reimbursement, Novartis Pharma AG, Basel, Switzerland
SHOULD HTA TAKE A BROAD SOCIETAL PERSPECTIVE ON VALUES?
Bengt Jönsson PhD, Scientific Advisor, European Health Economics, Stockholm, Sweden
SHOULD HTA BE CONDUCTED AT NATIONAL LEVEL?
Michael F. Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Finn Boerlum Kristensen PhD, Director, DACEHTA, National Board of Health, Copenhagen, Denmark
19:30 – 20:00 RECEPTION (All symposium attendees welcome)
MONDAY, 10 NOVEMBER 2008
7:00-8:00
Terpsichore ABC
Risk-sharing Agreements: All Pain or Some Gain?
Risk-sharing is increasingly becoming an important facet of pricing and reimbursement strategies in both Europe and the US. These types of agreements enable payers to transfer some (or all!) of the risk to manufacturers in situations where there is uncertainty as to a product’s value. By linking
reimbursement to patient outcomes, manufacturers try to secure appropriate pricing for successful innovations while payers are protected from paying
for ineffective options. UBC is pleased to invite you to an interactive panel discussion on what has been done so far with risk-sharing agreements, and
what the future might hold for their increased use.
Moderator: J. Jaime Caro MDCM, FRCPC, FACP, Senior Vice President, Health Economics, United BioSource Corporation, Lexington, MA, USA
Speakers:
Sean Sullivan PhD, Professor of Pharmacy and Public Health and Director, Pharmaceutical Outcomes Research and Policy Program,
University of Washington, Seattle, WA, USA
Jens Grueger PhD, Head, Global Pricing & Reimbursement, Novartis Pharma AG, Basel, Switzerland
Andrew Eggleston BPharm, MMedSc (Invited), Associate Director, Health Economics, Janssen-Cilag, North Ryde,
Australia
97
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
MONDAY, 10 NOVEMBER 2008
12:45-13:45
Terpsichore AB
Finding Synergies Between Pricing & Reimbursement and Health Economics and Outcomes Research
This symposium will outline the need to align strategy and implementation in pricing and reimbursement (P&R) and health economics and outcomes
research (HEOR) to meet the changing requirements of health care decision-makers. A framework to approaches and practical examples to address
this need will be presented both from a P&R and an HEOR perspective.
12:45-12:50INTRODUCTION
Moderator: Jonothan Tierce C.Phil, General Manager and Center of Excellence Leader Global Health Economics & Outcomes Research, IMS Health, Falls Church VA, USA
12.50-13.05HTA, COMPARATIVE EFFECTIVENESS, HEALTH ECONOMICS, BUT WHAT ABOUT INNOVATION?
Ansgar Hebborn PhD, Global Head - Economic Value Strategy, F. Hoffmann-La Roche AG, Basel, Switzerland
13.05-13.30APPROACHES AND PRACTICAL EXAMPLES OF STRATEGIC ALIGNMENT AND TACTICAL COLLABORATION OF P&R AND HEOR – AN
INTERACTIVE PRESENTATION
Pippa Anderson MSc, Senior Principal Pricing and Market Access, IMS Health, London, UK
Jon Resnick MBA, Vice President and Practice Leader, Pricing and Market Access, EMEA, IMS Health, London, UK
13.30-13.45
DISCUSSION/Q+A
TUESDAY, 11 NOVEMBER 2008
7:00-8:00 Terpsichore AB
The Do’s and Don’ts with Agencies like NICE or IQWiG – Generating the Right Health Economic Data
For Successful Appraisals
This symposium will give insights into what data NICE or IQWiG are looking for during HTA appraisals. Attendees will also receive guidance on how best
to prepare their HTA dossier, and how clinical and health economic NHS data can support this.
HOW TO GATHER THE RIGHT HEALTH ECONOMIC DATA WITHIN THE NHS - A NOVEL APPROACH
Andreas Guhl PhD, Head of Health Outcomes Unit, NHS Innovations London, London, UK
GATHERING THE RIGHT DATA FOR SUCCESSFUL NICE APPRAISALS
Meindert Boysen PharmD MSc, Associate Director, Single Technology Appraisal, NICE, Manchester, UK
GATHERING THE RIGHT DATA FOR SUCCESSFUL IQWiG APPRAISALS
J. Jaime Caro MDCM, FRCPC, FACP, Chair of Expert Committee Advisory Institute for Quality and Efficiency in Health Care (IQWiG), Lexington, MA, USA
TUESDAY, 11 NOVEMBER 2008
11:45-12:45
Terpsichore AB
Personalized Medicine and Targeted Therapy - Who Will Pay for Advances in Cancer Care?
The lifetime risk of developing cancer is approximately one in three, and will reach one in two in the near future. One in eight deaths are caused by cancer. With increased life expectancy, cancer is also becoming a major health care problem also in developing countries. Oncology is the focus of intense
research and drug development; the number of oncology drugs in development (phase II and later) are more then all other therapeutic areas combined.
Advances in diagnosis and therapy bring hope of turning incurable and fatal diseases into chronic but manageable conditions or even curing or preventing them altogether. Scientific progress is incremental; with each step the therapeutic value of a new medical innovation should be weighted against its
cost and against alternative uses of limited health care resources. The development of targeted therapy has already impacted the treatment of some
cancers (e.g. CML, breast-, colorectal- and lung cancer). Combination with diagnostic methods (cytology, pathology and functional imaging) for predicting which patients will benefit from treatment can improve both clinical outcomes and cost-effectiveness.
This symposium will discuss the difficult challenges for industry, health care systems and societies worldwide in providing access to new cancer therapies in an environment of budget restrictions and pressures for cost containment.
Moderator: Michael F. Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
THE MEDICAL AND ECONOMIC CHALLENGES OF TARGETED THERAPY
Nils Wilking MD, PhD, Associate Professor, Karolinska Institutet, Stockholm, Sweden
COST-EFFECTIVENESS OF GENETIC SCREENING STRATEGIES
Scott Ramsey MD, PhD, Cancer Prevention Faculty member, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
THE SWEDISH CANCER STRATEGY PLAN
Rickard Bergström, Director General, LIF - Swedish Pharmaceutical Industry Association, Stockholm, Sweden
98
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
congress committees
DECISION-MAKER CASE STUDY REVIEW COMMITTEE
Wojciech Bartminski MD, HE & PRA Manager, CEE Region, Eli Lilly, Windlesham, UK
Pascale Brasseur MBA, Medtronic International SA, Tolochenaz, Vaud, Switzerland
Ruth Brown MS, Senior Scientist and Director Scientific Services, UBC, Bethesda,
MD, USA
Kathy Cargill MSc, BSc, Senior Director, Reimbursement & Health Economics,
Medtronic Trading Int Sarl, Tolochenaz, Switzerland
Francois Everhard MSc, Head of Health-Economics and Pricing, Gilead Sciences,
Foster City, CA, USA
Christina Golna MSc, BA, Oncology Health Policy Manager, Roche Hellas SA,
Athens, Greece
Tomasz Hermanowski PhD, Professor of Marketing, Warsaw Technical University
Business School, Warsaw, Poland
Ernst Johannes MD, Executive Director, Quintiles Global Consulting, Hoofddorp, The
Netherlands
Shyam Karki PharmD, Pharmacy Director, Union Hospital of Cecil County, Pharmacy
Department, Elkton, MD, USA
Ivan Kocic PhD, MD, ScD, Head of Department, Department of Pharmacology,
Gdansk, Poland
Clare McGrath BS, Senior Director, Outcomes Research Europe and Canada, Worldwide Development, Pfizer, Walton on the Hill, Surrey, UK
Pedro Plans-Rubió MD, MBA, MSc, Health Registries, Departament de Salut, Sant
Pol, Spain
Karen Rascati PhD, RPh, Professor, University of Texas, Austin, TX, USA
Prabashni Reddy RPh, BS, MS, PharmD, Director of the Center for Drug Policy,
Partners Healthcare, Charlestown, MA, USA
Yevgeniy Samyshkin MSc, Senior Consultant, IMS Health, Health Economics and
Outcomes Research, Hammersmith, UK
Jayashri Sankaranarayanan PhD, MS, Assistant Professor, University of Nebraska
Medical Center, Omaha, NE, USA
Mark Schulz PhD, Director Market Access, Allergan Australia, Gordon, NSW, Australia
Michael Wonder BSc, Director, Health Technology Assessment, Novartis Pharmaceuticals Australia, North Ryde NSW, Australia
ISSUE PANEL REVIEW COMMITTEE
Roger Brice BA, Research Director, Adelphi Group ltd, Macclesfield, UK
Lei Chen PhD, MD, Statistician, Eli Lilly and Company, Indianapolis, IN, USA
Amy Grogg PharmD, Vice President, Xcenda, Palm Harbor, FL, USA
Chad Gwaltney PhD, Center for Alcohol and Addiction Studies, Brown University,
Providence, RI, USA
Dyfrig Hughes PhD, MSc, Senior Research Fellow in Pharmacoeconomics, Bangor
University, Bangor, UK
Don Husereau MSc, Director, Project Development - HTA, CADTH, Ottawa, ON,
Canada
Judith Kempf PhD, Executive. Director, CV Therapeutics, Palo Alto, CA, USA
Edward Kim MD, MBA, Associate Director, US Outcomes Research, Bristol-Myers
Squibb, Plainsboro, NJ, USA
Robert Launois PhD, Professor, REES France, Paris, France
Zhimei Liu PhD, Sr. Scientist, Cerner LifeSciences, Beverly Hills, CA, USA
Farzana Malik PhD, Mphil, BA, Global Pricing & Health Economics Director, Merck
Serono International SA, Geneva, Switzerland
Stephanie Manson PhD, Research Associate, United BioSource Corporation, London, UK
Kristen Migliaccio-Walle BS, Research Scientist, UnitedBioSource, Concord, MA, USA
Dan Ollendorf MPH, Chief Review Officer, Institute for Clinical & Economic Review,
Boston, MA, USA
Chris L. Pashos PhD, Vice President & Executive Director of HERQuLES, Abt BioPharma Solutions, Inc., Lexington, MA, USA
Kitty Rajagopalan PhD, Director, Health Economics, Biogen Idec, Wellesley, MA, USA
Brian Rittenhouse PhD, Sr. Director, Strategic Pricing & Reimbursement, ScheringPlough, Martinsville, NJ, USA
Sebastian Schneeweiss MD, ScD, Director of Drug Evaluation and Outcomes Research, Brigham and Women’’s Hospital and Harvard Medical School, Boston, MA,
USA
Paul Scuffham PhD, BA, Prof of Health Economics, Griffith University, Meadowbrook,
Australia
Richard Willke PhD, Senior Director, Global Outcome Research, Pfizer, Bridgewater,
NJ, USA
RESEARCH REVIEW COMMITTEE
Linda Abetz MA, Director, Questionnaire Development & Validation, Mapi Values,
Bollington, UK
Joyce Addo-Atuah PhD, Assistant Professor, Touro College of Pharmacy, New York,
NY, USA
Michael Adena PhD, BS, Director, Statistical Consultancy, Covance Pty Ltd, Braddon
ACT, Australia
Ahmad Fuad Afdhal PhD, Chief Executive Officer, Center for Socio-Economic Studies
in Pharmacy, Jakarta, Indonesia
Aysha Almas, Resident, aga Khan University, Karachi, Pakistan
Mayur Amonkar PhD, MSc, Manager, Global Health Outcomes, GlaxoSmithKline,
Philadelphia, PA, USA
Mallik Angalakuditi PhD, Global Health Economics Strategy & Communications,
Bristol-Myers Squibb, Belle Mead, NJ, USA
Lieven Annemans PhD, MSc, Health Economist, Ghent University - Brussels University, Ghent, Belgium
Mikael Asmussen MSc, International Pricing & Market Access Manager, Nycomed,
Roskilde, Denmark
Eun Young Bae PhD, Senior Researcher, Health Insurance Review & Assessment,
Seoul, South Korea
Alan Bakst PharmD, MBA, Senior Director, Global Health Economics and Reimbursement, Baxter Healthcare Corp, McGaw Park, IL, USA
Rajesh Balkrishnan PhD, MS, Merrell Dow Professor, Ohio State University College
of Pharmacy and School of Public Health, Columbus, OH, USA
Sanjeev Balu PhD, MBA, Senior Manager, Abbott Laboratories, Waukegan, IL, USA
Rod Barnes MBA, Senior Director, Alcon Laboratories, Inc., Fort Worth, TX, USA
Richard Barron MS, Director, Amgen, Thousand Oaks, CA, USA
Onur Baser PhD, MS, Assistant Professor of Surgery & President, University of
Michigan & STATinMED Research, Ann Arbor, MI, USA
Jennifer Beaumont BS, MS, Research Statistician, Center on Outcomes, Research
and Education (CORE), Evanston, IL, USA
Gilles Berdeaux PhD, MD, Health Economics Manager, Alcon France, Rueil-Malmaison Cedex, France
Beate Bestmann PhD, MA, WINEG, Hamburg, Germany
Gouri Bhattacharyya PhD, MD, Kolkata, India
Joseph Biskupiak PhD, MBA, Research Associate Professor, Pharmacotheray Outcomes Research Center, Salt Lake City, UT, USA
Rob Boer PhD, Director, New York, NY, USA
Vamsi Bollu PhD, Groton, CT, USA
Imre Boncz PhD, MD, MSc, Department Head, University of Pécs, Pécs, Hungary
Patrick O. Bonnet MS, PharmD, Sr. Manager Medical Outcomes Research and
Economics, Baxter BioScience, Westlake Village, CA, USA
Luke Boulanger MA, Director of Health Economics, Abt Bio-Pharma Solutions Inc.,
Lexington, MA, USA
Kathleen Bungay MS, PharmD, Assistant Professor of Psychiatry and Medicine,
Tufts-New England Medical Center, Boston, MA, USA
Ximena Burbano MD, Research Director, Fundacion Santa Fe de Bogota - HEORT,
Boca Raton, FL, USA
99
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
RESEARCH REVIEW COMMITTEE
Russel Burge PhD, MA, BA, Director, Health Economics & Outcomes Res, Abbott
Laboratories, Abbott Park, IL, USA
Jörg Burkowitz PhD, MPH, Senior Consultant, Alpha Care GmbH, Celle, Germany
Donald Bushnell MA, Associate Director, Health Research Associates, Inc., Mountlake Terrace, WA, USA
Shkun Chadda MSc, BSc, Health Economist, Health Outcomes Ltd, Newcastle Upon
Tyne, UK
Richard Chapman PhD, Senior Director, Health Economics, IMS Health US HEOR,
Falls Church, VA, USA
Chi-Chang Chen PhD, Manager, GEOR, Plainsboro, NJ, USA
Yan Chen MPH
Donna Chiefari RPh, PharmD, Director, Clinical Pharmacy, Clifton Park, NY, USA
Christos Chouaid PhD, Hopital Saint-Antoine, Paris, France
Therese Conner PhD, MS, Outcomes Research Consulting, Austin, TX, USA
Iris Contreras MSPH, Research, Instituto Mexicano del Seguro Social, Delegación
Cuauhtémoc. Distrito Federal, Mexico
Craig Currie PhD, Senior Research Fellow, Cardiff University, Cardiff, Wales, UK
Peter Lawrence Dale MSc, BSc, Research Associate, United BioSource Corporation,
London, UK
Charles Daniels PhD, RPh, BS, MS, Professor of Clinical Pharmacy and Pharmacist
in Chief, University of California San Diego, San Diego, CA, USA
Gregory Daskos MD, Head of Medical Affairs and Health Economics, AstraZeneca
Greece, Athens, Greece
Erwin De Cock MSc, Senior Research Associate, United BioSource Corporation,
Barcelona, Spain
H. Baris Deniz MSc, Researcher, UnitedBioSource Corporation, Concord, MA, USA
Joshua Devine PhD, PharmD, Pharmacoeconomic Analyst, DoD Pharmacoeconomic
Center, Fort Sam Houston, TX, USA
Boyan Doganov MD, CEO, Mediconsult Group of Companies, Sofia, Bulgaria
Tomas Dolezal PhD, MD, Pharmacology Institute, Prague, Czech Republic
Hendrik Duvenhage MD, Head Managed Care, Schering Plough, Johannesburg,
South Africa
Jenifer Ehreth PhD, Head Health Economics, Alexion International Sàrl, Paris, France
Hanaa Elhefni MD, MS, MPH, Technical Director, Macro International Inc, Silver
Spring, MD, USA
Haim Erder PhD, Executive Director, Health Economics, Forest Laboratories, Inc.,
Jersey City, NJ, USA
Steven Erickson RPh, PharmD, Associate Professor, University of Michigan, College
of Pharmacy, Ann Arbor, MI, USA
Frank R. Ernst RPh, MS, PharmD, Senior Research Scientist, Premier Inc, Charlotte,
NC, USA
Anthony Eti-ukwu RPh, Mphil, Senior Pharmacist, Clinical Services, The Presidency,
Abuja. F.C.T., Nigeria
Thomas Evers PhD, Global Network Leader, Bayer HealthCare AG, Wuppertal,
Germany
Alex Exuzides PhD, Director, ICON Clinical Research, San Francisco, CA, USA
Heather Falvey BS, MSc, Health Economics Manager, Novartis, Basel, Switzerland
Claudio Faria PharmD, MPH, Associate Director of Clinical Research, Univesity of
Massachusetts Medical School, Charlestown, MA, USA
Ancilla Fernandes PhD, MS, Associate Director, MedImmune, Gaithersburg, MD, USA
Christine Folia RPh, PharmD, BSc, Agro Health Associates Inc., Burlington, ON,
Canada
Duska Franic PhD, BS, MS, PharmD, Associate Professor, University of Georgia,
Athens, GA, USA
Christopher Frei PharmD, MSc, Assistant Professor, University of Texas at Austin
College of Pharmacy, San Antonio, TX, USA
Frank-Ulrich Fricke PhD, MSc, Principal, IMS Health Economics & Outcomes Research, Nuremberg, Germany
Michael Fronstin MBA, Vice President, Consumer Health Sciences International,
Princeton, NJ, USA
100
Alex (Zhenghong) Fu PhD, Assistant Professor, Cleveland Clinic, Cleveland, OH, USA
Sylvie Gabriel MD, MBA, Associate Vice President, Sanofi-aventis, Paris, France
Sabine Gaugris MSc, Associate Manager, Merck & Company, Whitehouse Station,
NJ, USA
Tobias Goeke RPh, Schellen & Partner GmbH, Düsseldorf, Germany
Amede Gogovor MSc, Research coordinator, Universite de Montreal, Montreal, QC,
Canada
Dan Greenberg PhD, MSc, Senior Lecturer, Ben-Gurion University of the Negev, BeerSheva, Israel
Wolfgang Greiner PhD, Professor, Universitat Bielefeld, Bielefeld, Germany
Diego Guarin MD, MPH, MA, HEOR Manager, Abbott, Bogota, Colombia
Shien Guo PhD, MHA, Senior Project Manager, United BioSource Corporation,
Concord, MA, USA
Silvia Guzman MD, Clinical Practitioner, National Rehabilitation Center, Mexico
Cheryl Hankin PhD, President and Chief Scientific Officer, BioMedEcon, LLC, Moss
Beach, CA, USA
Mariam Hassan DrPH, Manager, HEOR, AstraZeneca LP, Wilmington, DE, USA
Mark Helfand MD, MPH, Director, Oregon EPC, Portland, OR, USA
Franz Hessel MD, MPH, Senior Manager, Sanofi-Aventis, Berlin, Germany
Lanis Hicks PhD, Professor, University of Missouri, Columbia, MO, USA
Jennifer Hinnenthal MPH, Manager, Evidence and Publications, Medtronic Neurological, Minneapolis, MN, USA
Majbrit Holm MSc, Health Economist, Muusmann Research & Consulting, Copenhagen, Denmark
Shanlian Hu MD, MSc, Director and Professor, Training Center for Health Management, School of Public Health, Fudan Univ, Shanhgai, China
Sergio Iannazzo MBA, Administrator and researcher, Advanced Research, Turin, Italy
Michele Intorcia MSc, Associate Director, Bristol Myers Squibb, GEOR, Rome, Italy
Shrividya Iyer PhD, Associate Director, Wyeth Pharmaceuticals, Norristown, PA, USA
Vesa Jormanainen MD, MSc, Chief Physician, The Centre for Pharmacotherapy
Development, Helsinki, Finland
Zhanna Jumadilova MD, MBA, Director, Pfizer, Inc, New York, NY, USA
Sandra Kane-Gill MS, PharmD, Associate Professor, Univeristy of Pittsburgh, Pittsburgh, PA, USA
Peter Kaskel MD, MBA, Manager Outcomes Research, Msd Sharp & Dohme Gmbh,
Haar, Germany
Pawel Kawalec MD, Krakow, Poland
Donna Kerney PhD, BS, MS, Director, Program Analytics, InfoMedics, Woburn, MA,
USA
Victor Kiri PhD, MSc, BSc, Director, PAREXEL International, Uxbride, London, UK
Patricia Koochaki PhD, Principal Scientist, Procter & Gamble Pharmaceuticals,
Mason, OH, USA
Charalampia (Hara) Kousoulakou MSc, BA, Research Officer, Hellenic Association
of Pharmaceutical Companies, Chalandri, Greece
Andrey Kulikov DrPH, Pfizer International Russia, Moscow, Russia
Katsumasa Kuroi PhD, MD, Director, Depaetment of Surgery, Tokyo Metropolitan
Komagome Hospital, Tokyo, Japan
Andreas Kuznik PhD, Associate Director, Pfizer Inc, New Yrok, NY, USA
Steven Kymes PhD, MHA, Research Assistant Professor, Washington University
School of Medicine, Saint Louis, MO, USA
Antoine Lafuma MD, Consultant, CEMKA-EVAL, Bourg la Reine, France
Lincy Lal PhD, PharmD, Pharmacoeconomic Research Specialist, The University of
Texas M.D. Anderson Cancer Clinic, Houston, TX, USA
Deepa Lalla PhD, Senior Health Economist, Genentech, Inc, South San Francisco,
CA, USA
Jittrakul Leartsakulpanitch PhD, Outcomes Research, Pfizer (Thailand) Limited,
Bangkok, Thailand
Sang-Il Lee PhD, MD, MPH, Professor of Preventive Medicine, University of Ulsan
College of Medicine, Seoul, South Korea
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
RESEARCH REVIEW COMMITTEE
Karen Lee MA, Health Economist, Canadian Agency for Drugs and Technologies in
Health (CADTH), Ottawa, ON, Canada
Michael Lees BEc, MCom, Global Project Lead, Bayer plc, Uxbridge, UK
Christopher Leibman MS, PharmD, Sr. Director, Elan Pharmaceuticals, Inc., South
San Francisco, CA, USA
R. Scott Leslie MPH, Outcomes Researcher, MedImpact Healthcare Systems, Inc.,
San Diego, CA, USA
Josephine Li Mcleod PhD, RPh, Director, Medical Outcomes Research & Economics,
Baxter BioScience, Westlake Village, CA, USA
Nicky Liebermann MD, Head of Community Medical Division, Clalit Health Services,
Tel Aviv, Israel
Naphaporn Limpiyakorn MD, Doctor, Pranangkhlao Hospital, Nonthaburi, Thailand
Joanna Lis PhD, MSc, Health Economics Manager, Sanofi-Aventis Sp. z o.o., Warsaw,
Poland
Steve Lister MA, BA, Outcomes Research Manager, Pfizer Ltd., Tadworth, Surrey, UK
Andrew Lloyd, Director, Oxford Outcomes, Oxford, UK
Martin Lukac MD, Medical Director, Schering Slovakia s.r.o., Bratislava, Slovakia
Raf Magar MBA, BSc, Director, Health Economics & Reimbursement, PharmIdeas,
Raleigh, NC, USA
Wallace Marsh PhD, MBA, Associate Professor, Shenandoah University, Winchester,
VA, USA
Deborah Marshall PhD, Vice President, Health Economics & Outcomes, i3 Innovus,
Burlington, ON, Canada
Steve Marx RPh, MS, PharmD, BSc, Director, Global Health Economics & Outcomes
Research, Abbott, Abbott Park, IL, USA
Céu Mateus MA, BA, Lecturer, National School Public Health - UNL, Lisboa, Portugal
Susan Mathias MPH, President, Health Outcomes Solutions, Winter Park, FL, USA
Panagiotis Mavros PhD, Director, Outcomes Research, Merck & Co., Inc., Whitehouse Station, NJ, USA
Carrie McAdam Marx RPh, MS, Research Associate, University of Utah, Salt Lake
City, UT, USA
Doreen McBride MBA, BSc, RN, Research Scientist, Institute for Social Medicine,
Epidemiology and Health Ecomonics, Berlin, Germany
Stephen McKenna PhD, Director, Galen Research, Manchester, UK
Trent McLaughlin PhD, BSc, Director, Pharmacoeconomics, Elan Pharmaceuticals,
South San Francisco, CA, USA
David Meads MSc, BSc, BA, Senior Research Associate, Galen Research, Manchester, UK
Willem-Jan Meerding PhD, MSc, Head of Outcomes Research, Pfizer bv, Capelle a/d
Ijssel, The Netherlands
Joseph Menzin PhD, President, Boston Health Economics, Inc., Waltham, MA, USA
Xavier Mesrobian PharmD, Sanofi-aventis, Paris, France
Jeffrey Miller MS, Associate Director, Abt Associates, Lexington, MA, USA
Lesley-Ann Miller PhD, MS, BA, Pharmacoeconomics Research Specialist, University
of Texas, MD Anderson Cancer Center, Houston, TX, USA
Eileen Ming PhD, ScD, Director & Principal Scientist, Epidemiology, AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA
Michael Minshall BS, MPH, Principal, IMS-Health, Noblesville, IN, USA
Noormah Mohd Darus MSc, Principal Assisstant Director, Health Technology Assessment Unit, Medical Development Division, Ministry o, Putrajaya, Malaysia
Joaquin Federico Mould Quevedo PhD, MBA, MSc, Outcomes Research Manager,
Pfizer SA de CV, Mexico City, Mexico
Radhika Nair PhD, Abbott Laboratories, Round Rock, TX, USA
Siva Narayanan MS, MHA, VP & Practice Leader, TPO Global, TNS Healthcare,
Bethel, CT, USA
Christel Naujoks, HE&OR TA Head, IDTI, Novartis Pharma AG, Basel, Switzerland
Jack Newsom ScD, Senior Director - Analytics, Silverlink Communications, Newton,
MA, USA
Lars Nicklasson PhD, Associate Director Health Economics, Celgene, Limhamn,
Sweden
Judith O’Brien RN, Lincoln, MA, USA
Fredrick K. Orkin MD, MBA, MSc, Adjunct Professor of Anesthesiology, Yale University School of Medicine, Woodbury, CT, USA
Teresa Ortega PhD, MBA, Hospital Central de Astruias, Oviedo, Spain
Diego F. Ossa MD, MSc, Senior Health Economist Manager, Novartis, Camberley, UK
Massimiliano Panella PhD, MD, Professor, Università degli Studi del Piemonte Orientale A. Avogadro, Novara, Italy
Sotiria Papanicolaou, Health Economics & Governmental Affairs Manager, JanssenCilag Pharmaceutical S.A.C.I, Athens, Greece
Ashish Parekh BS, MS, Analyst, Humana Corporate Pharmacy Management, Louisville, KY, USA
Anuprita Patkar PhD, Analyst, Xcenda, Princeton, NJ, USA
Katherine Payne PhD, Senior Research Fellow, The University of Manchester, Manchester, UK
Elise Pelletier MSc, Director, HEOR, IMS Consulting, Watertown, MA, USA
James Piercy MSc, BSc, Commercial Director, phimap, Macclesfield, Cheshire, UK
Sharrel Pinto PhD, MS, PharmD, Assistant Professor, University of Toledo, Toledo,
OH, USA
Maria Pisu PhD, Assistant Professor, University of Alabama at Birmingham, Birmingham, AL, USA
Ana Cecilia Polanco MD, RN, Medical Adviser, AstraZeneca, S. A. de C. V., Estado
de México, Mexico
Ana Popielnicki BA, Supervisor, Linguistic Validation, Corporate Translations Inc.,
East Hartford, CT, USA
Barbara Poulsen Nautrup PhD, Principal, EAH Consulting, Juelich, Germany
Clare Proudfoot PhD, MA, Senior Health Outcomes Analyst, Heron Evidence Development Ltd, Letchworth Garden City, UK
Juvairiya Pulicharam MD, Director of Clinical Research, HealthCare Partners Medical
Group, Los Angeles, CA, USA
Yogesh Punekar PhD, MBA, Harrow, UK
Matthew Reaney MSc, BSc, Senior Scientist, AHP Research, Uxbridge, UK
Gregory Reardon PhD, RPh, Partner, Informagenics, LLC, Worthington, OH, USA
Craig Roberts PharmD, Director, Global Outcomes Research, Pfizer Inc, New York,
NY, USA
Diana Rofail MSc, BSc, Senior Project Manager, Mapi Values Ltd, Bollington,
Cheshire, UK
Matthew Rousculp PhD, MPH, Frederick, MD, USA
Sanjoy Roy MS, Manager, HEOR & Outcomes Research, Abbott Laboratories, Abbott
Park, IL, USA
Dale Rublee PhD, Director, Pfizer Global Outcomes Research, New York, NY, USA
Miguel A. Ruiz PhD, MBA, Lecturer, Universidad Autonomo de Madrid, Madrid, Spain
Mason W. Russell, Vice President and Executive Director, Abt Associates Clinical
Trials, Lexington, MA, USA
Melody Ryan PharmD, Associate Professor, University of Kentucky College of Pharmacy, Lexington, KY, USA
Ana Sabo ScD, Professor, Faculty of Medicine, Novi Sad, Serbia and Montenegro
Tracey Sach PhD, MSc, BA, Senior Lecturer in Health Economics, University of East
Anglia, Norfolk, UK
Alfred W. Sackeyfio RPh, BSc, Locum Pharmacist, Health Outcomes Researcher
Consultant, Manchester Lancashire, UK
Qayyim Said PhD, Assistant Professor, University of Arkansas for Medical Sciences,
Little Rock, AR, USA
Olga Sanchez-Solino PhD, MD, Medical Manager, Biogen Idec Iberia, S.L., Madrid,
Spain
Daniel Sarpong PhD, Director, Jackson State University, Jackson, MS, USA
Mete Saylan MD, Clinical Research Psychiatry, Abbott, Istanbul, Turkey
Richard Scranton MD, MPH, Veroscience, Tiverton, RI, USA
Lizheng Shi PhD, MS, Assistant Professor, Tulane University SPHTM, New Orleans,
LA, USA
101
ISPOR 11th Annual European Congress
8 - 11 November 2008 | Athens, Greece
RESEARCH REVIEW COMMITTEE / workshop review committee
Walter Siganga PhD, Professor, Southern Illinois University - Edwardsville, Edwardsville, IL, USA
Nuno Miguel Silverio PharmD, Pricing & Health Outcomes Officer, Lisbon, Portugal
Robert Simko PharmD, Assistant Director, Global Health Economics, Abbott Labs,
Chicago, IL, USA
Jana Skoupa, Medical Director, Pharma Projects s.r.o., Brno, Czech Republic
Harry Smolen MS, President, Medical Decision Modeling Inc., Indianapolis, IN, USA
Fabiano Souza MD, MSc, Clinical oncologist, Hospital de Cancer de Barretos, Barretos, Brazil
Stephen Stefani MD, Porto Alegre, Brazil
Elmar Stridde MD, Senior Outcomes Research Manager, Pfizer Pharma GmbH,
Karlsruhe, Germany
Gillian Stynes MSc, Manager Health Economics & Outcomes Research, Boehringer
Ingelheim GmbH, Ingelheim am Rhein, Germany
Yun Su MD, MS, MPH, Health Economics Manager, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA
Naeti Suksomboon PhD, PharmD, Faculty of Pharmacy, Mahidol University, Bangkok,
Thailand
Amir Abbas Tahami Monfared PhD, Senior Manager, Health Economics, ScheringPlough, Kirkland, QC, Canada
Osamu Takahashi MD, MPH, Chief of Medical Research, St.Luke’s Life Science
Institute, Tokyo, Japan
Boxiong Tang PhD, MD, Director, Outcomes Research, Centocor Ortho Biotech,
Johnson & Johnson, Horsham, PA, USA
Ljiljana Tasic PhD, MSc, Professor of Pharma Policy and Business, Head of Department, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Nelson Teich MD, MBA, CEO, MEDINSIGHT, Rio de Janeiro, Brazil
Theodora Theodoratou MSc, BSc, Health Economics Assistant, Boehringer Ingelheim, Athens, Greece
Yasuharu Tokuda MD, MPH, St. Luke’s Life Science Institute, Chuo City, Japan
Wendy Toler PharmD, Medical Science Liaison, Alpharma, Owings Mills, MD, USA
Alexander Tolkushin PhD, Post-graduate student, The I.M. Sechenov Medical Academy of Moscow, Moscow, Russia
Zdenko Tomic ScD, Assistant Professor, Faculty of Medicine, Novi Sad, Serbia and
Montenegro
F. Cankat Tulunay PhD, MD, Professor, Medical School of Ankara University, Ankara,
Turkey
Anthony Waka Udezi PharmD, Lecturer, University of Benin, Benin, Edo, Nigeria
Cara Usher PhD, BSc, Senior Research Fellow, Dublin, Ireland
David Van Brunt PhD, Research Advisor, Health Outcomes, Lilly Research Laboratories, Indianapolis, IN, USA
Anke Van Engen MSc, Senior Project Manager, Quintiles Consulting, Hoofddorp, The
Netherlands
Konrad Wallerstein BSc, MA, Partner, Adelphi Focus, Doylestown, PA, USA
Cheng Wang PhD, MD, Global Project Leader, Bayer HealthCare Pharmaceuticals,
Pine Brook, NJ, USA
Christian Weber MD, MPH, Medical Director, Institute for Medical Informatics and
Biostatistics, Basel, Switzerland
Jaro Wex PhD, MD, Director, PharmArchitecture Limited, London, UK
Cas Wiebinga PhD, Associate Director Pricing & Reimbursement, Quintiles Consulting, Hoofddorp, The Netherlands
Michael Willis PhD, Health Economist, The Swedish Institute for Health Economics,
Lund, Sweden
Sorrel Wolowacz PhD, Senior Health Economist, Research Triangle Institute, Manchester, UK
Jasmanda H. Wu PhD, MPH, Associate Director, Outcomes Research, Ortho-McNeil
Janssen Scientific Affairs, Annandale, NJ, USA
Jiuhong WU PhD, Director, 306 Hospital of PLA, Beijing, China
Kaoru Yamabe PhD, MSc, Manager, Banyu Pharmaceutical Co.,Ltd, Tokyo, Japan
102
Andrew Yu MS, MA, Associate, Analysis Group, Boston, MA, USA
Nicole Yurgin PhD, Sr Health Outcomes Scientist, Eli Lilly and Co, Indianapolis, IN,
USA
Vladimir Zah BSc, CEO, ZRX Outcomes Research Inc., Toronto, ON, Canada
Feng Zeng PhD, Health Economist, San Diego, CA, USA
Bin Zhang MD, MSc, Research Associate/Project Manager, Boston Health Economics Inc., Waltham, MA, USA
Zhongyun Zhao PhD, Director, J&J, Raritan, NJ, USA
Gergana Zlateva PhD, Director, Global Outcomes Research, Pfizer Inc., New York,
NY, USA
WORKSHOP REVIEW COMMITTEE
Benoit Arnould PhD, Senior Project Director, MAPI Values, Lyon, France
Carl Asche PhD, MBA, MSc, BA, Associate Professor, University of Utah, Salt Lake
City, UT, USA
Patricia Cerrito DrPH, Department of Mathematics, University of Louisville, Louisville, KY, USA
Michael Chambers MSc, MA, Health Economics, GlaxoSmithKline, Uxbridge, UK
Amit Chhabra MD, MPH, Director, New York, NY, USA
Lee-Yee Chong PhD, BSc, Senior Scientist, AHP Research Ltd, Uxbridge, UK
Suellen Curkendall PhD, Principal Investigator, Cerner Health Insights, Vienna, VA,
USA
Stephen George RPh, MS, Vice President, Coenxus Health, Tampa, FL, USA
Kirsten Gertsen MSc, Manager Health Economics & Strategic Pricing, N.V. Organon,
Oss/Brabant, The Netherlands
Femida Gwadry-Sridhar PhD, RPh, MSc, BSc, Assistant Professor, Scientist, University of Western Ontario, McMaster University, Lawson Health Research, London, ON,
Canada
Rolf Holle PhD, Head of Research Unit, GSF- National Research Centre, Institute of
Health Economics, Neuherberg, Germany
I-Chan Huang PhD, MSc, Assistant Professor, University of Florida, Institute for Child
Health Policy, Gainesville, FL, USA
Michael Iskedjian RPh, MSc, President, PharmIdeas USA Inc., Buffalo, NY, USA
Jeroen Jansen PhD, MSc, Associate Research Director, Mapi Values, Boston, MA,
USA
Paul Krabbe PhD, Senior Researcher, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Won Chan Lee PhD, Director of Health Economics, Abt Bio-Pharma Solutions Inc.,
Lexington, MD, USA
Tracy Li PhD, Director, Immunology, Bristol-Myers Squibb Co., Princeton, NJ, USA
Bradley Martin PhD, RPh, PharmD, Professor and Division Chair, College of Pharmacy University of Arkansas for Medical Sciences, Little Rock, AR, USA
Patrick Mollon MD, MBA, MSc, Associate Director, Pfizer Ltd, Sandwich, Kent, UK
Rose Mullen MBA, RN, Outcome Liaison, Eli Lilly, Greenfield, IN, USA
Olaf Pirk PhD, MD, Principal, IMS-HEOR Germany, Nuremberg, Germany
Maribel Salas MD, MSc, Assistant Professor of Medicine, The University of Alabama
at Birmingham, Birmingham, AL, USA
Fadia Shaya PhD, MPH, Associate Professor, Associate Director, University of Maryland School of Pharmacy & Medicine, Baltimore, MD, USA
Donald Stull PhD, Research Scientist, UBC Health Care Analytics Group, Bethesda,
MD, USA
Jeanni Van Loon MSc, Development Director- Europe, Mapi Values, Houten, The
Netherlands
Henri Vanden Baviere MD, MBA, i3 Innovus, Brussels, Belgium
George Wan PhD, MPH, Sr Director Outcomes Research - CNS, Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA
Roza Yagudina MD, PharmD, Head of Laboratory of PhE, Moscow Medical Academy,
Moscow, Russia